Phenotyping of a new conditional mouse model of alkaptonuria and investigation of nitisinone-induced tyrosinaemia by Hughes, Juliette
 
Phenotyping of a new conditional mouse model of 





Thesis submitted in accordance with the requirements of the University 
of Liverpool for the degree of Doctor in Philosophy by: 
 








This thesis could not have been possible without my three supervisors Prof James Gallagher, 
Prof George Bou-Gharios and Prof Lakshminarayan Ranganath, who have taught me many, 
many skills and have pushed, motivated me and supported me to produce the best work that 
I can. George, your knowledge of mouse models was incredibly important and you have 
taught me so much about transgenic models which was a huge part of my project. Ranga, the 
clinical expertise and knowledge that you brought to my scientific research was incredibly 
important, reminding me that AKU patients are the ultimate reason why we do our research. 
Jim, I thank you for all your wise advice and guidance - you have always been positive and 
boosted my confidence, and have supported me the whole way through my PhD to conduct 
research in a professional manner. I also had the chance to be part of your lab group (and 
will always be part of I hope no matter where I go!), without whom my PhD would not have 
been the same or possible.  
Huge thank you to all of my lab group, you have guided and supported me through my PhD, 
and more than that, been great friends. Dr Hazel Sutherland, you have taught me everything 
I need to know about how to work with the mice and I am thankful to have learnt the BSU 
ways under your wing, and had your help with numerous mouse and lab experiments. Dr 
Peter Wilson; you have taught me the ways of the lab, answered my many questions about 
my lab work, assisted me with many experiments and have always had great advice about 
non-work-related topics too. Hazel and Pete, you have both been very important in my PhD 
and I can’t thank you enough! Jane Dillon, you have been wonderful to work with, always 
taking the time to listen and give advice, and help me with anything I needed; usually with a 
cup of tea involved! Eman Alawadhi, working with you has been a joy; you are a caring and 
generous friend and have introduced my taste buds to many new Kuwaiti snacks! Dr Brendan 
Norman, you have looked out for me, especially at conferences – I was very glad to see you 
when I eventually made it to Valencia!! You are always willing to help, whether that be with 
mass spec or metabolomics or something else completely different. Dr Craig Keenan, thank 
you for your help, particularly with histology and staining in the lab, and for bringing much 
laughter to our lab group. 
Thank you to Andy Hughes, Dr Anna Milan, Dr Andrew Davison, Shirley Judd and Ella Shweihdi 
in the Royal Liverpool Hospital for any help and advice you have given me over my PhD. Andy 
and Anna in particular, thank you for introducing me to the world of mass spec, and for letting 
me loose on the QQQ and helping me to analyse my samples. Shirley, thank you for your help 
particularly with my dietary restriction work and NAC observational data. 
There are so many other people to acknowledge over the 3 and half years I have spent doing 
my PhD. I have to thank the other members of George’s lab group, particularly Dr Ke Liu for 
his help with mouse work and generation of the mouse model, Dr Steph Frost for all your 
help with molecular biology and Mohammed Alhashmi; both Prof Jonathan Jarvis and Prof 
George Bou-Gharios for their project licence supervision; Dr Antonius Plagge for culturing the 
ES cells to make the mouse model; Dr Takao Sakai for providing MxCre and expertise on the 
liver; Mandie Prior, Gemma Charlesworth and Cath Sperinck for their advice with histology; 
Joni Roachdown for assistance with the microscopes; all the BSU staff who took care of the 
mice and gave advice; all the joint lab meeting members that listened to and critiqued my 
work;  numerous IACD staff and all the PhD students, post-docs and PI’s who gave any advice 
or stopped for a chat. I also would like to thank Prof Nathan Jeffery for giving me the 
opportunity to demonstrate anatomy during my PhD, and everyone in HARC, particularly Neil 
Thomas, Dr Tom Butts, Dr Alistair Bond, Dr Claire Tierney and Paul Rothwell. 
ii 
 
I of course have to thank the AKU Society for funding my PhD and giving me the opportunity 
to be part of this amazing group of people dedicated to this ultra-rare disease, and being an 
inspiration to do research. I could not have done a PhD without the AKU Society, and would 
never have ran a half-marathon either!  
Finally, I have to thank my family and friends. I may not see you all anywhere near as often 
as I would like, but you are always there for me. To my Dad and Kelly, I hope that you are 
proud that I have conquered this alien world of research to finish a PhD, and more 
importantly, that I have not yet become a scouser, despite my 7½ years in Liverpool 
(disclaimer: I absolutely love this city). To my best friends, Amy and Amber, thank you for 
always being there since Year 9, you are the best of friends no matter which corner of the UK 
we all live in. Huge thanks to Ruby and Emma for being amazing friends since our anatomy 
degree days, who are now both amazing NHS A&E frontline workers, very relevant in this 
current covid-19 pandemic in which I am submitting; I hope you can spot an AKU patient if 
you ever meet one from my many years of rambling about my work. And to Jess, my literal 
other half, thanks for always being there by side, initially here in Liverpool when I started my 
PhD, and then when you moved to Manchester and then back home to Suffolk, and of course 
our whole lives. Your support through my PhD has been the best and I miss you all the time 
here in Liverpool. And last but not least Rob. You have put up with me through my whole 
PhD, through the ups and the downs, the stress and the joy, the end of nights out, the disaster 
of my travel to conferences (namely Valencia and Sienna) and my constant natter about my 
work (I think you could have written a good chunk of this thesis by now!), and you have 






Alkaptonuria (AKU) is an ultra-rare, autosomal recessive metabolic bone disease characterised by 
increased urinary and circulating homogentisic acid (HGA) caused by homogentisate 1,2-
dioxygenase (HGD) enzyme deficiency. The deposition of a dark, HGA-derived ochronotic pigment 
in cartilage and other connective tissues causes a severe and early-onset osteoarthropathy, due 
to ochronotic tissue being stiff and brittle. In addition to joint manifestations in AKU, eye 
pigmentation, tendon rupture, kidney and prostate stones, and heart valve stenosis are common 
features. An existing mutagenesis AKU mouse model has previously been used to investigate 
initial pigmentation of cartilage and to evaluate the effectiveness of the HGA-lowering drug 
nitisinone. Nitisinone therapy was proven to halt ochronosis in this mouse model and has been 
the subject of human clinical trials (DevelopAKUre), where it has been shown to reduce HGA and 
slow disease progression in AKU patients. Nitisinone-induced tyrosinaemia however is an 
upstream effect of 4-hydroxyphenylpyruvate dioxygenase inhibition that can cause keratopathy. 
The major aims of this thesis were to phenotype a new Hgd-targeted AKU mouse model, obtained 
from the KOMP repository, to use the LacZ gene which is expressed as a fusion transcript with 
the Hgd gene to determine the tissue expression of Hgd via ex vivo LacZ staining, to explore the 
effect of conditional liver-specific Hgd deletion on the AKU phenotype using double transgenic 
Hgd tm1d (fl/fl) MxCre mice, and finally to explore the effectiveness of dietary restriction and the 
potential application of an exogenous tyrosine-degrading enzyme at reducing tyrosine. 
The level of HGA and the tissue distribution of ochronotic pigmentation were evaluated using the 
knockout-first Hgd tm1a -/- model. HGA was shown to be increased in the plasma and urine, with 
the first signs of knee joint pigmentation found at 9 weeks in the knee joint, increasing linearly 
with age. Pigmentation was only found associated with chondrocytes within the calcified articular 
cartilage of joints, the calcified endplates of vertebrae, and the calcified knee joint meniscus. Hgd 
tm1a -/- mice exhibit the early stages of human ochronosis, with pigmentation confined to 
calcified tissues. Positive LacZ staining was identified in the cytoplasm of hepatocytes and kidney 
proximal convoluted tubule cells, beginning at E12.5 and E15.5 respectively, in addition to the 
developing male germ cells within the testis and epididymis, with qPCR showing liver Hgd mRNA 
expression to be approximately 2000-7,500-fold greater than the Hgd mRNA expression in the 
testis and epididymis. Germ cell expression was deemed insignificant and unlikely to contribute 
towards HGA metabolism. Liver-specific Hgd deletion via polyinosinic: polycytidylic acid induction 
of MxCre in Hgd tm1d (fl/fl) MxCre +/- mice demonstrated that 20% residual liver Hgd mRNA does 
not reduce circulating HGA leading to joint pigmentation and that kidney Hgd mRNA cannot 
rescue AKU. It was determined that the minimum level of liver Hgd mRNA required is 26-43% to 
reduce circulating HGA. The detection of downstream metabolites of intravenously injected 13C6-
HGA in Hgd tm1a -/+ plasma revealed that hepatocytes can take up and metabolise HGA. The 
liver should therefore be the target of future gene therapy in AKU.  
Nitisinone was shown to reduce HGA and increase tyrosine, phenylalanine, 4-
hydroxyphenylpyruvic acid and 4-hydroxyphenyllactic acid in the plasma of AKU mice. Dietary 
restriction of tyrosine/phenylalanine significantly reduced nitisinone-induced tyrosinaemia, with 
phenylalanine-only restriction not effective. Evidence of AKU patients reducing tyrosine was 
observed, although the reductions were not comparable with that of mice. Due to the proof-of-
principle provided by the dietary studies, preliminary experiments then demonstrated tyrosine 
degradation by the bacterial enzyme tyrosine ammonia lyase, which has the potential to be 
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1.1 Inborn errors of metabolism 
Inborn errors of metabolism (IEMs) make up a large group of rare genetic inherited disorders. 
These disorders are caused by a deficiency or absence of proteins that have important roles 
in cellular biochemical function, such as enzymes which are the most common, carriers, 
receptors or structural proteins 1. With defective enzymes making up the majority of IEMs, 
in most of these diseases, symptoms arise due to increased upstream substances, reduced 
downstream substances, or a switch to an abnormal substrate metabolism 2. IEM’s are 
traditionally characterized into groups of disorders that include carbohydrate metabolism, 
amino acid metabolism, organic acid metabolism or lysosomal storage diseases 3.  
An online database, the Online Mendelian Inheritance in Man (OMIM), is a continuously 
updated, freely available database of human genes and their associated genetic 
traits/disorders. On 21st January 2020, there were 16,254 gene descriptions, with 4,209 genes 
with a phenotype causing mutation entered, with 6,577 phenotypes with a known molecular 
basis (Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic 
Medicine, Johns Hopkins University (Baltimore, MD), {23/01/2020}. World Wide Web URL: 
https://omim.org/).  
Of the amino acid metabolism disorders, alkaptonuria (OMIM #203500), which is often 
described as the world’s first genetic disease due to it being the first disorder described to 
conform to Mendelian inheritance, is the subject of study in this thesis. 
 
1.2 Alkaptonuria 
Alkaptonuria (AKU) is an ultra-rare, autosomal recessive, multisystem disease in which 
homogentisate 1,2-dioxygenase enzyme activity (HGD; EC 1.13.11.5) is deficient 4. The HGD 
enzyme converts homogentisic acid (HGA) into maleylacetoacetic acid in the tyrosine 
metabolism pathway, see Figure 1.1. HGD deficiency leads to increased HGA in the urine, 
blood and tissues. Over time, this increased HGA accumulates and deposits as a dark brown, 
melanin-like pigment into connective tissues, termed ochronosis. Tissue ochronosis, which 
primarily affects articular cartilage, eventually leads to the manifestation of an early-onset 
and severe osteoarthropathy. AKU patients experience a decreased quality of life due to this 




Figure 1.1. Tyrosine metabolism pathway.  
Phenylalanine and tyrosine metabolites are broken down by a series of enzymes (italics). Genetic disorders 
associated with this pathway are shown in boxes, all of which are caused by an enzyme deficiency. Alkaptonuria 
is caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase, leading to an increase of its substrate 
homogentisic acid (HGA), which is a biochemical marker of alkaptonuria. Alkaptonuria is characterised by the 
presence of a HGA-derived ochronotic pigment within connective tissues, which is thought to involve 
benzoquinone acetic acid as an intermediate compound (dashed arrows). NTBC (nitisinone) is a drug that can 
inhibit the 4-hydroxyphenylpyruvic acid dioxygenase enzyme, reducing HGA production.  
 
1.2.1 History 
The earliest evidence of AKU was documented in an Egyptian mummy, Harwa, dating to 
1500BC. Radiological and biochemical analysis demonstrated that the mummy had narrowed 
and calcified joints with ochronotic articular surfaces that contained a pigment that was 
extracted and described as being identical to an air-oxidised HGA polymer 5,6. In 1584, 
Scribonius described the urine of a boy that turned as “black as ink” 7,8. In 1859, Boedeker 
then reported urine from a man with back pain that contained a substance that took up 
oxygen and caused the urine to turn black upon standing, accelerated by the addition of 
alkali, that he named “alcapton” 9. In 1866, Virchow described the term ochronosis, after 
performing an autopsy on a 67-year old man, where he found “black as ink” cartilage all over 
the body 10. On closer inspection, he found that not all the pigment was black, but a brown-
yellow “ochre” colour under microscopic examination and called it “ochronosis”. In addition, 
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Virchow also reported ochronosis in ligament, tendon, periosteum and arteries, in addition 
to deep ulcerations of knee joint articular cartilage down to the bony surface. In 1888, Kirk 
reported alcaptonuria urine containing an acid (that he named incorrectly) that was able to 
reduce both Fehling’s solution and ferric chloride, and that upon alkalinisation darkened the 
urine 11. In 1891, Wolkow and Baumann identified alkapton as 2,5-dihydroxyphenylacetic 
acid, and due its close structural relationship to gentisic acid, named it homogentisic acid 
(HGA) 12. They also demonstrated that feeding extra tyrosine to an “alcaptonuria” patient 
resulted in increased excretion of HGA. It wasn’t until 1902 however that Albrecht recognised 
the association between “alcaptonuria”, ochronosis and ochronotic arthritis in a patient who 
passed dark urine, and at autopsy presented with both ochronosis and arthritis 13. In 1904, 
Osler was the first to clinically diagnose AKU in two living brothers 14. 
Approximately 50 years before the discovery of DNA 15, AKU became renowned as the world’s 
first identified genetic disease. In 1902, Sir Archibald Garrod described the incidence of AKU, 
particularly the incidence within families and its relation to consanguineous marriage, 
concluding that AKU was somehow inheritable 16. With advice from Bateson, he suggested 
that AKU is inherited by the Mendelian theories of recessive inheritance. He also reported 
the consistency of HGA found within urine from different individuals as uniform, suggesting 
that only one degree of alkaptonuria exists, either with several grammes of HGA in the urine 
or none at all 17. In 1908, Garrod presented his work at the Croonian lectures, where he 
showed that AKU, along with other genetic disorders that included albinism and cystinuria, 
conformed to the laws of Mendelian inheritance 18. Here he unveiled the term inborn error 
of metabolism, proposing that the cause of AKU was lack of an enzyme that in normal 
individuals split the aromatic ring of HGA. A year later, Neubauer provided the first map of 
the tyrosine degradation pathway 19. Garrod’s enzyme defect theory preceded the work of 
Beadle and Tatum, who in 1941 published their conclusions that a single defective gene can 
be correlated with a metabolic block in one enzymatic reaction. It wasn’t until 1958 that 
biochemical evidence of the defect in AKU was provided by La Du, where he demonstrated 
the absence of HGD activity in a liver homogenate prepared from an AKU patient, establishing 
that failure to synthesize active enzyme was the sole cause of AKU 4.  
 
1.2.2 Epidemiology  
AKU is an ultra-rare disease; the worldwide incidence is approximately 1:250,000 to 
1:1,000,000 20. There are however specific areas where the incidence is much higher, such as 
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in Slovakia and the Dominican Republic where the incidence is estimated to be 1:19,000 21,22. 
The high incidence in the Dominican Republic can be attributed to classical founder effect, 
where 87% of the tested AKU chromosomes had the same mutation, with C120W identified 
as the founder mutation in this population 23. It is not known if the mutation originated in 
the Dominican Republic or if it was introduced through immigration. In Slovakia on the other 
hand, the incidence of AKU is difficult to explain by a founder affect, as high allelic 
heterogeneity has been found in this relatively small country, with little contribution from 
the most common European mutations. This suggests that several other independent 
founders may have contributed to the gene pool in Slovakia, combined with a greater 
mutation rate, as 7 of 12 mutations that most likely originated in Slovakia are associated with 
regions of hyper-mutation within the HGD gene, and have been traced to a small isolated 
area in the north-west of the country 22. Although the incidence has not been calculated, 
Jordan has been recently identified as a hotspot for AKU, where 40 cases were identified in 
one village, with 9 cases occurring in one family 24,25. This greater incidence is thought to have 
occurred due to consanguineous marriage which is common in Jordanian culture; a recent 
study by the Jordan Population and Family Health Surveys reports that 35% of all marriages 
were consanguineous in 2012, reduced from 57% in 1990 26. 
 
1.2.3 Clinical presentation 
1.2.3.1 Tyrosine and phenylalanine 
AKU is a disorder of tyrosine/phenylalanine metabolism. Phenylalanine is an essential amino 
acid obtained only from the diet whereas tyrosine is a non-essential amino acid, produced 
by the hydroxylation of phenylalanine within the body 27, although it can become an essential 
amino acid if phenylalanine intake is insufficient. Both of these amino acids can also be 
obtained from endogenous protein turnover. Tyrosine and phenylalanine are used for 
synthesis of hormones, melanin and other new proteins, however this only accounts for 
about 5% of dietary tyrosine intake, with the majority of tyrosine being metabolised to 
maleylacetoacetic acid and fumarylacetotacetic acid in the tyrosine metabolism pathway, via 
HGA (see Figure 1.1) 28. Metabolism of phenylalanine and tyrosine produces metabolites that 
enter intermediate metabolism, namely ketogenesis by the production of acetoacetic acid 
which enters the TCA (tricarboxylic acid) cycle for the production of ATP, and for the 
production of fumaric acid which too can enter the TCA cycle, in addition to gluconeogenesis 
for the production of glucose. Tyrosine and phenylalanine are therefore both ketogenic and 
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glucogenic amino acids. Disruption of this metabolic pathway in AKU leads to a complete 
metabolic block, characterised by increased HGA in the urine and blood.  
 
1.2.3.2 Homogentisic acid 
It is not uncommon for individuals with AKU to reach adolescence/adulthood without a 
diagnosis, as children are usually asymptomatic with the exception of homogentisic aciduria. 
Dark staining of nappies/urine from babies is often observed, due to the presence of HGA, 
which becomes oxidised, turning the urine black 29–31. AKU urine that is left to stand turns 
dark after several hours 8,20. To further confirm the diagnosis, a fresh urine sample can be 
alkalinised to accelerate the oxidation of HGA, resulting in black/dark urine 32–34. Various 
methods to assess HGA levels in urine have been reported and are used to diagnose AKU, 
some of which include an oxidation/alkalinisation step, such as spectrophotometric analysis 
of alkalinised urine 35, urine spots on filter paper followed by capillary electrophoresis 36,37, 
and colorimetric analysis of alkalinised dried urine spots 38. 
Whilst filter paper methods that do not require complex laboratory equipment may be useful 
for screening or diagnosis where specialist services are not available, the gold standard for  
clinical diagnosis of AKU is quantitation of HGA in urine using methods such as 
spectrophotometric analysis 20,39,40, gas chromatography 41, high performance liquid 
chromatography (HPLC) 42, gas chromatography/mass spectrometry (GC/MS) 43–45 and liquid 
chromatography/mass spectrometry (LC/MS) 46. Quantitation of HGA in serum is also used 
to monitor AKU and the effectiveness of therapeutic intervention 47–49. 
Various studies have reported HGA levels in the plasma and urine of AKU patients. HGA is 
excreted in millimolar concentrations in the urine of AKU patients, see Table 1.1 for the 
reported urinary HGA excretion in the literature, which equates to several grams per day. 
The daily excretion of HGA has been investigated in 22 healthy individuals; in 15 of these, 
HGA excretion was below the lower limit of quantitation <1.0 µmol/L (LC/MS assay) and 
could not be determined, with the remaining 7 excreting HGA above this value, with a 
maximum excretion of 2.91 µmol/24hr which equates to approximately 0.49 mg/day 50.  
Circulating HGA (either plasma or serum) is reported to be on average 30-50 µmol/L in AKU 
patients, see HGA in healthy individuals (n=22) 50: <1.0 µmol/L (n=15), maximum 0.00291 mmol/24hr or 0.00049 g/24hr 
in remaining 7 individuals. 




Table 1.2 for values from the literature. Within the 22 healthy individuals aforementioned, 
serum HGA was not detected as it was below the lower limit of quantitation (LC/MS assay) 
and therefore reported as <3.1 µmol/L 50. A more sensitive method (GC/MS) was used to 
quantitate HGA in 9 healthy individuals, and determined to be 2.4-12.0 ng/ml, which is 
approximately 0.05 µmol/L 49. Tyrosine in both the urine and serum/plasma is often reported 
in AKU patients, see Table 1.1 and HGA in healthy individuals (n=22) 50: <1.0 µmol/L (n=15), maximum 0.00291 
mmol/24hr or 0.00049 g/24hr in remaining 7 individuals. 
Tyrosine in healthy individuals (n=22) 50: 14-147 µmol/24hr. 
 
Table 1.2 respectively, and are comparable with healthy adult reference ranges. In these AKU 
patients, tyrosine is about 40-80 µmol/L in plasma/serum and 100 µmol/24hr in the urine. In 
the 22 healthy individuals already mentioned, serum tyrosine was 30-87 µmol/L, and urinary 
tyrosine was reported to be 14-147 µmol/24hr 50. 
 














3 2.51 - - - Hughes et al. 2014 46 
58 3.12 - - - 
Phornphutkul et al. 
2002 20 
1 1.22 - - - Wolff et al. 2015 51 
40 - 5.68 [0.84-9.60] - - Introne et al. 2011 40 
17 - 0.95 [0.46-1.5] - - 
Al-Sarayreh et al. 2014 
44 
1 - - 5.78 - Öztekin et al.2018 37 
40 2.7 [1.9-4.3] [2.43-11.7] - 32.1 [14.4-69.5] Ranganath et al. 2014 52 
28 2.26 - - 20.56 Milan et al. 2017 53 
Tyrosine 
3 0.017 - - - Hughes et al. 2014 46 
28 0.011 - - 0.103 Milan et al. 2017 53 
HGA in healthy individuals (n=22) 50: <1.0 µmol/L (n=15), maximum 0.00291 mmol/24hr or 0.00049 g/24hr in remaining 7 
individuals. 
Tyrosine in healthy individuals (n=22) 50: 14-147 µmol/24hr. 
 
Table 1.2. Mean serum/plasma concentrations of HGA and tyrosine in AKU patients from the literature. 
 Serum/plasma concentration 
n µmol/L [range] µg/ml [range] Reference 
HGA 
40 29.2 [5.8-45.5] - Ranganath et al. 2014 52 
58 - 6.6 [3.0-27.8] Phornphutkul et al. 2002 20 
3 49.3 [30.2-75.2] - Hughes et al. 2015 47 
38 - 5.74 [3.15-10.5] Introne et al. 2011 40 




40 60 [39-113] - Ranganath et al. 2014 52 
58 79 - Phornphutkul et al. 2002 20 
38 59.8 [41-108] - Introne et al. 2011 40 
3 51 [31-82] - Hughes et al. 2015 47 
28 42 [20-82] - Milan et al. 2017 53 
HGA in healthy individuals (n=22) 50: <3.1 µmol/L. 
Tyrosine in healthy individuals (n=22) 50: 30-87 µmol/L. 
 
1.2.3.3 Ochronosis 
The consequence of increased HGA in the circulation and extracellular fluid for decades, is 
the presence of a dark brown, HGA-related pigment found within connective tissues all over 
the body, termed ochronosis 8. Ochronosis affects a variety of connective tissues, most 
commonly the weight-bearing joints and spine but also the cardiovascular system 54, eyes, 
and skin 55,56. In addition to the change in appearance, pigmented tissues become stiff and 
brittle 57. Articular cartilage is particularly affected by pigmentation and degenerates 
prematurely, manifesting clinically first as lower back and joint pain, progressing to a severe 
and debilitating early-onset osteoarthropathy. 
 
1.2.3.3.1 Spinal and joint arthropathy 
Other than increased HGA causing dark urine, most patients are asymptomatic until 
adulthood. The onset of symptoms usually begins with the onset of lower back pain (usually 
lumbar and then thoracic), before the age of 30 years, preceding the involvement of the 
cervical spine 20. Intervertebral discs, in both the nucleus pulposus and annulus fibrosis, and 
ligaments become heavily pigmented and calcified over time 58. The spinal degeneration 
observed in AKU is progressive and can be seen with radiographs; initially the disc space 
becomes narrowed, followed by disc calcification and then fusion. In addition, kyphosis, 
reduced lumbar spinal flexion and loss of height is observed in AKU patients 20. AKU can be 
differentiated from ankylosing spondylitis, a form of inflammatory arthritis, by the lack of 
sacro-iliac joint involvement.  
In addition to severe spinal degeneration, ochronosis causes early-onset and severe joint 
disease (osteoarthropathy) in AKU, involving at first the larger joints such as the knee, hip 
and shoulder where a reduced range of motion is observed 59, before progressing to involve 
most joints of the body, including the smaller joints of the hands and wrists. A study involving 
58 AKU patients found that by the age of 55 years, half of patients had undergone at least 
one joint replacement due to osteoarthritis, with many patients requiring multiple joint 
replacements 20. This study also observed a roughly linear increase in joint disease severity 
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after 30 years of age, with men showing a more rapid increase in severity than women. Many 
case reports in the literature report ochronotic joint arthroplasty of the shoulder, hip and 
knee, where heavily pigmented cartilage was observed at surgery/autopsy 55,60–64.  
 
1.2.3.3.2 Connective tissue ochronosis 
In addition to osteoarthritic cartilage degeneration, other musculoskeletal tissues are 
affected by ochronosis. Tears and ruptures have been reported in the Achilles, patellar and 
shoulder rotator cuff tendons 43,65.  One report documents a 57% prevalence of tendon-
related symptoms, such as a thickened Achilles tendon, a 40% incidence of joint effusion 
(increased intra-articular fluid), and less common affects such as muscle tears after minor 
trauma, synovitis and ligament tears in load bearing joints 20. Pigmentation of the synovial 
membrane has been reported 43. Pigmentation of the trachea and primary bronchi cartilage 
has also been observed by bronchoscopy, that led to the diagnosis of AKU in a patient 66.  
Ochronosis of joints is usually only ever seen at the end stage of disease, either at joint 
replacement or at post-mortem. Ochronosis however is visible macroscopically in the sclera 
and conjunctiva of the eye, the cartilage of the ear and also in the skin, where its intensity 
can drastically vary between individuals 20,43,56,58,59. Perspiration may also be blue or brown 
59. 
At post-mortem, pigmentation can be found in areas that were not visible in life, unless 
observed during surgery. In addition to pigmented articular cartilage of the knee, hip and 
shoulder, pigmentation has also been identified in the costal cartilages, periosteum of bone 
(although not bone itself), cartilages of the larynx, trachea and bronchi, tendons, ligaments, 
epidermis of the skin, the dura of the brain, and within the cardiovascular system (see section 
1.2.3.3.3)58,59,67. Pigmented lymph nodes have also been reported in the hilar region of lung 
in the thorax 58. 
Ochronotic pigmentation is not seen within the pancreas, hepatobiliary system, or lung 
(excluding bronchial tree), gastrointestinal tract or spleen 55,58. Similarly, ochronosis of kidney 
tissue has not been reported, although a macroscopically grey proteinaceous tubular cast of 




1.2.3.3.3 Cardiac ochronosis 
Within the cardiovascular system, pigmentation has been identified in both the aortic and 
mitral heart valves, chordae tendinae, endocardium, pericardium, atheromatous plaques 
and roots and walls of major arteries such as the aorta and coronary arteries, where 
pigmentation was present within the intima and adventitia of the arterial wall 55,58–60,67–72. 
Pigmentation has also been described in the basilar and internal carotid arteries 58. 
Monckeberg arteries, which are vessels that have calcification, have also been reported in 
the extremities of an AKU patient 56. 
Aortic stenosis is the most commonly reported cardiac abnormality in AKU patients, with 
many patients requiring valve replacement 73. In a group of 58 AKU patients, 3 individuals 
>50 years had undergone a valve replacement, presenting at a mean age of 54 years, and 
50% had evidence of coronary artery calcification by 59 years 20. A larger study investigating 
cardiac involvement in a group of 76 AKU patients found that overall, there was a 17% 
prevalence of significant aortic valve disease with a high prevalence of aortic vascular 
calcifications that begin to manifest in the 6th and 7th decade of life, that did not correlate 
with standard cardiovascular risk factors 73. More specifically, 8% had undergone valve 
replacement, 16% had aortic sclerosis and 9% had aortic stenosis. Over 65 years, 50% had 
aortic stenosis or had undergone valve replacement. Within this group of 76 patients, 17 
patients with a mean age of 55 ± 7 years had CT scans that allowed evaluation of coronary 
and valve calcification; 18% had significant coronary calcification, 47% had valve calcification 
(18% severe), 65% had significant vascular calcifications, with calcifications predominately 
seen in the aortic root, descending aorta and iliac arteries, and by 60 years of age, there was 
a 100% prevalence of intra-cardiac calcification.  
 
1.2.3.3.4 Urogenital calculi 
In addition to the connective tissue pigmentation and degeneration described above, 
increased HGA is also thought to exhibit adverse effects in other tissues, such as urogenital 
complications. Kidney stones are common in AKU, with a prevalence of 28% found in a survey 
of 58 AKU patients, and are thought to be related to the very high level of HGA being excreted 
by the kidney 20. In the same group of patients, prostate stones  were documented in 30% of 
men aged 31-60 years, with no apparent link to the prevalence of kidney stones 20. Prostate 
stones have been reported elsewhere, and upon prostatectomy, black calculi have been 
observed 43,51,58,59,74–76. Bladder stones have also been reported in AKU 74–76. 
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Wolff et al. in a case report investigated dark/black kidney and prostate stones (at different 
times) found from one AKU patient who had normal renal function, using X-ray diffraction 
and infrared spectroscopy techniques respectively 51. Analysis revealed that the kidney 
stones were 100% calcium phosphate, although the authors acknowledged the technique 
may be limited in its detection of certain structures. Prostate stone analysis revealed the 
composition to be protein, carbapatite (carbonated calcium phosphate), and small amounts 
of weddellite (calcium oxalate dihydrate). This agrees with earlier reports analysing prostatic 
calculi composition 74–76, all of which were reported to be the standard components of non-
AKU prostatic calculi 51,77. The black substance within the black prostate stones was not 
identified in these reports; its absence from X-ray diffraction analysis suggest the pigment is 
amorphous, and was therefore undetectable with diffraction techniques that are limited to 
crystalline structure detection. The reported composition of the kidney and prostate stones 
from the AKU patient would suggest that the patient was suffering from proteinuria, 
hypercalciuria and hypophosphaturia, however this was not observed by Wolff et al. 51. They 
postulated instead that active bone resorption due to ochronosis in the joints may have been 
releasing calcium and phosphate into the blood stream, which when combined with HGA, 
lead to the formation of black stones. In addition, the alkali secretions of the prostate may 
accelerate HGA oxidation to pigment and therefore increase the likelihood of prostate 
stones.  
 
1.2.4 Pathophysiology of ochronosis 
Ochronotic pigment is found within connective tissues all over the body, with cartilage 
appearing to be the most susceptible tissue. In addition to the large weight bearing joints 
such as the hip, knee, shoulder and elbow, pigmentation is found within many other hyaline 
cartilages, including the costal cartilages, larynx, trachea and bronchi, sternoclavicular joints 
and sacroiliac joints 20,55,58,59,66. Pigmentation is also seen within fibrocartilaginous tissues 
such as the annulus fibrosis of intervertebral discs (IVDs) and pubic symphysis 55,58, and within 
elastic cartilage of the external ear and epiglottis 20,55. Pigmentation is also found within non-
cartilaginous tissue such as ligaments, tendons, synovial membrane, periosteum (although 
not the bone itself), perichondrium, sclera and conjunctiva of the eye, skin and dura of the 
brain 20,43,55,56,58,67. Within the cardiovascular system, pigmentation has been identified in 
heart valves, chordae tendinae and roots and walls of major arteries such as the aorta, where 
pigmentation was present within the intima and adventitia of the arterial wall 55,58,59,67.  
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Although the exact mechanism of pigment deposition/formation is currently unknown, the 
pattern and order of pigmentation within human cartilage has been elucidated, using AKU 
joints obtained at joint replacement surgery. Histological analysis of human AKU cartilage 
with varying pigment intensities revealed that pigmentation initiates as pericellular and 
intracellular pigmentation of individual chondrocytes within calcified articular cartilage, close 
to the subchondral bone 57. Initially, pigmentation was not found in the calcified articular 
cartilage inter-territorial matrix between cells, nor within the non-calcified hyaline cartilage. 
Pigmentation then advanced to the deep and middle hyaline cartilage zones as a blanket 
pigmentation covering both the territorial and inter-territorial matrix, despite the calcified 
articular cartilage showing only territorial matrix pigmentation. Within heavily pigmented 
samples, pigmentation of superficial articular cartilage and the inter-territorial matrix of 
calcified cartilage was observed 57. Furthermore, a complete absence of the calcified articular 
cartilage and subchondral bone was observed in severely affected cartilage, hypothesized to 
be due to stress shielding from the heavily pigmented and subsequently stiffer hyaline 
cartilage zones above, that causes osteoclast resorption of the unloaded calcified cartilage 
and subchondral bone. Elevated urinary collagen N-telopeptide, a marker of bone resorption, 
has been reported in AKU patients 20.  
It has been shown that ochronotic pigment has an affinity for fibrillary collagen surrounded 
by glycosaminoglycan-rich ground substance, particularly in hyaline cartilage 67. Analysis of 
pigmented collagen fibres from the ligamentous capsule of an AKU hip joint revealed 
intracellular (fibroblasts) and extracellular granular pigmentation associated with collagen 
fibres, in addition to a homogenous pigmentation that encrusted collagen fibres 78. The 
granular pigment associated with collagen fibres varied in position, distribution and intensity, 
with a periodic banding pattern of pigment observed on individual collagen fibres. In addition 
to granules, shards of pigment were observed that often bridged between collagen fibres. 
Taylor et al. suggest that the extracellular matrix (ECM) is normally resistant to pigmentation, 
and may become susceptible after biochemical or mechanical damage 57. They showed that 
pigmented cartilage is much stiffer than non-pigmented cartilage, and suggest that focal 
pigmentation of individual chondrocytes and their associated collagen is likely to make the 
ECM prone to damage through normal loading, leading to further damage in an inevitable 
downward spiral. This work led to a theory, termed the exposed collagen hypothesis, that 
small granule pigmentation on collagen fibres, similar to the pattern of proteoglycan binding, 
occurs due to proteoglycan and glycosaminoglycan loss, acting as a nucleation point for 
pigment polymerization, see Figure 1.2 79. Solid state nuclear magnetic resonance studies 
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have shown nanoscale collagen disorder and proteoglycan loss in AKU cartilage, supporting 





Figure 1.2. Schematic representation of the exposed collagen hypothesis of pigment deposition and progression 
in AKU.  
A shows homogentisic acid (HGA) is present in the extracellular environment, but cannot bind to undamaged 
collagen fibrils, which are decorated with protective molecules including proteoglycans (PGs). As a result of 
repetitive mechanical loading, chemical attack or ageing and degeneration, protective molecules including PGs 
are lost from the collagen fibrils (B). The exposed collagen fibrils are then susceptible to attack from small 
molecules such as HGA. The initial binding of HGA functions as a nucleation event and is followed by further rapid 
deposition of HGA as a pigmented polymer (C). Binding of HGA-derived pigment to the collagen fibrils makes them 
stiffer and susceptible to more mechanical damage. This leads to further ultra-structural changes in collagen, 
increased exposure to HGA and a downward spiral of increasing pigmentation and severe ochronosis. Adapted 
from Gallagher et al., 2016 79. 
 
Experiments conducted in an in vitro cell model of ochronosis, where osteosarcoma cell lines 
that can secrete ECM are incubated with HGA, have also shown pigment deposition to be 
intracellular and extracellular, with the latter associated with fibrillary structures in the 
matrix 81. Culture media incubated with HGA took weeks to darken in the absence of cells, 
compared to a few days in the presence of cells, highlighting that cellular activity accelerates 
pigment deposition. In vivo, pigment deposition is thought to take many years; pigment 
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deposition was observed within a few days in vitro. The authors suggest that the ECM in vivo 
is protective, inhibiting ochronosis; the ECM formed in vitro is not assembled correctly into a 
highly organised and complex matrix, with no periodicity observed in fibres, and may explain 
the rapid pigment deposition by a lack of protective factors. This would support the exposed 
collagen hypothesis that was later published, that the protective molecules shielding collagen 
could be proteoglycans and glycosaminoglycans 79. Interestingly, of these cell lines incubated 
with HGA, SaOS-2 cells were the most pigmented, but synthesised the least amount of 
collagen (the opposite was true for TE85 cells), suggesting that the amount of collagen is not 
a key factor associated with pigmentation 81. This supports an earlier comment by Taylor et 
al. that pigmentation appears to be of established matrix, and not newly formed matrix 57. 
HGA is a reducing agent, and especially under alkaline conditions, is rapidly oxidised to 
benzoquinone acetic acid, turning solutions and tissues black 59,82. Ferric chloride has been 
shown to cause AKU urine to turn an evanescent blue colour when added dropwise 59. A 
modified Schmorl’s stain, which incorporates ferric chloride in the incubating solution, has 
been used both in cells and in human tissue sections to enhance ochronotic pigment from a 
yellow-brown to an intense blue-green colour, whereby ferricyanide is reduced to 
ferrocyanide by the presence of ochronotic pigment, supporting that it is indeed a HGA-
derived pigment 81. Furthermore, Schmorl’s reagent is usually used to stain melanin pigments 
which may suggest that ochronotic pigment could be structurally similar to melanin. The 
structure and mechanism for ochronotic pigment deposition/formation remains to be 
elucidated; it is not known whether ochronosis occurs by initial binding of HGA, an oxidised 
intermediate, or as ochronotic pigment 83. For a more detailed review regarding the potential 
structure of ochronotic pigment, refer to Ranganath et al. 83. 
 
1.2.5 HGD 
Since the early 1900’s, AKU has been described as a disorder of tyrosine metabolism, with 
the assumption that there was an abnormality in the HGD enzyme (often referred to as HGO 
in older literature) that caused the excretion of HGA into the urine, however the nature of 
the defect had not been determined. In 1958, it was La Du et al. who determined that there 
was no detectable HGD activity in a liver homogenate obtained from a liver biopsy from an 
AKU patient, concluding that AKU was caused by a failure to synthesize active HGD enzyme, 
creating a complete metabolic block in the tyrosine catabolism pathway 4. They also 
determined that tyrosine catabolism followed the same series of reactions as other 
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mammals, with the conversion of tyrosine to 4-hydroxyphenylpyruvic acid (HPPA), HGA, 
maleylacetoacetic acid (MAA), fumarylacetoacetic acid (FAA) and acetoacetic acid, as shown 
in Figure 1.1, with the activity of enzymes in the AKU liver homogenate, other than HGD, 
shown to be comparable to those isolated from a non-AKU liver homogenate. It is now known 
that HGD cleaves the aromatic ring of HGA 84. 
 
1.2.5.1 HGD gene 
After the work by La Du in the 1950’s, it was generally accepted that AKU was caused by a 
defect in HGD that resulted in failure to synthesize active enzyme. It was not known whether 
the AKU defect was a result of a regulatory or structural gene mutation. No further progress 
was made on the molecular characterisation of the defect causing AKU until the 1990’s, when 
the HGD gene was cloned, allowing the identification of mutations (see section 1.2.5.3 for 
more detail on HGD mutations).   
The human HGD gene was mapped to chromosome 3q2 in 1993 via a homozygosity study 85. 
In 1994, a homologous murine mutation was discovered in chromosome 16 86. Inter-species 
linkage studies using conserved genetic linkage groups then confirmed this human 
chromosome 3q2 location 87. Schmidt et al. in 1995 purified murine liver HGD, as a 49 kDa 
protein 88. The first HGD enzyme, hmgA, was then cloned and characterized in 1995 in a 
fungus model (Aspergillus nidulans) that was being used to study inborn errors of 
phenylalanine metabolism, as a 448-residue polypeptide that was 50 kDa in size 89. From the 
cloned cDNA, the amino acid sequence was deduced and used to identify expressed tag 
sequence clones that corresponded to human (from liver cDNA libraries) and plant HGD 
homologues 89. They also showed that disruption of the hmgA resulted in HGA secretion and 
absence of the HGD enzyme.  
In 1996, human HGD, determined to be a single copy gene, was then further mapped to 
chromosome 3q13.33 (http://www.ncbi.nlm.nih.gov/gene/3081), and shown to comprise of 
14 exons encoding a 445-mer protein 90. In addition, the authors reported the first described 
mutations in the HGD gene, see below in section 1.2.5.3. The HGD exons range from 35 to 
360 bp in size, with the introns ranging from 605 to 17,687 bp and the 5’- and 3’- untranslated 
regions (UTRs) being 167 and 210 nucleotides, respectively 91. The full HGD nucleotide 
sequence, including both exons and introns is 54,363 bp, with 3% of this sequence 





Figure 1.3. Schematic representation of the HGD gene exons and introns.  
The gene spans 54,363 bp split into 14 exons (blue boxes) and intronic sequences (solid black line). HGD exons 
range from 35 – 360 bp in length, with introns ranging from 605 – 17,687 bp in length 91. Mutations have been 
found in every exon and within most of the introns. Exons 6, 8, 10 and 13 show the highest prevalence of 
mutations 92. Amongst all mutations, missense mutations are the most common with a prevalence of 
approximately 67% 92. Across 172 AKU patients, the 3 most common mutations are shown in red boxes, all of 
which are missense. The most common mutation is G161R in exon 8 found in 68 AKU chromosomes, followed by 
A122V in exon 6  found in 27 AKU chromosomes and M368V in exon 13  found in 24 AKU chromosomes 93. The 
mutation found within the ENU AKU mouse model BALB/c Hgd-/- is shown in a yellow box which is a splice 
mutation at the start of exon 12 (see section 1.3.2.3 for more information on this mouse model). This thesis 
reports a new AKU mouse model in chapters 3 & 4 that includes a knockout line (Hgd tm1a -/-) with a gene trap 
inserted into intron 5 and a conditional line (Hgd tm1d) that has exon 6 targeted for deletion (green boxes).  
 
1.2.5.1.1 Conservation of the HGD gene 
The HGD gene is a very well conserved gene across a variety of species, as can be observed 
using the Ensembl (Ensembl release 99, January 2020 ©) gene/protein tree tool, see 
Appendix, section 8.1, Figure 8.1. Shown in Figure 1.4 is a direct comparison of the human 
HGD and mouse Hgd from the Ensemble gene/protein tree. A comparison of the nucleotide 
sequences (CCDS; consensus CDS sequence) of human HGD (NCBI gene ID: 3081) and mouse 
Hgd (NCBI gene ID: 15233) using the NCBI nucleotide BLAST (basic local alignment search 
tool) alignment search was carried out. Both the mouse and human sequences contain 1338 
nt, with 88.42% of nucleotides being identical (1183/1338 nt identical). The aligned 
sequences can be found in the Appendix, section 8.1.1. 
 
Figure 1.4. Protein tree alignment of human and mouse HGD.  
Across most species, the HGD gene is very well conserved. A direct comparison of human HGD and mouse (Mus 
musculus) Hgd is shown, generated using the Ensemble gene tree tool (https://www.ensembl.org/index.html).  
17 
 
1.2.5.2 HGD protein 
Murine liver HGD enzyme was purified in 1995, and its molecular mass was determined to 
be approximately 49 kDa. The in vitro pH optimum for the activity of the purified enzyme was 
6.1. Schmidt et al. also determined that the presence of Fe2+ is an important co-factor for 
activity 88. Titus et al. then determined the crystal structure of the active form of HGD to be 
a highly complex and dynamic hexamer, arranged as a dimer of two disk-like trimers, see 
Figure 1.5 stacked base-to-base 84. The N-terminal domain of one protomer interacts with 
the C-terminal domain of the adjacent protomer in the trimeric structure 94. The HGD protein 
can be divided into 4 general structural sections: core, active site, surface and homohexamer 
interfaces 93. Each subunit (or protomer) has a single iron (Fe2+) co-factor, required for the 
binding of HGA. A very intricate network of non-covalent interactions that includes hydrogen, 
salt and hydrophobic bonds are required to maintain the structure of the HGD protomer, 
dimer and the hexamer, with the active site conformation appearing to be highly dependent 
on inter-subunit hydrogen bonding and hydrophobic interactions 84.  
 
Figure 1.5. Structure of the HGD protein.  
The HGD protein is a dimer of two disk-like trimers that stack base-to-base to form a hexamer. The foreground 
surface in this image forms the interface between the trimers in the HGD hexamer. Individual subunits are 
coloured light blue with red side chains, dark blue with light blue side chains and red with dark blue side chains. 
The iron cofactor in each subunit is drawn as a green sphere. Image adapted from Titus et al. 2000 84. 
 
1.2.5.3 Mutations in HGD 
Many different HGD mutations have been identified in AKU, with patients carrying either 
homozygous or compound heterozygous variants of the HGD gene, which is a single copy-
gene. At the same time as the cloning of the human HGD gene, Fernández-Cañón et al. 
showed that the HGD gene was mutated in AKU patients, describing the first reported HGD 
mutations in 1996 90. PCR-amplification was used to amplify the 14 HGD exons for members 
of two different Spanish AKU families, which were then directly sequenced. The heterozygous 
parents of one family both had a missense mutation where 1 nucleotide change caused 
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proline to be substituted by serine in exon 10 at amino acid position 230 (P230S), which is a 
conserved residue between fungal and human HGD 90. The two AKU children of these 
heterozygous parents were homozygous for the P230S mutation, and a healthy third child 
was heterozygous for this mutation. This P230S mutation was also found in the second 
family. One parent was heterozygous with the P230S mutation, whilst the other was 
heterozygous for a different missense mutation, whereby valine is substituted to glycine due 
to a single nucleotide change in exon 12 at amino acid position 300 (V300G), which is also a 
conserved amino acid in fungal HGD 90. Analysis of the children from this family revealed 
three AKU children who were compound heterozygotes for the P230S and V300G mutations, 
with two healthy heterozygous children (1 with the P230S and 1 with the V300G mutation) 
and two healthy children carrying no HGD mutations. This suggested that these mutations 
produce non-functioning alleles as they follow the recessive mode of inheritance pattern. 
The authors confirmed that the P230S mutation was non-functional, by expressing HGD with 
the P230S mutation in Escherichia coli and proving that the protein extract had no HGD 
activity, ultimately confirming that defects in the HGD gene cause AKU 90. 
Since the first reported HGD mutations in 1996, many AKU-causing mutations have been 
described in AKU patients. By 2011, 115 known mutations had been identified in the human 
HGD gene, with exons 6, 8, 10 and 13 showing the highest prevalence of mutations 92. These 
mutations range from missense mutations (66.4%), small deletions (12.2%) and insertions 
(12.2%), causing frameshift and splice mutations, and nonsense mutations (6%). To date, 203 
different human HGD variants have been identified 93,95 which can all be found in the HGD 
mutation database; http://hgddatabase.cvtisr.sk 95. In 2011, there were about 30 AKU 
chromosomes (both chromosomes must be studied as patients can have 2 different 
mutations) where no HGD mutation had been identified, and the authors suggested that the 
mutations may be deep within introns that have not yet been analysed, or within the 
promotor region or other regulatory sequences that have not yet been detected 92. Triplets 
of CCC together with CpG dinucleotides are considered to be mutational hotspots in the HGD 
gene 92,96. 
It has been shown that the delicate structure of HGD is easily disrupted by mutations, mainly 
the missense variants that represent 68% of all known AKU variants, compromising enzyme 
function 92,97. In 2000 when the crystal structure of HGD was determined, more than half of 
the AKU associated mutations were predicted to affect residues located close to the inter-
subunit interfaces, affecting the non-covalent contacts between the subunits of HGD 84. 
Other mutations were predicted to affect co-factor binding, hydrophobic core structure and 
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electrostatic interactions. Therefore rather than AKU mutations having a direct effect on the 
catalytic activity of the enzyme, the majority of AKU mutations are expected to disrupt 
substrate binding and/or catalysis through indirect structural effects and/or misfolding 84. A 
more recent paper in 2016 predicts that missense variants affect enzyme activity by 3 
molecular mechanisms; decreased stability of individual protomers, disruption of protomer-
protomer interactions or by modification of residues in the active site region 97. Ascher et al. 
in 2019 showed that missense variants affecting function were generally associated with 
highly conserved residues 93. 
 
1.2.5.4 Expression of HGD 
It has been known for many years that HGD is expressed in the liver and kidney. La Du et al. 
in 1958 and Zannoni et al. in 1962 were the first to demonstrate the location of HGD activity, 
reporting that HGD activity was not detected in tissue homogenates from the liver and 
kidneys of AKU patients, but was detectable in non-AKU liver and kidney homogenates 4,98. 
Murine HGD was then purified in 1995 from the liver 88. In 1996, Fernández-Cañón et al. used 
northern blot hybridisation using a human cDNA clone as a probe for HGD, and confirmed 
that HGD mRNA was present in the liver and kidney, and also reporting expression in small 
intestine, colon and prostate tissue 90. No HGD expression was found within the spleen, 
thymus, testis, ovary, peripheral blood lymphocytes, heart, brain, placenta, skeletal muscle, 
lung and pancreas 90. More recently, reports also suggest that HGD is expressed in brain tissue 
from both mice and humans using western blotting 99. In addition, further reports suggest 
that HGD is expressed within osteoarticular cells including chondrocytes, synoviocytes and 
osteoblasts, analysed via qPCR and western blotting 100. These reports have not been verified 
by in situ hybridisation or HGD-labelling. 
 
1.2.6 Therapy for alkaptonuria 
Despite AKU being an iconic Mendelian disease first described over a century ago by Sir 
Archibald Garrod, no effective therapy for AKU has emerged until very recently in the past 
decade. A pharmacological therapy has now emerged and has been the subject of a series of 




1.2.6.1 Past and current therapy options 
Until very recently, only palliative treatment such as analgesics and arthroplasty 28 were 
available for AKU, with low-protein diets, ascorbic acid and physiotherapy proven clinically 
ineffective 20,101,102. None of these treatment options tackle the intrinsic cause of the disease.  
Ascorbic acid (vitamin C) has been tried as a therapy for AKU, as the formation of ochronotic 
pigment is thought to involve the oxidation of HGA to benzoquinone acetic acid (BQA), see 
Figure 1.1. Reports showed that vitamin C was able to reduce urinary BQA excretion, but with 
no effect on HGA excretion 101. Another report found no association between vitamin C and 
urinary excretion of HGA 20. There have been no credible studies suggesting that vitamin C is 
clinically effective. Protein restriction, to remove excess tyrosine and phenylalanine from the 
diet, decreasing the flux down the metabolic pathway via HGA, would be difficult to comply 
with long-term and would also require specialist supervision from a dietician to ensure 
adequate growth and nutrition. There has been no systematic study investigating the 
effectiveness of protein restriction in AKU. One study investigated protein restriction in 16 
patients (from medical records) aged 3-27 years, with poor dietary compliance observed, 
which got progressively worse with age 102. Protein restriction in 12 of these patients resulted 
in reduced urinary HGA in children <12 years, with much less effect in adolescents and adults, 
suggesting that protein restriction was beneficial for AKU children and not adults, with the 
regime being questionable and impractical 102. Phornphutkul et al. also reported no 
association between protein restriction and urinary HGA excretion in AKU patients 20. 
Data is lacking with regards to lifestyle counselling in AKU; lifestyle factors such as hobbies, 
activities and occupation that affect joint loading are likely to be important but have not yet 
been addressed 28. Ranganath et al. report that pain control, which is only a palliative 
treatment, is tackled by a variety of drugs as well as physical modalities such as acupuncture 
and nerve blocks, but state that pain for many patients is constant and disabling, and is 
therefore not completely effective 28. Palliative surgery is used to treat at the end stage of 
the disease with regards to the musculoskeletal system, proving to be effective but invasive, 
expensive and not universally available 28. Finally, organ replacement of the liver due to 
cirrhosis 103 or the kidney due to diabetic renal failure 104 has been shown to fully or partially 
improve the metabolic symptoms of AKU in two case studies. Organ transplantation however 
is perhaps unjustified in a disease with a relatively normal lifespan and is therefore not used 
to treat AKU. Gene or enzyme replacement therapy has not yet been investigated in AKU.  
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Most likely due to lack of effective treatment options, many AKU patients reach adulthood 
before the disease is diagnosed, either as it was missed or ignored at an earlier age. Most 
descriptions of the disease until recently were qualitative, with no methodology existing to 
measure disease severity 28. To address this issue within the AKU field, a disease severity 
scoring system has been developed, allowing disease progression to be tracked and patients 
to be compared with one another. This scoring system is termed the ‘AKU Severity Score 
Index’ (AKUSSI), and is based on a quantitative and validated multidisciplinary assessment 
system 105,106.   
Recently, a very promising disease modifying treatment for AKU has emerged, using a drug 
called nitisinone that can block the enzyme responsible for the conversion of 4-HPPA into 
HGA. This is discussed in detail below in section 1.2.6.2.  
 
1.2.6.2 Nitisinone 
Recently there have been trials of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
cyclohexanedione (NTBC), more commonly referred to as nitisinone, in the treatment of AKU 
52. Nitisinone is a triketone herbicide that inhibits the 4-hydroxyphenylpyruvic acid 
dioxygenase (HPPD; E.C 1.13.11.27) enzyme that converts HPPA into HGA (Figure 1.1). It was 
not through drug screening that nitisinone was shown to inhibit HPPA, but through herbicide 
testing, as tyrosine metabolism is important for quinone synthesis in plants required for 
photosynthesis 107. In the early 1990’s, nitisinone was shown to be a potent, reversible 
inhibitor of rat and human liver HPPD 107–109. Hereditary tyrosinaemia type I (HT-1; OMIM 
#276700), is a fatal inborn error of metabolism where fumarylacetoacetate hydroxylase 
(FAH; E.C. 3.7.1.2) deficiency results in liver failure, hepatocellular carcinoma and renal 
tubular dysfunction due to accumulation of FAA 110. With the realisation that tyrosine 
metabolism could be blocked, nitisinone soon became the first effective treatment for HT-1, 
and has been licensed for the treatment of HT-1 since 2002 108,111,112. 
In 1998, Anikster et al. suggested that oral administration of nitisinone in combination with 
some dietary restriction of tyrosine and phenylalanine could be a potential therapy for AKU, 
as it would prevent the production of HGA 113. They suggested the addition of dietary 
restriction as there had been one documented case of a nitisinone-treated HT-1 child 
presenting with corneal crystals, which was resolved with a tyrosine-restricted diet. A mouse 
study the following year reported the use of nitisinone in an AKU mouse model, where a 
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single oral dose of 100 µg of nitisinone resulted in reduced urinary HGA excretion to <2% of 
the pre-treatment level 45. They also demonstrated a dose-responsive reduction in HGA in 
these mice, with nitisinone doses ranging from 1.25-100 µg. They also reported no side 
effects in the liver and kidney after histological assessment. In 2002, the first reported AKU 
patients were treated with nitisinone (0.35-1.4 mg/day, taken orally twice a day) for either 9 
or 10 days, at doses less than half of that given to HT-1 children which is approximately 1 
mg/kg/day 20. They were able to show that nitisinone reduced HGA by 69% or more, providing 
proof-of-principle that HGA production could be reduced 20. Low-dose nitisinone was then 
trialled in 9 AKU patients, starting with 0.35 mg/day (approximately 0.01 mg/kg/day), taken 
orally twice a day for 8 days, which was then increased to 1.05 mg/day (approximately 0.03 
mg/kg/day), taken orally twice a day for 3 months 114. Urinary HGA was effectively reduced 
from an average of 4 g/day to 0.2 g/day, with 1.05 mg/day nitisinone reducing urinary HGA 
by 94%.  
Following these reports of short term use of nitisinone in AKU patients, a 3 year randomized,  
clinical trial of nitisinone was carried in 40 AKU patients (20 nitisinone treated; 20 control) 
over 36 months at the National Institutes of Health (NIH), designed to confirm the 
biochemical efficacy, investigate clinical outcome and to further evaluate safety of nitisinone 
40. Biochemically, this study showed a consistent 95% reduction of HGA in the urine and 
plasma over the course of 3 years with an oral dose of 2 mg nitisinone daily. The primary 
outcome of this study however was not met; no improvement was seen in the total range of 
motion in the hip joint. Although not statistically different, hip rotation was decreased by 
0.31°/year more in the control group than the nitisinone group. In addition, no differences 
were observed in secondary outcome parameters that assessed the musculoskeletal system 
and included spinal flexion, functional reach and 6-minute walk tests. The authors suggested 
that due to the age of the patients in this trial (38-68 years), substantial hip degeneration 
was already present that could not be halted by the reduction in HGA as the damage and 
subsequent degeneration of the joint has already begun. They did however suggest that 
nitisinone needs to be trialled early in life, before the onset of joint changes. 
Although the NIH trial demonstrated that nitisinone could reduce HGA, it was deemed 
inconclusive and ineffective due to the lack of clinical joint improvement. Following this work, 
nitisinone was trialled in an AKU mouse model, where it was shown to reduce HGA and 
completely prevent knee joint ochronosis when given from birth 115,116, see section 1.3.2.4 
for more details. Furthermore, they also showed that ochronosis progression was halted, but 
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not reversed, when nitisinone was given mid-life to AKU mice, and that there was a clear 
dose-response between plasma HGA and the dose of nitisinone 116. This work led to the off-
label use of nitisinone at the National Alkaptonuria Centre (NAC, Liverpool, UK; 
http://www.akusociety.org/aku-national-aku-centre.html)53,117 and to a series of human 
clinical trials (DevelopAKure; http://www.developakure.eu/) investigating the use of 
nitisinone in AKU 52,118, where its use has proven safe and effective.  
The SONIA-1 (Suitability Of Nitisinone In Alkaptonuria 1) trial was a 4 week dose-response 
trial encompassing 5 groups of 8 patients at different nitisinone doses of 0 mg, 1 mg, 2 mg, 4 
mg and 8 mg daily 52. As with the mouse study, a clear dose-response relationship was 
observed between nitisinone and urinary HGA excretion. An 8 mg daily dose of nitisinone 
reduced urinary HGA by 98.8% and reduced serum HGA to <3.1 µmol/L in human AKU 
patients, concluding that nitisinone effectively reduced HGA to a level that is likely to prevent 
ochronosis, with no serious adverse events reported 52. A longer-term 4-year trial then 
followed called SONIA-2, with a group on 10 mg daily nitisinone (n=69) and a group with no 
treatment (n=69) for 4 years, which finished in early 2019. The trial aimed to show whether 
or not nitisinone could not only reduce HGA, but also slow down the progression of AKU, and 
to ensure that it is safe to use. Some preliminary 1-year results have been included on the 
DevelopAKUre website for SONIA-2 and state that after 1-year, urinary HGA levels had been 
decreased on average by 99.5% and serum HGA by 97.5% 
(http://www.developakure.eu/Results [accessed 08/10/2019]). The results of the trial have 
not yet been published, however the trial is deemed to have been successful as SOBI 
(Swedish Orphan Biovitrum) have announced that they are applying to the European 
Medicines Agency (EMA) to obtain market authorisation approval for nitisinone to be used 
to treat AKU.  
Also included in the DevelopAKUre series of clinical trial is the SOFIA (Subclinical Ochronotic 
Features In Alkaptonuria) trial. The SOFIA trial studied 30 AKU patients of different ages to 
identify the earliest age at which ochronosis can be detected in patients, and to identify an 
appropriate age at which nitisinone treatment could begin 119. Ear cartilage biopsies revealed 
that ochronosis, which increases with age, was found in a 20-year-old AKU patient 
microscopically, therefore ochronosis can begin before this age. Macroscopically, eye 
ochronosis was first detected at 22 years from photos, with ear ochronosis not being 
identified until 34 years in photos. Although MRI showed lack of spine and joints changes 
before 30 years, gait however was found to be abnormal early on in the younger AKU 
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patients. Overall, it was concluded that ochronosis starts at an early age before adulthood, 
with the SOFIA trial unable to assess the earliest age, highlighting that a paediatric study is 
required to establish when ochronosis first initiates 119. 
Alongside the DevelopAKUre clinical trials, nitisinone has been used off-licence at the 
National Alkaptonuria Centre (Liverpool, UK; opened in June 2012), where patients aged 16 
years or more receive free specialist care, assessment and off-licence prescription of 
nitisinone in a hospital setting. At the NAC, patients began taking 2 mg nitisinone on alternate 
days for 3 months, followed by daily 2 mg dosing thereafter 53. Patients are initially assessed 
at baseline, day 4, 3 months, 6 months and 1 year after commencing nitisinone, and then 
after 1 year, they are assessed annually. Urinary HGA was shown to decrease by 95.4% by 6 
months, 94.8% after 1 year and 94.1% after 2 years, accompanied by an 83.2% reduction in 
serum HGA, in 28 patients that attended the NAC for 2 years 53.  
An evaluation of 39 AKU patients attending the NAC for 3 years has recently been published, 
using the AKU Severity Score Index (AKUSSI) to assess the severity of AKU and compare the 
rate of progression of the disease between the pre-nitisinone and nitisinone treatment 
phases 117. Biochemically over the 3 years of nitisinone treatment, urinary HGA was 
decreased by 80.2-93.9% and serum HGA by 80.2-89.3% at all follow up visits. Due to some 
patients attending the NAC twice before commencing nitisinone treatment, it was possible 
to assess disease progression over approximately 3 years, without nitisinone treatment (pre-
nitisinone), where a consistent increase in all categories of the AKUSSI score was observed. 
Disease progression was then assessed over the 3-year duration of nitisinone treatment, with 
the rate of progression calculated for 1-year, 2 years and 3 years of nitisinone treatment. The 
sum of clinical, joint and spine AKUSSI features shows that the rate of change of 
score/patient/month was significantly lower for the 3 years post-nitisinone treatment phase 
compared to pre-nitisinone phase (in addition to the 1-year and 2 years treatment phases). 
The data suggests that nitisinone can slow down disease progression in AKU. Furthermore, 
the ear and eye pigment changes were stabilised with nitisinone treatment, suggesting that 
nitisinone, by lowering HGA, can reduce ochronotic pigment formation 117. 
Nitisinone appears to be very effective at reducing both the urinary excretion and circulating 
levels of HGA in AKU patients. Although no serious adverse events have been associated with 
the use of nitisinone in AKU patients in the above reports, plasma tyrosine, which is within 
the normal physiological range in untreated AKU patients 118, has been shown to significantly 
elevate in all nitisinone-treated AKU patients. For example, plasma tyrosine increased from 
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an average of 68 µmol/L pre-nitisinone to 760 µmol/L post-nitisinone with a regular diet in 9 
AKU patients 114. In the SONIA-1 trial, nitisinone treatment for 4 weeks at 1 mg increased 
serum tyrosine from an average of 68 µmol/L to 653 µmol/L, and at 8 mg increased serum 
tyrosine from an average of 55 µmol/L to 813 µmol/L 52. At the NAC after 2 years of 2 mg 
nitisinone treatment, serum tyrosine increased from an average of 42 µmol/L to 594 µmol/L 
53. In addition to increased circulating levels, tyrosine is also increased in the urine, for 
example from 103 µmol/24h to 1071 µmol/24h after 2 years of daily 2 mg nitisinone 53. The 
elevated tyrosine caused by nitisinone, often referred to as nitisinone-induced tyrosinaemia 
or just tyrosinaemia, is discussed below in the next section.  
 
1.2.6.3 Nitisinone-induced tyrosinaemia  
Tyrosinaemia (elevated tyrosine) can cause eye keratopathy and sometimes an eczema-like 
skin rash to occur. In relation to the eye, tyrosinaemia results in corneal lesions (also referred 
to as corneal keratopathy), that results in symptoms such as itching, burning, photophobia, 
corneal erosion and corneal clouding 112. Patients may complain of pain and/or blurred vision. 
 
1.2.6.3.1 Nitisinone-induced tyrosinaemia in animals 
The effect of nitisinone induced-tyrosinaemia has been researched in experimental animals 
in some depth. In all of these experimental animals (mouse, rat, rabbit, beagle dog and rhesus 
monkey), nitisinone has been shown to produce a marked and sustained tyrosinaemia in the 
plasma, which was reversible upon withdrawal of nitisinone 120–122. In the rat, daily nitisinone 
administration was shown to increase plasma tyrosine about 10-fold and to cause corneal 
lesions, described as corneal opacities, with an occurrence of about 75% at 6 weeks of 
treatment with 30 µmol/kg/day, with corneal lesions still observed at a lower doses of 0.3 
µmol/kg/day 120. No differences were observed in plasma tyrosine between rats that 
developed lesions and those who didn’t. Maximum tyrosine levels in these rats were about 
2500 µmol/L in the plasma and about 3500-4000 µmol/L in the aqueous humour of the eye 
(which is 7-fold greater than plasma levels in untreated rats).   
Interestingly in the mouse, despite marked tyrosinaemia, no corneal lesions or opacities were 
observed with nitisinone for 6 weeks at the same dose given to rats 121. Daily dosing up to 
160 mg/kg/day nitisinone produced a maximal tyrosinaemia level of 600-700 µmol/L in the 
plasma, which was about 50% lower than a single 10 mg/kg/day dose that resulted in 1200 
µmol/L tyrosine in the plasma and 2200 µmol/L tyrosine in the aqueous humour of the eye. 
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The authors suggest that the difference between the mouse and rat may be that the mouse 
is able to clear or metabolise tyrosine more efficiently than the rat. This however could not 
be through HPPD if it is blocked by nitisinone; perhaps tyrosine is excreted more efficiently 
by the kidney or perhaps metabolised via a different pathway. 
After the rat and mouse studies, further nitisinone experiments were carried out in the 
rabbit, beagle dog and rhesus monkey 122. As with the rodents, these animals all experienced 
tyrosinaemia that was sustained. A 34% occurrence of corneal lesions were observed with 
daily nitisinone dosing between 0.1-5 mg/kg/day in the dogs for 18 weeks, which is a lower 
occurrence than the rat. The lesions were present in either one eye or both eyes, and were 
often transient, with lesions shown to be reversible with withdrawal of nitisinone. 
Interestingly in the dog, tyrosine in the plasma was elevated to about 1800 µmol/L and to 
about 1400 µmol/L in the ocular fluid, which is lower than the plasma. In contrast to the dog, 
no corneal lesions were observed in the rabbit with plasma tyrosine about 1500 µmol/L or 
rhesus monkey with plasma tyrosine about 1700 µmol/L with daily dosing of 10 mg/kg/day 
nitisinone for 6 or 12 weeks, respectively. In the rabbit tyrosine was increased to 1500 µmol/L 
in the plasma and in the ocular fluid to 1250 µmol/L (in controls it was about 90 µmol/L). 
These animal studies highlight that the presence of corneal lesions due to nitisinone-induced 
tyrosinaemia, is not simply related to the concentration of tyrosine with the ocular fluid or 
blood tyrosine levels, see Figure 1.6 for a comparison between the plasma and ocular 
tyrosine levels in the experimental animals described, excluding the rhesus monkey. Firstly, 
not all of these animals developed corneal lesions despite tyrosinaemia being present in 
them all. The mouse for example had greater ocular tyrosine levels than that of the dog but 
did not develop corneal lesions. Secondly, of those species that did exhibit corneal lesions, 
the lesions were not present in all the animals, nor were they even present in both eyes, for 
unknown reasons. In addition, of the two species that did develop lesions, the rat had greater 
tyrosine levels in the eye than in the plasma, whereas the dog had lower levels of ocular 
tyrosine than the plasma. This data suggests that there must be other unknown factors 





Figure 1.6. Relationship between plasma tyrosine and ocular tyrosine associated with nitisinone treatment in 
experimental animals.  
The box in the bottom left hand corner of the graph represents untreated control animals. The beagle dog and 
rat experience corneal lesions associated with elevated tyrosine, whereas the rabbit and mouse do not experience 
corneal lesions. Graph from 122, that includes data from 120,121.  
 
1.2.6.3.2 Nitisinone-induced tyrosinaemia in patients 
Tyrosinaemia is known to cause keratopathy in nitisinone-treated HT-1 patients 40,53,123 which 
resembles the dermal and ocular symptoms seen in hereditary tyrosinaemia type II (HT-2; 
OMIM #276600), refer to Figure 1.1 124–126. Ocular and skin keratopathy linked to nitisinone-
induced tyrosinaemia has also been reported in AKU patients whose symptoms all resolved 
upon lowering the dose of nitisinone, stricter protein restriction or upon the cessation of 
treatment 40,127–130. Most AKU patients treated with nitisinone, including those with doses up 
to 8 mg daily in the SONIA-1 trial 52 and up to 10 mg daily in the SONIA-2 trial, tolerate 
nitisinone very well, including patients with plasma tyrosine levels >1000 µmol/L 40,129. The 
same finding is also reported in HT-1 patients, that some patients with extremely high 
tyrosine >1000 µmol/L do not present with keratopathy 112,131. The reason why some patients 
experience keratopathy whilst others do not despite having similar tyrosine concentrations 
remains to be elucidated.  
The recommended dose of 1 mg/kg/day nitisinone for HT-1 patients 132 is much higher than 
the doses used in AKU patients, therefore it’s reasonable to expect that more cases of 
keratopathy would be observed in HT-1. Low-dose nitisinone of 0.5 mg daily  in an AKU 
patient however has been shown to induce ocular irritation and photophobia that presented 
before the presence of corneal crystal deposition 129. More worryingly, a recent study has 
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reported the presence of mild corneal keratopathy in an AKU patient on 2 mg nitisinone daily 
that had not reported any ocular symptoms or pain 130. This is an added cause for concern as 
untreated keratopathy could be sight-threatening and may not be detected if patients are 
not having regular ophthalmological assessments. 
In addition to eye and skin keratopathy, it’s important to consider the potential effect of 
nitisinone-induced tyrosinaemia on neural cognition as tyrosine is a precursor to 
neurotransmitters such as dopamine, adrenaline and noradrenaline. Metabolites of these 
neurotransmitters have previously been shown to significantly alter with nitisinone 
treatment in AKU patients (no psychometric data reported)133, although a more recent study 
concluded that alterations in neurotransmitter metabolism due to nitisinone did not cause 
depression in adult AKU patients 134. Long before these neurotransmitter changes in adult 
AKU patients were reported, the potential negative impact of nitisinone on the 
neurodevelopment of children however had arisen from the treatment of HT-1. Since the 
introduction of nitisinone as a treatment for children with HT-1 in 1992 108, numerous reports 
and studies have documented impaired cognitive function (lower IQ, learning difficulties, 
impaired executive functioning, impaired social cognition and decreased motor function and 
speech) associated with nitisinone treatment and the subsequent elevated tyrosine, even 
with protein restricted diets 123,135–139. These neurodevelopmental effects in HT-1 however 
could be due to either nitisinone-induced tyrosinaemia or severe liver failure experienced 
before diagnosis/treatment. With the cause of impaired cognition in HT-1 remaining to be 
elucidated, the off-licence use of nitisinone has been restricted to ≥16 years of age in AKU, 
therefore no data is available in AKU children. 
Neurological symptoms have also been reported in HT-2 and hereditary tyrosinaemia type III 
(HT-3; OMIM #276710) patients where tyrosine is increased 140. HT-2, caused by a deficiency 
of the tyrosine aminotransferase (TAT; EC 2.6.1.5) enzyme (see Figure 1.1)141 is characterised 
by eye and skin lesions that typically develop during the first year of life 126 and has also been 
associated with neurological symptoms however these do not present consistently across all 
patients. HT-3, the rarest form of tyrosinaemia, is caused by HPPD deficiency causing 
neurological impairment and ataxia, with no signs of liver damage, eye or skin symptoms 142. 
Neurological symptoms can include developmental delay, attention deficit and behavioural 
problems, neurological motor issues, and learning difficulties 143. About 75% of cases report 
long term intellectual impairment in HT-3 patients 143. These neurological symptoms have the 
potential to be replicated in nitisinone-treated AKU children due to the HPPD inhibition, 
similar to the metabolic block seen in HT-3 patients. A study comparing HT-1 mice with 
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wildtype mice treated with nitisinone however concludes that the slower learning and 
cognitive differences are caused by HT-1 itself and not nitisinone treatment 144. 
Protein/tyrosine restriction is implemented in conjunction with nitisinone treatment in HT-1 
patients, with <400 µM considered a target for plasma tyrosine levels 132,145. A lack of 
compliance to a protein restricted diet however is commonly associated with the 
development of nitisinone-induced tyrosinaemia and the resulting corneal keratopathy 
events mentioned above, in both AKU and HT-1 patients. The ineffectiveness of protein 
restriction alone in treating AKU was attributed to a lack of dietary compliance as HGA 
differences were seen in younger children with restricted diets in comparison to older 
children who have more input into their diet 102. Phornphutkul et al. suggested that a protein 
restricted diet should be considered as a way of preventing tyrosinaemia, but recognised that 
compliance would be extremely difficult in adult patients 20. Sustaining a protein restricted 
diet can be difficult, expensive, has the possibility of health complications and may alter 
quality of life. Poor adherence to protein supplements coupled with an  inadequate low 
protein diet can lead to essential amino acid and micronutrient deficiency 146,147. Developing 
strategies other than a low-protein diet that can reduce elevated tyrosine, minimising the 
risk of eye, skin and neurological complications, would allow nitisinone-treated patients to 
eat a normal-protein diet. Although advised, no clinical study has investigated the 
effectiveness of dietary restriction at reducing nitisinone-induced tyrosinaemia in AKU. 
Until gene/enzyme replacement therapy becomes an option for AKU, treatment with 
nitisinone to reduce elevated HGA that eventually causes severe joint disease, will be the 
choice for most, if not all AKU patients. As well as preventing eye and skin keratopathy, 
finding a strategy to lower tyrosine levels to avoid the possible neurological issues associated 
with tyrosinaemia will be a vital step that may allow the prescription of nitisinone to AKU 
children. 
One possible strategy that could be applied to nitisinone-treated AKU patients is lowering 
the consumption of protein in the diet to decrease tyrosine and phenylalanine intake in order 
to reduce circulating tyrosine. As already mentioned above however, a low 
tyrosine/phenylalanine diet would most likely be ineffective in AKU patients due to 
compliance difficulties in adults 20,102, and would require expert dietetic intervention in adults 
and particularly in children in order to balance the nutritional requirements of growth and 
development with the possibly damaging effects of tyrosinaemia. An intervention that allows 
a normal protein diet to be consumed but prevents tyrosine/phenylalanine intake would be 
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much more desirable for both adults and children. Here in chapter 5, the effectiveness of 
decreasing dietary tyrosine/phenylalanine is investigated in mice by removing tyrosine and 
phenylalanine from the diet. If restriction of dietary tyrosine is effective, strategies that 
prevent the absorption of tyrosine from the intestine into the bloodstream could allow a 
normal protein diet to be consumed with nitisinone treatment. Potential strategies could 
involve the consumption of a therapeutic product that binds dietary tyrosine preventing its 
absorption into the circulation or a tyrosine-degrading enzyme (such as TAL discussed in the 
next section) that could break tyrosine down within the intestinal lumen. Although 
phenylalanine levels are not a concern with nitisinone treatment, phenylalanine restriction 
is also investigated in mice here to evaluate its effectiveness at reducing tyrosinaemia, as 
extensive research into a phenylalanine-reducing therapeutic enzyme called PAL exists for 
the treatment of phenylketonuria (PKU; OMIM #262600). If phenylalanine restriction is 
effective at reducing tyrosine, this PAL enzyme could potentially be applied to nitisinone-
induce tyrosinaemia in AKU. This PAL enzyme, along with its tyrosine analogue TAL, are 
introduced and discussed in the next section. 
 
1.2.6.4 Exogenous enzyme therapy: PAL/TAL 
A potential solution to nitisinone-induced tyrosinaemia in AKU, and also HT-1, is to prevent 
tyrosine from accumulating by removing or breaking down tyrosine within the body, by using 
an exogenous tyrosine-degrading enzyme. This concept of using an exogenous enzyme to 
breakdown a metabolite that is increased above normal physiological levels, in this case using 
an enzyme called tyrosine ammonia lyase (TAL; EC 4.3.1.23) to break down tyrosine, has 
arisen from research investigating the breakdown of phenylalanine in the metabolic disease 
PKU. A bacterial enzyme called phenylalanine ammonia lyase (PAL; EC 4.3.1.24) has been 
developed into a therapeutic that decreases phenylalanine in the blood, which is abnormally 
high in PKU. The PAL and TAL enzymes are both members of the aromatic amino acid 
ammonia lyase family, and are discussed below. 
 
1.2.6.4.1 Aromatic amino acid ammonia lyases 
Tyrosine ammonia lyase (TAL) catalyses the deamination of tyrosine to p-coumaric acid and 
phenylalanine ammonia lyase (PAL) catalyses the deamination of phenylalanine to trans-
cinnamic acid. TAL and PAL are part of a small group of enzymes called the aromatic amino 
acid ammonia-lyase family, which also includes histidine ammonia lyase (HAL; EC 4.3.1.3), 
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which all deaminate aromatic amino acids, with other classes of ammonia-lyases also existing 
148. A characteristic feature of the PAL/TAL/HAL enzyme family is the presence of a highly 
electrophilic co-factor named 4-methlidene-imidazole-5-one (MIO), produced by the post-
translational condensation of a Ala-Ser-Gly amino acid group within the enzyme 149. TAL is 
quite rare in nature when compared to PALs. PALs from bacteria and plants are responsible 
for the production of cinnamic acid which is further metabolised to molecules such as 
coumarins and flavonoids in plants through the phenylpropanoid pathway 
(phenylpropanoids are a diverse group of compounds derived from the carbon skeleton of 
phenylalanine), and antibiotic compounds in bacteria 150. In plants, phenylalanine and 
cinnamic acid are important precursors for the production of lignin and other secondary plant 
metabolites, and it was in 1961 that PAL was first isolated 151. PAL has since been researched 
quite extensively for its use in both commercial and therapeutic settings, as a biocatalyst for 
chemical production and its use as an enzyme substitution therapy (EST) in PKU. 
TALs may be less common due to the specialised role of p-coumaric acid as a co-factor for 
photoactive yellow protein in Rhodobacter bacteria 152 and the role that coumaric acid plays 
as a precursor to caffeic acid in the synthesis of saccharomicin antibiotics 153. A TAL enzyme 
was first discovered in 2001 by Kyndt et al. 154 in the bacterium Rhodobacter capsulatus. 
Understanding the journey of PAL to be used as an EST for PKU is important when considering 
the use of TAL for tyrosine breakdown in nitisinone-treated AKU patients, and possibly even 
HT-1 patients, due the synonymous nature of phenylalanine breakdown by PAL that will have 
worked through challenges and issues likely to be experienced during the application and 
development of a therapeutic TAL enzyme.  
 
1.2.6.4.2 PKU 
PKU is an autosomal recessive, inborn error of metabolism, caused by deficiency of 
phenylalanine hydroxylase (PAH; EC 1.14.16.1) that is responsible for the breakdown of 
phenylalanine to tyrosine 155. PKU is characterised by increased blood phenylalanine levels, 
with classical PKU classed as phenylalanine >1200 µmol/L, and is associated with cognitive 
dysfunction, memory impairment and behavioural and psychiatric problems 156,157. PKU is 
mainly treated with strict dietary restriction of phenylalanine, starting as early in life as 
possible to minimise neurocognitive abnormalities developing and continued throughout 
life, usually by consuming a low protein diet with phenylalanine-free amino acid 
supplements. As described for HT-1 and AKU, compliance with a low protein diet is a problem 
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in PKU patients, with phenylalanine levels often rising beyond optimal target ranges 158. Other 
treatment options have therefore been investigated for PKU. PAH activity requires the BH4 
(tetrahydrobiopterin) co-factor; an orally active, synthetic form of BH4 has been trialled in PKU 
patients that respond to a BH4 loading test, which is estimated to be a potential treatment 
option for 30-50% of PKU patients, although these patients tend to have a more mild form of 
PKU 159. For BH4 non-responders, which is proposed to be due to lack of residual PAH activity 
caused by different PAH mutations, enzyme replacement therapy is a potential treatment 
option 155. Enzyme replacement therapy with PAH, which is mainly found in the liver, has 
been challenging and so far, not successful. PAH requires its co-factor BH4, oxygen and Fe2+ 
in order to convert phenylalanine to tyrosine. EST with the phenylalanine-degrading, 
prokaryotic enzyme PAL has proved to be a more promising therapy for PKU, as PAL can be 
produced using a bacterial expression system on a large scale, does not require a co-factor 
and its phenylalanine-degradation product is not toxic. 
 
1.2.6.4.3 Development of PAL as a therapy for PKU 
The first attempt to treat PKU with PAL occurred in 1980; PAL extracted from yeast was 
loaded into a semi-permeable gel capsule and administered orally to healthy volunteers after 
a protein meal, and to an untreated PKU patient where it reduced blood phenylalanine by a 
quarter in the patient 160. If oral PAL administration was to succeed, the need to protect PAL 
from proteolytic degradation by digestive enzymes was recognised 161,162, in addition to the 
pH of the intestine typically being 6.0-7.4, with PAL having an optimal pH of 8-9 163. It was 
demonstrated in humans that cinnamic acid, the product of phenylalanine deamination, was 
eliminated as hippuric acid in the urine with benzoic acid as an intermediate compound, and 
that cinnamic acid had very low toxicity and no embryo-toxicity in laboratory animals 164,165. 
It was concluded that the conversion of phenylalanine by PAL to cinnamic acid (and 
ammonia) was harmless and paved the way for more research into PAL as an EST for PKU.  
Work in the 1970’s then investigated non-oral PAL administration in order to directly reduce 
circulating phenylalanine in PKU. The first challenge was the highly immunogenic nature of 
non-mammalian PAL protein; the biological half-life of Rhodotorula glutinis (yeast) PAL was 
approximately 21 hours in several mammalian species such as the mouse, rat and monkey 
after a single injection, with repeated administration shortening the biological half-life, likely 
due to clearance/inactivation by the immune system 166. A new administration method was 
subsequently tested; PAL was immobilised into a multi-tubular enzyme reactor within a 
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porous shell, and used as an extra-corporeal device in which blood could be shunted through 
167. This resulted in an 82% reduction in circulating phenylalanine in dogs with experimental 
hyper-phenylalaninaemia (HPA). Hollow-fibre enzyme reactors with immobilised PAL were 
then designed and tested in vitro 168,169, followed by in vivo studies in dogs and monkeys with 
experimental HPA 170. After 2 hours, an 84% phenylalanine reduction was observed, with no 
increase in blood urea nitrogen from ammonia generation, no cinnamic acid toxicity and no 
immune response with repeated application of PAL-reactors in vivo. It was suggested that 
immobilised PAL enzymes in extracorporeal shunts could be used temporarily in PKU patients 
struggling to control excess phenylalanine, in situations such as fever, infection or pregnancy 
170. The PAL enzyme reactor was subsequently applied to a PKU patient, with three rounds 
over 5.5 hours reducing phenylalanine by 30% from 1820 µM to 1270 µM, but was considered 
too invasive for patient use 167. 
Oral PAL administration was re-visited, with an attempt to protect PAL from proteolysis by 
immobilising PAL into “artificial cells” with a semi-permeable micro-encapsulation technique 
171, however activity was only 20% of the free PAL enzyme 172. The goal was to use this 
encapsulated PAL to reduce phenylalanine in the gastrointestinal tract, therefore its activity 
was tested at a range of pH levels in vitro to assess the feasibility of oral dosing, through 
which varying pH levels would be encountered 173. The optimum pH for both free and 
encapsulated PAL was 8.5, with encapsulated PAL being more active at lower pH levels than 
free PAL. Daily oral dosing of 5U encapsulated PAL in rats with experimental HPA reduced 
blood phenylalanine by 65% at day 2, and was not significantly different to normal rats by 7 
days of dosing 173. Similar artificial cell experiments then found comparable results, with 5U 
PAL reducing phenylalanine to normal levels with a 75% reduction in 6 days 174, in addition to 
a reduction in intestinal phenylalanine 175. This PKU model however reported fluctuations in 
phenylalanine levels in control and treated rats 174. When tested in a true genetic PKU mouse 
model (PahENU2/ENU2)176 with naturally high rather than artificially elevated phenylalanine 
levels, no significant decrease in phenylalanine was observed 177. 
At this point, PAL was not available in sufficient quantities and at reasonable cost. Sarkissian 
et al. therefore used a “recombinant” PAL gene from Rhodosporidium toruloides (red yeast; 
RtPAL) 178 and used an E. coli 179 expression system to obtain large amounts of RtPAL enzyme, 
and tested it in PKU mice 180. Intra-peritoneal (IP) injections of RtPAL (2, 20 and 200U) showed 
reductions in phenylalanine and a dose response, but with high variability. They then showed 
that PAL activity was abolished by proteolytic digestive enzymes but could be protected by 
retaining PAL within the expression E. coli, which could in vitro reduce phenylalanine by 76% 
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in vitro. With the addition of chymotrypsin and intestinal fluid to PAL retained in E. coli in 
vitro, phenylalanine was still reduced by 72% and 66%, respectively. Proof of pharmacological 
principle was then shown, with a single IP PAL injection in PKU mice significantly reducing 
plasma phenylalanine, persisting for 24 hours. Proof of physiological principle was then 
demonstrated by oral gavage of 25U PAL retained in E. coli, combined with inactivation of 
gastric acidity by sodium bicarbonate, which lowered plasma phenylalanine by 31% in 1 hour 
and 44% in 2 hours. To achieve similar phenylalanine reductions with unprotected PAL, 8-
fold more PAL (200U) was required, combined with aprotinin which is a protease inhibitor, 
highlighting the importance of protease protection 180. 
The aim then shifted to developing an injectable EST for PKU. In order to protect PAL from 
immune recognition and to increase its circulating half-life, chemical modification of PAL was 
investigated, attaching polyethene glycol (PEG) molecules to the PAL protein, in addition to 
creating and testing mutant PALs 181–185. PEGylation of RtPAL (R. glutinis PAL PEGylation was 
not successful) improved its effectiveness in vitro, with no antibody binding at greater 
PAL:PEG ratios when exposed to mouse antiserum 181. In vivo, unmodified PAL had reduced 
effectiveness with repeat subcutaneous injection into PKU mice (PahENU2/ENU2), whereas 
highly PEGylated PAL showed prolonged phenylalanine reduction, with low antibody 
production in PAL:PEG 1:16 at 42 days, indicating suppression of the immune response 181. 
PEG-PAL conjugates were generated with different formulations and the most promising 
screened for immuno-reactivity against PAL-antibodies, with in vitro data demonstrating that 
PEGylation abolishes immunogenicity 182. The best formulations were then tested in the PKU 
mouse, including PEG-PAL conjugates with varying degrees of linear 5- and 20-kDa 
PEGylation. The 20 kDa linear PEG:PAL 1:16 formulation was the most effective at reducing 
phenylalanine, with all PEG-PAL conjugates being as active as the unmodified enzyme, with 
minimal loss of catalytic efficiency with repeated injections 182.  
Screening of wildtype and mutant PAL proteins from different organisms (Anabaena 
variabilis (Av), Nostic punctiforme, Petroselinum crispum and Rhodosporidium toruloides (Rt)) 
in the PKU mouse model found that subcutaneously delivered PEGylated forms of AvPAL 
displayed a higher efficiency and slower clearance rate than PEGylated RtPAL, and was 
superior over other species for other characteristics such as greater thermal stability 184. 
Subcutaneous injection of mutant AvPAL effectively lowered blood and brain phenylalanine 
in PKU mice over a 90 day trial period, coupled with reduced PKU manifestations and 
enhanced animal health 184. Phenylalanine reduction was both dose- and load-dependent, 
with a higher dose and lower frequency of twice weekly dosing found to be more effective 
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than lower, daily dosing. This mutant (C503S and C565S mutations to reduce protein 
aggregation) and PEGylated AvPAL (mutant AvPAL) was then shown to have an optimal pH 
at 7.5-8.5, with both mutant AvPAL and RtPAL shown to retain activity after a 10 minute 
exposure to a broad pH range 185. This highlights the possibility that if protected from 
proteases, these PAL enzymes could survive the low pH of the stomach and be active in the 
intestine, which in a fasting state is approximately pH 1.8 and rises to 5.4-6.2 immediately 
after a meal 186. They also identified protease sites for trypsin and chymotrypsin that could 
be engineered in the future for oral administration, although this was not pursued, for both 
mutant AvPAL and RtPAL, with neither showing susceptibility to bloodstream proteases 
thrombin and factor X, beneficial for intravenous administration 185. 
After this series of experiments just described, the mutant PEGylated AvPAL was chosen to 
enter human clinical trials 184. BioMarin Pharmaceutical (a biotechnology company interested 
in enzyme replacement therapies) subsequently applied to the Food and Drug Administration 
(FDA) for approval to begin human trials with PAL in PKU. A phase I, multicentre clinical trial 
evaluated the safety, tolerability and efficacy of rAvPAL-PEG (recombinant A. variabilis PAL 
conjugated with PEG) in PKU patients 187. Single subcutaneous injections of rAvPAL-PEG were 
administered in escalating doses from 0.001-0.1 mg/kg to 25 PKU adults that had blood 
phenylalanine >600 µmol/L, and followed up for 6 weeks. Treatment was effective in the 
patients receiving the highest dose, with a 58% reduction in phenylalanine observed for up 
to a week. It was concluded that the PAL was safe and well tolerated, despite 80% 
experiencing an adverse event, with injection-site reactions and dizziness reported most. 
After separate parent phase II trials investigating rAvPAL-PEG (renamed pegvaliase) dosing 
188,189, a longer term phase II extension study was carried out 190, evaluating long-term 
efficacy, safety and immunogenicity. Pegvaliase was either continued at the same or at a 
higher dose used in the parent study ranging between 2.5–375 mg/week or between 0.001–
5 mg/kg/week, with doses and/or frequency adjusted for each patient to achieve a plasma 
phenylalanine concentration between 60–600 µmol/L. Pegvaliase was administered 
subcutaneously, rotating the site of injection, with a mean administration rate [range] of 2.5 
[1.0-5.0] days/week in the parent study and 4.5 [1.0-6.9] days/week in the extension study. 
Overall mean treatment duration was approximately 3.4 years; 66% received pegvaliase for 
>2 years and 38% >4 years. Mean plasma phenylalanine was reduced by 60% at week 48, and 
72% at week 120, with protein intake remaining relatively constant. Mean plasma 
phenylalanine decreased as mean pegvaliase dose increased, with both then remaining 
relatively stable from week 48–264. All participants reported at least one adverse event with 
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the most common being injection site reaction 72.5%, injection site erythema 67.5%, 
headache 67.5% and arthralgia 65.0%, with 12.5% and 76.3% of patients limited to mild and 
moderate adverse events, respectively, with serious adverse events experienced by 11.3%. 
One patient experienced anaphylaxis. All patients developed a sustained PAL antibody 
response, and a transient anti-PEG response. Hypersensitivity events were most frequent in 
the first 24 weeks then decreased to baseline levels near the end of the study. Differences in 
immune response is likely the reason why a variety of PAL doses in different patients were 
needed to achieve specific phenylalanine levels; patients with a lower antibody response had 
a greater phenylalanine reduction in early treatment.  
Phase III clinical trials were then carried out called PRISM-1 and PRISM-2 191,192. PRISM-1 
involved pegvaliase-naïve patients receiving either 20 or 40 mg/day pegvaliase via 
subcutaneous injection, using an induction (one weekly dose), titration (administered 2-7 
days/week) and maintenance dosing regime, with daily dosing in all patients once the 
maintenance dose was reached. PRISM-2 involved continued pegvaliase treatment as an 
extension of previous trials, using doses of 5-60 mg/day, with daily subcutaneous 
administration. Out of 262 patients, mean blood phenylalanine was 1232.7 µmol/L at 
baseline, 564.5 µmol/L at 12 months and 311.4 µmol/L at 24 months, with improved 
neuropsychiatric outcomes associated with reduced phenylalanine. Adverse event findings 
similar to the previous trials were reported, with all participants reporting at least 1 adverse 
event, with overall adverse events decreasing in number over treatment duration. Serious 
adverse events still occurred, including anaphylaxis (2.7%) and hypersensitivity events 
(4.6%). The adverse events were considered manageable in most patients. In May 2018, 
pegvaliase was approved by the US FDA under the product name PALYNZIQ®. In May 2019, 
the EMA issued marketing authorisation for pegvaliase throughout the European Union for 
the treatment of PKU in adults and adolescents from 16 years of age.  
 
1.2.6.4.4 TAL and tyrosinaemia 
The use of PAL to degrade phenylalanine in PKU raises the question as to whether or not a 
similar strategy could be employed in nitisinone-induced tyrosinaemia in AKU patients, using 
TAL to degrade tyrosine. Despite the extensive research into PAL, TAL research is much 
further behind due to TAL enzymes being much rarer than PAL enzymes, with the first TAL 
discovered in 2001 154 approximately 40 years after the first PAL 151. If a TAL-based 
therapeutic is considered a plausible tyrosine-reducing strategy, the challenges and issues 
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documented throughout all stages of PAL development, which are likely to be applicable to 
TAL, should all be considered and evaluated carefully. 
 
1.2.7 What remains to be identified in alkaptonuria for successful treatment? 
Although the use of nitisinone in AKU patients has so far been very successful, nitisinone can 
only treat, not cure the disease. Tyrosinaemia, as discussed in section 1.2.6.3, is a 
consequence of nitisinone therapy that needs to be tackled in order to decrease or abolish 
the occurrence of keratopathy, and is on-going research. The next big step and ultimate 
treatment for single-gene diseases like AKU would be to treat the underlying genetic cause 
with gene/enzyme replacement therapy. Treatment of other inborn errors of metabolism 
related to the phenylalanine/tyrosine pathway by enzyme replacement has been attempted 
with some success 193. In the past decade, liver-directed gene therapy has emerged as a 
promising alternative to transplantation in monogenic liver disorders such as AKU 194. Gene 
therapy for AKU however has not yet been investigated. Before such work begins, there are 
some important questions however that must be addressed. It’s currently unknown how 
much HGD (via enzyme or gene therapy) must be replaced in order to rescue the disease and 
whether HGD expression outside of the liver can affect the phenotype. 
 
1.3 Animal models of disease 
Model organisms such as fruit flies, worms, zebra fish and rodents have been used for many 
years to study elements of human disease. Many genes are conserved between species, in 
addition to many basic processes such as metabolism, cell division and growth. The house 
mouse (Mus musculus) is the most common laboratory model of human disease due to easy 
and cost-effective maintenance and breeding, similarities to humans in terms of 
phylogenetics, anatomy and physiology, and the ability to manipulate the genome. The 
ability to genetically modify the DNA of the mouse genome by manipulation technologies to 
create transgenic lines such as knock-in and knockout mouse models accelerated the use of 
mouse models in research, with thousands of strains now available.  
 
1.3.1 Mouse model strategies 
Mendelian diseases, such as AKU, are caused by a mutation in single gene, however the mode 
of inheritance can vary. Single-gene diseases for example can be autosomal recessive (i.e. 
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cystic fibrosis) requiring two mutated alleles or autosomal dominant (i.e. Huntington’s 
disease) requiring one mutant allele. Genetic diseases can also be X-chromosome linked 
dominant (i.e. hypophosphatemia rickets) requiring one mutant gene on the X-chromosome 
and X-chromosome linked recessive (i.e. haemophilia) requiring one mutant X-chromosome 
in males and two mutant X-chromosomes in females. AKU is an autosomal recessive disease 
therefore both Hgd alleles need to be mutated to induce the AKU phenotype in mice. There 
are two main ways of creating a model of a genetic disease; directed and disease driven 
approaches, also known as reverse genetics, whereby a gene of interest is targeted, or non-
directed and mutation based approaches, also known as forward genetics, whereby mice 
undergo random mutagenesis and subsequently screened for phenotypes 195,196.  
 
1.3.1.1 Non-directed approaches (forward genetics) 
1.3.1.1.1 Chemical mutagenesis 
Ethylnitrosourea (ENU) mutagenesis is the most common mutagen used for large-scale 
phenotyping programs 197,198. ENU acts as a point mutagen by transferring its ethyl group to 
oxygen or nitrogen radicals in DNA, resulting in mispairing and base-pair substitutions to 
occur at high rates in germ cells, particularly in spermatogonial stem cells. Within a single 
gene locus, the mutation frequency can reach up to 6 x 10-3 199. Point mutations can induce 
different types of mutated alleles, such as loss-of-function alleles, hypomorphic alleles that 
have reduced gene function, antimorphic alleles that antagonize the gene’s normal function 
and gain-of-function alleles 198. Dominant mutations can be screened in F1 generation 
screening, with recessive mutations identified among F3 offspring (heterozygous F2 females 
can be backcrossed to F1 males). 
 
1.3.1.1.2 Insertional mutagenesis 
Gene trap screens are another type of mutagenesis strategy, termed insertional 
mutagenesis,  whereby phenotypes are identified after transfecting embryonic stem (ES) cells 
with a gene trap vector that can randomly integrate into the genome, causing mutations 195. 
The mutant ES cells would then need to be re-introduced into an early-stage embryo, where 
they can contribute to the formation of the mouse. As with ENU mutagenesis, the offspring 
would require screening to identify a phenotype, which can be difficult and expensive, 
especially for recessive mutations that require F3 progeny. The inclusion of a promotorless 
reporter gene, typically β-galactosidase, into the gene trap can aid identification of the 
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mutant gene 200. If inserted in an intron in the correct orientation and reading frame, a fusion 
transcript is formed between the endogenous interrupted gene and the reporter gene in the 
gene trap, mimicking its endogenous expression. 
 
1.3.1.2 Directed approaches (reverse genetics) 
Sequencing of the mouse (2002) and human (2001) genomes 201,202 led to an international 
effort to determine the function of protein-coding genes 203, with particular attention drawn 
towards inherited diseases (https://www.omim.org/statistics/geneMap) of which there are 
over 6,500 described, using mouse models to determine the genetic basis of these diseases. 
It was therefore more efficient and necessary to target specific genes in the genome of mice, 
rather than use a mutagenesis approach. 
Once a disease gene has been identified, characterised and cloned, there are various 
methods that can be applied to create a genetic disease model, allowing the phenotypic 
consequences of a specific genetic mutation to be studied. In addition to genome modifying 
capabilities, the ability to harvest and grow mouse ES cells in culture that retain the ability to 
contribute to the formation of a mouse upon reintroduction into an early-stage embryo has 
established the mouse as the leading mammalian model system for studying the effect of 
genes in vivo 200. Targeting a specific gene in ES cells with mutations has become the method 
of choice to create genetic models in mice, and is termed gene targeting.  
Homologous recombination is a common technique used to precisely insert modified DNA 
into the mouse genome, usually designed to knockout a gene by replacing or deleting one or 
multiple coding exons 196. At the very simplest, an artificial exogenous fragment of DNA in a 
gene targeting vector usually with a selectable marker such as an antibiotic resistance gene 
that allows selection of modified ES cells will have regions at either end that are homologous 
to endogenous gene of interest, allowing an exchange of the DNA between the two 
homologous regions, transferring the exogenous DNA into the host gene. This method can 
be used to delete a gene, remove exons, add in a gene and also introduce point mutations 
by modifying individual base pairs.  
 
1.3.1.2.1 Transgenic mice 
Transgenic mice can be generated via a simple random integration transgenic approach, 
whereby an exogenous gene is microinjected into the pronuclei of a 1 cell embryo which then 
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should incorporate into all future cells of the mouse 195,204. The injected DNA construct inserts 
randomly into the genome, at one or more genetic loci, either as single or multiple copies, 
all of which can affect the level of gene expression. This approach is a targeted mutagenesis 
approach as a specific gene has been introduced and used to study simple overexpression. 
Although a gene of interest is injected, there is no control over the integration of the 
exogenous gene with this method, hence why targeting a specific gene in ES cells is a 
preferred method. 
 
1.3.1.2.2 Gene targeting 
Gene knockouts are the most common type of genetic model for studying disease. Using 
homologous recombination in ES cells to introduce a deletion of an important exon, or by a 
gene trap which disrupts a gene, creates a ubiquitous knockout where the gene is 
deleted/interrupted in every cell. The modified ES cells can then be introduced to an early-
stage embryo and incorporated into the germ line 195,196. This technique was then followed 
by the introduction of conditional alleles, whereby a gene could be deleted in a specific tissue 
and/or at particular time.  
Currently, the most common technique to manipulate alleles to obtain conditional, tissue-
specific and/or time-dependant deletion, is the use of the site specific recombination via the 
bacterial Cre/LoxP system 205,206, or the Flp/FRT system 207 from yeast 204. Both LoxP and FRT 
sequences are not found within the mammalian genome. Exogenous LoxP (34 bp: 
ATAACTTCGTATAATGTATGCTATACGAAGTTAT 208) or FRT (34 bp: 
GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC 209) sequences can be introduced either side 
of a piece of DNA such as a coding exon in a gene of interest in the mouse genome, to 
generate a floxed allele or FRT-flanked allele, respectively, that does not affect transcription 
of the target gene. Cre recombinase or Flp recombinase enzymes can then recombine the 
LoxP/FRT sequences to excise the flanked target sequence or invert the sequence, see Figure 
1.7. To achieve Cre recombination, which is the more common method, you need double 
transgenic mice that are genetically modified with a floxed target gene, generated by 
homologous recombination in ES cells, and must also express a Cre recombinase enzyme. 
Creating a floxed allele in an ES cell that transmits to the germ line results in every cell 
containing the floxed allele. If Cre is present under a ubiquitous promoter, the gene will be 





Figure 1.7. Cre/LoxP recombination.  
(A) LoxP sites placed head-to-tail around a target sequence, in this case an exon, will cause the floxed sequence 
to be deleted by Cre recombinase. (B) LoxP sites placed head-to-head around a target sequence, in this case an 
exon, will cause the floxed sequence to be inverted by Cre recombinase. The mechanism of Flp/FRT recombination 
is the same as Cre/LoxP recombination.  
 
Restricting the expression of the Cre recombinase enzyme using a tissue-specific or cell-
specific promotor can restrict the deletion of the allele to a specific tissue or cell type. 
Different promotors can also be active at different developmental stages, allowing deletion 
of the floxed gene to occur after birth for example, which can be useful for genes that are 
embryonically lethal. Alternatively, Cre enzymes can be under the control of an inducible 
promoter, such as a drug responsive promotor, therefore deletion can also be induced at any 
developmental stage once the drug is given. An example of this is Cre ER where the Cre is 
fused to the oestrogen receptor (ER) and modified by a mutation to respond to tamoxifen 
and not oestrogen 210. Once a double transgenic is given tamoxifen, the Cre is translocated 
to the nucleus where it can cleave floxed DNA, usually a critical coding exon to disrupt 
expression of the gene, creating a null allele via a deletion 204.  
 
1.3.1.2.3 Knockout-first strategy 
More recently, the International Knockout Mouse Consortium (IKMC), with the  European 
Conditional Mouse Mutagenesis (EUCOMM) and the National Institutes of Health Knockout 
Mouse (KOMP) programs suggested another gene targeting strategy called knockout-first, 
which combines both gene trapping and conditional gene targeting 211. The first allele 
generated is a LacZ-tagged knockout-first allele, which has an FRT-flanked gene trap vector 
inserted into an intron of a gene, see Figure 1.8A. The vector has a splice-acceptor sequence, 
then a LacZ reporter gene followed by a polyadenylation stop sequence, creating an in-frame 
fusion transcript of the gene of interest up to the position of the target vector that then 
terminates at the stop sequence, disrupting the gene. The LacZ gene is expressed as a fusion 
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transcript with the gene of interest but not as a fusion protein, due to an internal ribosome 
entry site (IRES) element between the splice acceptor site and the LacZ sequence, allowing 
independent translation.  Downstream of the gene-trap cassette, the next exon is flanked by 
LoxP sites (floxed), but is usually not transcribed, although in some target genes low-level 
transcription may after the gene trap (hypomorphic mutation). This knockout-first allele is 
inserted into ES cells via homologous recombination, and will be present in every cell, 
therefore the allele is disrupted in every cell in which it is usually expressed. 
 
 
Figure 1.8. Knockout-first strategy.  
A shows a knockout-first allele. A gene trap vector, flanked by FRT sites has been inserted into the intron of a 
gene. Within the gene trap vector is a splice-acceptor (SA), a LacZ reporter gene and a polyadenylation (pA) 
sequence that prematurely terminates transcription of the target gene. The LacZ gene is expressed as a fusion 
transcript with the start of the target gene, but not as a fusion protein due to the presence of an internal ribosome 
entry site (IRES) between the SA and LacZ. Adjacent to the gene trap, the next downstream exon is flanked by 
LoxP sequences. This allele would be interrupted by the gene trap. Cre recombinase can then convert this allele 
in A to become a null, LacZ-tagged allele as shown in B, by removal of the floxed target exon. Flp recombination 
of the allele in A results in removal of the gene trap vector, leaving behind a floxed target exon, with the gene 
being transcribed as normal (C). Exposure of the conditional allele (C) to Cre then creates a null allele (D) by 
Cre/LoxP recombination that removed the floxed target exon.  
 
This knockout-first allele can then be modified by either Cre of Flp recombinase 211. Cre 
recombination would remove the floxed exon, resulting in a null, LacZ-tagged allele (Figure 
1.8B). Flp recombination on the other hand would result in a conditional allele (Figure 1.8C), 
where the gene trap has been removed, leaving a residual FRT site and the floxed 
downstream exon; this allele is transcribed as normal. The conditional allele can then be 
converted to a null allele (Figure 1.8D) by Cre recombination due to the presence of LoxP 
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sites that are usually flanking a critical exon. Any suitable Cre line can be used to obtain 
tissue-specific and/or time-specific deletion of the gene. This knockout-first strategy is 
versatile and has been to generate thousands of gene knockouts in ES cells through targeted 
mutagenesis programs such as the International Knockout Mouse Consortium 212, which was 
reported to have 17,473 targeted and trapped alleles for protein-coding genes in 2012.  
 
1.3.1.2.4 RNA interference 
The introduction of double-stranded RNA (dsRNA) that is homologous in sequence to a 
specific gene can results in its post-transcriptional silencing, first reported in 1998 in C. 
elegans. 213. This type of gene silencing is termed RNA interference (RNAi). An enzyme called 
Dicer processes dsRNA into a smaller dsRNA fragments termed small interfering RNAs 
(siRNAs), which are incorporated into a nuclease complex called RISC (RNA-induced silencing 
complex) 204. The RISC finds homologous target mRNAs using a strand of the siRNA as a guide 
strand, and then cleaves the target mRNA. It was first shown that siRNA could knockdown 
gene expression in mice in 2003 214. RNAi models are advantageous as the method is much 
more rapid and inexpensive in comparison to generating knockout mice as described in the 
above sections. On the other hand, the knockdown of genes via RNAi can be variable and 
transient, and can therefore be less reliable and reproducible than a knockout model. The 
RNAi can either be injected into mice or an RNAi expression cassette could be engineered 
into the genome of mice. 
 
1.3.1.2.5 Other methods for genetic manipulation of DNA 
In recent years, a series of programmable nuclease-based genome editing technologies have 
been developed, where site-specific nucleases are used to introduce specific DNA breaks in 
the genome 215. The DNA break can then be repaired either by homology directed repair 
(HDR) mechanisms or via non-homologous end joining (NHEJ), resulting in genome editing. 
Programmable nucleases that use proteins to recognise the target DNA sequence, which 
require new proteins to be engineered each time, which is expensive and labour-intensive, 
include meganucleases, zinc-finger nucleases and transcription-activation-like effector 
nucleases. More recently, the clustered regularly interspaced short palindromic repeat 
(CRISPR) associated proteins 9 (CRISPR/Cas9) technology has been developed that uses RNAs 
for site recognition 216. An engineered single guide RNA is used to find the target DNA and 
used to introduce a double strand break by the Cas9 endonuclease protein. CRISPR/Cas9 
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could be used to generate models of disease by introducing mutations into genes, and 
perhaps more importantly, it can be used as a tool for gene therapy to correct mutations in 
genetic diseases. 
 
1.3.2 Mouse models of AKU 
1.3.2.1 Importance of animal models in AKU 
The primary metabolic consequences of AKU are relatively straightforward to study; 
metabolites such as HGA and tyrosine from urine 44,46 and blood 217 samples can be measured 
and monitored. More recently, technology and software has led to metabolomic analysis in 
AKU, enabling the wider consequences of this metabolic disease to be studied, which can be 
performed on blood/urine samples that are relatively easy to obtain 218. Studying the 
ochronotic process in human joints however has been much more limited. Currently, only 
joints from patients undergoing joint replacement 57 or autopsy 55 are available to study as it 
is highly unethical and impractical to investigate younger, less diseased joints. Therefore, the 
only insight into human joint pathology in AKU is at the end stage of the disease.  
The development of HGD deficient AKU mouse models has allowed examination of joints 
from the very onset of pigmentation. In addition, AKU mouse models can be used to study 
metabolites relevant to AKU, to further characterise disease pathophysiology and to 
investigate new and experimental treatments.  
 
1.3.2.2 Early animal work in AKU 
Many reports have documented spontaneous AKU in various animals such as the rabbit 219, 
chimpanzee 220, orangutan 221 and macaque 222, where urine was found to darken after 
standing, leading to the identification of AKU. However, no evidence of osteoarthropathy or 
pigmentation was found. In addition, these findings were all isolated case reports. Early 
animal work involved attempts to induce ochronosis by injection of HGA into rabbits, with 
intra-articular injection shown to produce joint ochronosis resembling that of human lesions 
223. Intravenous and intraperitoneal injection failed to produce ochronosis in this rabbit 
model. A dietary model was also reported, with rats fed a diet excess in tyrosine (8%) for a 
minimum of 9 months, which appeared to induce ochronosis 224.  
These early reports of AKU occurred before the advent of genome modifying technology. The 
world’s first transgenic mouse model was developed in 1976 and the first knockout mouse 
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in 1987 225. After the injection of HGA into rabbits to induce ochronosis in 1961, which did 
not attempt to create a model of AKU, it was not until the 1990s that a murine model for 
AKU was discovered.  
 
1.3.2.3 BALB/c Hgd-/- mouse model of AKU 
The first AKU mouse model was generated by ENU mutagenesis, whereby random mutations 
are induced into the genome 198. The AKU phenotype was identified by Montagutelli et al. in 
1994 at the Pasteur Institute (Paris, France) due to darkened cage bedding, caused by 
elevated HGA in the urine turning a dark brown/black colour 86. Subsequent mice were 
confirmed to have AKU by urine spots on sodium hydroxide-soaked filter paper, which causes 
AKU urine to turn brown in 30–60 seconds (alkaline conditions speed up the colour change; 
urine eventually turns dark after standing for several days). An example of dark stained cage 
bedding from these AKU mice is shown in Figure 1.9. This Hgd mutation was then backcrossed 
onto the BALB/cByJ and C57BL/6J murine backgrounds. Urine analysis then confirmed that 
HGA was elevated to >0.55 mol/mol creatinine in homozygous mice and was non-detectable 
in wildtype and heterozygotes.  
 
Figure 1.9. BALB/c Hgd-/- AKU mouse cage bedding.  
Mice with deficient homogentisate 1,2-dioxygenase (HGD) activity (shown on the right) are unable to metabolise 
homogentisic acid (HGA), leading to its excretion into the urine, causing dark urine stained cage bedding after 
several days of exposure to the air. A wildtype mouse is shown on the left. Image used with the permission of Dr 
Jean Louis Guenet.  
 
In 1997, the murine Hgd gene was cloned and the ENU-induced mutation was identified in 
1998 to be a point mutation that resulted in a truncated HGD protein with 6% activity 
compared with wildtypes 226,227. The mutation changed the splice donor site within intron 12, 
from GTAAGT → GAAAGT, leading to deletion of exon 12 and causing a frameshift mutation 
and premature stop codon at the start of exon 13 228. Despite the extreme level of 
pigmentation seen in human AKU cartilage, no connective tissue pigmentation in these 
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homozygous AKU mice was found, despite increased urinary HGA 45,86. Ochronosis however 
was later detected using Schmorl’s staining to intensify the colour of the pigment in a 
crossbred murine model of AKU, Hgd-/-Fah-/-, derived from the original ENU mutagenesis 
mouse from the Pasteur Institute, showing microscopic pigmentation synonymous to human 
ochronosis 229. Pigmentation was shown to initiate in the pericellular matrix of chondrocytes 
found in calcified articular cartilage 229. Although pigmentation was identified, the complex 
Hgd-/-Fah-/- model was not deemed a suitable model for AKU due to the confounding HT-1 
Fah-/- mutation that exhibits severe hepatic and renal pathology. Furthermore, the model 
requires nitisinone treatment from birth to survive by blocking the tyrosine pathway 
upstream of the fatal Fah-/- mutation, with subsequent removal in adulthood to cause 
spontaneous loss of heterozygosity from Hgd+/-Fah-/- to Hgd-/-Fah-/- in a subset of mice to 
generate the AKU genotype.  
In 2014, a consistent murine model of AKU in the BALB/c background, Hgd-/-, was described 
with no confounding HT-1 pathology 115. This AKU model demonstrated relatively stable 
increased plasma HGA levels, the first reported in an AKU animal model, and extensive 
chondrocyte pigmentation via a modified Schmorl’s stain. It was shown here that initial 
chondrocyte pigmentation is pericellular, progressing to the intracellular compartment. The 
ability to then score the number of pigmented chondrocytes in the tibio-femoral (knee) joint 
showed a linear increase in pigmentation with age. This AKU mouse model has provided the 
means to study early ochronosis in a predictable and systematic manner.  
Establishment of this BALB/c Hgd-/- AKU model has led to work looking at various aspects of 
the disease, such as preventing HGA formation and therefore disease progression with 
nitisinone (discussed in section 1.3.2.4 below) 115,116, metabolomic evaluation of the wider 
effects of nitisinone 218,230,231, investigation of the ultrastructure of murine AKU calcified 
cartilage by electron microscopy 232, expression of enzymes related to tyrosine metabolism 
(Wilson et al., manuscript in preparation) and the effectiveness of tyrosine dietary restriction 
on nitisinone-induced tyrosinaemia 233 which is discussed in chapter 5. 
 
1.3.2.4 Nitisinone-treatment in the BALB/c Hgd-/- AKU mouse model 
As discussed in section 1.2.6, only palliative treatment such as analgesics and arthroplasty 28 
were available for AKU, with low-protein diets, ascorbic acid and physiotherapy proven 
clinically ineffective 20,101,102. Nitisinone, which blocks the HPPD enzyme that forms HGA, was 
shown to completely prevent chondrocyte pigmentation in the BALB/c Hgd-/- mouse model 
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115. This mouse study followed a human trial of nitisinone that saw a reduction in HGA, but 
was deemed inconclusive and ineffective due to no clinical joint improvement, assessed by 
hip rotation, which is now deemed an inappropriate primary outcome 40. Further work in this 
mouse model showed that nitisinone can arrest, but not reverse, ochronosis progression, 
and also demonstrated a clear-dose response between nitisinone and plasma HGA 116.  
The investigation of nitisinone in this BALB/c Hgd-/- model was highly influential, providing 
evidence of HGA reduction and disease prevention. This led to the off-label use of nitisinone 
at the NAC and within the DevelopAKure series of human clinical trials investigating the use 
of nitisinone in AKU 52,118, where its use has proven safe and effective (see section 1.2.6.2).  
Although the use of nitisinone in these clinical trials has so far been very successful, nitisinone 
can only treat, not cure the disease. The next big step in single-gene diseases like AKU would 
be to treat the underlying genetic cause with gene/enzyme replacement therapy.  
 
1.3.2.5 Why create a new AKU mouse model? 
It is clear that the ENU mutagenesis Hgd-/- AKU mouse model has greatly contributed to our 
knowledge of AKU, in terms of both disease pathophysiology and treatment, and will 
continue to be utilised for AKU research. ENU mutagenesis however is not a targeted 
approach to create a model of genetic disease due to the high frequency of DNA mutations 
that ENU causes 197,198. Other unknown and uncharacterised mutations could potentially exist 
in the mutagenesis AKU model that could affect the phenotype, as the ENU model has never 
been fully sequenced. Newer, more complex mouse models offering additional tools such as 
endogenous reporter genes and conditional potential are now available, whereby a specific 
gene is targeted. Conditional alleles in particular are extremely useful as they have the ability 
to be induced in a specific tissue and at a specific time point in the animal’s life course.  
 
1.4 Overall aims 
1. The first aim of this work was to generate and phenotype a new targeted conditional 
mouse model of AKU, raised in the C57BL/6 background using a mutant knockout-
first allele obtained from the KOMP repository (www.komp.org). The aim was to 
phenotype the mouse model biochemically by quantifying HGA and then 




2. The second aim of this project was to use the LacZ reporter gene situated within the 
Hgd locus of the knockout-first mouse model to localise gene expression of Hgd. The 
Flp/FRT and Cre/LoxP site-specific recombination system within the new mouse 
model was then used to obtain an inducible and tissue-specific knockout, with the 
aim of investigating the effect of partial Hgd knockout on the AKU phenotype. With 
gene therapy becoming a likely tool in the future, this conditional mouse model was 
used to provide an insight into the level and location of Hgd expression that could 
rescue the AKU phenotype. 
 
3. Treatment of AKU with the HGA-lowering drug nitisinone has emerged as the first 
and most promising disease-preventing treatment for AKU. Nitisinone therapy 
however is associated with tyrosinaemia that in a minority of patients causes 
keratopathy. The third major aim of this work was to investigate nitisinone-induced 
tyrosinaemia in AKU mice and potential strategies that may lower circulating 
tyrosine. Initially, dietary studies were carried out to investigate the effectiveness of 
reducing oral/intestinal uptake of tyrosine and/or phenylalanine. Subsequently, a 























2.1 Mouse generation 
Embryonic stem (ES) cells containing a modified Hgd allele, clones Hgd C10 and Hgd C11 
(origin strain C57BL/6N-Atm1Brd (non-agouti mutation; ES cell line JM8A3.N1), were purchased 
from the UC Davis KOMP repository (KOMP is now the Mutant Mouse Resource & Research 
Centres (MMRRC) at UC Davis; Hgd KOMP ES cell line 
https://www.mmrrc.org/catalog/cellLineSDS.php?mmrrc_id=56778). The ES cells were 
grown on G419-resistant primary embryonic fibroblasts, as described 234. Following G418 
antibiotic selection, healthy ES cells were injected into blastocysts of C57BL/6 (Harlan, UK) at 
the blastula stage, in the blastocoel cavity close to the inner cell mass. The modified 
blastocysts were then transferred into pseudopregnant recipient CD1 females (Charles River, 
UK), and chimeric offspring identified. Further breeding was used to confirm germline 
transmission of the modified allele. Only C10 chimeras achieved germline transmission, and 
were subsequently bred to homozygosity. The C10 line was then referred to as Hgd tm1a, 
either as homozygous (-/-) or heterozygous (-/+). 
 
Figure 2.1. Modified Hgd alleles; Hgd tm1a, Hgd tm1c, Hgd tm1d.  
The Hgd tm1a allele has an AKU phenotype due to disruption by the gene trap cassette situated between exons 
5 and 6. Flp-mediated FRT site recombination removes the gene trap cassette, leaving LoxP sequences either side 
of exon 6 in the Hgd tm1c allele, which is transcribed as normal. The Hgd tm1d floxed (fl/fl) allele is obtained by 
breeding the Hgd tm1c floxed allele with MxCre mice (Hgd tm1d (fl/fl) MxCre) and is inducible. When MxCre 
expression is induced, the floxed sixth exon in Hgd tm1d is removed by Cre/LoxP site recombination, resulting in 
Hgd deletion (post-cre). 
 
To obtain the conditional Hgd tm1d line, Hgd tm1a mice were crossed with Flpo mice to 
remove the FRT-flanked gene trap cassette, leaving a floxed target exon (Hgd tm1c +/+) 235, 
see Figure 2.1. Homozygote floxed Hgd tm1c mice were crossed with MxCre mice 236 (Mx-1 
Cre); referred to as Hgd tm1d (fl/fl) MxCre (-/+ or WT). The removal of the floxed 6th exon in 
Hgd tm1d was induced with administration of polyinosinic: polycytidylic acid (pIpC)236,237, 
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which increases interferon levels, driving the interferon-responsive Mx-1 promoter and 
therefore the Cre expression (see section 2.3.2 for more details).  
 
2.1.1 Genotyping 
Mice were ear notched after weaning at approximately three weeks of age in order to be 
identified and genotyped.  
 
2.1.1.1 Ear Notch Digestion 
100 µl of lysis buffer (50 mM tris-HCl (pH 8.0), 0.1 M NaCl, 1% SDS w/v, 20 mM EDTA in 
distilled H20) and 10 µl of 10 mg/ml proteinase k (100 mg reconstituted in 10 ml 50% glycerol; 
Sigma Aldrich UK, P2308 or Bioline UK, BIO-37037)) were added to the ear notch in an 
Eppendorf, then incubated at 55°C overnight in a water bath. The following day, samples 
were removed from the water bath, cooled to room temperature and vortexed to ensure the 
tissue had been digested. DNA was then isolated from the digested ear notch using an 
isopropanol DNA extraction. 
 
2.1.1.2 Isopropanol DNA extraction 
DNA was isolated from digested ear notch tissue using an isopropanol DNA precipitation 
method.  
1. Digested ear notch samples removed from 55°C water bath, cooled and vortexed. 
2. Lysate was centrifuged at ≥12,000 g for 10 minutes to form a protein pellet. 
3. Supernatant was transferred into a new Eppendorf, leaving the protein pellet behind.  
4. An equal volume of 100% isopropanol at room temperature was added to the 
supernatant (usually about 80 µl). 
5. The tubes were inverted several times to aid the DNA precipitation, then centrifuged 
at ≥12,000 g, for 10 minutes. DNA will form a pellet (may not be visible). 
6. The supernatant was then removed and discarded. 
7. 100 µl of 70% ethanol was then added to wash the DNA pellet, then discarded, 
followed by brief centrifugation for 30 seconds. 
8. The remaining supernatant was then removed with a pipette, and the DNA pellets 
left to air dry for approximately 10 minutes. 




After reconstituting the DNA, the concentration (ng/µl) was measured by spectrophotometry 
using NanodropTM 2000 (ThermoFisher Scientific). DNA was stored at -20°C if not being used 
straightaway. Extracted ear notch DNA was then used as the template for PCR reactions. See 
below for PCR reaction mixtures, cycling parameters and expected band sizes for the 
different mouse lines. See Table 2.1 for primer sequences. 
 
Table 2.1 Genotyping primer sequences. 
Primer 
Name 
Sequence (5’ to 3’) Mouse line  Source 
Lox-F GAGATGGCGCAACGCAATTAATG Hgd tm1a/c/d 
KOMP repository, 
supplied with 
modified ES cells 
Hgd-R CTTGGCTTTGGACTTGAACCCTAGC Hgd tm1a/c/d 
Hgd-F GCCTTTATCCCTACAAGTCTCCCCG Hgd tm1a/c/d 
Hgd-ttR TAGATGGATTTTGTGGGGAGAGGGC Hgd tm1a/c/d 
MxCre F CATGTGTCTTGGTGGGCTGAG Hgd tm1d MxCre 
Dr Takao Sakai 238 
MxCre R CGCATAACCAGTGAAACAGCAT Hgd tm1d MxCre 
Internal F TGGACAGGACTGGACCTCTGCTTTCCTAGA Used with MxCre Prof George Bou-
Gharios Internal R TAGAGCTTTGCCACATCACAGGTCATTCAG Used with MxCre 
Hgd290 F CATTTTCACCGTGCTGACTG BALB/c Hgd-/- Dr Andrew 
Preston 115 Hgd290 R TTTAGTCGCTGCATCACCTG BALB/c Hgd-/- 
 
 
2.1.1.3 PCR Reaction Mixtures 
GoTaq® G2 Flexi DNA polymerase (Promega, UK) was used to amplify DNA products for 
genotyping. Approximately 100 ng of template DNA was used in each reaction. Primers, 
purchased from Eurofins Genomics (Ebersberg, Germany) were reconstituted in 1 x TE buffer 
to a concentration of 100 pmol/µl, then diluted 1 in 10 in 1 x TE buffer to 10 pmol/µl; aliquots 
were stored at -20°C.  
 
2.1.1.3.1 Hgd tm1a and Hgd tm1c/d (pre-cre) 
To distinguish the genotype of the Hgd gene in Hgd tm1a, Hgd tm1c (post-flp) and Hgd tm1d 
(pre-cre), the same PCR reaction mixture and primers were used (Table 2.2), producing 
different bands for the different lines. The expected band sizes were as follows: 
• Hgd tm1a 
o WT (2 unmodified alleles) has only 561bp band.  
o Homozygous Hgd flox (2 modified alleles) has only 257bp band.  
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o Heterozygous Hgd flox (1 modified allele, 1 unmodified allele) has 561bp and 
257bp bands. 
 
• Hgd tm1c (fl/fl) (post-flp) and Hgd tm1d (fl/fl) (pre-cre) 
o WT (2 unmodified alleles) has only 561bp band. 
o Homozygous Hgd flox (2 modified alleles) has 673bp and 257bp bands. 
o Heterozygous Hgd flox (1 modified allele, 1 unmodified allele) has 673bp, 
561bp and 257bp bands. 
 
Table 2.2 PCR reaction mixture and cycling parameters for Hgd tm1a, Hgd tm1c (post-flp)/d (pre-cre) genotyping. 
  
2.1.1.3.2 MxCre 
MxCre genotyping only produces a band when MxCre is present, it is unable to distinguish 
between homozygous or heterozygous; positive is denoted as +/-. To ensure that the PCR 
amplification was successful (i.e. to show that DNA was present in the reaction mixture at 
sufficient quality, to show that the PCR reaction worked) and to prevent false-negative 
results, the reaction mixture included primers for a control gene; specifically, exon 1 of the 
Fabp2 (fatty acid-binding protein 2) gene. The PCR reaction mixture and cycling parameters 
are shown in Table 2.3. The expected bands are: 
• WT has only a 194bp band corresponding to the internal control gene 
• MxCre positive, denoted +/-, has both the internal control band at 194bp and a band 
at 520bp corresponding to MxCre. The Cre primers are specific to MxCre. 
 
PCR Reaction: 




 x1 (µl) 1 94°C 5 min 
 5x Buffer 6 2 94°C 15 sec 
 25 mM MgCl2 2.1 3 65°C 30 sec 
 10 mM dNTP 1 4 72°C 1 min 
 
DMSO 0.325 5 
GOTO step 2, x10, -
1°C per cycle 
 
 Go taq 0.3 6 93°C 1 min 
10 pmol/µl 
Lox-F primer 0.5 7 65°C 1 min 
Hgd-R primer 0.5 8 72°C 30 sec 
Hgd-F primer 0.5 9 GOTO step 2, x30  
Hgd-ttR primer 0.5 10 72°C 5 min 
Adjust to 
approximately 
100 ng/µl DNA 
H20 17.2 11 4°C ∞ 
DNA  1 
 
 Total 30 
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Table 2.3 PCR reaction mixture and cycling parameters for MxCre genotyping. 
 
2.1.1.3.3 BALB/c Hgd-/-  
To genotype the BALB/c Hgd-/- colony, the region containing the AKU-causing mutation within 
the Hgd gene is amplified by PCR (see Table 2.4) to generate a 290bp sequence. In a wildtype, 
this sequence contains a HypCH4III restriction enzyme binding site; the mutated AKU 
sequence does not. A restriction enzyme digest (see  
Table 2.5) followed by agarose gel electrophoresis (3% w/v gel) is used to determine the 
presence or absence of the AKU mutation. The expected bands are: 
• WT would have two bands at 170bp and 120bp. 
• Homozygous would have one non-digested band at 290bp. 
• Heterozygous would have three bands at 290bp, 170bp and 120bp. 
Table 2.4. PCR reaction mixture and cycling parameters for BALB/c Hgd-/- genotyping. 
 
PCR Reaction: MxCre 
 
Cycling parameters 
  x1 (µl) 1 95°C 3 min 
 5x Buffer 5 2 94°C 30 sec 
 25 mM MgCl2 2 3 63°C 30 sec 
 10 mM dNTP 0.5 4 72°C 30 sec 
 Go taq 0.1 5 
GOTO step 2, x9, -
1°C per cycle 
 
 DMSO 1.25 6 95°C 30 sec 
10 pmol/µl 
MxCre F primer 0.5 7 53°C 30 sec 
MxCre R primer 0.5 8 72°C 30 sec 
Internal F primer 0.5 9 GOTO step 6, x35  
Internal R primer 0.5 10 72°C 5 min 
Adjust to 
approximately 
100 ng DNA 
H20 13.15 11 4°C ∞ 
DNA template 1 
 
 Total 25 
PCR Reaction: BALB/c Hgd-/- 
 
Cycling parameters 
  x1 (µl) 1 95°C 15 min 
 Qiagen HotStarTaq 
Mastermix 
12.5 2 94°C 30 sec 
10 pmol/µl 
Hgd290 F primer 0.5 3 52°C 30 sec 
Hgd290 R primer 0.5 4 72°C 1 min 
Adjust to 
approximately 
100 ng DNA 
H20 8.5 5 GOTO step 2, x30  
DNA template 2 6 72°C 7 min 
 Total 25 7 4°C ∞ 
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Table 2.5. Restriction enzyme digest reaction mixture and incubation parameters for BALB/c Hgd-/- genotyping. 
Reaction components Volume (µl) Cycling Parameters 
NEB4 (New England BioLabs 
Buffer 4) 
1.5 
37°C for 2 hours 
HypCH4III 0.3 
H20 11.7 




2.1.1.4 Gel electrophoresis 
Agarose gels were used for gel electrophoresis to separate DNA bands from genotyping PCR 
reactions. Tris-acetic acid EDTA (ethylenediaminetetraacetic acid) (TAE) buffer was used to 
cast and run gels. 1x TAE buffer was obtained by diluting 50x TAE stock (242 g Tris base, 57.1 
ml glacial acetic acid, 18.6 g EDTA disodium salt dehydrate in distilled H2O to a total volume 
of 1 L). Gels of 1.5% w/v were typically used, unless stated otherwise, made using 1x TAE 
buffer and molecular grade agarose powder (Bioline UK, BIO-41025). To stain the gel, 2 µl of 
SYBR safe (10,000X concentrate; ThermoFisher Scientific, S33102, UK) per 50 ml gel is added 
(1 in 25,000 dilution). Gels were loaded with 20 µl of PCR product, and run in a Bio-Rad Sub-
Cell® agarose gel electrophoresis system, in 1x TAE buffer, at 100 volts for 70 minutes. A 
Quick-Load® Purple 2log-DNA ladder (now called 1kb Plus DNA ladder (N3200S), New 
England BioLabs, US) was used to determine band sizes, unless indicated otherwise. A Bio-
Rad ChemiDocTM XRS+ Imaging System coupled with Bio-Rad Image LabTM Software (Version 
5.0), was used to image gels; UV light was used to excite the SYBR-safe nucleic acid stain.  
 
2.2 Histology 
2.2.1 Tissue processing 
Tissues for paraffin wax embedding were processed following fixation in 10% formalin for a 
minimum of 24 hours. Hard tissues were decalcified in 10% EDTA pH 8.0 (changed a few to 
several times depending on the size of the tissue) until the tissue was flexible and soft enough 
to bend prior to processing to enable histological sectioning. For example, the knee joint of 
mice was decalcified over 1-2 weeks, with 3 changes of EDTA solution. Table 2.6 shows the 
tissue processing steps for soft tissues and hard tissues, using a Leica ASP300 tissue 




Table 2.6. Tissue processing stages for soft and hard tissues. 
Step Chemical Soft tissue Hard (decalcified) tissue 
1 70% ethanol 30 mins 15 mins 
2 90% ethanol 30 mins 1 hour 
3 100% ethanol 10 mins 1 hour 
4 100% ethanol 10 mins 1 hour 
5 100% ethanol 10 mins 1 hour 
6 100% ethanol 10 mins 1 hour 
7 Xylene 30 mins 1 hour 
8 Xylene 30 mins 1 hour 
9 Paraffin wax 2 hours 2 hours 
10 Paraffin wax 2 hours 2 hours 
Total time 6 hours 40 minutes 11 hours 15 minutes 
 
2.2.2 Sectioning of tissues 
Leica RM 2235 or RM 2245 manual microtomes were used to section paraffin wax embedded 
tissues at a thickness of 5/6 µM. Sections were transferred to a 45°C water bath and mounted 
on glass Superfrost® Plus microscope slides (ThermoScientific, UK). Slides were then dried 
overnight in a 37°C oven. Frozen samples embedded in OCT (Leica Tissue Freezing Medium) 
were sectioned using a Leica CM 1900 cryostat, using glass Superfrost® Plus microscope slides 
(ThermoScientific, UK). Slides were then stored at -20°C until staining. 
 
2.2.3 Staining of sections 
Tissue sections were stained using the following protocols.  
 
2.2.3.1 Haematoxylin and eosin 










Table 2.7. H&E staining of paraffin sections. 
Step Chemical Duration 
1 Xylene  3 minutes 
2 Xylene  3 minutes 
3 100% ethanol 2 minutes 
4 90% ethanol 2 minutes 
5 70% ethanol 2 minutes 
6 Running tap water 1 minute 
7 Harris Haematoxylin 5 minutes 
8 Running tap water 1 minutes 
9 Acid alcohol 15 seconds 
10 Running tap water 5 minutes 
11 Eosin Y (alcoholic) 3 minutes 
12 Running tap water 15 seconds 
13 70% ethanol 1 minute 
14 90% ethanol 1 minute 
15 100% ethanol 1 minute 
16 Xylene 2 minutes 
17 Xylene 2 minutes 
18 Mount coverslip with DPX - 
 
2.2.3.2 Schmorl’s staining 
Schmorl’s staining of paraffin sections to detect ochronotic pigment was carried out 
according to Table 2.8. 
Schmorl’s incubating solution 
The incubating solution for Schmorl’s staining (1% ferric chloride, 1% potassium chloride, in 
dH2O) was prepared fresh prior to staining and was not used for more than 1 day. 
 
Nuclear fast red 
Nuclear fast red was filtered before staining, and stored in the fridge between use. To 
prepare the stain, 15 g of aluminium sulfate hexadecahydrate (Al2(SO4)3.16H2O) was 
dissolved in 300 ml dH2O (approximately 5% solution), then 0.3 g nuclear fast red added 
(0.1%). The solution was heated and stirred until boiling, cooled to room temperature and 
then filtered. A few grains of thymol were added to prevent bacterial growth, then stored in 







Table 2.8. Schmorl's staining of paraffin sections. 
Step Chemical Duration Notes 
1 Xylene  3 minutes  
2 Xylene  3 minutes  
3 100% ethanol 2 minutes  
4 90% ethanol 2 minutes  
5 70% ethanol 2 minutes  
6 Tap water 1 minute Not running water 
7 Schmorl’s incubating solution 1 - 15 minutes Usually 15 minutes 
8 Running tap water 3 minutes  
9 1% acetic acid 5 minutes Prevents overstaining 
10 Nuclear fast red 2 – 4 minutes Time dependant on intensity 
11 Running tap water 5 minutes Agitate 
12 70% ethanol 2 minutes  
13 90% ethanol 2 minutes  
14 100% ethanol 2 minutes  
15 Xylene 3 minutes  
16 Xylene 3 minutes  
17 Mount coverslip with DPX -  
 
 
2.2.3.2.1 Ochronosis scoring 
To score the severity of ochronosis, the first coronal knee joint section, sectioned posterior 
to anterior, that encompassed the entire tibio-femoral joint (knee) containing all four joint 
quadrants (medial tibia, medial femur, lateral tibia, and lateral femur) was used as a 
representative section and stained with Schmorl’s stain. The number of pigmented 
chondrons was recorded for each joint quadrant in the calcified articular cartilage and 
entheses of the femoral condyles where collateral ligaments attach, see Figure 2.2. This 
ochronosis scoring system was then adapted to the vertebral column; pigmented chondrons 
were counted in both the cranial and caudal endplates (then summed) either side of an IVD 
stained with Schmorl’s stain, across 5 sections in the coronal plane. Scoring was carried out 





Figure 2.2. Areas of scoring ochronosis in the knee joint.  
The red lines indicate the articular cartilage in the (tibio-femoral) knee joint where the number of pigmented 
chondrons were recorded in a representative section containing all four joint quadrants and the entheses of the 
femoral condyles (*). MT = medial tibia. LT = lateral tibia. MF = medial femur. LF = lateral femur. Haematoxylin & 
eosin stain. Scale bar = 50 µM. Image used with permission from Dr Craig Keenan 239. 
 
2.2.3.3 Eosin 
Eosin staining of paraffin sections was carried out according to Table 2.9. If the tissue had 
previously been LacZ stained, HistoClear was uses instead of xylene. 
Table 2.9. Eosin staining of paraffin sections. 
Step Chemical Duration Notes 
1 Xylene  2 minutes HistoClear used if tissue was 
LacZ stained 2 Xylene  2 minutes 
3 100% ethanol 2 minutes  
4 90% ethanol 2 minutes  
5 70% ethanol 2 minutes  
6 Dip in running tap water 10 seconds  
7 Eosin Y (alcoholic) 2 minutes  
8 Dip in running tap water 10 seconds  
9 70% ethanol 30 seconds   
10 90% ethanol 30 seconds   
11 100% ethanol 30 seconds   
12 Xylene 30 seconds  HistoClear used if tissue was 
LacZ stained 13 Xylene 30 seconds 
14 Mount coverslip with DPX -  
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2.2.3.4 Nuclear fast red 
Nuclear fast red staining of paraffin sections was carried out according to Table 2.10. If the 
tissue had previously been LacZ stained, HistoClear was uses instead of xylene. 
Table 2.10. Nuclear fast red staining of paraffin sections. 
Step Chemical Duration Notes 
1 Xylene  2 minutes HistoClear used if tissue was 
LacZ stained 2 Xylene  2 minutes 
3 100% ethanol 2 minutes  
4 90% ethanol 2 minutes  
5 70% ethanol 2 minutes  
6 Dip in running tap water 10 seconds  
7 Nuclear Fast Red 2 – 4 minutes Time dependant on intensity 
8 Dip in running tap water 10 seconds  
9 70% ethanol 30 seconds   
10 90% ethanol 30 seconds   
11 100% ethanol 30 seconds   
12 Xylene 30 seconds  HistoClear used if tissue was 
LacZ stained 13 Xylene 30 seconds 
14 Mount coverslip with DPX -  
 
2.2.3.5 Periodic acid Schiff/haematoxylin 
Table 2.11  shows the protocol for paraffin section periodic acid Schiff/haematoxylin (PAS/H) 
staining. For frozen section PAS/H staining, slides were fixed in 10% formalin for 
approximately 20 minutes, rinsed with dH2O then stained using the protocol in Table 2.11, 
commencing at step 7 (periodic acid). For PAS staining performed immediately after frozen 
section LacZ staining (section 2.2.5.6 below), slides were fixed in 10% formalin for 
approximately 20 minutes, rinsed with dH2O then stained for PAS (Table 2.11), commencing 













Table 2.11. PAS/H staining of paraffin sections. 
Step Chemical Duration 
1 Xylene  3 minutes 
2 Xylene  3 minutes 
3 100% ethanol 1 minute 
4 90% ethanol 1 minute 
5 70% ethanol 1 minute 
6 Dip in tap water 5 seconds 
7 0.5% periodic acid solution  10 minutes 
8 Dip in running tap water 5 seconds 
9 Rinse with distilled water 5 seconds 
10 Schiff reagent 10 minutes 
11 Wash in lukewarm tap water 5 minutes 
12 Mayer’s Haematoxylin 1 minute 
13 Running tap water 5 minutes 
14 70% ethanol 30 seconds 
15 90% ethanol 30 seconds 
16 100% ethanol 30 seconds 
17 Xylene 30 seconds 
18 Xylene 30 seconds 
19 Mount coverslip with DPX - 
 
 
2.2.3.6 Safranin O fast green 
Safranin O / fast green staining of paraffin sections was carried out according to Table 2.12. 
Table 2.12. Safranin O / fast green staining of paraffin sections.  
Step Chemical Duration 
1 Xylene  10 minutes 
2 Xylene  10 minutes 
3 100% ethanol 2 minutes 
4 90% ethanol 2 minutes 
5 70% ethanol 2 minutes 
6 Running tap water 1 minute 
7 Harris Haematoxylin 30 seconds 
8 Running tap water 5 minutes 
9 0.2% fast green 10 minutes 
10 1% acetic acid 20 seconds 
11 1% acetic acid 20 seconds 
12 Running tap water 10 seconds 
13 0.5% safranin O 8 minutes 
14 70% ethanol 2 minutes 
15 90% ethanol 2 minutes 
16 100% ethanol 2 minutes 
17 Xylene 3 minutes 
18 Xylene 3 minutes 





2.2.4 Light microscopy 
Histology slides were all examined using light microscopy. A Nikon Eclipse Ci microscope was 
used, with a Ds-Fi2 camera and NIS Elements Br software (version 4.13.04).  
 
LacZ stained brain sections were imaged using light microscopy and stitched together using 
a using a Zeiss Axio Imager Z2 microscope and Zen Blue software. 
 
2.2.5 LacZ staining 
The Hgd tm1a mouse harbours a LacZ transgene between exons 5 and 6 of the modified Hgd 
gene that is transcribed before the gene is interrupted by the gene trap cassette. LacZ is a 
bacterial gene encoding the enzyme β-galactosidase, which will from a blue product when 
given the substrate X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside). By staining a 
tissue for the presence of LacZ, a blue colouration indicates the tissue is LacZ positive and 
therefore expresses Hgd. 
 
2.2.5.1 Time-mated embryos 
Mice were mated overnight and checked the next morning for signs of mating (a vaginal plug 
is usually observed). It is assumed that fertilization took place at night and that the embryos 
are half a day old by the morning (E0.5). The embryos were harvested a specific number of 
days after the plug was found, i.e. 11 days later would give E11.5 embryos.  
The pregnant mother was culled by cervical dislocation in order to collect the time-mated 
embryos. The uterus was removed and immersed immediately in ice cold PBS until dissection. 
Embryos were removed from the uterus, and the yolk sac and placenta dissected away. 
Embryos were then used for LacZ staining, frozen sectioning or for mRNA collection. Embryos 
for frozen sectioning (for frozen LacZ staining) were fixed as for whole mount LacZ staining 
(see below), then placed into 30% sucrose until they sank. They were then embedded in OCT 
on dry ice and stored at -80°C until sectioning. Samples for mRNA (embryonic liver) were 
collected immediately after harvesting the embryos, and placed into either liquid nitrogen or 






2.2.5.2 LacZ fix and stain solutions for embryos/whole tissues 
X-gal fix solution: 50 ml 
0.2% glutaraldehyde    400 µl of 25% solution 
2% paraformaldehyde    12.5 ml of 8% solution 
0.1 M Na Pi buffer at pH 7.4  5 ml of 1 M stock 
5 mM EGTA (pH 8.0 with NaOH)  2.5 ml of 0.1 M stock 
2 mM MgCl2    100 µl of 1 M stock 
Top up to 50 ml with dH20   
 
X-gal rinse solution: 1L 
0.1 M Na Pi Buffer pH7.4 100 ml of 1 M stock 
2 mM MgCl2   2 ml of 1 M stock 
0.1% sodium deoxycholate 1 g  
0.2% NP40   2 ml 




X-gal stain solution: 100 ml 
5 mM potassium ferricyanide 165 mg (mw 329.2) 
5 mM potassium ferrocyanide 211 mg (mw 422.4) 
1 mg/ml X-gal   4 ml of 25 mg/ml stock (add fresh)  
100 ml X-gal rinse solution  
(Store wrapped in foil) 
 
X-gal stock: 25 mg/ml 
1 g X-gal (≥98.0%, VWR, 437132J, US) 
40 ml N,N-dimethylformamide 
 
2.2.5.3 LacZ staining of embryos 
The procedure for LacZ staining time-mated embryos was as follows: 
1. After separation from the placenta and yolk sac, embryos were fixed (X-gal fix) on ice 
at 4°C, using Table 2.13 as a guide for fixation time. 
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2. The fix solution was discarded and the embryos washed 3 times for 30 minutes in X-
gal rinse, whilst rotating at room temperature. 
3. X-gal substrate was then added to the prepared X-gal stain solution (X-gal always 
added fresh) to obtain a final concentration of 1 mg/ml X-gal. For example, 10 ml 
stain solution has 400 µl of 25 mg/ml X-gal.  
a. Embryos were immersed in X-gal stain solution, wrapped in foil (staining 
must be carried out in the dark) and stained overnight whilst rotating at 
room temperature. 
4. After staining, 3 x 30-minute washes of the embryos were carried out in X-gal rinse 
solution, at room temperature whilst rotating. 
5. Images were taken if required of the embryos (in a dish with PBS) using an Olympus 
SZX12 dissection microscope equipped with a QCapture camera and software 
(version 2.8.0, QImaging, Canada). 
6. Embryos were then fixed overnight in 10% formalin. 
7. Transferred to 70% ethanol.  
8. If required, embryos were then processed for paraffin wax embedding using the soft 
tissue processing program (Table 2.6). 
 
Table 2.13. Fixation times for time-mated embryos to be stained with LacZ. 
Embryo Age Fixation time Notes 
E7.5 – E8.5 10 minutes  
E8.5 – E9.0 20 minutes  
E9.5 30 minutes  
E10.0 – E11.5 45 minutes  
E12.5 1 hour  
E13.5 1.5 – 2 hours  
E14.5 2.5 hours  
E15.5  3 hours Embryos aged E15.5 and over need to be opened by an 
incision through the abdomen and thorax to allow fix 
solutions to penetrate through skin that has begun to 
form 
E16.5 – E17.5 4 hours 
 
2.2.5.4 LacZ staining of adult tissues 
Adult tissues were LacZ stained by the same method used for embryos (section 2.2.5.3), with 
soft tissue fixation times adjusted relative to the size of embryos. Bones were cut to expose 





2.2.5.5 Frozen section LacZ fix and stain solutions 
Frozen X-gal fix solution: 100 ml 
0.2% glutaraldehyde  800 µl of 25% stock 
100 ml PBS 
 
Frozen X-gal stain solution: 100ml 
0.1 M NaPi   10 ml of 1 M stock 
2 mM MgCl2   200 µl of 1 M stock 
0.01% sodium deoxycholate 0.01 g  
0.02% NP40   20 µl stock 
5 mM potassium ferricyanide 165 mg (mw = 329.2) 
5 mM potassium ferrocyanide 211 mg (mw = 422.4) 
1 mg/ml X-gal   4 ml of 25 mg/ml stock (added fresh) 
Top up to 100 ml with dH2O 
 
2.2.5.6 Frozen section LacZ staining 
Embryos and adult tissues were harvested and fixed as for whole mount LacZ staining (2% 
PFA, 0.2% glutaraldehyde). Tissues were then placed in 30% sucrose until they sunk, 
embedded in OCT on dry ice and stored at -80°C until cryo-sectioning. Frozen sections were 
then stored at -20°C until staining. The frozen section LacZ staining protocol is as follows: 
1. Fix slides on ice in 0.2% glutaraldehyde in PBS for 10 minutes if not fixed before cryo-
embedding. Samples not fixed with this step if fixed prior to cryo-embedding. 
2. 5 minutes wash in cold PBS (1). 
3. 5 minutes wash in cold PBS (2). 
4. 5 minutes wash in cold PBS (3). 
5. Immerse slides in frozen X-gal stain in the dark at 37°C for a 2-3 hours, or at room 
temperature overnight. 
a. Embryos were stained overnight at room temperature. 
b. After optimization, adult liver and kidney were stained at 37°C for 2 hours. 
6. After staining, rinse slides with PBS (use Pasteur pipette). 
7. Fix slides in formalin (10%) for 20-30 minutes. 
8. Rinse slides with PBS (use Pasteur pipette). 
9. Rinse slides with distilled water (use Pasteur pipette). 
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a. If not counterstaining, coverslip with an aqueous mounting agent or 
dehydrate (70%, 90% and 100% ethanol), clear (HistoClear, not xylene) and 
mount with DPX. 
10. Counterstain with eosin (aqueous) or nuclear fast red. 
11. Dip in running tap water. 
12. Coverslip with an aqueous mounting agent or dehydrate (70%, 90% and 100% 
ethanol), clear (HistoClear, not xylene) and mount with DPX. 
 
2.3 Mouse studies 
All mice were housed and maintained within the University of Liverpool Biomedical Services 
Unit (BSU) in specific pathogen-free conditions in accordance with UK Home Office 
Guidelines. Food and water were available ad libitum. Under the Animal (Scientific 
Procedures) Act 1986, Juliette Hughes held a personal licence (PIL 42023) allowing 
experiments and procedures to be carried out under two project licence holders; Professor 
George Bou-Gharios (PPL 70/9047) and Professor Jonathan Jarvis (PPL 40/3743, PA693D221).  
 
2.3.1 Urine and Blood Collection 
Urine samples of volumes <50 µl were acidified using 5% v/v 1 M H2SO4 and volumes >50 µl 
with 1% v/v 5 M H2SO4. Acidified urine was stored at -80°C until analysis via HPLC tandem 
mass spectrometry 46. Venous tail bleed samples were collected by a small incision made into 
one of the lateral tail veins in lithium heparin microvettes (CB 300 LH, Sarstedt, UK) and kept 
on ice until processed. Whole blood was centrifuged at 1500 g for 10 minutes at 4°C and the 
plasma supernatant acidified using 10% v/v 5.8M perchloric acid and vortexed. The acidified 
plasma was then centrifuged at 1500 g for 10 minutes at 4°C, the supernatant removed 
(leaving behind a protein pellet) and stored at -80°C until analysis analysed via HPLC tandem 
mass spectrometry 47. 
The amount of blood that can be withdrawn at any one time must be calculated to be within 
Home Office guidelines. A mouse has approximately 75 ml/kg blood (LASA Good Practice 
Guidelines), with a 25 g mouse having approximately 1.8 ml blood. Tail bleeding must include 
room for error as the bleeding site may not stop instantly (pressure is applied until bleeding 
stops). Therefore, 65 ml/kg was used here as an estimation of total blood volume for 
calculating bleed sizes, as also recommended by the LASA Good practice guidelines. A 
maximum of 10% of the total blood volume may be taken at any one time (≈160 µl per 25 g 
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mouse) and a maximum of 15% (≈240 µl per 25 g mouse) across a month across multiple 
bleeds.  
 
2.3.2 Hgd tm1d liver-specific Hgd knockout 
To remove the floxed 6th Hgd exon in Hgd tm1d (fl/fl) MxCre +/- mice, two intraperitoneal 
injections of polyinosinic: polycytidylic acid (pIpC, GE Healthcare: Poly(I).Poly(C), double 
strand, sterile, 27-4732-01) were given, initially at 10 µg/g body weight 237, see section 4.3. 
Injections of pIpC were mainly carried out by Dr Ke Liu. The initial pIpC stock solution was 5 
mg/ml in sterile PBS, which was diluted 1 in 10 to 500 µg/ml in sterile PBS prior to injection. 
To obtain 10 µg/g body weight, injection volume was calculated for each mouse; a 25 g 
mouse would receive 500 µl of 500 µg/ml for example. A short-term and long-term study 
investigated the effect of two 10 µg/g body weight pIpC injections. A dose response study 
was then carried out, using diluted pIpC to obtain doses ranging from 3.33 µg/g to 0.01 µg/g 
body weight pIpC. 
Hgd tm1a -/- mice were injected with pIpC (highest dose used in the experiment) as AKU 
controls and wildtype controls were either Hgd tm1d (fl/fl) MxCre WT mice injected with pIpC 
(highest dose used in the experiment) or Hgd tm1d (fl/fl) MxCre +ve mice injected with PBS. 
To assess the resulting phenotype, HGA was measured in plasma and urine samples collected 
pre-injection and at time points post-injection. Liver and kidney Hgd mRNA were analysed 
from all mice. In the long-term study, knee joints were collected for ochronosis scoring (see 
section 2.2.3.2.1).  
 
2.3.3 Isotopic HGA injection 
Hgd tm1a -/- (n=4) and Hgd tm1a -/+ (n=4) mice were injected with 13C6-HGA into the lateral 
tail vein, adjusted to body weight to achieve a final blood concentration of approximately 1 
mmol/L. Injections were carried out by Dr Hazel Sutherland assisted by BSU technical staff. 
Venous tail bleeds were collected at various time points post-injection from 2-60 minutes. 
The whole procedure of injections and bleeds was carried out under isoflurane anaesthesia 
(0.8 L O2, with up to 2% isoflurane to effect). Whole blood was centrifuged and the 
supernatant removed and immediately frozen.  
Non-targeted metabolic flux analysis was performed to trace metabolism of 13C6-HGA. 
Metabolic profiling was performed using a published mass spectrometric technique 218. 
Briefly, plasma was diluted 1: 9 plasma: deionised water and HPLC performed on an Atlantis 
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dC18 column (3x100 mm, 3 µm, Waters, UK) coupled to a 6550-quadrupole time-of-flight (Q-
TOF) mass spectrometer (Agilent, UK). An accurate-mass compound database with potential 
association to HGA was generated for data mining using Agilent Pathways to PCDL. Data were 
mined for these compound targets with an accurate mass window of ±5 ppm using ‘batch 
isotopologue extraction’ in Profinder (build 08:00, Agilent). Isotopologue extraction 
investigates association with the injected 13C6-HGA by examining the relative abundances of 
the M+0 – M+6 isotopologues for compound targets. 
 
2.3.4 Nitisinone treatment in mice 
Mice received nitisinone in the drinking water at a concentration of 4 mg/L, which was freely 
available. For a 30 g mouse drinking approximately 6 ml/day, this equates to 0.8 mg/kg 
nitisinone. 
 
2.3.5 Dietary restriction studies 
To investigate the effect of tyrosine and phenylalanine dietary restriction on nitisinone-
induced tyrosinaemia, BALB/c Hgd-/- AKU mice (groups of n=6; 3 male, 3 female) were treated 
with nitisinone for 1 week on a normal diet, then switched to either tyrosine/phenylalanine 
free or phenylalanine-only free diets with phenylalanine supplemented into the drinking 
water, whilst still on nitisinone. Controls remained on normal diet whilst still on nitisinone. 




The normal control mouse diet (CRM(P), product code 801722, Special Diet Services (SDS), 
UK), contained 0.88% phenylalanine and 0.59% tyrosine. Restricted diets were synthetically 
made by SDS in pellet form. Synthetic raw materials were used to produce an amino acid 
defined diet which has an amino acid profile similar to the normal CRM(P) diet, with tyrosine 




2.3.5.2 Nitisinone and phenylalanine provision in the drinking water 
Nitisinone was added to the drinking water at 4 mg/L. Phenylalanine was added to the 
drinking water at various doses (0-5 mg). Drinking water was freely available. Tyrosine 
supplementation in the drinking water was not investigated due to water insolubility. 
 
2.4 Mass spectrometry 
Analysis of tyrosine pathway metabolites (phenylalanine, tyrosine, HGA, HPPA and HPLA) in 
both urine and plasma samples was performed on an Agilent 6490 triple quadruple LC-
MS/MS with Jet-Stream electrospray ionization (ESI-MS/MS) equipped with an Agilent 1290 
infinity II Ultra High-Performance Liquid Chromatography pump and autosampler. 
Chromatographic separation of the sample was performed using an Atlantis C18 column (100 
mm x 3.0 µm, 3 µm) (Waters, UK). Matrix-matched calibration standards were used to form 
a calibration curve used for quantification of metabolites. 
 
2.4.1 Sample preparation 
Samples, stored at -80°C until analysis, were defrosted and centrifuged at full speed for 5 
minutes to ensure that any residual protein/debris/residue formed a pellet. 10 µl of the 
supernatant was pipetted into a 10 ml glass tube and diluted in 10 ml of the internal standard 
solution containing isotopically-labelled 13C6-HGA, d4-tyrosine, d5-phenylalanine, with 0.1% 
formic acid in dH2O. Samples <10 µl were diluted 1 in 1000 using smaller volumes, for 
example 5 µl in 5 ml. Tubes were capped and inverted to mix the sample. 1 ml of this solution 
was then pipetted into 2 ml mass spec vials (VI-03-12-01L, Chromatography Direct, UK) and 
capped or 500 µl pipetted into a 96 well plate (186002481, Waters, UK), which is heat sealed. 
The vials or plate were then loaded into the auto sampler. The samples, calibrators and 
quality control samples were prepared in an identical way and injected from the same type 
of container (i.e. vial or plate) within each analysis.  
 
2.4.2 Plasma metabolite analysis 
2 µl of the prepared plasma sample was injected into the HPLC system with a total run time 
of 7.0 minutes. Initial gradient conditions were 80:20 water: methanol with 0.1% formic acid 
(v/v) increasing linearly to 10:90 in 2.5 minutes. The mobile phase was maintained for a 
further 1.1 minutes, increased to 100% methanol for 1 minute and then returned to starting 
conditions (flow rate 0.4 ml/min). The column was reconditioned for 2 minutes prior to the 




2.4.3 Urine metabolite analysis 
2 µl of the prepared urine sample was injected into the HPLC system with a total run time of 
7.0 minutes. The same chromatographic conditions were used as for plasma metabolite 
analysis (section 2.4.2) with a flow rate maintained at 0.6 ml/min. 
 
2.4.4 Metabolite quantitation 
For quantitative analysis, Mass Hunter software was used to process the data. For a more 
detailed description see Hughes et al., 2014 for the urine method 46 and Hughes et al., 2015 
for plasma/serum method 47.  
 
2.4.5 In vitro experiments 
To measure tyrosine/phenylalanine in TAL/PAL in vitro experiments, the plasma metabolite 
method (section 2.4.2) was altered to measure only tyrosine and/or phenylalanine, using 
calibrators that were matrix-matched to the sample. The same sample preparation and HPLC 
mass spectrometry conditions were used.  
 
2.5 RNA extraction and qPCR 
2.5.1 Sample collection and RNA extraction 
Fresh samples were either snap-frozen in liquid nitrogen or placed in RNAlater RNA 
stabilization reagent (Qiagen) overnight in the fridge at 4°C, then the liquid removed and the 
sample stored at -80°C until needed. RNA was extracted using the Qiagen RNeasy Mini Kit 
and protocol. Samples were reconstituted in 30-50 µl RNase-free H20. All samples were 
treated with DNase (RNase-Free DNase set, Qiagen). 
 
Fresh RNA was immediately quantified using the NanodropTM 2000 (ThermoFisher Scientific).  
The concentration was recorded (µg/µl) as well as the 260/280 and 260/230 ratios to check 
purity/contamination. Synthesis of cDNA was carried out immediately from the fresh RNA, 




2.5.2 cDNA synthesis 
Reverse transcription of RNA to produce cDNA was carried out using the Applied Biosystems 
RNA-to-cDNA kit. 1 µg of RNA was loaded into the reaction mixture with water adjusted to 
make up the correct volume, see Table 2.14. For example, 1 µl of 1 µg/µl RNA would be used 
with 8 µl water. The final concentration of RNA in the reaction mixture is 50 ng/µl. The 
amplification conditions for cDNA synthesis are shown in Table 2.14. After synthesis, cDNA is 
diluted 1 in 10 (20 µl reaction in 180 µl) in nuclease-free H20, then stored at -20°C.  
 
Table 2.14. Reaction mixture for cDNA synthesis from RNA and the amplification conditions. 
Reaction Components Volume (µl) 
 
Amplification conditions 
2x RT Buffer 10 1 37°C 60 mins 
20x Enzyme Mix 1 2 95°C 5 mins 
RNA 
9 (total 1 µg RNA) 
3 4°C ∞ 
Nuclease-free H20  
 Total: 20 µl 
 
2.5.3 qPCR reaction 
Quantitative PCR (qPCR) was performed with a Bio-Rad CFX Connect™ Real-Time System, 
using Bio-Rad 96 well Hard-Shell PCR plates, sealed with Bio-Rad optical tape. Bio-Rad iQ™ 
SYBR® Green Supermix was used for the reaction mixture; see Table 2.15 for the reaction 
mixture and amplification conditions. Samples were run in triplicate. A non-template control 
for each reaction mixture was run for each plate (reaction mixture, with water substituted in 
place of cDNA). 
 
 






SYBR green 7.5 1 95°C 3 mins  
Forward primer 
(5 µM) 
1 2 95°C 30 secs  
Reverse primer 
(5 µM) 
1 3 60°C 30 secs plate read 
Nuclease-free 
H20 
3.5 4 GOTO step 2, x39   
cDNA 2 5 95°C 10 secs  
 Total: 15µl 6 
65°C to 95°C, 
increments of 0.5°C 








2.5.4 qPCR primer design 
The NCBI Primer-BLAST (Primer Basic Local Alignment Search Tool) online primer tool was 
used to design specific primers (https://www.ncbi.nlm.nih.gov/tools/primer-blast/), which 
utilises the Primer3 (http://bioinfo.ut.ee/primer3/) tool to design the primers for a specific 
gene and then uses BLAST to screen the primers against the whole genome of interest, in this 
case Mus musculus. Primer specifications were: 100-150bp product size, 18-22bp primer size, 
58-62°C primer Tm (melting temperature) and 20-50% primer GC% content. DNA mfold 
(http://unafold.rna.albany.edu/?q=mfold/DNA-Folding-Form) was then used to look for 
secondary structures within the PCR product that the chosen primers will amplify, such as 
hairpin loops. The criteria for this search was: linear sequence type, 58-62°C folding 
temperature, and ionic conditions of 50 mM Na+ and 3 mM Mg2+. Beacon Designer 
(http://www.premierbiosoft.com/qOligo/Oligo.jsp?PID=1) was then used to check to see if 
the chosen primers dimerize with each other or create other structures. The search criteria 
were 500 nm nucleic acid, 50 mM mono ion and 3 mM free Mg2+. 
Once designed, primers were purchased from ThermoFisher Scientific as a lyophilized 
powder, see Table 2.16 for sequences. Primers were reconstituted to 100 µM in 1x TE buffer 
for storage at -20°C, then diluted 1 in 20 (nuclease-free H20) to give a working concentration 
of 5 µM. The final concentration of the primers in the reaction mixture (1 in 15 dilution) was 
333 nM.  
 
Table 2.16. Primer sequences used for qPCR. 
Name Forward sequence Reverse sequence Notes 
Hgd1 5’- TGTCCACGGAACACCAATAA-3’ 5’- GCCAACTTCATCCCAGTTGT-3’. 
spanning 
exons 3-4 
Hgd2 5’-GACCCATCGGAGCAAATGGC-3’ 5’-AGTGTAACCACCTGGCACTC-3’ 
spanning 
exons 9-10 
18S 5’- GAAAATAGCCTTCGCCATCA -3’ 5’-AGTTCTCCAGCCCTCTTGGT-3’  
 
2.5.5 Calculating primer efficiency 
In order to test the primers for qPCR (Hgd1, Hgd2 and 18S), the standard qPCR reaction, as 
shown in Table 2.15, was used with the primers with a range of cDNA concentrations. The 
primers were tested using a serial dilution of WT liver cDNA, with dilutions of 1/10, 1/50, 
1/250, 1/1250, 1/6250, 1/31,250 (dilution factor of 5) and a non-template control (no cDNA), 
all in triplicate. The mean Ct (cycle threshold) value, the number of cycles required for the 
fluorescent signal to reach the threshold exceeding background levels, for each cDNA dilution 
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was plotted to produce a graph with a straight line for each primer. The R2 value should be 
>0.980 (Bio-Rad Laboratories, Inc. Real-Time PCR Applications Guide, 2006). The R2 for Hgd1, 
Hgd2 and 18S was 0.9995, 0.9990 and 0.9993 respectively. The gradient of the slope was 
then used to calculate the efficiency of the primer using the following equation: 
Efficiency = 100 x n(-1/gradient) – 1 (n = dilution factor, in this case 5) 
The resulting efficiency must be in the range of 90-105% for the primers to be acceptable 
(Bio-Rad Laboratories, Inc. Real-Time PCR Applications Guide, 2006). The efficiencies 
calculated for Hgd1, Hgd2 and 18S primers were 98.9%, 95.8% and 98.4% respectively.   
 
2.5.6 Calculating relative gene expression 
To calculate relative gene expression, the Ct values obtained from the qPCR were used. For 
each sample triplicate, mean Ct was calculated for the gene of interest and the housekeeping 
gene. Delta Ct (ΔCt) was then calculated (gene of interest Ct – housekeeping gene Ct). 
Relative expression was then calculated as 2(-ΔCt).  
 
2.6 PAL and TAL 
2.6.1 In vitro PAL assay 
Phenylalanine ammonia lyase (PAL) from Rhodotorula glutinis (yeast) was purchased from 
Sigma, UK (P1016) as a Grade I buffered aqueous glycerol solution. PAL was supplied in 
international enzymes units (U), with Sigma stating that 1U of PAL will deaminate 1.0 
µmol/minute of L-phenylalanine to trans-cinnamic acid and NH3 (ammonia) at pH 8.5 at 30°C. 
1 mM stock solutions of L-tyrosine (Sigma, UK; T8566) (with tyrosine initially dissolved at 1 
M in 5 M H2SO4) and L-phenylalanine (Sigma, UK; P5482) were prepared in 50 mM Tris-HCl 
(pH 8.5). These stock solutions were then used to prepare the working solutions (10-500 
µmol/L) in an Eppendorf, combining the required amount of tyrosine or phenylalanine stock 
solution and PAL enzyme (either 0.01 or 0.1 U; added last when experiment is initiated), with 
a total volume of 1 ml made up with 50 mM Tris-HCl. 
To begin the assays, PAL enzyme was added to each Eppendorf, gently vortexed and placed 
in a 30°C water bath. 50 µl aliquots of each experimental condition were taken at various 
time points, ranging from 0-24 hours. The aliquot was immediately acidified with 5 µl 5.8 M 
perchloric acid (10% v/v) to stop the enzymatic activity and to deproteinise the sample. The 
acidified samples were then centrifuged at full speed for 5 minutes, and the supernatant 
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removed and stored at -20°C until analysis. Tyrosine and phenylalanine were analysed by 
mass spectrometry, using matrix-matched tyrosine and phenylalanine calibrators made up in 
50 mM Tris-HCl, see section 2.4.5. 
 
2.6.2 TAL expression and purification 
A pETDuet:Tal expression vector containing a synthetic, codon optimised Rhodobacter 
capsulatus TAL gene was obtained from The Protein Expression Facility, Manchester Institute 
of Biotechnology, University of Manchester, UK. Codon optimisation involves synonymous 
substitution mutations so that the same amino acid is encoded, with codons preferentially 
used by the host expression organism, in order to favour efficient soluble protein expression 
240. Chemically competent Escherichia coli JM109(DE3) bacteria (Promega, UK; P9801) was 
used for TAL protein expression. 
Dr Peter Wilson carried out the transformation and expression of pETDuet:Tal in addition to 
the purification of the TAL protein, SDS-PAGE gel and protein quantitation procedures, all 
described below.  
 
2.6.2.1 Transformation and expression of pETDuet:Tal 
To transform the bacteria with the expression vector and to induce TAL protein expression, 
the following steps were carried out: 
1. 0.5 µl pETDuet:Tal plasmid added to 100 µl competent JM109(DE3) cells then mixed 
by flicking the tube (not vortexed) and left on ice for 15 minutes. 
2. The bacteria were then heat shocked at 42°C for 50 seconds and then placed on ice 
for 2 minutes. 
3. 900 µl of LB broth was then added to the bacteria, which were then incubated for 1 
hour at 37°C whilst shaking at 200 rpm.  
4. 100 µl of the bacteria culture were then spread onto an LB agar plate containing 100 
µg/ml ampicillin, air dried for 5 minutes and left overnight at 37°C, upside down. 
a. Bacterial colonies that have grown on the plate will have successfully been 
transformed with the pETDuet:Tal vector, as it has an ampicillin resistance 
gene.  
5. A single colony was then selected to inoculate 30 ml selective LB broth containing 
100 µg/ml ampicillin and grown over night at 37°C, shaking at 200 rpm. 
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6. 10 ml of this culture was then removed and added to 1 L of selective LB broth at 37°C, 
shaking at 200 rpm, until the cells reached an optical density (OD) of 0.6 at OD600, 
measured using a spectrophotometer.  
7. Protein expression was then induced with 0.2 mM IPTG (isopropyl β-D-1-
thiogalactopyranoside), and grown for 20 hours at 25°C, at 200 rpm.  
8. The culture was then spun at 4000 rpm, for 10 minutes, at 4°C, in 4 x 50 ml falcon 
tubes. This was repeated in the same tubes using all of the remaining culture. 
a. The cell pellets were then snap-frozen in liquid nitrogen and stored at -80°C. 
 
2.6.2.2 Purification of TAL 
To isolate and purify the TAL enzyme from the bacterial pellets, the following procedure was 
carried out. 
1. 1 x 50 ml falcon tube containing the pellet of bacteria from the expression of TAL 
protein was thawed on ice.  
2. The cell pellet was then re-suspended in 7.5 ml of lysis buffer (Buffer 1 (25 mM Tris-
HCl pH 8.0, 300 mM NaCl, 10% glycerol) with 1:1000 proteinase inhibitor cocktail and 
5 mM imidazole and 1% Triton X-100). 
a. An alternative lysozyme extraction method was also used. The cell pellet was 
re-suspended in 7.5 ml buffer 1 with 1:1000 proteinase inhibitor cocktail, 1% 
Triton X-100 and 2 mg lysozyme (imidazole left out as it inhibits lysozyme). 
The sample was gently mixed on a rocking platform for 30 minutes at 4°C. 
The sample was then clarified as stated in step 3, without the sonication, and 
then the rest of the purification procedure followed as below. 
3. The sample was then sonicated 7 times for 30 seconds on ice at an amplitude of 6 
microns, resting on ice in between to ensure the sample remained cold, and then 
clarified at 10,000 g for 30 minutes at 4°C.  
a. The supernatant, referred to as soluble fraction, was then taken for 
purification and kept on ice. 
b. The insoluble fraction (pellet) was frozen at -80°C. 
4. 1 ml of the Ni-NTA (nickel-nitrilotriacetic acid) slurry (0.5 ml bead volume) (Ni-NTA 
agarose; 157049819, Qiagen, Germany) was prepared for purification of the 
supernatant, by briefly centrifuging in a 15 ml falcon tube, then the supernatant 
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removed. Lysis buffer (2 ml) was then added to the beads left in the tube, mixed and 
briefly centrifuged, then the supernatant removed. 
5. The bacterial cell lysate supernatant, approximately 7.5 ml from step 3a, was then 
added to the Ni-NTA beads and mixed gently on a rotary shaker at 4°C for 1 hour.  
6. This lysate-Ni-NTA mixture was then loaded into an empty PD10 column (17-0851-
01, GE Healthcare), the cap removed and the flow through collected. 
a. At this stage, the TAL protein is bound to the Ni-NTA beads within the column 
via a His tag.  
7. The column was then washed twice with 2.5 ml wash buffer (buffer 1 + 50 mM 
imidazole), and each wash fraction collected. 
8. Bound TAL protein was then eluted with 2.5 ml elution buffer A (buffer 1 + 250 mM 
imidazole). 
9. The eluted protein was then buffer exchanged using a PD10 desalting column (17-
0851-01, GE Healthcare), to obtain a desalted fraction. 
a. The column was equilibrated with 25 ml elution buffer B (25 mM Tris-HCl pH 
7.5, 150 mM NaCl, 10% glycerol) and the flow through discarded. 
b. Elute containing the TAL protein (2.5 ml) was added to the column, allowed 
to enter the packed bed completely, then the flow through discarded. 
c. The TAL protein was then eluted with 3.5 ml elution buffer B and the flow 
through collected. 
 
2.6.2.2.1 SDS-PAGE gel protein visualisation 
TAL protein purification was assessed by analysis of samples from each step of the process 
by SDS-PAGE (sodium dodecyl sulfate – polyacrylamide gel electrophoresis). 6.5 µl of each 
sample was added to 2.5 µl NuPAGE®LDS sample buffer (4X) and reduced with 1 µl NuPAGE® 
reducing agent (10X), heated at 70°C for 10 minutes before loading onto a NuPAGE® Bis-Tris 
4-12% Mini Gel (IM-8042, Invitrogen, UK) and run for 55 minutes at 200 volts in NuPAGE™ 
MOPS SDS running buffer (NP00102, Invitrogen, UK) with 500 µl NuPAGE® antioxidant in the 
upper buffer chamber. 5 µl of a Full Range GE Healthcare RainbowTM Molecular Weight 
Marker (11580684, FisherScientific) and 5 µl of a Novex™ Sharp Unstained Protein Standard 
(LC5801, ThermoFisher, UK) was used to identify the TAL protein. To visualise the protein 
bands, the gel was immersed in a 0.25% Coomassie Brilliant Blue R250 stain solution (0.25 g 
Coomassie Blue in 100 ml made up with 90 ml methanol: H2O (1:1 v/v) and 10 ml glacial acetic 
acid) for 1 hour on a rocking platform at room temperature. The gel was then de-stained (de-
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stain solution: 100 ml made up with 90 ml methanol: H2O (1:1 v/v) and 10 ml glacial acetic 
acid) by immersion in de-stain solution for 1 hour, on a rocking platform at room 
temperature, repeated 2-3 times with fresh de-stain solution until the protein bands were 
visible. The gel was then photographed. 
 
2.6.2.2.2 Protein quantitation 
In order to quantify the amount of TAL protein purified, a Pierce™ BCA (bicinchoninic acid) 
protein assay kit (23225, Thermo Scientific, UK) and protocol was followed. The reaction 
involves the reduction of Cu2+ to Cu1+ by protein in an alkaline medium, followed by the 
chelation of 2 BCA molecules with 1 Cu1+ ion that produces a purple coloured reaction that 
exhibits strong linear absorbance at 562 nm with increasing protein concentration. 
Briefly, the working reagent is prepared and mixed (50:1, Reagent A: B), and then mixed with 
albumin protein standards at known concentrations and unknown samples (TAL protein) (25 
µl sample + 200 µl working reagent) and then incubated at 37°C for 30 minutes and then left 
to cool to room temperature. A spectrophotometer, set at 562 nm, was then used to measure 
the absorbance of the samples. A standard curve of absorbance was plotted against 
concentration (µg/µl), and used to determine the protein concentration of the unknown TAL 
samples.  
 
2.6.2.3 In vitro TAL experiments 
In vitro assays of the purified TAL enzyme were carried out using 2 mM TAL protein (unless 
otherwise stated) and 100 µmol/L L-tyrosine (Sigma, UK; T8566) (with tyrosine initially 
dissolved at 1 M in 5 M H2SO4 and then diluted using Tris-HCl) made up to 1 ml in 25 mM 
Tris-HCl (pH 8.5). The activity of TAL at different pH’s was tested, using 25 mM Tris-HCl buffer 
at pH 1.5, 4.5 and 8.5. The assays were carried out at 37°C. 50 µl aliquots of each 
experimental condition were taken at various time points, ranging 0-24 hours. The aliquot 
was immediately acidified with 5 µl 5.8 M perchloric acid (10% v/v) to stop the enzymatic 
activity and to deproteinise the sample. The acidified samples were then centrifuged at full 
speed for 5 minutes, and the supernatant removed and stored at -20°C until analysis. 
Tyrosine was analysed by mass spectrometry, using matrix-matched tyrosine calibrators 




2.7 Statistical analysis 
Statistical analysis was performed using Stats Direct 3 (UK) and GraphPad Prism 6 (USA). 
Significance is denoted as p<0.05 *, p<0.01 ** and p<0.001 ***. Error bars represent 
standard error of the mean (SEM). In order to see if there was a statistical difference between 
groups, various statistical tests were used: 
• When comparing the means of two separate or unrelated samples/groups, a two-
tailed unpaired t-test was used. This analysis was used to determine if significant 
differences were observed in Figure 3.13 (number of pigmented chondrons in the tail 
versus lumbar spine), in Figure 3.22 (OARSI scores for each joint quadrant between 
Hgd tm1a -/- and -/+ mice) and in Figure 5.2 (tyrosine concentration in untreated 
mice versus nitisinone-treated mice).  
• To compare the mean metabolite concentration in mice pre- and post-treatment, a 
two-tailed, paired t-test was used as the samples were from the same mice pre- and 
post- treatment. This analysis was used in Figure 3.25 (average metabolite level pre- 
and post- nitisinone in Hgd tm1a -/- mice) and Figure 5.1 (average metabolite level 
pre- and post- nitisinone in BALB/c Hgd-/- mice).  
• When comparing the mean of 3 or more groups, one-way ANOVA was used to test 
for statically significant differences. Where ANOVA detected significant differences, 
a post-hoc multiple comparisons test was used to determine the significant pairwise 
differences between means. 
o Where group sizes were equal, one-way ANOVA was followed by a Tukey 
post hoc test. This analysis was used in the dietary restriction studies in 
Figure 5.3, Figure 5.4, and Figure 5.5, (differences in metabolite levels 
between the groups at each post-dietary restriction time point, in addition 
to comparing body weight changes between the groups), in Figure 5.6 
(difference in metabolite level at three time points), and in Figure 5.7 (body 
weight changes between different dietary conditions).  
o Where group sizes were unequal, one-way ANOVA was followed a Tukey 
Kramer post hoc test. This analysis was used in Figure 3.6 (mean HGA 



















3 Results:  






An existing HGD deficient AKU mouse model, BALB/c Hgd-/-, created by ENU mutagenesis 86 
has previously been shown to exhibit an AKU phenotype 115,116. This mouse has been shown 
to have increased HGA in the plasma, and ochronosis of the knee joint presenting as 
pigmentation of individual chondrons within the calcified articular cartilage. This mouse has 
proven to be a useful model for studying both the pathological effects of AKU and the 
effectiveness of treatments. However, due to the high mutation efficiency of ENU 
mutagenesis, this ENU AKU model could potentially possess other unknown mutations in the 
genome 197, that could affect the phenotype. In addition to the mutagenic strategy used to 
generate the BALB/c Hgd-/- mouse, this model has no further tools such as a reporter gene or 
the presence of site-specific recombinase sequences to allow further manipulation of the 
model. More modern techniques now exist to generate targeted and specific mouse models 
that allow multiple alleles to be generated. 
Here in this chapter, a new mouse model of AKU (Hgd tm1a) has been generated using a 
knockout-first strategy, whereby the Hgd gene is specifically disrupted by gene targeting, 
using a gene trap. This strategy ensures that no other potentially confounding mutations are 
present in the genome. Additionally, the gene trap cassette used to disrupt the gene contains 
a LacZ reporter gene which has been used for localising Hgd gene expression and contains 
site-specific recombinase sites that allow the generation of a conditional allele (both 
presented in the next chapter), both of which were unavailable in the ENU mutagenesis AKU 
model. The generation and phenotyping of this new Hgd tm1a -/- AKU model is presented in 
this chapter, reporting both the metabolic nature and joint pathology characteristics of AKU, 
including comparisons with the mutagenesis model.  
 
3.2 Generation of conditionally targeted mouse model of alkaptonuria 
3.2.1 Establishment of the conditionally targeted Hgd colonies 
Two murine ES cell lines, clones Hgd C10 and C11, were obtained from the UC Davis KOMP 
repository, containing a modified Hgd allele. They were grown on G418-resistant primary 
embryonic fibroblast feeder cells, as described 234. The neo gene within the gene trap cassette 
(see Figure 3.1A) allowed G418 antibiotic selection of healthy ES colonies, see Figure 3.2. The 
selected ES cells were then injected into blastocysts of C57BL/6 at the blastula stage, into the 
blastocoel cavity close to the inner cell mass (Figure 3.3). The modified blastocysts were then 
transferred into pseudopregnant recipient females. Chimeric offspring were then identified 
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by the presence of the non-agouti grey coat colour (C57BL/6N-Atm1Brd), see Figure 3.4. Further 
breeding confirmed that only C10 chimeras achieved germline transmission of the modified 
allele. C10 mice were subsequently bred to homozygosity, using C57BL6/J and referred to as 




Figure 3.1. Schematic and genotyping of the modified Hgd allele.  
A schematic of the modified Hgd allele is shown in A. Hgd tm1a: AKU phenotype. Hgd tm1c/Hgd tm1d (pre-cre): 
wildtype phenotype. Hgd tm1d (post-cre): tissue specific and inducible deletion of Hgd. Using the primer pairs 
Hgd-F/Hgd-ttR and Lox-F/Hgd-R, B shows the genotyping of tm1a; C shows the genotyping of tm1cand tm1d 
(before cre recombination). D shows the genotyping of MxCre (top band) with the Fabp2 control gene (bottom 





Figure 3.2. Culture of embryonic stem cell lines Hgd-C10 and Hgd-C11.  
These stem cell lines contain a modified Hgd allele. The ES cells were grown on feeder cells; primary mouse 
embryonic fibroblasts (EMFIs). The modified Hgd allele contain a neo gene for G418 antibiotic resistance which 
was used for selection. ES cells from the good-looking colonies (yellow arrows) were used for subsequent 




Figure 3.3. Injection of modified ES cells into a blastocyst at the blastula stage.  





Figure 3.4. Selection of chimeric offspring carrying the non-agouti wildtype allele (Atm1Brd).  
Arrows indicate the non-agouti coat colour derived from the modified ES cells. 
 
To obtain the conditionally targeted Hgd tm1d line, Hgd tm1a mice were crossed with Flpo 
mice to remove the FRT-flanked gene trap cassette, leaving a floxed target exon in the Hgd 
tm1c (+/+) allele, see Figure 3.1 235. Homozygote floxed Hgd tm1c +/+ mice were crossed with 
MxCre mice 236 to obtain Hgd tm1d (fl/fl) MxCre (+/- or WT). The removal of the floxed sixth 
exon in Hgd tm1d (fl/fl) MxCre +/- was inducible with administration of polyinosinic: 
polycytidylic acid (pIpC) 236,237. Removal of the floxed sixth exon causes a frameshift mutation, 
triggering nonsense medicated decay of the transcript.  
These novel Hgd alleles can also be presented using the following nomenclature:  
• Hgd tm1a -/- or -/+ → Hgdtm1a(KOMP)Wtsi = Hgd-/- or Hgd-/+.  
• Hgd tm1c +/+ → Hgdtm1c(KOMP)Wtsi = Hgdflox/flox.  
• Pre-Cre Hgd (fl/fl) tm1d MxCre +/- → Hgdflox/floxMxcre+/- 
• Hgd tm1d MxCre +/- post-cre → Hgdtm1d(KOMP)Wtsi = HgdΔMx-1/ΔMx-1 
Here in this thesis, the alleles are termed Hgd tm1a -/- or -/+, Hgd tm1c +/+ and Hgd tm1d 
(fl/fl) MxCre +/- or WT.  
 
3.2.2 Genotyping 
DNA extracted from ear notch tissue was used to genotype mice; see section 2.1.1 for a 
detailed description. Briefly, tissue was digested using proteinase k and lysis buffer at 55°C 
overnight, followed by an isopropanol DNA extraction to isolate genomic DNA. PCR 
amplification of specific sequences using the isolated DNA as a template was then carried out 
using specific primers, followed by gel electrophoresis to separate and visualise DNA bands. 
The resulting DNA bands were used to determine the genotype of mice.  
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3.2.2.1 Hgd tm1a, tm1c and tm1d colonies 
ES cells from clone C10 resulted in chimeras which achieved germline transmission. This 
knockout-first allele (Hgd tm1a) contained a promotorless IRES:LacZ gene trap cassette, 
flanked by an En2 splice acceptor and polyadenylation (poly(A)) sequence,  and a promoter-
driven neo cassette, flanked by a human beta-actin promoter (hBactP) and poly(A) sequence, 
inserted into the fifth Hgd intron with the sixth exon flanked by LoxP sequences, see Figure 
3.1 (adapted from Collins and Rossant, 2007 241; Skarnes et al., 2011 211). The poly(A) 
sequence in the LacZ trapping element causes early termination of Hgd gene transcription; 
Hgd is transcribed up to exon 5 as a fusion transcript with LacZ, but are translated 
independently due to the IRES element. Homozygous Hgd tm1a mice showed an AKU 
phenotype due to Hgd gene disruption. In C10/Hgd tm1a mice, Lox-F/Hgd-R primers 
amplified the LoxP sequence (257bp) showing the allele was floxed (Figure 3.1B). Hgd-F/Hgd-
ttR primers produced a 561bp band in the wildtype allele only; the gene trap cassette 
sequence in the modified allele was too large to be amplified. Homozygous Hgd tm1a 
therefore had only the 257bp floxed band, heterozygous had both the floxed 257bp and 
wildtype 561bp bands and wildtype had only the 561bp band (Figure 3.1B). 
 
Hgd tm1c +/+ had restored Hgd gene expression due to removal of the gene trap and was 
shown to have a wildtype phenotype. To achieve inducible and conditional Hgd deletion, the 
floxed Hgd tm1c +/+ line was bred with an interferon-inducible Mx-1 (Interferon-Induced 
GTP-binding protein Mx1) cre recombinase mouse line,  MxCre 236, generating the Hgd tm1d 
MxCre line. In the Hgd tm1c (restored Hgd allele, floxed) and pre-cre Hgd tm1d (floxed) alleles 
(tm1c and tm1d are both Hgd floxed alleles, with the Hgd tm1d mouse line name 
demonstrating that it has been bred with an MxCre line), Lox-F/Hgd-R primers showed the 
allele was floxed (257bp) and Hgd-F/Hgd-ttR primers showed that Flp recombination had 
occurred (673bp), see Figure 3.1C. Wildtype Hgd tm1c/d (WT/WT; not shown as no mice with 
this genotype were generated) would only have the 561bp band (Hgd-F/Hgd-ttR). 
Homozygously floxed Hgd tm1c/d (+/+) had both the 257bp floxed bands with the 673bp 
post-flp band and heterozygously floxed Hgd tm1c/d (WT/+) had all three bands (257bp 
floxed, 673bp post-flp and 561bp wildtype). Primers specific to MxCre (one primer in the Mx-
1 promoter, one primer in the cre sequence) produced a band at 520bp when MxCre was 
present (Figure 3.1D), denoted as +/-. The genotyping for MxCre does not distinguish the 
copy number as either heterozygous or homozygous. To prevent false-negative MxCre 
genotyping, control primers were included in the PCR reaction mix that amplify exon 1 of the 
Fabp2 gene, a sequence that should always be present, showing that DNA was present in the 
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reaction mixture and that the PCR amplification was successful, preventing false-negative 
genotyping. The control primers produce a band at 194bp, see Figure 3.1D.  
 
3.2.2.2 BALB/c Hgd-/- colony 
In addition to the new targeted Hgd tm1a AKU colony, the existing BALB/c Hgd-/- AKU mice 
115 were used for experiments, established at the University of Liverpool using the original 
ENU AKU mouse from the Pasteur Institute 86. The BALB/c Hgd-/- colony is bred homozygous 
x homozygous, meaning that genotyping was not necessary as all resulting offspring would 
be homozygous. Periodically however, the colony must be genotyped to ensure that the mice 
are still the correct genotype. To identify the mutation present in these AKU mice, the region 
within Hgd containing the AKU mutation is amplified by PCR, producing a 290bp band. Within 
this region in the wildtype, there is a HypCH4III restriction enzyme binding site. This binding 
site is not present in the AKU mutant sequence. Digestion with HypCH4III is therefore used to 
detect the AKU mutation. With reference to Figure 3.5, wildtype mice show bands at 170bp 
and 120bp, due to the action of the restriction enzyme. Homozygous BALB/c Hgd-/- show a 
single intact band at 290bp due to the inability of the restriction enzyme to cut the DNA. 
Heterozygous mice would therefore exhibit bands at 290bp, 170bp and 120bp (not shown as 
no DNA was available from heterozygous mice). 
 
 
Figure 3.5. Genotyping of BALB/c Hgd-/-.  
Following amplification of the region within Hgd containing the AKU mutation, a restriction enzyme digest is used 
to determine the presence or absence of the AKU mutation. The absence of the restriction enzyme binding site 
results in a single intact band in homozygous BALB/c Hgd-/- mice. Wildtype (WT) mice show 2 bands as a result of 






3.3.1 Homogentisic acid 
One of the first signs of AKU in humans is urine that turns dark brown/black after several 
hours due to exposure to the air, due to the presence of HGA. Figure 3.6A demonstrates dark 
urine stained cage bedding from Hgd tm1a -/- mice. This was the first observed sign that this 
new targeted model had AKU. Heterozygous cages did not have any dark urine stained cage 
bedding.  
Following this, HGA was measured in urine and plasma of mice (Figure 3.6B-C). Urinary HGA 
(mean ±SEM) was increased approximately 10,000 - 100,000-fold (99,575 ±30,851 µmol/L) 
and plasma HGA elevated about 50-fold (100.5 ±34.9 µmol/L) in the Hgd tm1a -/- mice 
compared to Hgd tm1a -/+ (plasma: 2.0 ±0.5 µmol/L; urine: 15 ±25.3 µmol/L), Hgd tm1c +/+ 
(plasma: 2.0 ±1.0 µmol/L; urine: 2.4 ±2.9 µmol/L) and C57BL/6 wildtype (plasma: 1.7 ±0.6 
µmol/L; urine: 0.8 ±0.2 µmol/L) mice. These differences were all statistically significant 
(p<0.001; one-way ANOVA, Tukey-Kramer post-hoc). For comparison, urine and plasma HGA 
levels (mean ±SEM) for BALB/c Hgd-/- mice (n=48) are shown in Figure 3.7, and were 151,520 






Figure 3.6. HGA levels in Hgd tm1a -/- AKU mice compared to non-AKU controls.  
A shows dark urine stained cage bedding of Hgd tm1a -/- mice compared to Hgd tm1a +/- and fresh bedding. B 
and C show urine and plasma HGA levels respectively. Urinary HGA is increased approximately 10,000 - 100,000-
fold in Hgd tm1a -/- mice (n=8; mean age [range] = 18.7 [9.0-31.1] weeks; 7 M, 1 F) compared with C57BL/6 
wildtype (n=4; all 26.0 weeks, all F), Hgd tm1c +/+ (n=7; mean age [range] = 23.1 [18.3-25.4] weeks; 2 M, 5 F) and 
Hgd tm1a -/+ (n=16; mean age [range] = 24.6 [7.3-43.6] weeks; 12 M, 6 F) controls. Plasma HGA is increased 
approximately 50-fold in Hgd tm1a -/- mice (n=16; mean age [range] = 16.1 [7.1-31.1] weeks; 13 M, 3 F) compared 
to C57BL/6 wildtype (n=7; mean age [range] = 24.9 [22.3-26.0] weeks; 5 F, 2 M), Hgd tm1c +/+ (n=7; mean age 
[range] = 24.1 [18.3-26.7] weeks, 2 M, 5 F) and Hgd tm1a -/+ (n=18; mean age [range] = 23.9 [7.3-43.6] weeks, 12 
M, 6 F) controls. HGA = homogentisic acid. M = male. F = female. Significance: p<0.05 *, p<0.01 ** and p<0.001 
***. Error bars represent SEM. 
 
AKU is present at birth therefore plasma HGA was measured in day 1 Hgd tm1a -/- pups (2 
pools of n=3; gestation: 19.5 days), see Figure 3.8. Plasma HGA (mean ±SEM) was elevated 





Figure 3.7. HGA levels in BALB/c Hgd-/- mice.  
Urine and plasma HGA levels from 48 adult BALB/c Hgd-/- AKU mice. Mean age [range] = 31.9 [5.8-60.1] weeks. 




Figure 3.8. HGA levels in day 1 Hgd tm1a -/- pups.  
Plasma samples from the pups were combined due to volume constraints into 2 pools of n=3. HGA levels were 




In the BALB/c Hgd-/- mouse model, ochronosis has previously been reported in the tibio-
femoral (knee) joint, using a modified Schmorl’s stain to stain pigment a dark-blue colour 
81,229. Ochronosis was therefore initially assessed in the knee joints of the Hgd tm1a -/- mice 
for comparison, followed by investigation of other joints and tissues. 
An example of Schmorl’s staining from the tibia of a 52-week-old Hgd tm1a -/- AKU mouse is 
shown in Figure 3.9A. Several pigmented chondrons can be seen in the calcified articular 
cartilage, stained a dark-blue colour, indicated by arrows. An unstained section was also 
observed (Figure 3.9B), in which native, unstained ochronotic pigment can be seen, 
appearing yellow-brown (or ochre) in colour. This confirms that the Schmorl’s stain is 
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identifying ochronotic pigment, which allows for easier identification of pigmented cells. The 
use of a nuclear fast red as a counterstain with Schmorl’s stain allows other, non-pigmented 
cells to be identified. 
 
 
Figure 3.9. Identification of ochronotic pigment.  
A shows Schmorl’s staining of the tibio-femoral joint of a 52-week-old Hgd tm1a -/- mouse; arrows indicate 
pigmented chondrons found within the calcified articular cartilage of the tibia. The dashed arrow shows a 
chondron with pericellular pigmentation only. White arrow heads show the tidemark separating the calcified 
articular cartilage from the hyaline cartilage. B shows native ochronotic pigment without Schmorl’s staining. Scale 
bar = 50 µM.   
 
3.3.2.1 Knee joint ochronosis 
In order to determine when ochronosis first appears, knee joints from Hgd tm1a -/- mice 
aged 7–15 weeks were examined for pigmentation. Ochronosis was only found in the 
calcified articular cartilage (Figure 3.10A), first appearing at 9 weeks of age (Figure 3.10B). 
The pigment was initially pericellular (9-11 weeks) and very infrequent. At 26 and 40 weeks 
of age in Hgd tm1a -/- (Figure 3.10C and E respectively), the number and intensity of 
pigmented chondrons was increased and showed advancement of pigmentation to the 
intracellular compartment, including the nucleus. At 40 weeks of age, pigmentation was still 
confined to the calcified articular cartilage. Heterozygous controls (Hgd tm1a -/+) showed no 





Figure 3.10. Initiation and progression of ochronosis in Hgd tm1a -/- mice.  
H&E staining in A shows the division of the articular cartilage into different zones: hyaline cartilage (HC) and 
calcified articular cartilage (CAC) separated by the tidemark (T). Deep to CAC is subchondral bone (SB). B–F show 
femoral condyles from Hgd tm1a mice that have been Schmorl’s stained (stains ochronotic pigment a blue colour). 
B shows pericellular pigmentation of chondrocytes situated in the CAC in a 9-week-old Hgd tm1a -/- femoral 
condyle. C and E show the femoral condyle of Hgd tm1a -/- mice at 26 and 40 weeks of age respectively. The 
pigmentation has advanced to the inner compartment of the cell, with more numerous affected chondrocytes 
showing varying pigment intensities. The pigmentation is still confined to the CAC layer. Hgd tm1a -/+ mice at 26 
and 40 weeks of age (D and F respectively) show no pigmentation. H&E, haematoxylin and eosin. All sections: 6 
µM. Scale bar = 25 µM. 
 
The lifetime progression of the number of pigmented chondrons within the knee joint of the 
BALB/c Hgd-/- colony has previously been reported by both Preston et al. 115 and Keenan et 
al. 116, with a linear pattern of increase observed with increasing age. To show the progression 
of ochronotic pigment with age in the Hgd tm1a -/- colony, knee joints from Hgd tm1a -/- 
mice aged 7-52 weeks were scored; the total number of pigmented chondrons in a 
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representative knee joint section encompassing all 4 joint quadrants was obtained (see 
section 2.2.3.2.1 of methods). With reference to Figure 3.11, the previously reported BALB/c 
Hgd-/- pigmentation progression is compared with that of the newer Hgd tm1a -/- model. The 
progression of the pigmentation observed is comparable in both models, with both showing 




Figure 3.11. Quantification of pigmented chondrons with age in BALB/c Hgd-/- and Hgd tm1a -/- mice.  
The number of pigmented chondrons were quantified in a representative knee joint section from mice of various 
ages from both the BALB/c Hgd-/- (n=28; 16 female aged 7-66 weeks, 12 male aged 8-47 weeks) and Hgd tm1a -/- 
(n=25; 8 female aged 8-48 weeks, 17 male aged 7-52 weeks) mouse models. Progression of pigmentation is similar 
in both models, with the number of pigmented chondrons increasing with age. BALB/c Hgd-/- data from Dr Craig 
Keenan’s thesis and used with his permission 239, some of which was also reported in Preston et al. 2014 115. 
 
3.3.2.2 Investigation of ochronosis in other tissues 
Previously, ochronotic pigmentation in AKU mice has only been reported in the calcified 
articular cartilage of the knee joint. Histological analysis of the elbow, hip and shoulder joints 
identified the presence of ochronotic pigmentation within these joints (Figure 3.12A-C), as 
pigmented chondrons within the calcified articular cartilage. No pigmentation was observed 
in the non-calcified hyaline cartilage, bone, periosteum, nor within ligaments or tendons 
associated with these joints. Within the vertebral column, pigmentation was only associated 
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with chondrons located in the calcified endplates of the vertebral bodies, adjacent to the 
growth plate, located either side of the IVD, and not within the disc itself Figure 3.13D).  
 
 
Figure 3.12. Schmorl’s staining showing ochronotic pigmentation in various joints.  
Pigmented chondrons can be observed within the calcified articular cartilage located on the femoral head of the 
hip joint (A), the articulation of the humerus and radius of the elbow joint (B), and the humeral head and glenoid 
fossa of the shoulder joint (C). Within the vertebral column (D), pigmented chondrons are observed in the calcified 
endplates of the vertebral bodies, either side of the intervertebral disc, but not within the disc itself. A-D from 52-
week-old Hgd tm1a -/-. Scale bar = 50 µM.  
 
The severity of pigmentation appeared to be affected by mechanical loading and force. With 
reference to Figure 3.13, significantly more pigmented chondrons (mean ±SEM) were 
observed within the endplates of the vertebral bodies adjacent to the 2nd lumbar (L2) IVD 
(48.4 ±4.5) compared to an IVD from the base of the tail (2.2 ±0.6) (p = 0.002). Clustering of 
pigmented chondrons was observed in areas of greater tensile stress such as the insertion of 
tendons and ligaments in joints; the Achilles tendon on the calcaneus in the ankle (Figure 
3.14A), the cruciate ligaments on the intercondylar area of the tibial plateau in the knee joint 
(Figure 3.14B), and calcified fibrocartilage found at the entheses attached to the femoral 
condyle where collateral ligaments insert (Figure 3.14C). Pigmentation was also observed 
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within the calcified fibrocartilage of the meniscus of the knee joint associated with chondrons 
(Figure 3.14D) that is subjected to compressive loading. No pigmentation was observed in 
52-week-old Hgd tm1a -/+ control joint tissue, that includes the shoulder, hip, elbow, knee 




Figure 3.13. Comparison of pigmentation within the endplates of tail and lumbar IVDs.  
A+B shows numerous pigmented chondrons within the vertebral endplates of the 2nd lumbar(L2) IVD from the 
lumbar spine. C+D shows the presence of few pigmented chondrons present in the vertebral endplates of an IVD 
from the base of the tail. E shows the difference in the number of pigmented chondrons within the endplates of 
the L2 and tail IVD; 5 sections were scored, taken every 3rd slide. IVD = intervertebral disc. Two-tailed, unpaired 
t-test; p = 0.002. Significance: p<0.05 *, p<0.01 **, p<0.001 ***. Tissue from 52-week-old Hgd tm1a -/-, sectioned 




Figure 3.14. The relationship between ochronotic pigment and mechanical loading and force.  
Large numbers of pigmented chondrons can be seen adjacent to the insertion of the Achilles tendon on the 
calcaneus of the ankle (A) and adjacent to the insertion of a cruciate ligament on the intercondylar area of the 
tibial plateau (B). Pigmented chondrons are observed in the calcified fibrocartilage of entheses attached to the 
femoral condyles (C) and the calcified fibrocartilage within the meniscus of the knee joint (D). A from 65.7-week-
old BALB/c Hgd-/-. B from 40-week-old Hgd tm1a -/-. C from 38-week-old Hgd tm1a -/-. D from 52-week-old Hgd 
tm1a -/-. Scale bar = 50 µM. Image A used with permission from Dr Craig Keenan 239. 
 
In addition to musculoskeletal tissues, sections from the larynx, ear, eye and heart of a 52-
week-old Hgd tm1a -/- mouse were stained with Schmorl’s stain to look for ochronotic 
pigmentation and compared to a 52-week-old Hgd tm1a -/+ (non-AKU) control. Ochronotic 
pigmentation was not observed in the hyaline laryngeal cartilage (Figure 3.15), nor the 
hyaline cartilages of the trachea, and was comparable with the non-AKU control. Ochronotic 
pigmentation was not observed in the eye, where only the dark-black pigmentation of the 
pigmented retinal epithelium was observed (Figure 3.16), nor the ear (Figure 3.17), and was 
comparable to the non-AKU control. In the heart, no ochronotic pigmentation was observed 
in the roots and walls of the vessels nor in the muscular wall/septum of the heart chambers. 
Interestingly, a dark, punctate black pigment was observed within the heart valves of the 
AKU Hgd tm1a -/- heart, however due to the presence of this pigmentation also in the non-
AKU valves it is not thought to be ochronotic pigment (Figure 3.18). This pigment also did not 
stain a dark-blue colour with Schmorl’s staining. This black, punctate pigment was also 
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observed macroscopically within the hearts of Hgd tm1a -/-, Hgd tm1a -/+ and C57BL/6 WT 
mice during whole LacZ staining, see Figure 3.19. Sections from the liver (Figure 3.20) and 
kidney (Figure 3.21) of 52-week-old AKU (Hgd tm1a -/-) and non-AKU (Hgd tm1a -/+) were 
also stained with Schmorl’s stain, with no differences observed. 
 
 
Figure 3.15. Schmorl’s staining of laryngeal cartilage from AKU and non-AKU mice.  
Sections from Hgd tm1a -/- (AKU) showed no ochronotic pigmentation in the laryngeal cartilage and was 
comparable with Hgd tm1a -/+ (non-AKU). Boxes show area of magnification. Tissue from 52-week-old mice. Scale 





Figure 3.16. Schmorl’s staining of eyes from AKU and non-AKU mice.  
Sections from Hgd tm1a -/- (AKU) showed no ochronotic pigmentation (only the pigmented retinal epithelium 
shows pigmentation) and were comparable with Hgd tm1a -/+ (non-AKU) eyes. The pigmented retinal epithelium 
showed a dark black pigment as expected in both Hgd tm1a -/- and Hgd tm1a -/+. Eyes from 52-week-old mice. 





Figure 3.17. Schmorl’s staining of ear tissue from AKU and non-AKU mice.  
Sections from Hgd tm1a -/- (AKU) showed no ochronotic pigmentation and were comparable with Hgd tm1a -/+ 
(non-AKU) ear tissue. Ear tissue from 52-week-old mice. Scale bar in top two rows = 100 µM. Scale bar in bottom 
row = 50 µM. 
 
 
Figure 3.18. Schmorl’s staining of the heart valves from AKU and non-AKU mice.  
The presence of a black pigment was observed in histological sections of the heart valves of both AKU (Hgd tm1a 





Figure 3.19. Presence of a black pigment within the heart valves of AKU and non-AKU mice.  
The presence of a black, punctate pigment was observed in the heart valves of both AKU (Hgd tm1a -/-, 31 weeks 
old) and non-AKU (Hgd tm1a -/+, 23 weeks old; C57BL/6 WT, 22 weeks old) mice, indicated by arrows. 
 
 
Figure 3.20. Schmorl’s staining of liver from AKU and non-AKU mice.  
Sections from AKU Hgd tm1a -/- showed no ochronotic pigmentation and were comparable with non-AKU Hgd 




Figure 3.21. Schmorl’s staining of kidney from AKU and non-AKU mice.  
Sections from AKU Hgd tm1a -/- showed no ochronotic pigmentation and were comparable with non-AKU Hgd 
tm1a -/+ control kidney sections. Tissue from 52-week-old mice. Scale bar = 50 µM. 
 
3.3.2.3 Osteoarthritis 
To investigate whether the AKU phenotype causes osteoarthritis in the Hgd tm1a -/- mouse 
model, knee joints from Hgd tm1a -/+ (n=5) and Hgd tm1a -/- (n=5) male mice aged 52 weeks 
were taken. Every fourth, coronal paraffin section was stained with safranin O/fast green. 
Safranin-O stains cartilage red, with the intensity reflecting the proteoglycan content, and 
fast green stains the bone green. This staining allows the cartilage to be scored histologically 
for osteoarthritis, using the OARSI histopathology initiative scoring system 242. Briefly, each 
joint quadrant throughout the knee joint is scored individually, given a score between 0 and 
6. Normal cartilage would score 0. Proteoglycan loss only, with no structural changes would 
score 0.5. Minor damage, with superficial vertical clefts and some loss of the surface lamina 
would score 2. Scores of 3-6 would represent vertical clefts/erosion to the calcified cartilage, 
ranging from <25% of the articular surface (score 3) to >75% of the articular surface (score 
6).  
OARSI scores are presented as both the mean OARSI score and maximum OARSI score for 
each joint quadrant (medial tibia; medial femur, lateral tibia and lateral femur). With 
reference to Figure 3.22, no significant differences (two-tailed, unpaired t-test) were 
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observed between Hgd tm1a -/+ and Hgd tm1a -/- mice, across all 4 joint quadrants, for both 
the mean and maximum OARSI scores. Figure 3.23 shows safranin O/fast green staining of 
the knee joint cartilage from 52-week-old Hgd tm1a -/- and Hgd tm1a -/+ mice, which look 
comparable. No subchondral bone sclerosis was observed in Hgd tm1a -/- or -/+. The 
presence of osteophytes was also documented; an osteophyte was observed in one Hgd 
tm1a -/- mouse (on the medial tibia), and an osteophyte observed in three Hgd tm1a -/+ 
mice (2 on the medial tibia 1 on the medial femur), see Figure 3.24. 
 
 
Figure 3.22. Osteoarthritis scoring of the knee joint in Hgd tm1a -/+ and Hgd tm1a -/- mice.  
Coronal knee joint paraffin sections from 52-week-old, male Hgd tm1a -/+ (n=5) and Hgd tm1a -/- (n=5) were 
stained with safranin-O/fast green and the cartilage scored using the OARSI scoring system. No significant 
differences were found between Hgd tm1a -/+ and Hgd tm1a -/- mice for the mean and maximum OARSI score 
across all joint quadrants (two-tailed unpaired t-test). MT = medial tibia. MF = medial femur. LT = lateral tibia. LF 





Figure 3.23. Safranin-O/fast green staining of 52-week-old Hgd tm1a -/+ and Hgd tm1a -/- knee joint cartilage.  
Coronal paraffin section of the knee joints from 52-week-old, male Hgd tm1a -/+ (n=5) and Hgd tm1a -/- (n=5) 
were stained with safranin-O/fast green and the cartilage scored using the OARSI scoring system. No differences 
were observed between Hgd tm1a -/- and Hgd tm1a -/+ knees. Top row shows a whole knee joint. MT = medial 
tibia. MF = medial femur. LT = lateral tibia. LF = lateral femur. Scale bar in top row = 100µM. Scale bar in bottom 




Figure 3.24. Presence of osteophytes in 1-year AKU and non-AKU mice.  
Safranin O/fast green staining of knees from 5 Hgd tm1a -/- (AKU) and 5 Hgd tm1a -/+ (non-AKU) male mice 
revealed the presence of osteophytes (indicated by circles). An osteophyte was observed on 1 AKU mouse knee 
on the medial tibia. Osteophytes were observed on 3 non-AKU mouse knees; 2 on the medial tibia and 1 on the 
medial femur (bottom right). Each section: femur top, tibia bottom, lateral towards left, medial towards right. 
Scale bar = 100 µM.  
 
 
3.4 Response to nitisinone therapy 
Nitisinone has been tested in both the existing BALB/c Hgd-/- mouse model and in human 
patients, where it has been shown to lower circulating HGA and increase tyrosine. Hgd tm1a 
-/- mice (n=6) were therefore treated with 4 mg/L nitisinone (the dose previously used in 
AKU mice), with tail bleed samples taken pre- and post-treatment to assess the response of 
HGA, tyrosine and other associated metabolites.  
With reference to Figure 3.25, HGA (mean ±SEM) was decreased 10-fold from 81.7 ±10.5 
µmol/L to 8.2 ±0.6 µmol/L whilst all other metabolites increased; all changes were significant 
(two-tailed paired t-test). Tyrosine increased 14-fold from 65.3 ±10.3 µmol/L to 940.3 ±55.7 
µmol/L. Phenylalanine increased 1.2-fold from 78.1 ±2.1 µmol/L to 95.8 ±5.2 µmol/L. HPPA 
increased 9-fold from 18.0 ±0.4 µmol/L to 169.3 ±29.0 µmol/L. 4-hydroxyphenyllactic acid 





Figure 3.25. Nitisinone treatment of Hgd tm1a -/- mice.  
Hgd tm1a -/- mice (n=6; 3 male, 3 female; mean age [range]: 12.2 [11.1-17.3] weeks) were treated with 4 mg/L 
nitisinone (NTBC) for 1 week, with tail bleed samples taken pre- and post-treatment. HGA = homogentisic acid. 
Tyr = tyrosine. Phe = phenylalanine. HPPA = 4-hydroxyphenylpyruvic acid. HPLA = 4-hydroxyphenyllactic acid. 
Error bars represent SEM. Paired t-test (two-tailed) significance: p<0.05 *, p<0.01 **, p<0.001***. 
 
3.5 Discussion  
The pathophysiology of AKU has been investigated in ex vivo tissue samples 57,78,99, in vitro 
models 81,100 and also within an ENU mutagenesis mouse model of AKU, BALB/c Hgd-/- 115. To 
investigate the metabolic consequences of AKU and novel therapeutic approaches further, a 
new conditionally targeted mouse model of AKU in the C57BL/6 background has been 
generated using a mutant knockout-first Hgd allele obtained from the UC Davis Knockout 
Mouse Project (KOMP) Repository.  
Targeted gene disruption in Hgd tm1a removes any potentially confounding mutations that 
could be present in the existing BALB/c Hgd-/- ENU AKU mouse model 115, as ENU mutagenesis 
causes a high frequency of genomic mutations 198. The LacZ reporter gene within the Hgd 
gene locus has enabled precise localisation of Hgd expression, which is shown in chapter 4. 
Manipulation of this Hgd tm1a knockout-first allele by FRT/flp and Cre/LoxP site-specific 
recombination enabled liver-specific Hgd deletion in double transgenic Hgd tm1d MxCre +/- 
mice, highlighting important considerations for future therapy in AKU, which is also shown in 
chapter 4. Here within this chapter, the new conditional Hgd tm1a mouse model of AKU has 




3.5.1 Phenotyping the new Hgd tm1a mouse model 
The new targeted mouse model of AKU (Hgd tm1a -/-) was shown to exhibit an AKU 
phenotype comparable to the BALB/c Hgd-/- mouse, of increased HGA in the urine and 
plasma, and joint pigmentation 243.  
Plasma HGA levels in Hgd tm1a -/-, which were on average about 100 µmol/L, were 
comparable to the values previously reported in the ENU BALB/c Hgd-/- model 115,116, which 
ranged from approximately 100-200 µmol/L, measured via a different HPLC system. Serum 
HGA values in human AKU patients are lower than that of AKU mice; fo example the mean 
[range] serum HGA reported in 40 patients was 29.2 [5.8-45.5] µmol/L 52 and in 3 patients 
was 49.3 [30-75] µmol/L 47. The methods used here to quantitate HGA, both in plasma and 
urine, are state-of-the-art, clinically validated assays, developed for use on human samples 
at the NAC and for the SONIA-1 and SONIA-2 clinical trials 46,47. Shown for the first time are 
HGA values for heterozygous mice (Hgd tm1a -/+) that do not have AKU, with HGA levels 
comparable to C57BL/6 or Hgd tm1c +/+ wildtype control mice. Also reported for the first 
time are urine HGA values in AKU mice, which are on average 100,000 µmol/L in Hgd tm1a -
/- mice, which had not previously been reported for the BALB/c Hgd-/- model within recent 
publications in 2014 115 nor 2015 116, where only plasma HGA was reported. Urine HGA had 
been reported for the original ENU BALB/c Hgd-/- model in 1994, determined by organic 
solvent extraction and GC/MS, and determined to be >0.55 mol/mol creatinine 86, which is 
not a comparable measure to the urine HGA levels obtained here. Therefore, for a direct 
comparison, urine and plasma HGA was measured in BALB/c Hgd-/- mice, taken from the pre-
treatment values of a separate experiment to this thesis, measured via the same HPLC system 
used to analyse samples from Hgd tm1a -/-. The plasma HGA in BALB/c Hgd-/- was 
comparable, at approximately 100 µmol/L, and urine HGA was approximately 150,000 
µmol/L, which is higher than the approximate 100,000 µmol/L level reported in Hgd tm1a -
/-, but still within the same order of magnitude. This urinary HGA difference could be due to 
differences in urine concentration, as the urine HGA values (and plasma) are not normalised 
to creatinine, which can minimise variation due to the differences in sample concentration. 
In human AKU patients, HGA is measured in urine that is collected over a 24-hour period. For 
a direct comparison, mice would have to be single-housed in metabolic cages, which was not 
deemed necessary in this case as it is very stressful 244. The HGA quantitation method used 
here has very recently been developed to incorporate creatinine quantitation for both 
plasma and urine (Andrew T Hughes, unpublished) and would be more ideal to use in the 
future, especially for urine samples where the concentration can vary drastically. 
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Both the BALB/c Hgd-/- and Hgd tm1a -/- AKU models reflect the metabolic nature of AKU, 
demonstrating increased HGA, and both show signs of ochronosis, as pigmentation of 
chondrocytes located within calcified articular cartilage (see section 3.5.1.1 below for a more 
in-depth discussion on pigmentation). The appearance and progression of ochronosis is very 
similar between the two models. The new targeted Hgd tm1a -/- AKU model presenting with 
an almost identical metabolic and joint phenotype to the mutagenesis BALB/c Hgd-/- model 
provides confidence that no confounding mutations affecting the AKU phenotype, with 
regards to HGA and joint pigmentation at least, are present in the BALB/c Hgd-/- model; other 
mutations affecting aspects of the disease not yet investigated could exist. In addition, this 




With the introduction of Schmorl’s staining in AKU 81, ochronosis was first detected in a 
mouse model of AKU (BALB/c Hgd-/- Fah-/-) in the calcified articular cartilage of the knee joint, 
as pigmented chondrocytes with dense intracellular granular pigmentation and a uniform 
pigmentation of the territorial matrix 229. No pigmentation was identified in the bone or 
hyaline cartilage, nor in the inter-territorial matrix. Pigmented kidney nodules were observed 
in this Hgd-/- Fah-/- AKU model but were deemed to be associated with the severe renal 
pathology caused by the confounding HT-1 (Fah) mutation. Subsequently, ochronosis was 
studied in a specific mouse model of AKU, BALB/c Hgd-/-115. The earliest sign of pigmentation 
was identified in the pericellular matrix of chondrocytes which then progressed to the 
intracellular compartment, appearing synonymous with the initial stages of ochronosis 
described in human calcified cartilage 57. Pigmented chondrons were only observed on the 
calcified articular cartilage with no end stage blanket pigmentation of any cartilage layers 
observed, even at 71 weeks of age, with the authors suggesting that lifespan and loading 
differences due to quadrupedal gait and size between mice and humans may account for this 
115.  
Pigmentation of knee joint chondrons in BALB/c Hgd-/- mice were quantified, with 
pigmentation shown to begin at 15 weeks of age (mice aged 6, 8 and 15 weeks were 
investigated), then progress linearly with age. In Hgd tm1a -/- mice aged 7-15 weeks, 
pericellular pigmentation was first identified at 9 weeks within the calcified articular cartilage 
(Figure 3.10); progression was then similar to BALB/c Hgd-/- AKU mice. The ability to score the 
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progression of ochronosis in AKU mice is a very useful method for assessing future 
therapeutic interventions, as utilised by Keenan et al. in 2015, where nitisinone was shown 
to prevent ochronosis from birth and halt ochronosis progression when given mid-life 116. The 
counting of pigmented chondrons however is not a perfect quantitation/assessment of joint 
pigmentation; the observer has to decide whether or not a chondron is pigmented, which 
can sometimes be unclear. The scoring here, and in the previous BALB/c Hgd-/- publications, 
was also carried out using one section to represent the whole joint, which is the first coronal 
section to encompass all joint quadrants (medial and lateral parts of both the femur and tibia) 
when sectioning posterior to anterior through the knee. Although the knees are embedded 
for sectioning in the same orientation, the position is also not always perfect and may lead 
to areas of the joint being positioned slightly different to other joints for example. This 
pigment scoring system could be slightly improved, by using a method similar to the 
osteoarthritis scoring system, in which the joint is scored in multiple sections taken at fixed 
intervals across a joint (i.e. every 4th slide encompassing all joint quadrants), which would 
eliminate variation due to positioning of the joint and the location of the section.  
 
3.5.1.1.1 Anatomical distribution of ochronotic pigment 
Pigmentation within the BALB/c Hgd-/- and Hgd tm1a -/- models had previously only been 
reported in the knee joint, within the calcified articular cartilage. Here, other large weight 
bearing hyaline joints were investigated with similar findings; ochronosis was only found as 
pigmentation of chondrons within the calcified articular cartilage of the femoral head, 
shoulder joint and elbow joint. Investigation of the vertebral column revealed pigmented 
chondrons within the calcified cartilaginous endplates of the vertebral bodies, however no 
pigmentation was found within the fibrocartilaginous annulus fibrosis of the IVD itself, which 
is a reported site of pigmentation in humans 55,58. Pigmentation was observed within the 
fibrocartilaginous menisci within the knee of mice, which is calcified, and also a site of 
pigmentation in humans.  
It would appear in mice, that non-calcified tissue, including non-calcified cartilage, is not 
susceptible to pigmentation. The superficial layer of hyaline articular cartilage, hyaline 
laryngeal cartilages, elastic cartilage within the pinna of the ear and the fibrocartilaginous 
IVDs, which are all composed of non-calcified cartilage, did not show pigmentation even 
though humans with AKU show pigmentation in these tissues. Pigmentation was also absent 
in the eyes, tendon, ligament and heart valves. The calcified articular cartilage is clearly the 
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initial site of pigment deposition in mice and if the lifespan of mice was longer, or if the 
disease process could somehow be accelerated, they may also eventually exhibit 
pigmentation of non-calcified tissue such as hyaline cartilage. 
 
3.5.1.1.2 Loading and force influences ochronotic pigment 
From the observations here in mice, it would appear that mechanical loading increases 
pigmentation, as a significantly greater number of pigmented chondrons were observed in 
the lumbar vertebral endplates compared to those found in the base of the tail. The degree 
of loading and compression in the mouse lumbar spine is much greater than that of the tail. 
Furthermore, clustering of pigmented chondrons at the insertion of both ligaments and 
tendon, such as the Achilles tendon on the calcaneous and the cruciate ligament on the tibia, 
into calcified articular cartilage appears to reflect the increased tensile stress exerted in these 
areas. 
The effect of physical stress/loading on pigmentation has also been seen in human AKU 
patients. It has been reported that macroscopic pigmentation on the surface of human 
calcified articular cartilage appears to be centralised rather than peripheral, and found to be 
localised in areas of greater loading such as the medial tibial plateau compared to the lateral 
tibial plateau of the knee joint 57. Additionally, an autopsy of an AKU patient revealed that 
whilst the aortic valve of the heart was heavily pigmented along with the mitral valve, the 
tricuspid valve was unaffected and minimal pigmentation was observed in the pulmonary 
valve 55. The authors suggested that the difference in blood pressure and haemodynamic 
factors between the pulmonary and systemic circulation may influence ochronotic 
pigmentation. Further to this, prominent pigmentation has been observed in the carotid 
sinus, which is known to have more turbulent blood flow than the rest of the common carotid 
artery, which showed little pigmentation 245. Lichtenstein and Kaplan also documented that 
pigment was barely found in veins which are under less pressure than the arterial system 58. 
Pigmentation within the sclera of the eye is also postulated to be due to UV light damage and 
stress arising from ocular muscle contractions 83. This pattern of pigmentation in both mice 
and humans supports the exposed collagen hypothesis that increased mechanical loading 
may lead to damage of collagen fibrils within the ECM resulting in loss of protective 
molecules, increasing the susceptibility of the collagen fibrils to pigment deposition 79. This 
would suggest that the ECM associated with chondrons located in calcified cartilage is the 
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first matrix to exhibit damage through normal physiological loading and ageing, becoming 
susceptible to HGA-derived pigmentation. 
The relationship of mechanical loading with ochronotic pigment could be investigated further 
using the AKU mouse model. In humans, AKU is a rare form of osteoarthritis, exhibiting a 
severe and early-onset osteoarthropathy caused by ochronotic pigment deposition. 
Osteoarthritis is commonly studied using mouse models, investigating pathophysiology, 
therapeutic interventions/prevention measures or the involvement of specific genes using 
genetically-modified mice for example. Histological analysis is the main method of evaluating 
osteoarthritis in the mouse, often utilising scoring systems to compare the severity of 
cartilage destruction such as the OARSI scoring system 242. This system was used here to 
compare the knee joints of untreated Hgd tm1a -/- mice with the non-AKU Hgd tm1a -/+. 
Although human AKU patients experience a very severe osteoarthropathy, no differences in 
OARSI scores were observed at 52-weeks of age in the AKU mice. Although the OARSI scores 
were not significantly different, the Hgd tm1a -/+ mice had slightly increased OARSI scores in 
all the knee joint compartments except for the lateral femur which was comparable. Also, 
more osteophytes were also observed in Hgd tm1a -/+ mice than Hgd tm1a -/-, which are a 
common feature of osteoarthritis. This may suggest that the initial, localised chondrocyte 
pigmentation could actually be protective in Hgd tm1a -/- mice, although only a small number 
of mice were investigated for osteoarthritis here. We know from human AKU patients 
however that this is not the case for more advanced ochronosis where extreme joint 
degeneration occurs and pigmentation is clearly not protective, but is detrimental to the 
joint. If the mice were aged for longer, perhaps a difference in OARSI scores would be 
observed. Induction of experimental osteoarthritis in the knee joint of the AKU mice however 
could provide an alternative, quicker way of investigating osteoarthritis; the severity of 
cartilage damage could be assessed and compared to the non-AKU controls.  
Various different murine osteoarthritis models are used in the literature. In addition to using 
spontaneous mouse models of osteoarthritis such as the STR/ort mouse 246, other post-
traumatic models are available where an osteoarthritic phenotype is induced such as intra-
articular collagenase injection 247, surgical models such as anterior cruciate ligament 
transection (ACLT) 248 or destabilisation of the medial meniscus (DMM) 249, and non-invasive 
joint loading/injury 250,251.  
Glasson et al. compared ACLT and DMM, concluding that DMM had good reproducibility, was 
less invasive and resulted in slower disease progression than ACLT, in which erosion of tibial 
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subchondral bone could be observed 249. DMM however still produces moderate-to-severe 
osteoarthritis by 4-8 weeks post-surgery 249. Non-invasive joint injury involves using 
externally applied mechanical loading to the knee that does not break the skin or disrupt the 
joint capsule to initiate osteoarthritic joint degeneration by injuring the cartilage 251. Cyclic 
tibial compression of articular cartilage is a commonly used loading method, whereby cyclic 
axial compressive loads, considered to be sub-injury forces, are applied to the lower leg 
through the knee and ankle joints, with the ability to adjust the compressive load, the 
number of cycles and the frequency that loading is carried out 251. Cyclic tibial compression 
is also a very consistent and repeatable method, with the loading controlled by a machine, 
and is versatile as the loading force, time that the knee is loaded for, how often the knee is 
loaded and the length of time post-loading can all be altered. 
Techniques that induce osteoarthritis in mice could be applied to the AKU Hgd tm1a -/- 
mouse model, to see how changes in loading caused by either surgically-induced joint 
instability (i.e. DMM) or increased ex-vivo mechanical loading affect both pigmentation of 
chondrons with the knee joint, and the severity of the induced osteoarthritis. For 
pigmentation scoring to be possible however, the calcified articular cartilage must remain 
intact to enable quantification of chondrons within this region. Additionally, as discussed 
above, pigmentation may be a time-dependant process as the first pigmented chondrons 
were observed at 9 weeks in Hgd tm1a -/- mice, meaning that a period longer than 8 weeks 
for pigmentation changes to be observed post-injury or post-loading may be required. DMM 
would therefore most likely be unsuitable, as knees are typically analysed 8-12 weeks post-
surgery, where erosion of the calcified articular cartilage may occur, destroying the region 
where pigmented chondrons need to be counted 252. The adjustability of the cyclic tibial 
compressive loading model, coupled with the milder joint degeneration observed due to the 
sub-injury forces used, representing chronic overuse rather than acute injury, would 
probably make it the most suitable experimental osteoarthritis model to apply to AKU mice 
to investigate the effect of mechanical loading on pigmentation and severity of joint 
degeneration.  
 
3.5.1.1.3 Extracellular matrix and collagen 
In human tissue, it has been shown that ochronotic pigment has an affinity for fibrillar 
collagen surrounded by glycosaminoglycan-rich ground substance, particularly in hyaline 
cartilage 67. Analysis of the ligamentous capsule of an AKU hip joint revealed intracellular 
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pigmentation of fibroblasts and extracellular granular pigmentation associated with collagen 
fibres that varied in position, distribution and intensity, with individual collagen fibres 
showing a periodic banding pattern of pigment 78. It was this work that preceded the exposed 
collagen hypothesis, with Taylor et al. suggesting that the ECM is normally resistant to 
pigmentation, becoming susceptible after biochemical or mechanical damage 57. They also 
demonstrated that pigmented cartilage is much stiffer than non-pigmented cartilage and 
suggested that focal pigmentation of individual chondrocytes and their associated collagen 
is likely to make the ECM prone to damage through normal loading, leading to further 
damage in an inevitable downward spiral. This then led to the exposed collagen hypothesis 
as the small granule pigmentation observed on collagen fibres was similar to the pattern of 
proteoglycan binding, leading to the theory that proteoglycan and glycosaminoglycan loss 
exposes collagen fibrils, allowing initial HGA/pigment binding that acts as a nucleation point 
for pigment aggregation 79.  
In addition to tissue calcification and loading, it is likely that other factors influence 
pigmentation as many non-calcified tissues in humans are pigmented, such as the sclera of 
the eye, the walls of blood vessels and the hyaline articular cartilage of various joints. 
Differences in the composition of the ECM between tissues could be a factor in ochronotic 
pigment deposition. With collagen being the most abundant protein in the ECM, the collagen 
distribution (amount and type) in different tissues may explain why some tissues are more 
susceptible to ochronosis, in addition to differential expression of other ECM proteins. 
Furthermore, tissues with different compositions of ECM will likely transmit force/load 
differently, which may cause damage to occur at different rates. The initiation of 
pigmentation in the calcified cartilage before any other tissue matrix suggests it is the first 
matrix to become damaged and subsequently susceptible to attack, as demonstrated by the 
presence of pigmentation in AKU. Cellular activity may also have a role in pigmentation, as 
the pigment first identified in mice is associated with the chondrocytes of the calcified 
articular cartilage and their immediate pericellular matrix. It has been shown in vitro that 
culture media incubated with HGA took weeks to darken in the absence of cells, compared 
to a few days in the presence of cells (osteosarcoma cell lines), highlighting that cellular 
activity accelerates pigment deposition 81. Interestingly, of the osteosarcoma cell lines 
incubated with HGA, SaOS-2 cells were the most pigmented, but synthesised the least 
amount of collagen (the opposite was true for TE85 cells), suggesting that the amount of 
collagen is not a key factor associated with pigmentation 81. The authors suggested that the 
ECM formed in vitro is not assembled correctly into a highly organised and complex matrix, 
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with no periodicity observed in fibres, and may explain the rapid pigment deposition by a 
lack of protective factors. This work suggests that the type of collagen and associated 
proteins may have a role in pigment deposition, or protection from pigmentation, as certain 
matrices maybe be more easily damaged than others, whilst others such as mineralised bone 
are protective in AKU. The absence of pigmentation within tendons and ligaments of mice 
may be due to the structural organisation of collagen fibrils into fibril bundles, fascicles and 
then fibre bundles, which may initially protect the collagen from HGA binding. If this 
assumption was correct, ligaments and tendons may eventually pigment in mice. It is 
unknown in human AKU patients whether the initiation of pigmentation in calcified articular 
cartilage occurs at the same time as ligament and tendon pigmentation. Although mentioned 
above that cellular activity may be a factor accelerating ochronosis, tissues such as cartilage, 
tendon and ligament have comparatively less cells, in addition to substantially less blood flow 
or none in the case of cartilage, than tissues such as liver that does not show any 
pigmentation despite being extremely cellular, very well perfused and the main site of HGA 
production. The liver is mainly composed of equal amounts of type I and type III collagen, in 
addition to non-fibrillary basement membrane collagens 253. The main collagen found within 
articular cartilage is type II 254, with ligaments and tendons mainly composed of type I 
collagen 255,256. The organic matrix of bone is also mainly formed of type I collagen, alongside 
type V collagen, and is resistant to pigmentation; perhaps mineralized collagen is protected 
from HGA binding.  
 
3.5.1.1.4 Mice represent the early stages of human ochronosis 
No pigmentation was identified in the eyes, ears, laryngeal cartilage, IVDs or the heart valves 
of the AKU mice, which are all sites of pigmentation in humans. The black punctate pigment 
seen within the heart valves of both the AKU (Hgd tm1a -/-) and non-AKU (Hgd tm1a -/+) 
mice has been reported in normal C57BL/6 mice, thought to be produced by melanocytes 
derived from a neural crest cell lineage 257. The AKU mice here appear to represent only the 
early stages of human ochronosis, with pigmentation only observed in calcified cartilage. The 
initial site of ochronosis in human tissues may also be chondrons within calcified articular 
cartilage of the joints, with other tissues subsequently becoming pigmented. The deposition 
of ochronotic pigment is likely to be a time-dependant process that is related to the 




3.5.2 Limitations of AKU mouse models 
Both the mutagenesis and targeted AKU mouse models exhibit the main characteristics of 
AKU. The degree of pigmentation however appears to reflect early-stage joint disease even 
when aged up to 52-80 weeks 115 which is comparable with 40-60 years in humans 258, with 
no pigmentation observed in the superficial hyaline cartilage, despite humans exhibiting a 
severe blanket pigmentation present in all layers of articular cartilage 57. Furthermore, AKU 
patients develop an early-onset and severe osteoarthritis which is not seen in the AKU mouse 
models at 1 year of age, with no difference in OARSI scores between homozygous and 
heterozygous Hgd tm1a mice, supported by Preston et al. reporting that the rate of 
development of osteoarthritis in the BALB/c Hgd-/- model was not greater than the 
spontaneous osteoarthritis rate reported for the background strain 115. The absence of 
osteoarthritis in AKU mice is likely due to the ochronotic phenotype being mild and early-
stage. 
In addition to the absence of macroscopic and microscopic hyaline cartilage pigmentation, 
there has been no pigmentation observed in other connective tissues such as tendons, 
ligaments, and the cardiovascular system in mice, that are pigmented in humans. 
Endogenous vitamin C production in mice 259 has previously been suggested as a protective 
mechanism against the formation of ochronotic pigmentation due to its anti-oxidant activity. 
In the 1990s, the absence of pigmentation in the first ENU BALB/c Hgd-/- mice aged up to 14 
months was attributed to vitamin C production. Differences in urinary excretion of HGA in 
mice and humans may also have explained the lack of joint pigmentation. However, with 
subsequent detection of ochronotic pigment and plasma HGA levels that were 3-4-fold 
greater than human levels 115,116,243, differences in ochronosis severity cannot be attributed 
to increased urinary excretion nor vitamin C production. Furthermore, treatment with 
vitamin C in human patients has not proven to be clinically effective 28. Lack of severe 
pigmentation in mice could be attributable to their smaller size and quadrupedal gait, and 
therefore reduced mechanical loading of the joints compared to humans, although it should 
be noted that the shoulders, which are a non-weight bearing joint in humans, are affected in 
human patients. If ochronotic pigment deposition is a time-dependant process, the short 
mouse lifespan may prevent the accumulation of ochronotic pigment to the severe level 
observed in humans. As discussed in section 1.2.5.3, several different HGD mutations exist in 
human AKU patients, which can have different impacts on the residual activity of the enzyme 
93,95,260. The BALB/c Hgd-/- model, was shown to have <6% HGD activity compared to WT, due 
a truncated protein 86. Residual activity in the Hgd tm1a -/- model has not been reported or 
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investigated, however no mRNA is detected after the gene trap which causes early 
termination of transcription (chapter 4 includes liver and kidney Hgd mRNA data from Hgd 
tm1a -/- in the Hgd deletion studies, Figure 4.31B+C Figure 4.32B+C Figure 4.33B+C, using 
primers after the gene trap cassette spanning exons 9-10). A recent study reporting the first 
human genotype-phenotype data however suggests that different residual HGD activity due 
to the nature of the different mutations is likely not responsible for the observed differences 
in ochronosis between mice and humans. No differences in serum or 24-hour urine HGA, eye 
pigmentation and hip bone density were found between patients with 1% or 31-34% residual 
HGD activity 93.  
 
3.5.3 Future of AKU mouse models 
Both the mutagenesis BALB/c Hgd-/- and targeted Hgd tm1a -/- model show a very similar 
phenotype of increased plasma and urine HGA and joint pigmentation, therefore either 
model is suitable for future AKU research. Although these AKU mouse models may not exhibit 
a severe joint pathology like the human condition, they provide insight into early joint disease 
that currently cannot be investigated in human patients. Biochemically however, these 
models represent the AKU phenotype very well, showing the same metabolic features of 
increased HGA and response to nitisinone.  AKU mouse models provide controlled conditions 
in which to test potential therapies where the effectiveness can be investigated to a much 
greater extent than is possible in humans, in addition to the opportunity to conduct research 
into the slow, progressive pathophysiology of AKU, which is not achievable in human patients 
where disease manifestation takes decades to present. The requirement for these AKU 
mouse models will exist whilst new therapies and potential treatments are being established, 
such as enzyme replacement and gene therapy, the latter being the ultimate cure for AKU 
and other Mendelian diseases.  
Studying a rare disease such as AKU can also provide valuable lessons for other more 
common diseases such as osteoarthritis, as AKU exhibits a severe and early 
osteoarthropathy. Additionally, attempts to treat the metabolic defect in AKU, via enzyme 
replacement or gene therapy, will undoubtedly uncover fundamental information applicable 



















4 Results:  





It is well known that HGD is expressed in the liver and the kidney, where other enzymes in 
the tyrosine metabolism pathway are also present. There have however been reports that 
HGD is also expressed in the small intestine, colon and prostate 90, the brain 99 and also within 
osteoarticular cells 100. Here in this chapter, the tissues in which Hgd is expressed in the 
mouse was investigated using the new Hgd tm1a model that expresses a LacZ reporter gene 
as a fusion transcript with the first 5 exons of Hgd. The initiation of Hgd expression in 
embryonic development was also investigated.  
Having determined the location of Hgd expression, the Hgd tm1a model was then 
manipulated to create the conditional knockout model Hgd tm1d. The aim was to investigate 
the effect of Hgd removal on the AKU phenotype in order to determine the minimum level 
of Hgd mRNA required. In determining which Cre to use the following points were 
considered; which cells in the liver expressed Hgd and can the Cre be used at different levels 
in order to achieve a dose response curve of the deletion. The main liver Cre available 
worldwide was the albumin Cre. However, when we looked at the expression of HGD in liver, 
the albumin expressing cells were not the same as the HGD cells, (data extracted 
from Aizarani et al. (2019) 261). MxCre has been shown to delete floxed genes in the liver 236 
in addition to being inducible and able to produce a dose response.  
Mx-1 Cre (MxCre) was therefore used here for liver-specific deletion of Hgd as firstly it is an 
inducible model, using pIpC to increase interferon levels in order to promote MxCre 
expression, which allowed phenotyping before and after deletion to be carried out. Secondly, 
the use of this interferon-inducible MxCre allowed for a dose response study to be performed 
by using a range of pIpC doses, resulting in different levels of residual Hgd expression. 
Although Mx-1 is active in other tissues outside of the liver, Hgd is only expressed in the liver 
and kidney, therefore Mx-1 activity which is low in the kidney will only remove Hgd from the 
liver. In addition to the investigating the amount of liver Hgd mRNA needed to rescue AKU, 
other important considerations for future therapy are addressed in this chapter.  
 
4.2 Hgd expression 
LacZ, a bacterial gene not found within the mammalian genome, encodes the enzyme β-
galactosidase (β-gal). The presence of this enzyme in tissues can be determined ex vivo by 
staining tissues for LacZ, where the colourless substrate x-gal (5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside) is converted into galactose and 5-bromo-4-chloro-3-hydroxyindole; 
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the latter dimerizes and oxidises to 5,5'-dibromo-4,4'-dichloro-indigo, an intense blue 
product that can be visualised. The Hgd tm1a mouse has a LacZ reporter gene situated within 
the gene trap cassette, see Figure 4.1. Positive blue LacZ staining therefore represents Hgd 
expression. 
 
Figure 4.1. Position of LacZ within the Hgd tm1a allele.  
In the Hgd tm1a allele, the LacZ gene is situated within the gene trap cassette between exons 5 and 6. This LacZ 
gene, which follows a splice acceptor sequence and internal ribosome entry site (IRES), is expressed as a fusion 
transcript with the first 5 exons of the Hgd gene, after which the gene is then interrupted by a poly(A) sequence 
in the gene trap. The first 5 Hgd exons and the LacZ gene are translated independently due to the IRES element.  
Positive LacZ expression therefore indicates the expression of the Hgd gene. 
 
4.2.1 Whole-tissue LacZ staining  
Macroscopic LacZ staining was carried out across a variety of adult tissues from Hgd tm1a -
/- mice to identify the tissues expressing Hgd. Briefly, tissues were dissected, lightly fixed in 
2% paraformaldehyde, 0.2% glutaraldehyde on ice (fixation for too long will diminish/abolish 
activity of the β-gal enzyme), rinsed in X-gal rinse solution, then stained in X-gal stain solution 
containing 1 mg/ml X-gal in the dark, at room temperature whilst rotating. Tissues were then 
rinsed in X-gal rinse, then photos taken with the tissue submerged in PBS, followed by fixation 
in 10% formalin for a minimum of 24 hours, and then transferred to 70% ethanol.  
Tissues from Hgd tm1a -/- and -/+ mice containing the LacZ reporter gene were stained for 
LacZ alongside tissues from control mice that do not have a LacZ gene. These LacZ negative 
controls included Hgd tm1c +/+, Hgd tm1d (fl/fl) MxCre WT or +/- and C57BL/6 WT; the 
controls varied due to availability at the time of staining. Positive LacZ staining was observed 
macroscopically in the liver and kidney (Figure 4.2, Figure 4.3) of Hgd tm1a mice. Positive 
staining was observed across the liver parenchyma. In the kidney, only the cortex stained 
positive; the medulla and renal pelvis did not stain. At 1 and 2 hours, the intensity of LacZ 
staining in the heterozygous liver was less intense than the staining in the homozygous liver. 
After overnight staining, the difference in staining intensity was no longer obvious. In Hgd 
tm1a -/- mice, kidney expression was observed at 2 hours but not at 1 hour as was observed 
in the liver. In LacZ negative controls, the liver and kidney both stained negative after 





Figure 4.2. LacZ staining of adult liver.  
Liver from Hgd tm1a -/- (31.1 weeks) and Hgd tm1a -/+ (23.1 weeks) stained LacZ positive indicated by the blue 
colour. Liver from LacZ negative Hgd tm1c +/+ (26.7 weeks) and C57BL/6 WT (22.3 weeks) controls did not stain. 




Figure 4.3. LacZ staining of adult kidney.  
The kidney cortex, and not the medulla, from Hgd tm1a -/- (31.1 weeks) and Hgd tm1a -/+ (23.1 weeks) stained 
LacZ positive indicated by the blue colour. Kidney from LacZ negative Hgd tm1c +/+ (26.7 weeks) and C57BL/6 WT 
(22.3 weeks) controls did not stain. o/n = overnight. 
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To determine the histological localisation of positive LacZ staining in the liver and kidney, 
overnight LacZ-stained tissue was paraffin sectioned. Upon sectioning however, it became 
apparent that the LacZ staining was only at the periphery of the tissue, and in the area 
immediately surrounding blood vessels, see Figure 4.4. Upon sectioning, the tissues were 
also very crumbly; it was very difficult to obtain a section that didn’t shatter. This suggested 
that the tissue was not fixed or processed sufficiently. LacZ staining was performed 
overnight; this is standard procedure for LacZ staining. The Hgd gene here is highly expressed, 
taking only an hour for blue staining to appear in the Hgd tm1a -/- mice. During staining, the 
X-gal must penetrate the tissue. Here, the blue product (5,5'-dibromo-4,4'-dichloro-indigo), 
which is insoluble, appears to have formed a physical barrier that prevented further 
penetration of the stain deeper into the tissue. This insoluble layer may also have prevented 
proper fixation and processing of the tissue for paraffin embedding; poor cell morphology of 
the liver was observed, see Figure 4.4B. The same issues were observed with the kidney. 
Frozen section LacZ staining (section 4.2.2) was therefore undertaken in order to determine 
the histological location of positive LacZ staining in the liver and kidney. 
 
 
Figure 4.4. Paraffin wax sectioning of LacZ stained liver from Hgd tm1a -/-.  
A shows intense blue LacZ staining that can only be seen at the periphery of the liver (top left) and the area 
immediately surrounding blood vessels (arrows in top right). Penetration of the LacZ stain appears to be limited. 
Higher magnification images are shown in B. Scale bar = 100 µM.  
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The adrenal gland, situated at the superior pole of the kidney, was also LacZ stained; no LacZ 
staining was observed macroscopically after overnight staining, with the adrenal gland from 
Hgd tm1a -/- looking comparable to that of Hgd tm1d (fl/fl) MxCre +/-, which does not 
possess a LacZ gene, see Figure 4.5A. Histological sectioning confirms that no blue LacZ 
staining was observed at the histological level, see Figure 4.5B. 
 
 
Figure 4.5. Overnight LacZ staining of the adult adrenal gland.  
A shows overnight LacZ staining of the adrenal gland from Hgd tm1a -/- (16.3 weeks), which did not show any 
positive blue staining, and was comparable to the LacZ negative Hgd tm1d (fl/fl) MxCre +/- (5.4 weeks) control. B 
shows histological sections of overnight LacZ adrenal glands, counterstained with eosin. No LacZ staining was 
observed histologically in Hgd tm1a -/- (13.1 weeks) nor the LacZ negative control. Scale bar = 50 µM.  
 
With reference to Figure 4.6, the heart, lung and spleen were LacZ negative. Staining was 
observed in the intestinal lumen (indicated by arrows) of Hgd tm1a -/- and Hgd tm1a -/+ 
mice, however this was due to false-positive bacterial staining, also seen in the LacZ negative 
C57BL/6 WT intestine. The intestine was further investigated via histology; histological 
sections of LacZ stained small intestine (Figure 4.7), caecum (Figure 4.8) and large intestine 
(Figure 4.9) all show that the blue LacZ staining is within the intestinal lumen, and not within 
the cells making up the intestinal wall, in both the Hgd tm1a -/-  and LacZ negative Hgd tm1d 





Figure 4.6. Overnight LacZ staining of adult heart, lung, spleen and intestine.  
The heart, lung and spleen were LacZ negative in Hgd tm1a. LacZ staining was seen in the lumen of the intestine 
in Hgd tm1a and also in the WT LacZ negative control, due to false-positive bacterial LacZ staining. Hgd tm1a -/- 
= 31.1 weeks. Hgd tm1a -/+ = 23.1 weeks. Hgd tm1c +/+ weeks = 26.7 weeks. C57BL/6 WT = 22.3 weeks.  
 
Figure 4.7. Histological sectioning of LacZ stained small intestine.  
After LacZ staining overnight and fixation, the tissue was paraffin sectioned and counterstained with eosin. False-
positive LacZ staining was observed within the lumen of the small intestine, in both in Hgd tm1a -/- (aged 42.7 
weeks) and the LacZ negative Hgd tm1d (fl/fl) MxCre WT (aged 34.4 weeks). No LacZ staining was observed within 




Figure 4.8. Histological sectioning of LacZ stained caecum.  
After LacZ staining overnight and fixation, the tissue was paraffin sectioned and counterstained with eosin. False-
positive LacZ staining was observed within the lumen of the caecum, in both in Hgd tm1a -/- (aged 42.7 weeks) 
and LacZ negative Hgd tm1d (fl/fl) MxCre WT (aged 34.4 weeks). No LacZ staining was observed within the cells 
of the caecum intestinal wall. Scale bar in top row = 100 µM. Scale bar in bottom row = 50 µM.  
 
Figure 4.9. Histological sectioning of LacZ stained large intestine.  
After LacZ staining overnight and fixation, the tissue was paraffin sectioned and counterstained with eosin. False-
positive LacZ staining was observed within the lumen of the large intestine, in both in Hgd tm1a -/- (aged 42.7 
weeks) and LacZ negative Hgd tm1d (fl/fl) MxCre WT (aged 34.4 weeks). No LacZ staining was observed within 
the cells of the intestinal wall. Scale bar in top row = 100 µM. Scale bar in bottom row = 50 µM.  
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With reference to Figure 4.10, the muscle, skin, eye and brain also showed no macroscopic 
LacZ staining; Hgd tm1a tissues were comparable with the LacZ negative controls. Due to the 
eye being naturally dark and pigmented, histological sectioning was performed to ensure 
that there was no positive LacZ staining masked by the dark colour of the eye. Histologically, 
the eye from Hgd tm1a -/- and C57BL/6 WT mice are both comparable; no LacZ staining 
observed Figure 4.11.  
 
Brain that had been LacZ stained was also histologically sectioned to ensure that it was LacZ 
negative. Areas of particular interest was the cerebral cortex, cerebellum, midbrain, basal 
forebrain and hippocampus and striatum (caudate putamen), see Figure 4.12A. Figure 4.12B 
shows H&E staining of C57BL/6 WT and Hgd tm1a -/+ sagittal brain sections encompassing 
all of the specific areas of interest. The H&E stain was used to help identify regions of the 
eosin stained sections from the C57BL/6 wildtype control and Hgd tm1a -/+ sections. At this 
low magnification, no blue LacZ staining was observed. Figure 4.13 then shows specific areas 
of the brain in higher magnification, in which no blue LacZ staining was identified. 
 
 
Figure 4.10. Overnight LacZ staining of muscle, skin, eye and brain.  
No LacZ staining was observed in any of these tissues from Hgd tm1a mice or LacZ negative controls. Hgd tm1a -





Figure 4.11. Histological sectioning of LacZ stained eyes.  
After LacZ staining overnight and fixation, eyes were paraffin sectioned and counterstained with eosin. No 
positive LacZ staining was observed in Hgd tm1a -/- (31.1 weeks) nor the LacZ negative C57BL/6 WT (22.3 weeks) 




Figure 4.12. Histological anatomy of LacZ stained brain sections.  
A shows the anatomy of the mouse brain. After LacZ staining overnight and fixation, brains were paraffin 
sectioned in the sagittal plane and counterstained with eosin (B; right). Additional sections were also stained with 
H&E to aid localisation of structures within the brains (B; left). Individual images were stitched together in order 
to visualise the whole brain section, to allow anatomical areas of the brain to be identified more easily. At low 
resolution, no positive LacZ staining (blue) was observed in Hgd tm1a -/+ (23.1 weeks) or the LacZ negative 
C57BL/6 WT (22.3 weeks) brain sections. BF, basal forebrain; CB, cerebellum; CCa, corpus callosum; CP, caudate 
putamen; H, hippocampus; Hy, hypothalamus; M, medulla; MB, midbrain; OB, olfactory bulb; ON, olfactory 
nucleus; P, pons; RC, rostral commissure; T, thalamus. H&E, Haematoxylin and eosin. Source of image used in A: 





Figure 4.13. Histological sectioning of LacZ stained brains.  
After LacZ staining overnight and fixation, brains were paraffin sectioned and counterstained with eosin, in 
addition to H&E staining to aid identification of brain regions. No positive LacZ staining (blue) was observed in 
Hgd tm1a -/+ or C57BL/6 WT brain sections. BF, basal forebrain; CB, cerebellum; CCa, corpus callosum; CP, 
caudate putamen; H, hippocampus; Hy, hypothalamus; M, medulla; MB, midbrain; OB, olfactory bulb; ON, 
olfactory nucleus; P, pons; RC, rostral commissure; T, thalamus. Scale bar = 200 µM. 
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With reference to Figure 4.14, cartilage was LacZ negative; the hip did not show any staining. 
Overall, bones of the knee (femur and tibia), hip (femur) and ribs were LacZ negative. There 
was however positive blue staining present at the growth plates observed in both Hgd tm1a 
and wildtype LacZ negative controls, see the arrows in Figure 4.14. The presence of staining 
in the wildtype LacZ negative control mice suggests this is false-positive staining. Paraffin 
sectioning of the ribs in Figure 4.15 shows that the blue staining is localised to multinucleate 
osteoclasts present at the resorption zone of the growth plate. False-positive osteoclast 
staining has been previously reported 263. Further staining was then carried out in other 
skeletal areas. The vertebral column was LacZ stained and shown to be negative, with no 
macroscopic staining observed in the vertebrae, intervertebral disc and spinal cord, see 
Figure 4.16. Also investigated were the bones of the lower jaw and craniofacial skeleton, 
which are derived from the neural crest of the ectodermal germ layer, whereas the bones of 
the rest of the body are derived from the mesodermal germ layer. Overnight LacZ staining of 




Figure 4.14. Overnight LacZ staining of bone and cartilage from the knee, hip and ribs.  
In some of tissues where the growth plate is observable, positive blue staining was observed in the growth plates 
(indicated by arrows), including from the LacZ negative Hgd tm1c +/+ and C57BL/6 WT controls that do not 
possess a LacZ reporter gene. No other staining was observed. Hgd tm1a -/- = 31.1 weeks. Hgd tm1a -/+ = 23.1 





Figure 4.15. False-positive LacZ staining of osteoclasts within the rib growth plate.  
Rib tissue was stained for LacZ overnight, fixed, embedded in paraffin wax, sectioned and counterstained with 
nuclear fast red. A shows the region of the rib in which false-positive LacZ staining (blue) of osteoclasts was found 
in Hgd tm1a -/- mice (B) and C57BL/6 WT mice (C), indicated by arrows.  Hgd tm1a -/- = 31.1 weeks. C57BL/6 WT 





Figure 4.16. Overnight LacZ staining of bone and cartilage from the lumbar spine, lower jaw and craniofacial 
skeleton.  
No LacZ staining was observed in Hgd tm1a -/- (spine 13.1 weeks, jaw and craniofacial skeleton 16.3 weeks), with 
the staining comparable to the LacZ negative Hgd tm1d (fl/fl) MxCre +/- (all tissue 5.4 weeks) control.  
 
As it was previously reported that HGD is expressed in the human prostate, the prostate from 
male mice was LacZ stained, along with the bladder, seminal vesicles, urethra and vas 
deferens, see Figure 4.17A. Positive LacZ staining was seen in the vas deferens, in addition to 
slightly less intense positive LacZ staining in the prostate, in both Hgd tm1a -/- and the LacZ 
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negative Hgd tm1d (fl/fl) MxCre WT mice, see Figure 4.17B. In order to show that the staining 
is false-positive, the prostate and vas deferens were paraffin sectioned, see Figure 4.18, to 
demonstrate that the pattern of staining in the Hgd tm1a -/- mice was identical to the 
staining observed in Hgd tm1d (fl/fl) MxCre WT mice, where a LacZ gene is not present, and 
is therefore not representative of Hgd expression. Within the vas deferens, the staining was 
localised to the luminal border of the tubule wall (Figure 4.18A), with no blue staining present 
within the luminal contents which consists of mature sperm. Within the prostate, small 
diffuse spots of blue staining were observed (Figure 4.18B). 
 
 
Figure 4.17. Overnight LacZ staining of the prostate.  
A shows the anatomical location of the prostate, which surrounds the urethra, below the urinary bladder. In B, 
LacZ staining was not observed in the seminal vesicles, urethra or bladder. Positive LacZ staining was observed in 
the vas deferens (arrows) and prostate (asterix) of Hgd tm1a -/- (29.3 weeks), however this was also present in 




Figure 4.18. Histological sectioning of LacZ stained vas deferens and prostate.  
After LacZ staining overnight and fixation, the prostate and vas deferens were paraffin sectioned and 
counterstained with nuclear fast red. A shows the vas deferens and B shows the prostate from Hgd tm1a -/- (29.3 
weeks) and Hgd tm1d (fl/fl) MxCre WT (13.0 weeks) mice. Blue staining in both the vas deferens and prostate, 
indicated by arrows, was present in both Hgd tm1a -/- mice and in the LacZ negative control Hgd tm1d (fl/fl) 
MxCre WT mice, indicating false-positive LacZ staining. The pattern and intensity of staining in the Hgd tm1a -/- 
tissue is the same as the Hgd tm1d (fl/fl) MxCre WT tissue. Scale bar = 50 µM. 
 
 
The gonads were also LacZ stained. With reference to Figure 4.19, macroscopic LacZ staining 
revealed that the ovary, fallopian tubes and uterus in female mice did not stain LacZ positive 
in Hgd tm1a -/- mice. Histological sectioning confirmed that no blue LacZ staining was 
observed (Figure 4.20), and was comparable with the LacZ negative control. Overnight LacZ 
staining of the testis, epididymis and part of the vas deferens revealed positive blue staining 
in Hgd tm1a -/-, see Figure 4.21. Due to positive blue staining also being observed in the LacZ 
negative control mouse (Hgd tm1d (fl/fl) MxCre WT) within the epididymis and vas deferens, 





Figure 4.19. Overnight LacZ staining of adult ovaries, fallopian tubes and uterus.  
After overnight LacZ staining, no positive staining was observed in the ovaries, fallopian tubes and the uterus from 
female Hgd tm1a -/- (13.1 weeks). The Hgd tm1a -/- staining was comparable to the LacZ negative Hgd tm1d (fl/fl) 
MxCre +/- (5.4 weeks) control. O = ovary, F = fallopian tube, U = uterus.  
 
  
Figure 4.20. Histological sectioning of LacZ stained ovary, fallopian tubes and uterus.  
After LacZ staining overnight and fixation, the ovary, fallopian tubes and uterus were paraffin sectioned and 
counterstained with eosin. No positive LacZ staining was observed in any of these tissues from Hgd tm1a -/- (13.1 





Figure 4.21. Overnight LacZ staining of adult testis and epididymis.  
Positive blue LacZ staining was observed in the testis, epididymis and part of the vas deferens from male Hgd 
tm1a -/- (16.3 weeks). The LacZ negative control (Hgd tm1d (fl/fl) MxCre WT; 23.1 weeks) shows positive blue 
staining in the epididymis and vas deferens, but not in the testis.  
 
Histological sectioning of the testis and epididymis is shown in Figure 4.22; the vas deferens 
was investigated above in Figure 4.18 with the prostate. Within the testis, positive blue 
staining was observed within the luminal aspect of the seminiferous tubules of Hgd tm1a -/-
, and not within the LacZ negative control, which indicated that Hgd is expressed in the testis, 
see Figure 4.22A-C. The middle tubules of the testis were not stained blue, most likely due to 
the stain solution not penetrating the centre of the tissue fully. The staining was not observed 
within the extra-tubular Leydig cells or peri-tubular myoid cells. The positive blue staining 
appears to be in the cytoplasm of the developing sperm, which progress through a series of 
developmental stages, beginning at the basal aspect of the seminiferous tubule then passing 
through the somatic Sertoli cells that form the walls of the tubules (these are very hard to 
identify even with histology), finishing at the luminal aspect of the seminiferous tubule wall, 
with the spermatozoa tails projecting into the lumen, see Figure 4.23. The blue staining 
shown in Hgd tm1a -/- matches the pattern of staining observed within the testis of a 
different knockout mouse model called Paskin -/- in the literature, where the authors report 
positive blue staining within the cytoplasm of developing spermatids and spermatozoa, see 
Figure 4.22D 264. The positive blue staining in Figure 4.23B appears to be within the cytoplasm 
of secondary spermatocytes, round spermatids and the elongated spermatozoa towards the 
luminal side of the seminiferous tubules. The small punctate dots near the basal surface may 
be cytoplasmic residual bodies released from the round spermatids as they alter their 
morphology to become elongated spermatozoa. 
Within the epididymis (see Figure 4.24), positive blue LacZ staining was observed within the 
innermost aspect of the tubule wall (see arrows) in both Hgd tm1a -/- and the LacZ negative 
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Hgd tm1d (fl/fl) MxCre WT control, indicating that the staining is false-positive and does not 
represent Hgd expression. Although not identified macroscopically in Figure 4.21, there was 
positive blue LacZ staining with in the lumen of the tubules of the epididymis in Hgd tm1a -
/-. This staining is could either be within the cytoplasm of the spermatozoa contained within 
the epididymis and/or the cytoplasm droplets from the developing spermatids released from 
the seminiferous tubules. The epididymis from the Paskin -/- mice shown in Figure 4.22D also 







Figure 4.22. Histological sectioning of LacZ stained testis.  
After LacZ staining overnight and fixation, the testis was paraffin sectioned and counterstained with eosin (A), 
nuclear fast red (B) or stained with haematoxylin & eosin (C). Positive blue LacZ staining can be observed within 
the tubules of the testis from Hgd tm1a -/-. The testis of the LacZ negative control (Hgd tm1d (fl/fl) MxCre WT) 
shows no LacZ staining. The blue LacZ staining appears to be within the developing germ cells undergoing 
spermatogenesis. D shows positive blue LacZ staining in cryosectioned testis from Paskin -/- (has LacZ reporter 
gene) and Paskin +/+ (LacZ negative) mice, counterstained with neutral red, reported by Katschinski et al. in 2003 
264. The blue LacZ staining is localised to the developing germ cells within the seminiferous tubules around the 
luminal surface, specifically within the cytoplasm of spermatids and within the tail region of maturing 
spermatozoa. The pattern of blue staining in D is comparable to B. Hgd tm1a -/- 16.3 weeks. Hgd tm1d (fl/fl) 




Figure 4.23. Histological identification of the cell types within the testis.  
A shows a schematic representation of the cell types, both somatic and germ cells, within the testis. B shows 
nuclear fast red counterstaining of LacZ stained testis from Hgd tm1a -/-. The developing germ cells that migrate 
through the seminiferous tubule germinal epithelium have been identified. Abbreviations: BM, basement 
membrane; AdC, adluminal compartment; BTB, blood testis barrier; BcS, basal compartment; Le, Leydig cells; My, 
myoid cells; S1, spermatogonia; PS, primary spermatocytes; SS, secondary spermatocytes; RS, round spermatids; 




Figure 4.24. Histological sectioning of LacZ stained epididymis.  
After LacZ staining overnight and fixation, the epididymis was paraffin sectioned and counterstained with eosin 
(A), nuclear fast red (B) or stained with haematoxylin & eosin (C). Positive blue LacZ staining can be observed at 
the luminal edge of the tubule walls within the epididymis (indicated by arrows) in both Hgd tm1a -/- and the 
LacZ negative Hgd tm1d (fl/fl) MxCre WT control. Positive blue LacZ staining is also observed within the lumen of 
the epididymis tubules in Hgd tm1a -/-, which is not observed in the control. Hgd tm1a -/- 16.3 weeks. Hgd tm1d 
(fl/fl) MxCre WT 23.1 weeks. Scale bar in top row of A = 100 µM. Scale bar in bottom row of A, and in B and C = 
50 µM. 
 
4.2.2 Frozen section LacZ staining  
OCT-embedded frozen liver and kidney from Hgd tm1a -/- were sectioned with a cryostat to 
obtain frozen tissue sections. As with LacZ staining of whole tissue, fixing the section before 
staining is required if the tissue was not fixed prior to cryo-embedding. X-gal was used at the 
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same concentration as whole tissue staining, at 1 mg/ml. Protocols in the literature were 
greatly varied, therefore the frozen section LacZ staining procedure required optimization, 
with regards to fixation time, staining temperature and staining duration. Initially, a 3-minute 
0.2% glutaraldehyde (GA) fix was used, followed by staining overnight at 37°C, with the 
section fully immersed in the frozen X-gal stain solution. With reference to Figure 4.25, the 
sections were overstained, with a poor cell morphology, likely due to prolonged exposure to 
37°C. The same staining procedure was then undertaken at room temperature; the staining 
intensity was better and not overstained, however the morphology of the cells was still poor. 
This may have been due to the 3-minute GA fix not being long enough, and also due to the 
tissue being immersed in stain solution for too long. Thinner sections would also improve 
tissue morphology. Eosin, a cytoplasmic stain, was also tested as a counterstain, and was not 
useful in the liver, as the LacZ staining was present in the cytoplasm. Subsequently, a 10-
minute GA fix with staining at 37°C for 2 hours to minimise the time in the stain solution but 
with a quicker reaction was performed, on 6 µM sections. The staining intensity and tissue 





Figure 4.25. Optimisation of frozen section LacZ staining of liver and kidney from Hgd tm1a -/-.  
Liver and kidney tissue from 26.7-week-old Hgd tm1a -/-. GA, glutaraldehyde. Scale bar = 50 µM. 
 
Positive LacZ staining, and therefore Hgd expression, was observed throughout the 
parenchyma of the liver, in the cytoplasm of hepatocytes and not in the nucleus (Figure 
4.26A). In the kidney cortex, staining was also observed in the cytoplasm of certain tubule 
cells with no staining seen in the glomeruli (Figure 4.26B). In order to determine whether the 
tubule cells that stained positive were proximal convoluted tubule (PCT) or distal convoluted 
tubule (DCT) cells, a periodic acid Schiff (PAS)/haematoxylin stain was performed. Figure 
4.26C shows PAS/haematoxylin staining of a paraffin section of kidney cortex and how it 
distinguishes PCTs by the presence of a PAS-positive dark pink/purple brush border that is 
not present on DCTs. The PAS/haematoxylin stain was then performed on frozen sectioned 
kidney cortex to ensure the stain was suitable for frozen sections and gave the same result 
(Figure 4.26D). Frozen section LacZ staining of the kidney cortex was then performed, 
139 
 
followed immediately by PAS staining with no haematoxylin which is too similar in colour to 
the LacZ staining, see Figure 4.26E. The blue LacZ staining was localised with the PAS-positive 




Figure 4.26. Histological location of Hgd in the liver and kidney cortex.  
Liver (A) and kidney cortex (B) from Hgd tm1a -/- (26.7 weeks) show positive LacZ staining after 2 hours 
(counterstain = NFR). In the liver, positive staining is throughout the parenchyma, in the cytoplasm of hepatocytes. 
In the kidney cortex, staining is not in the glomerulus, and is only in some of the tubule cells. PAS/H staining of 
paraffin sectioned (C) and frozen sectioned (D) kidney cortex distinguishes PCTs from DCTs by the presence of a 
PAS-positive dark pink/purple brush border. Combined LacZ and PAS staining (with no haematoxylin) of the kidney 
cortex (E) localises the LacZ positive blue cells with the PAS-positive PCT cells. All sections: 6 µM. NFR, nuclear fast 
red. PAS, periodic acid Schiff. H, haematoxylin. PCT, proximal convoluted tubule. DCT, distal convoluted tubule. 
Scale bar = 100 µM. 
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4.2.3 Hgd mRNA distribution 
In addition to using the LacZ reporter gene to localise Hgd expression, qPCR analysis of Hgd 
mRNA was also performed. A range of tissues from Hgd tm1d (fl/fl) MxCre WT mice (male; 
n=4) were harvested, immediately frozen in liquid nitrogen or immersed in RNAlater solution. 
RNA was then isolated, reverse transcribed to produce cDNA and qPCR performed using Hgd-
specific primers. Hgd mRNA expression was found within the liver and kidney, with no 
expression detected within the skin, cartilage, bone, brain, spleen, eye, intestine, lung, heart 
or muscle (Figure 4.27).  
 
 
Figure 4.27. Analysis of Hgd mRNA expression by qPCR.  
Relative Hgd expression, normalised to 18S, is shown in a variety of adult Hgd tm1d (fl/fl) MxCre WT (male, n=4; 
mean age [range] = 16.5 [16-18] weeks) tissues. Hgd expression was found in the liver and kidney. Hgd1 primers 
(spanning exons 3-4). Error bars represent SEM. Dr Peter Wilson performed the RNA extraction, cDNA synthesis 
and qPCR.  
 
Due to LacZ staining indicating that Hgd is expressed in the developing germ cells of the testis 
and epididymis, mRNA was collected from the testis, epididymis and liver of adult Hgd tm1a 
-/- mice (male, n=3, aged 13.9 weeks). Primers were used that span exons 3-4 before the 
gene trap cassette. With reference to Figure 4.28, the Hgd expression detected via qPCR in 
the testis was 7,612-fold lower than the liver, and in the epididymis was 2,036-fold lower. 
Although the mean value for the epididymis was higher than the testis, it was only one value 
of the three that was higher, with the other values being comparable. With the highest 
epididymis value removed, the expression of Hgd mRNA is 16,700-fold lower than the liver 
in the epididymis, which would reflect the lower staining intensity observed in the lumen of 
the epididymis compared to the tubules in the testis. This analysis by qPCR confirms the 
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presence of Hgd mRNA, albeit a very low level of expression comparted to the liver, within 
the testis and epididymis.  
 
 
Figure 4.28. Analysis of Hgd mRNA expression by qPCR in the testis and epididymis.  
Relative Hgd expression, normalised to 18S, is shown in the testis and epididymis of Hgd tm1a -/- mice (male, 
n=3, aged 13.9 weeks) and compared with the liver from the same mice. Hgd1 primers (spanning exons 3-4).  
 
 
4.2.4 Embryo Hgd expression 
To investigate when Hgd expression begins during development, time-mated Hgd tm1a -/- 
embryos were collected and used for LacZ staining, both as whole embryos and for frozen 
section staining, in addition to Hgd mRNA analysis from the liver (the kidney was too small 
to isolate).  
Macroscopically, LacZ staining of whole embryos showed positive staining at E14.5 onwards 
in the liver (Figure 4.29A). Frozen section LacZ staining at the histological level however 
revealed positive, punctate LacZ staining at E12.5 onwards in the liver (Figure 4.29B). In the 
kidney, positive LacZ staining was observed at E15.5 in some of the developing kidney tubules 
(Figure 4.29C). All other embryonic tissues examined in frozen sections, including the brain, 
eye, bones and other internal organs were LacZ negative.  
Liver Hgd mRNA expression in Hgd tm1a -/- was analysed by qPCR (Hgd1 primers spanning 
exons 3–4 before gene trap cassette) at E12.5 (n=3), E13.5 (n=3), E14.5 (n=4) and E15.5 (n=3), 
day 1 pups (n=6) and compared with adult mice (n=4, male, mean age 18.9 weeks), see Figure 
4.29D. Compared to the adult, liver Hgd mRNA expression was 0.3% at E12.5, 0.8% at both 
E13.5 and E14.5, and 2.3% at E15.5. This considerable difference in Hgd mRNA was reflected 
in the LacZ staining intensity seen between the adult liver (Figure 4.26A) compared to the 
142 
 
embryo liver (Figure 4.29B). Day 1 pup liver Hgd expression was 12.6% of the adult expression 
level (8-fold lower). 
 
 
Figure 4.29. Hgd expression in Hgd tm1a -/- embryos.  
A shows macroscopic LacZ staining of time-mated embryos, with positive blue LacZ staining seen at E14.5 onwards 
in the liver. B shows microscopic LacZ staining of liver from E11.5 to E13.5. At E11.5, the liver showed no visible 
LacZ staining; positive LacZ staining was seen at E12.5 onwards. C shows microscopic LacZ staining of the kidney, 
with positive LacZ staining seen at E15.5. D shows Hgd mRNA expression in E12.5 (n=3), E13.5 (n=3), E14.5 (n=4) 
and E15.5 (n=3) embryos, day 1 pups (P1) (n=6) and adult Hgd tm1a -/- mice (n=4; all male; mean age [range] = 
18.9 [16.6-19.7] weeks), analysed via qPCR (Hgd1 primers spanning exons 3-4). Sections: 7 µM. Error bars 




4.3 Inducible and liver-specific Hgd knockout 
The HGD enzyme is expressed in the liver and kidney where it metabolises HGA as part of the 
tyrosine metabolism pathway. In order to investigate liver-specific Hgd gene deletion in mice, 
the double transgenic Hgd tm1d (fl/fl) MxCre line was generated. Hgd tm1c +/+ mice with a 
floxed Hgd gene were bred with another transgenic mouse line expressing MxCre 
recombinase. MxCre is a cre recombinase under the control of the Mx-1 promotor. This Mx-
1 promotor should be silent in healthy mice, therefore pre-cre, Hgd tm1d (fl/fl) MxCre +/- 
mice have a wildtype phenotype as they are expressing Hgd. Only when the Mx-1 promotor 
is induced will cre recombination remove the floxed target exon within Hgd. Mx-1 
(interferon-induced GTP-binding protein Mx-1) encodes the interferon-induced GTP-binding 
protein Mx-1 protein which has antiviral activity. Mx-1 activity can be induced by interferon 
alpha/beta, viral infection or synthetic double-stranded RNA, causing it to accumulate in the 
cytoplasm where it acts to inhibit viral replication. In mice, Mx-1 is responsible for the 
antiviral state against influenza. The C57BL/6J genome contains a mutation in Mx-1 that 
results in a non-functional gene product (https://www.ncbi.nlm.nih.gov/gene/17857). Here 
pIpC (polyinosinic: polycytidylic acid), a synthetic double-stranded RNA, is used to induce the 
Mx-1 promotor, see Figure 4.30. Intra-peritoneal injection of pIpC increases levels of 
interferon alpha/beta, which induces the Mx-1 promotor and therefore the Cre expression 
(referred to as MxCre), see Figure 4.30A. The expression of MxCre then leads to site-specific 
Cre/LoxP recombination within the floxed Hgd gene (Figure 4.30B), removing the floxed 6th 
exon, as depicted in the post-cre Hgd tm1d allele. The Mx-1 promotor is very active in the 
liver but not in the kidney, therefore pIpC injection into Hgd tm1d (fl/fl) MxCre +/- mice 





Figure 4.30. Induction of MxCre by pIpC.  
Injection of pIpC, a synthetic double-stranded RNA, into mice can replicate a viral infection (A). Levels of interferon 
α/β subsequently are increased, inducing the interferon-responsive Mx-1 promotor that is controlling Cre 
expression. With pIpC injection, cells that are interferon responsive with the Mx-1 promotor will express Cre 
(referred to as MxCre). Where MxCre has been induced, site-specific cre recombination via LoxP sites will occur, 
removing the floxed 6th exon within the Hgd tm1d allele (B). IP, intraperitoneal. 
 
To investigate the effect of liver-specific Hgd gene deletion, double transgenic Hgd tm1d 
(fl/fl) MxCre +/- mice (n=5; MxCre +ve) and Hgd tm1d (fl/fl) MxCre WT (n=3; wildtype control) 
and Hgd tm1a -/- (n=4; AKU control) controls were injected with pIpC. Blood and urine 
samples were collected according to the scheme in Figure 4.31A. Fifteen days after the first 
pIpC injection (post-cre activation), MxCre +ve mice showed a 77.6% decrease in liver Hgd 
mRNA compared with wildtype controls (Figure 4.31B). Kidney Hgd expression in MxCre +ve 
mice did not change and was comparable to wildtype controls (Figure 4.31C). AKU mice had 






Figure 4.31. Liver-specific Hgd knockout, induced by pIpC injection, in Hgd tm1d (fl/fl) MxCre +/- mice.  
A shows the timescale of blood and urine sampling and pIpC injections. B and C show Hgd mRNA (Hgd2 primers; 
relative to 18S) in Hgd tm1a -/- (AKU controls, n=4, 2 M, 2 F, mean age [range] = 19.4 [19.0-19.7] weeks), Hgd 
tm1d (fl/fl) MxCre WT (WT controls, n=3, 1 M, 2 F, mean age [range] = 15.1 [13.4-16.6] weeks) and Hgd tm1d 
(fl/fl) MxCre +/- mice (MxCre +ve, n=5, 5 M, mean age [range] = 15.1 [9.1-18.7] weeks) in the liver and kidney 
respectively, 15 days after pIpC injection. MxCre +ve mice show reduced liver, but not kidney, Hgd expression 
compared to WT controls. D and E show plasma and urine HGA, respectively, at pre-injection and at 9 and 15 days 
after pIpC injection. Pre-injection, HGA in the plasma is not detected in MxCre +ve or WT mice. Hgd tm1a -/- mice 
show high HGA. Post-pIpC, plasma HGA in MxCre +ve mice is increased. Pre-injection, urinary HGA is low in MxCre 
+ve and WT mice compared to Hgd tm1a -/-. Post-pIpC, urinary HGA shows a relatively small increase in MxCre 
+ve mice.  M = male. F = female. 
 
Following the knockout of approximately 78% liver Hgd mRNA in MxCre +ve mice, mean 
plasma HGA (±SEM) increased from 0.2 ±0.2 µmol/L to 129.3 ±35.6 µmol/L at 15 days post-
pIpC (Figure 4.31D). MxCre +ve urinary HGA (Figure 4.31E) was increased from 9.4 ±7.1 
µmol/L to 11,807 ±974 µmol/L at 15 days post-pIpC but remained low in comparison to AKU 
controls (134,948 ±18,479 µmol/L). Both plasma and urinary HGA remained high in AKU 
controls and low in wildtype controls as expected. 
 
4.4 Long-term liver-specific Hgd knockout  
MxCre +ve mice (Hgd tm1d (fl/fl) MxCre +/-; n=15) and AKU Hgd tm1a -/- controls (n=5) were 
injected with pIpC. MxCre +ve mice were injected with PBS (Hgd tm1d (fl/fl) MxCre +/-; n=5) 
as wildtype controls. Injections and sampling of blood and urine was carried out according to 
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the scheme in Figure 4.32A. MxCre +ve mice injected with pIpC were culled at 9 (n=5), 15 
(n=5) and 20 (n=5) weeks post-injection, with wildtype and AKU controls culled at 20 weeks 
only. Liver and kidney mRNA were taken for analysis and knee joints were taken to assess 
ochronosis. 
As with the previous study, liver Hgd mRNA was reduced in pIpC-injected MxCre +ve mice 
(post-cre activation), which was sustained to 20 weeks post-injection, see Figure 4.32B. 
Compared to wildtype controls, Hgd expression was 11.7%, 17.7% and 18.4% at 9, 15 and 20 
weeks respectively. Kidney Hgd expression in the MxCre +ve mice remained comparable to 
wildtype controls (Figure 4.32C). The reduction of liver Hgd mRNA in the MxCre +ve mice 
subsequently caused plasma HGA to increase (Figure 4.32D) to a level comparable with AKU 
controls. Urinary HGA (Figure 4.32E) was increased in the MxCre +ve mice but not to that of 
AKU controls. Knee joint sections stained with Schmorls’ stain were scored to obtain the 
number of pigmented chondrons found in a representative knee joint section (Figure 4.32F). 
Few or no pigmented chondrons were found in the MxCre +ve knee joints at 9 weeks post-
pIpC, increasing in number at 15 and 20 weeks. Wildtype controls showed no pigmentation. 




Figure 4.32. Long-term study of Hgd tm1d (fl/fl) MxCre +/- mice injected with pIpC. 
A shows the timescale of blood and urine sampling and pIpC injections. Hgd tm1a -/- were injected with pIpC 
(AKU controls, n=5, 4 M, 1 F, mean age [range] = 16.6 [7.1-23.6] weeks). Hgd tm1d (fl/fl) MxCre +/- were injected 
with PBS (WT controls, n=5, all M, mean age [range] = 19.9 [13.6-31.7] weeks). Hgd tm1d (fl/fl) MxCre +/- mice 
were injected with pIpC (MxCre +ve, n=15, all M, mean age [range] = 18.9 [12.1-29.4] weeks). B and C show relative 
Hgd mRNA (Hgd2 primers; relative to 18S) in the liver and kidney respectively, of MxCre +ve mice at 9-, 15- and 
20-weeks (n=5) after the first injection, and in AKU and WT controls at 20 weeks. Liver Hgd mRNA was reduced 
compared to WT controls in MxCre +ve mice at 9 weeks and was sustained at this level until 20 weeks. Kidney 
expression was not reduced by pIpC injection in MxCre +ve mice. D and E show plasma and urine HGA levels 
respectively, pre-injection, and at 2-, 9-, 15- and 20-weeks post-injection. Pre-injection, plasma HGA is not 
detected in MxCre +ve or WT mice and AKU mice showed increased HGA. Post-pIpC, plasma HGA in MxCre +ve 
mice was increased at 2 weeks and remained at this level at 20 weeks. Pre-injection, urinary HGA is low in MxCre 
+ve and WT mice compared with AKU controls. Post-pIpC, urinary HGA showed a relatively small increase in MxCre 
+ve mice compared with AKU controls. The total number of pigmented chondrons in a representative section of 





4.5 Liver-specific Hgd knockout: dose response 
In order to investigate the effect of varying Hgd mRNA expression levels on the AKU 
phenotype, a short-term dose response study was carried out. Figure 4.33A demonstrates 
the study design. MxCre +ve mice (Hgd tm1d (fl/fl) MxCre +/-) were given two injections of 
pIpC at the following doses; 3.33 µg/g (n=3), 1 µg/g (n=3), 0.33 µg/g (n=3), 0.1 µg/g (n=5), 
0.03 µg/g (n=3) and 0.01 µg/g (n=3) body weight. AKU (Hgd tm1a -/-; n=4) and wildtype (Hgd 
tm1d (fl/fl) MxCre WT; n=7) controls were given the highest dose of 3.33 µg/g pIpC. With the 
exception of the 0.01 µg/g group, liver Hgd mRNA in MxCre +ve mice was reduced at 15 days 
post-injection (Figure 4.33B) in all groups, with a dose response observed at the lower pIpC 
doses. The mean liver Hgd mRNA expression in MxCre +ve mice 15 days post-pIpC compared 
to wildtype controls was 17.0%, 20.5%, 20.5%, 53.4%, 54.5% and 107.2% (decreasing pIpC 
doses). Kidney expression was unchanged (Figure 4.33C). 
Mean (±SEM) plasma HGA in MxCre +ve mice at 15 days post-pIpC were 75.0 ±20.9, 57.9 
±20.9, 27.2 ±9.6, 22.7 ±13.4, 26.1 ±24.1 and 1.3 ±0.4 µmol/L with decreasing pIpC doses 
(Figure 4.33D), in a dose responsive manner. Mean (±SEM) urine HGA demonstrated a dose 
response at 15 days post-pIpC, at 45,074 ±14,977, 14,169 ±13,783, 6,137 ±6,064, 5,717 
±5,667, 31,043 ±31,041 and 2.0 ±0.2 µmol/L with decreasing pIpC doses (Figure 4.33E). These 
were increased compared with wildtype (1.9 ±0.2 µmol/L), but lower than AKU (113,067 
±10,609 µmol/L) controls. Figure 4.33F-G shows the relationship between liver Hgd mRNA 
(expressed as percentage of the mean wildtype level) and HGA in both the plasma and urine. 
A non-linear, exponential curve has been fitted to the MxCre +ve mice in Figure 4.33F, to 





Figure 4.33. Liver-specific Hgd knockout, induced by decreasing doses of pIpC, in Hgd tm1d (fl/fl) MxCre +/- 
mice.  
A shows the timescale of blood and urine sampling and injections of pIpC. B and C show relative Hgd expression 
(Hgd2 primers; relative to 18S) in Hgd tm1a -/- (AKU controls, n=4, 4 M, mean age [range] = 52.8 [51.0-56.9] 
weeks), Hgd tm1d (fl/fl) MxCre WT (WT controls, n=7, 2 M, 5 F, mean age [range] = 22.9 [20.3-26.4] weeks) and 
Hgd tm1d (fl/fl) MxCre +/- mice (MxCre +ve; 3.33 µg/g, n=3; 0.1 µg/g, n=3; 0.33 µg/g, n=3; 0.1 µg/g, n=5; 0.03 
µg/g, n=3; 0.01 µg/g, n=3) in the liver and kidney respectively, 15 days post-pIpC. Varying the dose of pIpC resulted 
in a range of liver Hgd expression in the MxCre +ve mice, with lower doses resulting in higher Hgd expression. 
Kidney Hgd expression was unchanged by pIpC. D and E show plasma and urine HGA, respectively, 15 days post-
pIpC. A dose response in HGA was observed in both the plasma and the urine of MxCre +ve mice, with higher pIpC 
doses resulting in more elevated HGA. HGA was elevated in Hgd tm1a -/- and was low in WT controls. F and G 
show the relationship between liver Hgd mRNA (expressed as a percentage of the mean WT level) with plasma 
and urinary HGA respectively, at 15 days post-pIpC. MxCre +ve mice sex and mean age [range]; 3.33 µg/g = 1 M, 
2 F, 9.3 [8.4-9.9] weeks; 1 µg/g = 2 M, 1 F, 8.9 [8.4-9.9] weeks; 0.33 µg/g = 2 M, 1 F, 8.9 [8.4-9.7] weeks; 0.1 µg/g 
= 3 M, 2 F, 14.2 [8.4-27.0] weeks; 0.03 µg/g = 2 M, 1 F, 17.1 [12.4-26.4]; 0.01 µg/g = 2 M, 1 F, 17.1 [12.4-26.4]. M 




4.6 Metabolism of circulating HGA 
To determine if circulating HGA can be taken up by HGD-expressing cells to be metabolised 
intracellularly, both Hgd tm1a -/- (n=4) and Hgd tm1a -/+ (n=4) mice were injected with 13C6-
HGA into the tail vein. Plasma samples were then collected at various time points, from 2–60 
minutes post-injection. HGA in its native form (m+0) was detected in plasma of Hgd tm1a -/- 
mice at all time points, and was absent in Hgd tm1a -/+ mice (Figure 4.34). 13C6-HGA was 
detected in both Hgd tm1a -/- and Hgd tm1a -/+ mice after injection (Figure 4.35). M+6 
isotopologues of fumarylacetoacetic acid (13C6-FAA)/maleylacetoacetic acid (13C6-MAA), 13C6-
labelled downstream metabolites of HGA, were detected in Hgd tm1a -/+ mice after 13C6-
HGA injection, and were not detected in Hgd tm1a -/- mice. Native FAA/MAA was not 







Figure 4.34. LC-QTOF-MS plasma flux analysis data for native compounds acquired following injection of Hgd 
tm1a -/- and Hgd tm1a -/+ mice with 13C6-HGA.  
Plots show extracted ion chromatograms (theoretical accurate mass ±5 ppm) for HGA and fumarylacetoacetic 
acid (FAA)/maleylacetoacetic acid (MAA). Traces are for individual plasma samples taken 2-60 minutes post-
injection and colour-coded to represent individual mice. HGA was detected in Hgd tm1a -/- only. FAA/MAA was 
not detected in either Hgd tm1a -/+ or Hgd tm1a -/-. Hgd tm1a -/+ mice; n=4; all females; mean age [range] = 
58.9 [58.7-59.0]. Hgd tm1a -/- mice; n=4; 3 males, 1 female; mean age [range] = 56.8 [55.0-58.6]. Sample analysis 






Figure 4.35. LC-QTOF-MS plasma flux analysis data for isotopically-labelled compounds acquired following 
injection of Hgd tm1a -/- and Hgd tm1a -/+ mice with 13C6-HGA.  
Plots show extracted ion chromatograms (theoretical accurate mass ±5 ppm) for 13C6-HGA and 13C6-
fumarylacetoacetic acid (FAA)/13C6-maleylacetoacetic acid (MAA). Traces are for individual plasma samples taken 
2-60 minutes post-injection and colour-coded to represent individual mice. 13C6-HGA was detected in Hgd tm1a -
/- and Hgd tm1a -/+ indicating presence of the tracer. 13C6-MAA/FAA was observed at 2-60 minutes post-injection 
in Hgd tm1a -/+, and was not observed in Hgd tm1a -/- at any time point. Hgd tm1a -/+ mice; n=4; all females; 
mean age [range] = 58.9 [58.7-59.0]. Hgd tm1a -/- mice; n=4; 3 males, 1 female; mean age [range] = 56.8 [55.0-
58.6]. Sample analysis performed by Dr Brendan Norman. 
 
4.7 Discussion 
The BALB/c Hgd-/- AKU model is deficient in HGD, however it has no ability to be manipulated 
further nor does it possess a reporter gene. The targeted Hgd tm1a model on the other hand 
has a LacZ reporter gene within the gene trap cassette situated in the Hgd locus, which has 
enabled precise localisation of Hgd expression to hepatocytes and proximal convoluted cells 
of the kidney cortex, in addition to determining when embryonic expression of Hgd initiates. 
Low level expression of Hgd was also discovered in the testis and epididymis, specifically 
within the developing sperm cells contained within these organs. Furthermore, this 
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knockout-first Hgd tm1a allele contains FRT and LoxP sequences which enabled a double 
transgenic conditional Hgd knockout mouse to be generated using Flp/Cre site-specific 
recombination 211,241. The use of Mx-1 Cre recombinase (MxCre) allowed inducible and liver-
specific knockout of Hgd mRNA by removal of the LoxP flanked (floxed) sixth Hgd exon in the 
Hgd tm1d (fl/fl) MxCre +/- conditional mouse model which has highlighted important 
considerations for gene/enzyme replacement therapy.  
 
4.7.1 Hgd expression 
The endogenous LacZ reporter gene has enabled both temporal and spatial histological 
localisation of Hgd showing that Hgd was expressed throughout the liver parenchyma and 
kidney PCT cells. This expression was then verified by qPCR analysis of Hgd mRNA. A few 
reports however have suggested HGD expression in various other tissues. In 1996, in addition 
to the liver and kidney, it was reported that HGD was expressed in human small intestine, 
colon and prostate tissue via northern blot hybridisation using a human cDNA clone as a 
probe for HGD (the spleen, thymus, testis, ovary, peripheral blood lymphocytes, heart, brain, 
placenta, skeletal muscle, lung and pancreas were reported negative) 90. Although positive 
LacZ staining of the intestine, colon and prostate was observed in the Hgd tm1a mice, the 
same pattern of staining was also observed in LacZ negative control tissue, indicating false-
positive staining and therefore no Hgd expression.  
Histological sectioning of the intestine, caecum and large intestine (also known as colon) 
demonstrated that the LacZ staining was present in the intestinal lumen where bacteria are 
present (LacZ is a bacterial gene), and not within the cells making up the intestinal wall, in 
both the Hgd tm1a and LacZ negative control tissue. False-positive LacZ staining has been 
reported in C57BL/6 wildtype mice within the gastrointestinal tract 266. In addition, no Hgd 
mRNA was found in the intestine via qPCR. In the prostate, macroscopic LacZ staining was 
observed alongside positive staining within the vas deferens, both of which were also 
observed in the LacZ negative control tissues. Histological sectioning of the LacZ stained 
prostate and vas deferens showed an identical pattern of staining in Hgd tm1a and the LacZ 
negative control, indicating false-positive staining and no Hgd expression. It has been 
reported in the literature that non-specific LacZ staining is a particular problem in the male 
reproductive tract, with positive staining observed in wildtype C57BL/6 in the testis, 
epididymis, vas deferens and prostate 266. This reported non-specific LacZ data in wildtype 
mice of the same background strain as the mice used here supports the false-positive findings 
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presented here, that Hgd is not expressed in the gastrointestinal tract or male prostate or 
vas deferens. 
Another tissue later investigated was the male testis and epididymis. Macroscopically, 
positive LacZ staining was observed in the testis of Hgd tm1a -/-, and not within the LacZ 
negative control. Histological sectioning revealed the staining within the testis to be of the 
developing male germ cells within the seminiferous tubules, and not within the somatic 
Sertoli cells that form the tubule wall, nor within the extra-tubular Leydig cells or peri-tubular 
myoid cells. The staining appeared to be localised within the cytoplasm of the developing 
sperm cells, which undergo a series of stages called spermatogenesis as they move from the 
basal surface of the Sertoli cell where they begin as round spermatogonia, ending up 
elongated, motile spermatozoa at the luminal edge of the Sertoli cell 265,267. Identifying the 
cell types staining blue in the Hgd tm1a -/- testis using histology was a challenge but was 
aided by a report of a gene called Paskin that was identified in the mouse testis using LacZ, 
that had the same pattern of staining as the Hgd tm1a -/- testis, see Figure 4.22D 264. The 
expression of Paskin was found to be localised to spermatids and spermatozoa within the 
seminiferous tubules. This provided confidence that the cells identified in Hgd tm1a were 
indeed developing male germ cells.  
Spermatogonia in the seminiferous tubules of the testis undergo mitosis to produce primary 
spermatocytes, which then undergo meiosis I to become secondary spermatocytes, which 
then undergo meiosis II to become spermatids, all of which are round cells, progressing from 
the basal surface towards the luminal surface 265,268. The round, non-motile spermatids then 
undergo a process called spermiogenesis, where the spermatid becomes an elongated, 
motile spermatozoa that has a rectangular head and a tail, with the latter projecting into the 
lumen of the seminiferous tubule 268. During spermiogenesis, the elongating spermatids shed 
most of their cytoplasm as they leave the seminiferous tubule in a process called spermiation, 
discarding the cytoplasm as residual bodies, leaving behind a small intracellular cytoplasmic 
residue known as the cytoplasmic droplet 265,269,270. Most of the residual bodies are 
phagocytosed by the Sertoli cells. The residual bodies may explain the presence of small 
punctate blue LacZ staining near the basal edge of the seminiferous tubules, which have 
migrated towards the basal side of the Sertoli cells before being phagocytosed. Within the 
epididymis, the spermatozoa then mature into sperm that have the ability to fertilize an egg.  
Positive blue LacZ staining was present within the contents of the epididymal tubules in Hgd 
tm1a -/- that was not present in the LacZ negative control, suggesting that the expression of 
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Hgd was within the spermatozoa and/or within the cytoplasm droplet that was shed during 
spermiogenesis; the histology is not able to clearly show which of the aforementioned 
structures is staining blue within the epididymal lumen. Within the Paskin -/- mice mentioned 
above, diffuse blue lacZ staining was also observed within the epididymal lumen, which the 
authors attributed to be due to cytoplasmic droplets 264.  
Cytoplasmic droplets are believed to play a role in osmoregulation in sperm 271. A report in 
2013 however also demonstrated that the cytoplasmic droplet is a transient organelle with 
an additional role in energy metabolism essential for epididymal sperm maturation; 
proteomic analysis of cytoplasmic droplets purified from murine epididymal spermatozoa 
revealed that 68% of the identified proteins were enzymes involved in energy metabolism, 
particularly glycolytic enzymes 271. There is evidence to suggest that mitochondrial activity is 
low in the sperm of mice in the epididymal head and body, coupled with lower ATP levels, 
compared to the caudal end which has increased mitochondrial activity and more ATP 
production 271. Pyruvate levels are also higher in at the epididymal head and body compared 
to the tail end 271. Pyruvate is an intermediate substrate of both glycolysis and the TCA cycle; 
it can be converted to lactate for anaerobic glycolysis or into acetyl-coenzyme A to enter the 
TCA cycle for ATP production.   
No tyrosine pathway enzymes were identified in the proteomic analysis of cytoplasmic 
droplets described in the previous paragraph 271. The proteomic analysis however did not 
analyse all proteins present in the purified cytoplasmic droplets, but instead analysed 5 
selected bands from an SDS-PAGE gel that represented proteins unique or highly enriched in 
purified cytoplasmic droplets compared to the rest of the spermatozoa. It is therefore 
possible that HGD and other tyrosine pathway enzymes was missed due to being expressed 
in both the cytoplasmic droplet and the remaining cytoplasm of the spermatozoon, and was 
therefore not present in one of the investigated groups of proteins in the report. The LacZ 
staining presented here, along with mRNA evidence, suggests that Hgd is present in the 
cytoplasm of spermatids and spermatozoa in the testis, and in the remaining cytoplasmic 
droplet and/or cytoplasm of the sperm itself within the epididymis. Downstream metabolites 
of HGA include fumaric acid and acetoacetic acid which can both enter the TCA cycle, in 
addition to acetoacetic acid being an intermediate metabolite for ketogenesis and fumaric 
acid for gluconeogenesis. It could therefore be hypothesized that Hgd expression in sperm 
within the testis and epididymis also has a role in energy metabolism in the absence of 
mitochondrial activity, providing alternative metabolic pathways to glycolysis. Once the 
mitochondrial production of ATP has increased at the caudal epididymis, perhaps the 
156 
 
expression of Hgd and other energy metabolism enzymes are then downregulated, as no 
blue LacZ staining was observed within the vas deferens that was in close proximity to the 
prostate gland, where mature sperm could be observed in the lumen via histology.  
Further investigation of Hgd expression within the testis and epididymis was carried out via 
qPCR analysis of Hgd mRNA. The expression of Hgd in the testis of adult mice aged 13.9 weeks 
(sexually mature) was approximately 7600-fold lower than that of the liver, and 2000-fold 
lower in the epididymis compared with the liver. This enormous difference in Hgd expression 
suggests that the expression in the testis and epididymis is very unlikely to contribute 
towards metabolism of the HGA pool within the circulation, which would be metabolised by 
the liver and kidney in non-AKU individuals. Due to being expressed at a low level, the 
absence of Hgd within the developing and maturing sperm within the testis and epididymis 
is unlikely to affect male fertility if the role of HGD here is to contribute towards energy 
metabolism, as other major glycolytic pathways would be capable of generating enough 
energy. It is likely that the role of HGD in sperm is fairly insignificant with regards to the AKU 
phenotype. 
Recently, there has been a report suggesting that HGD is expressed in brain tissue from both 
mice and humans using western blotting 99. Specifically, HGD was reported in the midbrain, 
cerebellum, basal forebrain and hippocampus of male CD-1 mouse brain, and within the 
cortex, hippocampus, basal forebrain, cerebellum and striatum of human brain samples 
obtained from a tissue archive. The mouse brain from Hgd tm1a mice was therefore LacZ 
stained, with no positive staining observed in any region of the brain via histology, with 
particular attention paid towards the regions stated in the aforementioned report, some of 
which were very large regions such as the cerebellum. In addition to negative LacZ staining, 
no Hgd mRNA was found in the brains of mice here. Perhaps the anti-body used in the 
western blotting paper investigating brain tissue was not specific; there was no reported use 
of HGD-positive or -negative control tissue. The brain was also negative in the northern blot 
hybridisation study from 1996, although the interpretation of that data set should perhaps 
be approached with caution, as the LacZ and mRNA findings presented here for the intestine 
and prostate did not support the findings of the northern blot study 90.  
Other work from the same group reporting HGD expression within the brain also reported 
that HGD is expressed in human osteoarticular cells 100. Using western blotting with an anti-
HGD antibody from the same source as used for the brain expression data, the authors report 
that HGD is expressed in chondrocytes, synoviocytes and osteoblasts, and demonstrate HGD 
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expression via qPCR in human primary cultured chondrocytes. LacZ staining in Hgd tm1a -/- 
however did not show that Hgd is expressed in these tissues. False-positive osteoclast 
staining was observed in the Hgd tm1a and LacZ negative controls along the resorption zone 
of the growth plate and were identified via histological sectioning, which showed no other 
LacZ positive cells, indicating that no Hgd is expressed there. False-positive staining of 
epiphyseal growth plates is reported in the literature and has been attributed to endogenous 
galactosidase activity within osteoclasts along the resorption zone of the epiphyseal growth 
plates where they phagocytose apoptosing chondrocytes 263. In addition, qPCR analysis did 
not detect any Hgd mRNA in bone (taken from the femur) nor cartilage (hip joint femoral 
head), further supporting the lack of LacZ staining and the absence of Hgd in these tissues.  
The major sites of Hgd expression have been identified here, with the expression localised to 
the cytoplasm of hepatocytes in the liver and of PCT cells in the kidney cortex. Hgd expression 
was also identified in the cytoplasm of developing and maturing sperm cells within the testis 
and epididymis, but at a level that is unlikely to contribute to the metabolism of HGA in the 
rest of the body, but is possibly required for energy production in the sperm, which are 
isolated from the rest of the body by the blood-testis barrier. The liver and kidney are the 
major sites of expression of other tyrosine pathway enzymes, such as PAH, TAT, HPPD and 
FAH, see Table 4.1 for a summary of tissue expression for these enzymes from the literature. 
The liver is a metabolically active organ and directly receives the blood from the digestive 
tract which will be rich in amino acids such as tyrosine and phenylalanine. The kidney 
proximal convoluted tubule is also the main site of amino acid reabsorption from the filtrate 
back into the blood. The presence of Hgd within the liver and kidney is therefore not 
surprising considering the role of HGD, which is an intermediate enzyme in tyrosine and 










Table 4.1. Expression of tyrosine pathway enzymes in the literature. 






Human 1northern blot, 2RNA ISH, 
3immunoperoxidase 
staining 
Lichter-Konecki et al, 1999 272  
Liver1,2 Mouse 1western blot, 2mRNA Shedlovsky et al, 1993 176 
Liver1,2 Rat 1enzyme assay, 2flux assay Stanley et al, 1985 273 
TAT 
Liver1 Human 1enzyme assay Kida et al, 1982 274, Goldsmith et 
al, 1979 275 
Liver1,2,3 Mouse 1northern blot, 2mRNA 
(primary hepatocytes), 
3enzyme assay 
Ruppert et al, 1992 276, Endo et 
al. 1991 277, Grompe et al, 1993 
278 
Liver1b,e,2 Rat 1enzyme assay, 2flux assays Lock et al, 1996 120, Stanley et al, 
1985 273, Hargrove & Mackin, 
1984 279 
HPPD 
Liver1,2, kidney1c Human 1enzyme assay, 2cDNA 
sequence analysis 
Kida et al, 1982 274, Endo et al, 
1992 280, Fellman et al, 1972 281 
Liver1,2 Mouse 1enzyme assay, 
2immunoblot 
Endo et al. 1991 277 
Liver1,2,3 Pig 1cDNA sequence analysis, 
2enzyme assay, 
3immunoprecipitation 
Endo et al, 1992 280, Roche et al, 
1982 282 
Liver1, kidney1 Monkeyd 1enzyme assay Fellman et al, 1972 281 






Mouse 1northern blot, 2mRNA 
(primary hepatocytes), 
3ISH, 4enzyme assay, 
5southern blot 
Ruppert et al, 1992 276, Endo et 
al. 1991 277, Grompe et al, 1993 
278 
Liver1,2, kidney2 Rabbit 1western blot, 2IHC Li et al, 2017 283 
Liver1,2, 
kidney1,2 
Rat  1northern blot, 2western 
blot 
Labelle et al, 1991 284 
Abbreviations: PAH, phenylalanine hydroxylase. TAT, tyrosine aminotransferase. HPPD, 4-hydroxyphenylpyruvic acid 
dioxygenase. FAH, fumarylacetoacetate hydrolase. PCT, proximal convoluted tubules. ISH, in situ hybridisation. IHC, 
immunohistochemistry. 
Footnotes 
a PAH brain activity never demonstrated; no activity using 14C-Phe-hydroxylation assay and no protein detected by western 
blotting in crude brain tissue (McDonald et al. 2002)285.  
b kidney, heart and brain negative (Hargrove & Mackin, 1984)279 
c shown to be cytosolic in rat kidney (Fellman et al, 1972)281 
d negative in heart, muscle and brain (Fellman et al, 1972)281 
e also report HGD activity in liver (Lock et al, 1996)120 
 
After determining that Hgd is expressed mainly in the liver and kidney, time-mated embryos 
were investigated to determine when expression begins in these tissues although the 
developing testis was not investigated here. Macroscopic LacZ staining was limited in its 
detection of Hgd as the embryonic kidneys were too small and the staining in the liver was 
microscopic. Frozen section LacZ staining of time-mated embryos was therefore used to 
demonstrate that hepatic Hgd expression begins at E12.5 as a diffuse staining. This 
expression was then further verified by qPCR analysis of liver Hgd mRNA from E12.5-E15.5. 
During embryonic development, hepatic cords that contain hepatoblasts, have formed by 
E10.0 in the developing liver alongside haematopoietic cells. The liver then expands due to 
hepatoblast proliferation and haematopoietic activity from E10.5-E11.5 286. Haematopoietic 
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activity then rapidly increases, peaking at E13.5 and does not start to decline until E15.5 286. 
Haematopoietic cells encompass almost 75% of total liver volume at E13.0 287, with 
hepatoblasts at E13.5 having limited contact with each other 286, explaining the diffuse and 
punctate LacZ staining and low Hgd mRNA level in the embryonic liver compared to the adult 
expression. Murine hepatoblasts begin to differentiate into hepatocytes at E14.5 286. 
Haemaotpoietic activity continues into the first post-natal week, which may explain why day 
1 pups have about an eighth of adult Hgd expression 286. Adult LacZ staining suggests that the 
LacZ positive cells observed at E15.5 in the kidney are developing PCT cells of the kidney 
nephron.  
Hgd expression has been shown here to begin in embryonic development at a very low 
expression level compared to adult mice. It was also shown that the Hgd expression level in 
day 1 Hgd tm1a -/- pups was approximately 8-fold lower than that of adults, in conjunction 
with a 3-fold greater HGA level in the plasma. In addition to highlighting the importance of 
HGD and its role in HGA metabolism, this high HGA/low Hgd expression at birth suggests that 
therapeutic strategies such a nitisinone 52 or gene/enzyme replacement therapy should begin 
at birth or as soon as possible in order to prevent any detrimental or pathological effects of 
the HGA within the body. Knee joint pigmentation was observed here as early as 9 weeks of 
age in Hgd tm1a -/- mice (section 3.3.2.1). Due to similar concentrations of HGA being 
observed in both humans and mice, and due to the greater size of humans and therefore 
greater loading, it’s plausible that human children too could begin to show the earliest stages 
of ochronotic pigmentation at a similar time point to mice. The onset of pigmentation in 
human children has not yet been investigated. 
 
4.7.2 Liver-specific Hgd deletion  
Management of inborn errors of metabolism such as AKU has traditionally consisted of 
dietary and supportive therapy. However, other treatment options have become available, 
including enzyme inhibition 53,110, enzyme replacement 193, cell and organ transplantation 194, 
gene therapy 194 and CRISPR technology 288. Before curative strategies such as enzyme 
replacement and gene therapy are implemented in disease such as AKU, it’s important that 
the target cells have been identified and that the level of enzyme activity and/or gene 
expression required to rescue the phenotype has been determined. Having demonstrated 
that the liver and kidney are the main Hgd-expressing tissues, liver-specific Hgd deletion was 
investigated using MxCre recombinase for liver-specific Hgd deletion within double 
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transgenic Hgd tm1d (fl/fl) MxCre +/- mice 236,289. The deletion of Hgd from the liver here 
gives an insight into the contribution of non-hepatic Hgd mRNA (i.e. renal) towards overall 
HGA metabolism, and whether or not the liver and/or kidney should be a target for 
gene/enzyme therapy for AKU. 
Both the short-term and long-term Hgd tm1d MxCre studies used two doses of 10 µg/g body 
weight pIpC that resulted in resulted in an approximate 80% reduction in liver Hgd mRNA 
post-cre, whilst kidney Hgd mRNA was maintained at the wildtype level, at 15 days post-pIpC 
and at 20 weeks post-pIpC administration respectively. This reduction of liver Hgd mRNA 
caused a subsequent increase in plasma HGA in both studies to a level comparable with AKU 
controls, suggesting that hepatic HGD activity, and not kidney HGD which is intact, is crucial 
for HGA metabolism and clearance from the plasma. The intact kidney Hgd mRNA in the pIpC 
injected Hgd tm1d (fl/fl) MxCre +/- mice did not have an impact on plasma HGA, but instead 
caused reduced urinary HGA compared to AKU controls.  
In the short-term Hgd tm1d MxCre study, urinary HGA was increased with the removal of 
80% of liver Hgd mRNA in the MxCre +ve mice compared to the wildtype controls, but the 
level was substantially lower than the urinary HGA of the AKU controls. This elevation in 
urinary HGA was slightly more evident in the long-term study, but again, the urinary HGA in 
the MxCre +/- mice was not elevated to the level of the AKU control. This was a surprising 
finding; with HGA being increased to an ‘AKU’ level in the plasma, it would have been 
expected that the HGA in the urine would also be increased to the ‘AKU’ level. This effect of 
reduced urinary HGA in the presence of elevated plasma HGA suggests the PCT cells are 
reabsorbing HGA from the filtrate, which is most likely already transmitting its maximum load 
of HGA from the circulation to be excreted, that is then metabolised by the intact HGD within 
the PCT cells. In addition, HGA-derived from the reabsorption and breakdown of 
tyrosine/phenylalanine from the filtrate within the PCT cells will also likely be metabolised 
by the intact HGD. 
The mechanism of HGA transport within the kidney, including reabsorption and tubular 
secretion, is currently unknown, but has recently been elucidated to by Ranganath et al. 290. 
The authors determined that the amount of HGA within the urine of AKU patients is far more 
than the theoretical amount that can be accounted for by filtration and maximal renal blood 
flow alone, emphasizing that the tubular secretion of HGA, that is likely produced by the 
breakdown of tyrosine and phenylalanine in the PCT cells, contributes significantly to the 
renal production and secretion of HGA into the filtrate; the HGA derived from 
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tyrosine/phenylalanine in non-AKU individuals would be metabolised by HGD and is 
therefore not detectable in the urine. This would suggest that the difference in the Hgd tm1d 
MxCre +/- HGA levels in the urine post-cre recombination compared to AKU control mice 
could be the amount of HGA that can be metabolised by kidney HGD. Perhaps crossing the 
floxed Hgd tm1d mouse line with a kidney-specific Cre recombinase system, such as the Pax8-
CreERT2 transgenic line that is directed to all renal tubular compartments or a Slc22a6-CreERT2 
knock-in line that is specific to the epithelium of the proximal convoluted tubules, both of 
which are tamoxifen-inducible, would enable a more in-depth study of Hgd/HGA in relation 
to the kidney 291. Fundamentally, the importance of this finding is that intact kidney Hgd does 
not rescue the disease and therefore liver Hgd is critical for the correction of AKU.  
A report of an AKU patient who received a kidney transplant in 2002 reportedly had 
normalised plasma HGA and decreased urinary HGA , both approximately half pre-transplant 
levels, inferring that kidney transplantation would benefit AKU patients 104. Liver-specific Hgd 
deletion shown here in mice however suggests that kidney Hgd mRNA is unlikely to rescue 
the AKU phenotype as blood HGA levels were elevated. The improvement reported with 
kidney transplantation was likely due to improved renal elimination as the patient had renal 
failure (a case where renal transplantation would be beneficial) and subsequently very high 
HGA pre-transplant, rather than donor HGD expression. 
The elevation of plasma HGA in the absence of 80% liver Hgd mRNA, and the presence of 
renal Hgd mRNA, indicates that future gene/enzyme replacement therapy should target the 
liver in order to combat increased plasma HGA that causes ochronosis in AKU. The intact 
kidney HGD was unable to metabolise the HGA load within the circulation. The importance 
of the liver is supported by a case report of an AKU patient receiving a liver transplant, after 
which they found no HGA in the urine and reported a halt in progressive arthropathy 103. The 
data here in mice suggests that approximately 20% liver Hgd mRNA, delivered by gene 
therapy for example, will not rescue AKU; the increased HGA subsequently caused ochronosis 
in the knee joints of the mice in the long-term study. Full liver Hgd mRNA knockout was not 
achieved with two 10 µg/g doses in the short-term and long-term Hgd tm1d MxCre studies. 
Further reducing liver Hgd mRNA however would not provide further insight into the level of 
liver Hgd mRNA required to rescue the phenotype, as the HGA level at an 80% reduction in 
liver Hgd mRNA was comparable to AKU controls. A pIpC dose response study, using lower 
pIpC doses, in the Hgd tm1d (fl/fl) MxCre +/- mice was therefore carried out in order to try 
and determine the amount of liver Hgd mRNA required to rescue the phenotype.  
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The dose response study intended to estimate how much liver Hgd mRNA would lower 
circulating HGA. A dose response was observed in both the plasma and urine HGA levels. 
However, for liver Hgd mRNA, there was only a dose response between the lower four pIpC 
doses (0.33-0.01 µg/g), with no dose response observed at the higher doses (3.33-0.33 µg/g). 
One possible explanation for Hgd mRNA not corresponding to plasma HGA in the higher dose 
groups could be that the mRNA:protein ratio is not linear. The dose response data obtained 
however indicates that the minimum level of liver Hgd mRNA required to eliminate 
circulating HGA must fall between the dashed lines of Figure 4.33F, between 26% and 43% 
of liver Hgd mRNA. 
 
4.7.3 HGD activity and HGA metabolism: considerations for gene therapy 
Restoring HGD activity in all cells, via gene therapy or enzyme replacement, is currently 
unachievable by any current method, but the data here suggests that it is not necessary. In 
heterozygous mice and humans, one functioning copy of the HGD gene is sufficient to deal 
with HGA metabolism. Assuming heterozygous mice possess 50% of the Hgd mRNA 
compared to wildtypes (adult LacZ staining suggests this assumption is correct), then 50% 
Hgd mRNA in every hepatocyte can rescue AKU. Deletion of liver Hgd by 80%, leaving 20% 
residual Hgd mRNA expression, did not rescue the phenotype. However, it could not be 
determined how many cells were expressing the gene, either as one or two alleles, nor the 
distribution of expression which could be variable from cell to cell. The proportion of 
corrected cells and the level of therapeutic gene expression per cell required to rescue AKU 
is therefore still not clear. A recent study providing the first human genotype-phenotype 
correlation data for the three most frequent HGD mutation variants (this included 33 patients 
homozygous for these variants) identified in the SONIA-2 trial supports the data here that 
between 26% and 43% is the minimum level of Hgd mRNA required to rescue AKU 93. This 
genotype-phenotype study demonstrated no difference in baseline visit serum or 24-hour 
urine HGA, or clinical symptoms such as eye pigmentation, hip bone density or degree of 
scoliosis between patients predicted to have either 1% (16 patients) or 31%-34% (17 patients) 
residual HGD catalytic activity that was determined in vitro against wildtype recombinant 
human HGD enzyme 93. Other studies have also reported no correlation between the 
presence or absence of any type of HGD mutation with HGA excretion or disease severity, 
although residual enzyme activity was not reported 20,260.  
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Another consideration is whether or not hepatocytes can take up HGA from the 
circulation/extracellular fluid/other hepatocytes and then metabolise it. A scenario could 
exist whereby hepatocytes with insufficient HGD activity post-therapy are unable to 
metabolise HGA, with neighbouring HGD-restored cells unable to take up this non-
metabolised HGA, leading to its accumulation in the circulation. The ability of hepatocytes to 
take up HGA is an important consideration for gene/enzyme therapies, and may be a key 
factor in the success of these strategies. The uptake of HGA into Hgd expressing-cells was 
therefore investigated using both AKU (Hgd tm1a -/-) and non-AKU (Hgd tm1a -/+) mice. 
Intravenous injection of isotopically labelled HGA (13C6-HGA) provides evidence that 
circulating HGA can re-enter Hgd-expressing cells to be metabolised by intracellular HGD, as 
isotopically labelled FAA/MAA was detected in the blood of the non-AKU Hgd tm1a -/+ mice. 
Thus, it should not be necessary to repair 100% of liver cells because HGA produced by HGD-
deficient hepatocytes could be taken up and metabolised by genetically repaired cells, see 
Figure 4.36.  
 
Figure 4.36. HGA uptake by hepatocytes and gene therapy.  
A represents the hepatocytes within AKU liver. The hepatocytes are deficient in HGD and cannot breakdown HGA, 
which accumulates and enter the circulation. B represents a liver that has restored HGD activity in some of the 
hepatocytes, which can metabolise HGA. Some of the hepatocytes however are still deficient in HGD and are 
producing HGA, which can be taken up into the restored hepatocytes to be metabolised, as can HGA from the 



































The treatment of AKU with the 4-HPPD inhibiting drug nitisinone has proven to be effective 
at reducing circulating HGA in both humans 52,53 and mice, and has been shown to completely 
prevent ochronotic pigmentation in AKU mice 115,116. A consequence of nitisinone treatment 
however is elevated tyrosine, or tyrosinaemia, which can cause eye and skin keratopathy. A 
strategy/treatment option that could reduce circulating tyrosine would improve nitisinone 
treatment in AKU patients by removing this potentially damaging tyrosinaemia side effect.  
Here, the effectiveness of dietary restriction of tyrosine and phenylalanine at reducing 
tyrosinaemia was investigated in nitisinone-treated AKU mice. Additional observational data 
in human AKU patients is also discussed.  
Also reported in this chapter are a series of preliminary in vitro experiments investigating a 
potential tyrosine-reducing strategy. The expression, purification and in vitro activity of a 
tyrosine-degrading, bacterial enzyme called tyrosine ammonia lyase (TAL) is shown. The 
potential application of TAL to nitisinone-induced tyrosinaemia is discussed.  
 
5.2 Dietary restriction studies 
5.2.1 Dietary restriction study design 
To investigate the effect of tyrosine and phenylalanine dietary restriction on nitisinone-
induced tyrosinaemia and on other tyrosine pathway metabolites, AKU BALB/c Hgd-/- mice 
(groups of n=6; 3 male, 3 female) were treated with nitisinone for 1 week on a normal diet, 
then switched to either tyrosine/phenylalanine free or phenylalanine-only free diets with 
phenylalanine supplemented into the drinking water to investigate dose response (tyrosine 
is not water soluble), whilst still on nitisinone. Controls remained on normal diet whilst still 
on nitisinone. Blood samples were taken pre-nitisinone, after 1 week of nitisinone and then 
during dietary restriction (see schemes in Figure 5.3A, Figure 5.4A, Figure 5.5A) to assess 
tyrosine and other related metabolites in the pathway. 
 
5.2.1.1 Calculating dietary restriction 
The level of dietary restriction in the following studies was estimated using the approximate 
food and water intake for the background strain of the mice used, which were all BALB/c Hgd-
/- in this chapter. Daily food and water intake is approximately 5 g and 6 ml respectively, per 
30 g bodyweight for the BALB/cByJ strain 292. These values are used to estimate the level of 
dietary restriction of tyrosine and phenylalanine, with a 30 g mouse on the normal CRM(P) 
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diet consuming approximately 44 mg/day phenylalanine and 29.5 mg/day tyrosine. Table 5.1 
shows the estimated consumption of tyrosine and phenylalanine across the dietary 
restriction studies.  
 
Table 5.1. Estimated tyrosine and phenylalanine consumption. 
Study (Figure) Diet 
Phe supplementation in 
drinking water (mg/ml) 
Estimated level of tyr / 
phe consumed (%) 
Tyr/phe free diet study 
(Figure 5.3). 
Tyr/phe free 
5 0% tyr / 68% phe 
2.5 0% tyr / 34% phe 
1.25 0% tyr / 17% phe 
Lower tyr/phe free diet 
study (Figure 5.4). 
0.625 0% tyr / 8.5% phe 
0.3125 0% tyr / 4.25% phe 
None 0% tyr / 0% phe 
Phe free diet study 
(Figure 5.5). 
Phe free diet 
2.5 100% tyr / 34% phe 
0.625 100% tyr / 8.5% phe 
None 100% tyr / 0% phe 
Abbreviations: tyr = tyrosine; phe = phenylalanine 
 
 
5.2.2 The effect of nitisinone on tyrosine pathway metabolites 
To show the effect that nitisinone has on tyrosine pathway metabolites, BALB/c Hgd-/- (n=24) 
were treated with 4 mg/L nitisinone in the drinking water, available ad libitum. Blood samples 
were taken pre-nitisinone, and after 7 days of treatment. With reference to Figure 5.1, HGA 
(mean ±SEM) was decreased 8-fold from 255.1 ±43.2 µmol/L to 32.9 ±3.2 µmol/L whilst all 
other metabolites increased; all changes were significant (p<0.001; two-tailed paired t-test). 
Tyrosine increased 11-fold from 72.9 ±3.6 µmol/L to 813.3 ±37.6 µmol/L. Phenylalanine 
increased 1.5-fold from 67.3 ±2.4 µmol/L to 100.8 ±4.9 µmol/L. HPPA increased 14.5-fold 
from 10.5 ±0.4 µmol/L to 151.8 ±12.9 µmol/L. 4-Hydroxyphenyllactic acid (HPLA) increased 
19-fold from 2.0 ±0.2 µmol/L to 38.6 ±3.0 µmol/L. 
Although mice are not reported to experience keratopathy of the eye in response to 
nitisinone-induced tyrosinaemia, the eyes of AKU mice were taken from another nitisinone 
study (not in this thesis), in order to determine the concentration of tyrosine within the eye. 
The eyes were dissected from both control BALB/c Hgd-/- mice (normal drinking water; n=4) 
and nitisinone-treated BALB/c Hgd-/- mice (4 mg/L in drinking water; n=4), homogenised in 
70% methanol, centrifuged and the supernatant collected. The mass spectrometry method 
used to measure tyrosine in plasma 47 was used to quantitate tyrosine within the eye 
supernatants. The obtained concentrations however may not be truly representative of the 
actual concentration, as matrix-matched calibrators were not used (calibrators with a serum 
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matrix were used to quantitate tyrosine in the samples that were homogenised in a 
methanol/water matrix); but importantly, the control and nitisinone-treated groups will be 
comparable, as they were measured by the same method. The concentrations obtained from 
mass spectrometer were then multiplied by 33.3 as the eyes were diluted in 70% methanol 
at 30 mg/ml for homogenisation, which diluted the tyrosine within the eye by 33.3-fold. With 
reference to Figure 5.2, tyrosine within the eyes (mean ±SEM) of nitisinone-treated AKU mice 
was 4.4-fold greater than the controls, at 1,175.0 ±66.9 µmol/L and 270.8 ±35.3 µmol/L 
respectively. This difference was extremely significant (p<0.0001). Plasma tyrosine (mean 
±SEM) was also measured in these mice and was 10.6-fold greater in the nitisinone-treated 
mice at 609.3 ±52.8 µmol/L, compared to the controls at 57.1 ±4.3 µmol/L (p<0.0001). In the 
nitisinone-treated mice, tyrosine within the eyes was 1.9-fold greater than the plasma. In the 





Figure 5.1. Changes in tyrosine pathway metabolites after 1 week of nitisinone treatment.  
BALB/c Hgd-/- AKU mice were (n=24; 12 males, 12 females; mean age [range] = 42 [9-55] weeks) treated for 1 
week with nitisinone (NTBC), with tail bleed samples taken pre- and post-treatment. HGA was significantly 
reduced, whilst the other metabolites were significantly increased. HGA = homogentisic acid. Tyr = tyrosine. Phe 
= phenylalanine. HPPA = 4-hydroxyphenylpyruvic acid. HPLA = 4-hydroxyphenyllactic acid. Error bars represent 





Figure 5.2. Tyrosine concentration within the plasma and eye after 1 week of nitisinone treatment.  
After 1 week of treatment, plasma was taken and the eyes dissected from control (normal drinking water; n=4; 
male; mean age [range] = 30.1 weeks [29.0-31.1]) and nitisinone-treated (4 mg/L nitisinone; n=4; male; mean age 
[range] = 29.8 [25.7-31.1] weeks) BALB/c Hgd-/- mice. The eyes were homogenised and the supernatant collected. 
Tyrosine was quantitated in both the plasma and eye supernatant. Tyrosine was significantly greater in both the 
eyes and plasma of nitisinone-treated mice. Unpaired t-test (two-tailed) significance: p<0.05 *, p<0.01 **, p< 
0.001 ***. 
 
5.2.3 Tyrosine/phenylalanine dietary restriction  
To investigate the effect of tyrosine and phenylalanine dietary restriction on nitisinone-
induced tyrosinaemia and on other tyrosine pathway metabolites, BALB/c Hgd-/- mice were 
given nitisinone (4 mg/L) in drinking water, and then whilst still on nitisinone fed a tyrosine 
and phenylalanine free diet. To look at dose response, phenylalanine was supplemented into 
the drinking water at three different doses (5 mg/ml, 2.5 mg/ml and 1.25 mg/ml) in the 
restricted groups. A control group remained on the normal diet with nitisinone treatment. 
Blood samples were taken according to the scheme in Figure 5.3A. 
With reference to Figure 5.3B, tyrosine (mean ±SEM), which was increased from 72.9 ±3.6 
µmol/L to 813.3 ±41.5 µmol/L (all groups, n=24) after 1 week of nitisinone treatment, is 
reduced in the restricted groups after 3 days of dietary restriction in a dose responsive 
manner (389.3 ±42.3 µmol/L, 274.8 ±6.3 µmol/L, 144.3 ±13.0 µmol/L). After 14 days of 
restriction, this reduction was still maintained in all groups. All comparisons to the control 
group at both 3 and 14 days were significant (p<0.001; one-way ANOVA, Tukey post-hoc). 
After 3 days of dietary restriction, significant reductions in the other metabolites investigated 
(phenylalanine, HGA, HPPA and HPLA) were present, however the dose response was not as 
clear in these metabolites (Figure 5.3B). After 14 days of dietary restriction, only HGA and 
HPLA showed significant reductions compared to the control group (but trends were similar 
at 3 and 14 days).  
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Individual body weight was monitored over the duration of dietary restriction. At 14 days of 
restriction, the restricted groups showed no significant change in body weight (Figure 5.3C) 
compared to the control group (one-way ANOVA; p=0.841).  
 
 
Figure 5.3. Dietary restriction of tyrosine and phenylalanine in NTBC-treated BALB/c Hgd-/- AKU mice.  
A shows when blood samples were taken and when diet conditions were altered. B shows the plasma metabolite 
levels before NTBC treatment (all mice; n=24; 12 males, 12 females; mean age [range] = 42 [9-55] weeks), after 1 
week of NTBC treatment (all mice; n=24), then after 3 (n=6) and 14 days (n=6) of diet restriction of tyrosine and 
phenylalanine. C shows the change in bodyweight of individual mice in each group from day 7 (start of dietary 
restriction) and day 21 (after 14 days of dietary restriction). Mean age [range] of each group; control = 39.6 [9-
48] weeks; 5 mg/ml = 39.6 [25.4-49.4] weeks; 2.5 mg/ml = 43.4 [11.6-50.0] weeks; 1.25 mg/ml = 45.5 [14.4-55.0]. 
NTBC = nitisinone. HGA = homogentisic acid. HPPA = 4-hydroxyphenylpyruvic acid. HPLA = 4-hydroxyphenyllactic 
acid. Error bars represent SEM. One-way ANOVA (Tukey post-hoc) significance: p<0.05 *, p<0.01 **, p<0.001 ***.  
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5.2.4 Lower tyrosine/phenylalanine dietary restriction 
To investigate the effect of further dietary restriction on nitisinone-induced tyrosinaemia, a 
second study was conducted using the tyrosine/phenylalanine free diet, supplementing less 
phenylalanine than was used in Figure 5.3. One of the restricted groups in this study was 
given no phenylalanine supplementation to investigate a diet completely free in both 
tyrosine and phenylalanine. Although no weight loss was seen in the previous study with 
higher phenylalanine supplementation, this study was shorter in anticipation of weight loss 
(project license weight loss limits must be adhered to and considered when planning/carrying 
out a study).   
With reference to Figure 5.4B, tyrosine (mean ±SEM) which is increased from 59.0 ±2.0 
µmol/L to 548.8 ±43.2 µmol/L (all groups, n=24) after 1 week of nitisinone treatment, is 
reduced in the restricted groups after 3 days of dietary restriction to 112.3 ±14.3 µmol/L, 
170.6 ±12.0 µmol/L, 180.9 ±30.0 µmol/L in the 0.625 mg/ml, 0.3125 mg/ml and 0 mg/ml 
groups. After 4 days of restriction, this reduction was still maintained in all groups with no 
further decrease. All comparisons to the control group at both 3 and 4 days were significant 
(p<0.001; one-way ANOVA, Tukey post hoc). No dose response was seen at 3 or 4 days of 
restriction.  
After both 3 and 4 days of dietary restriction, significant reductions in the other metabolites 
investigated (phenylalanine, HGA, HPPA and HPLA) were seen with dietary restriction, with 
the 4-day levels being comparable to the 3-day levels. As observed with tyrosine in this study, 
no dose response affect was observed.   
Body weight was monitored over the duration of the dietary restriction. Figure 5.4C shows 
the weight change of individual mice at 4 days of dietary restriction. No significant differences 
were observed; the restricted groups showed weight changes comparable with the control 







Figure 5.4. Lower dietary restriction of tyrosine and phenylalanine in NTBC-treated BALB/c Hgd-/- AKU mice.  
A shows when blood samples were taken and when diet conditions were altered. B shows the plasma metabolite 
levels before NTBC treatment (all mice; n=24; 12 males, 12 females; mean age [range] = 23.2 [8.1-27.9] weeks), 
after 1 week of NTBC treatment (all mice; n=24), then after 3 (n=6) and 4 days (n=6) of diet restriction of tyrosine 
and phenylalanine. C shows the change in bodyweight of individual mice in each group from day 7 (start of dietary 
restriction) and day 11 (after 4 days of dietary restriction). Mean age [range] of each group; control 26.3 [24.9-
27.9] weeks; 0.625 mg/ml = 20.7 [8.1-27.4] weeks; 0.3125 mg/ml = 21.8 [8.1-24.9] weeks; tyr/phe free = 24.1 
[23.6-24.9] weeks. NTBC = nitisinone. HGA = homogentisic acid. HPPA = 4-hydroxyphenylpyruvic acid. HPLA = 4-
hydroxyphenyllactic acid. Error bars represent SEM. One-way ANOVA (Tukey post-hoc) significance: p<0.05 *, 




5.2.5 Phenylalanine-only dietary restriction 
To investigate the effect of phenylalanine-only dietary restriction on nitisinone-induced 
tyrosinaemia, BALB/c Hgd-/- mice were given nitisinone in the drinking water, then fed a 
phenylalanine free diet with normal tyrosine, whilst still on nitisinone, with phenylalanine 
supplemented in the drinking water (2.5 mg/ml, 0.625 mg/ml and 0 mg/ml) to look at dose 
response. Blood samples were taken according to the scheme in Figure 5.5A. 
With reference to Figure 5.5B, plasma tyrosine was 63.5 ±2.7 µmol/L pre-nitisinone and 
increased to 748.9 ±26.8 µmol/L post-nitisinone (n=24, all groups). After 3 days of 
phenylalanine restriction, tyrosine levels were 757.3 ±54.9 µmol/L, 533.2 ±28.8 µmol/L and 
656.2 ±69.6 µmol/L, with only the latter two groups, (0.625 mg/ml and phenylalanine free), 
being significantly different to control (p<0.001 and p=0.014, respectively). A clear dose 
response effect was not seen in plasma tyrosine with dietary restriction of phenylalanine 
after 3 days. After 7 days of dietary restriction, none of the restricted groups had a 
significantly lower tyrosine level compared with the control group.  
Significant reductions in plasma phenylalanine were seen at both 3 days (all groups p<0.001 
compared to control) and after 7 days (0.625 mg/ml and phenylalanine free, both p<0.001 
compared with control; 2.5 mg/ml not significantly different, p=0.065) of phenylalanine 
dietary restriction. HPLA demonstrated significant differences after 3 days in the 0.625 mg/ml 
and phenylalanine free groups however these significant differences were not maintained 
after 7 days. HGA showed significant differences after 7 days of dietary restriction in all the 
restricted groups however these differences were not seen after 3 days. HPPA was not 
significantly reduced in the restricted groups compared with control, at neither 3 nor 7 days 
of dietary restriction. 
Figure 5.5C shows the changes in body weight after 7 days of restriction. One-way ANOVA 
demonstrated a significant difference in weight change between the groups (p=0.014). Post-
hoc Tukey tests demonstrate that the differences were between the 2.5 mg/ml group 
compared with the 0.625 mg/ml (p=0.023) and phenylalanine free (p=0.021) groups. None 
of the restricted groups however showed a weight change that was significantly different to 








Figure 5.5. Dietary restriction of phenylalanine in NTBC-treated BALB/c Hgd-/- AKU mice.  
A shows when blood samples were taken and when diet conditions were altered. B shows the plasma metabolite 
levels before NTBC treatment (all mice; n=24; 12 males, 2 females; mean age [range] = 27.7 [16.4-53.9] weeks), 
after 1 week of NTBC treatment (all mice; n=24), then after 3 (n=6) and 14 (n=6) days of diet restriction of 
phenylalanine. C shows the change in bodyweight of individual mice in each group from day 7 (start of dietary 
restriction) and day 14 (after 7 days of dietary restriction). Mean age [range] of each group; control = 32.9 [19.3-
53.9] weeks; 2.5 g/ml = 19.5 [16.4-20.3] weeks; 0.625 mg/ml = 27.1 [20.3-31.6] weeks; phe free = 26.1 [20.3-34.7] 
weeks. NTBC = nitisinone. HGA = homogentisic acid. HPPA = 4-hydroxyphenylpyruvic acid. HPLA = 4-
hydroxyphenyllactic acid. Error bars represent SEM. One-way ANOVA (Tukey post-hoc) significance: p<0.05 *, 
p<0.01 **, p<0.001 ***.  
 
5.2.6 Tyrosine and phenylalanine restriction in the absence of nitisinone treatment 
Phenylalanine, and tyrosine in the absence of sufficient phenylalanine, are essential amino 
acids obtained via ingesting dietary protein. Both phenylalanine and tyrosine however can 
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be obtained through endogenous protein turnover. Bodyweight has therefore been 
monitored in the dietary restriction studies shown here, with no significant changes in 
bodyweight observed in the restricted groups compared to the control in Figure 5.3C, Figure 
5.4C and Figure 5.5C. The increased tyrosine level associated with nitisinone treatment could 
potentially be preventing weight loss in the dietary restriction groups here due to the 
tyrosine pool taking longer to deplete. One group of BALB/c Hgd-/- mice (n=6) were therefore 
fed the tyrosine/phenylalanine free diet, with no phenylalanine supplementation in the 
water, in the absence of nitisinone treatment. Tyrosine pathway metabolites were measured 
in the blood and body weight recorded. 
Figure 5.6A shows the time points at which blood samples were taken. At 3 and 6 days of 
complete dietary restriction of tyrosine and phenylalanine (Figure 5.6B), plasma tyrosine 
levels (mean ±SEM) were reduced from 77.3 ±5.0 µmol/L pre-diet to 24.7 ±3.2 µmol/L and 
24.2 ±2.8 µmol/L, respectively. This reduction was highly significant at both 3 and 6 days 
(one-way ANOVA, Tukey post-hoc; p<0.001). Phenylalanine, HGA, HPPA and HPLA were all 
significantly reduced at 3 and 6 days of dietary restriction compared to pre-diet levels.  
Bodyweight was closely monitored. Figure 5.6C shows after 3 and 6 days of dietary 
restriction, that the mean change in body weight from day 0 was -5.7% and -6.3% 
respectively. To determine whether this change in body weight was consistent with normal 
weight fluctuations or due to dietary restriction, and to see if nitisinone had any affect, it was 
compared against both the control and tyrosine/phenylalanine free groups from Figure 5.4, 
at 3 days of restriction. Figure 5.7 shows that the reduction in body weight in the 
tyrosine/phenylalanine free group without nitisinone was significantly different to the 









Figure 5.6. Dietary restriction of tyrosine and phenylalanine in BALB/c Hgd-/- AKU mice in the absence of 
nitisinone and phenylalanine supplementation.  
A shows when blood samples were taken and when diet conditions were altered. B shows the plasma metabolite 
levels pre-dietary restriction (n=6; 2 males, 4 females; mean age [range] = 25.7 [23.6-26.7] weeks) and then after 
3 and 6 days (n=6) of diet restriction of both tyrosine and phenylalanine. C shows the change in bodyweight of 
individual mice in each group from day 0 (start of dietary restriction) and day 3 and day 6 (after 3 and 6 days of 
dietary restriction). HGA = homogentisic acid. HPPA = 4-hydroxyphenylpyruvic acid. HPLA = 4-hydroxyphenyllactic 





Figure 5.7. Changes in body weight of tyrosine/phenylalanine restricted BALB/c Hgd-/- AKU mice in the 
presence/absence of nitisinone at 3 days.  
Control (n=6) and tyr/phe free (+NTBC) (n=6) body weight taken from the tyrosine/phenylalanine restriction study 
in Figure 5.4, at 3 days of restriction. Tyr/phe free (no NTBC) (n=6) body weight taken from the 
tyrosine/phenylalanine restriction study in Figure 5.6, at 3 days of restriction. One-way ANOVA (Tukey post-hoc) 
significance: p<0.05 *, p<0.01 **, p<0.001 ***.  
 
5.2.7 Food and water consumption during dietary restriction 
A consideration throughout the dietary restriction studies was the food and water intake of 
the mice. Supplementation levels were based on assumptions of food and water intake for 
the background strain as mentioned above in the experiment design (section 5.2.1.1). It’s 
possible that due to differences in the normal mouse diet and the custom restricted diets, 
such as the consistency of the diet, and potentially taste, the mice may have consumed more 
or less food. The same is applicable to the drinking water supplemented with nitisinone and 
phenylalanine; it may have had an altered taste.  
The nutritional content of the custom diets is matched to the control normal diet, with a 
normal level of protein and calories, but specifically deficient in tyrosine and phenylalanine. 
Another consideration is whether or not the mice consumed more food due to potential 
amino acid deficiency from the restricted diets. In an attempt to investigate whether food 
and water consumption was affected by the restricted diets and water supplementation, a 
study was designed to measure food and water intake of mice subjected to the dietary 
conditions in Figure 5.3, the first tyrosine/phenylalanine free diet study.  
Food and water consumption were measured for 4 male BALB/c Hgd-/- mice (aged 53.4-53.7 
weeks), who were individually housed in an OxyletPro System Physiocage (Panlab, Harvard 
Apparatus, UK), equipped with food and water dispensers designed to accurately record food 
and water consumption via weight transducer technology. The mice were provided with 
standard cage enrichment of red dome house, clear tunnel and cage bedding). According to 
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the scheme in Figure 5.8A, the mice were fed a normal diet in week 1, then received 
nitisinone in the drinking water at 4 mg/L during week 2, then were switched to the 
tyrosine/phenylalanine free diet with phenylalanine supplementation (5 mg/ml, n=1; 2.5 
mg/ml, n=1; 1.25 mg/ml, n=1) in the drinking water, whilst still on nitisinone, during week 3. 
One mouse remained on the normal diet and nitisinone throughout week 3 as a control.  
Food and water intake monitoring was found to be extremely difficult to monitor. Food 
intake (Figure 5.8B) was at first consistent during weeks 1 and 2, with mean (±SEM) 
consumption of the normal diet found to be 4.2 ±1.1 g (all 4 mice). During week 3, the control 
mouse consumed 4.0 ±0.3 g of food, consistent with weeks 1 and 2. Measuring consumption 
of the tyrosine/phenylalanine free diet however was not straightforward. The diet was very 
crumbly and the crumb tray was often overflowed. Vast amounts of the diet were also found 
on the floor of the cage, as both small pellets and crumbled almost to a powder, either due 
to its crumbliness or due to the mouse bringing the food into the cage. Attempts were made 
to gather all the food to calculate the amount eaten by the mouse. The values shown from 
day 14 onwards however are very unlikely to be a true representation of the amount of food 
consumed, due to the extreme variation and difficulty recording the intake. 
Water intake (Figure 5.8C) was similarly unreliable. The water bottles were found to drip, 
overflowing the drip tray beneath. This explains the huge variation seen over the first week 
in water intake. After this, attempts were made to catch water overflowing from the drip tray 
in a small container, in addition to pipetting up any liquid not caught, although water spilled 
during each 24-hour period may have evaporated before recordings were made. The 
variability of water intake measurements was minimised slightly after day 7, however, the 
measurements obtained were still deemed unreliable. The degree of dripping/leaking 
appeared to be variable between the cages. In addition, small pieces of food and cage 
bedding were often found at the water spout or in the drip tray, due to activity of the mouse, 
absorbing water, again making it difficult to get an accurate reading.  
Body weight was monitored over the duration of the food and water intake study (Figure 
5.8D). One mouse did not finish the study (tyr/phe free diet + 1.25 mg/ml phe) due to weight 
loss. It’s unlikely however that this mouse lost weight due to dietary restriction; in the 
tyrosine/phenylalanine dietary restriction study shown in Figure 5.3, on which this study was 
based, no weight loss was seen after 14 days of restriction. The mouse, which was also 53-
weeks old, had only been on a restricted diet for 4 days, therefore it’s likely that another 
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unknown factor caused its weight loss. The other 3 mice all showed a gradual increase in 
body weight over the 3-week period.  
 
Figure 5.8. Food and water intake of BALB/c Hgd-/- AKU mice subjected to altered dietary conditions and 
nitisinone.  
A shows when diet conditions were altered. Phenylalanine was supplemented into the drinking water (5 mg/ml, 
n=1; 2.5 mg/ml, n=1; 1.25 mg/ml, n=1) of mice fed the tyrosine/phenylalanine free diet. One mouse remained on 
the normal diet with NTBC during week 3. B shows food consumption, C shows water consumption and D shows 
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body weight throughout altered diet conditions and addition of nitisinone. All mice (n=4) aged 53.6 weeks, male. 
NTBC = nitisinone.  
5.2.8 Dietary restriction in AKU patients attending the National Alkaptonuria Centre  
NAC patients receive off-licence treatment of 2 mg nitisinone daily, dietary advice from a 
specialist dietician and have serum tyrosine monitored at yearly visits (Milan et al. 2017). The 
NAC aims to achieve tyrosine <500 µmol/L. Tyrosine thresholds of 500-700 µmol/L and 700-
900 µmol/L are used as guidelines for reducing dietary protein consumption to 0.9 g and 0.8 
g protein/kg bodyweight/day, respectively. Patients with tyrosine >700 µmol/L are more 
closely monitored with additional blood sampling if required. Fasting blood samples were 
taken in the morning. An observational study of 10 anonymised AKU patients attending the 
NAC with tyrosine levels >700 µmol/L are reported in Figure 5.9. All patients received advice 
to reduce dietary protein intake to a recommended minimum level of 0.75 g protein/kg 
bodyweight/day, to reduce circulating tyrosine whilst meeting minimum nutritional 
requirements. A TYR cooler® (Vitaflo, UK) protein substitute, free in tyrosine/phenylalanine, 
drink was used by 7/10 patients. TYR cooler dosage was determined by the dietician for each 
individual; protein removed from the diet, below the recommended minimum, was 
exchanged for the equivalent amount of protein in the cooler. These patients had been 
attending the NAC for a mean of 36.5 months [range 29-48] at the initial tyrosine 
concentration, with a mean age of 56 years [range 29-71]. The gender of patients was 5 
males, 5 females. 8 were white British, 1 was Indian and 1 was Pakistani. 
Average estimated protein intake from 7-day food diaries in all AKU patients attending the 
NAC was 1.0 g protein/kg bodyweight/day at baseline visit 1 293 before any intervention, 
which is comparable with the general population (National Diet & Nutrition Survey, 2016, 
Gateway Number 2016248). In an attempt to lower circulating tyrosine with nitisinone, 
dietary protein intake is restricted to a recommended minimum level of 0.75 g protein/kg 
bodyweight/day (Scientific Advisory Committee on Nutrition, 2017/Committee on Medical 
Aspects of Food Policy, 1991), with additional metabolic requirements provided by 
prescribed tyrosine/phenylalanine-free amino acid supplements in some patients.  
Overall, significant reductions in serum tyrosine (Figure 5.9) were seen in the 10 NAC patients 
observed (p=0.002; two-tailed Wilcoxon’s signed rank test), with 4 patients reducing serum 
tyrosine <700 µmol/L. Three patients (Figure 5.9, dashed lines) reduced serum tyrosine 
(mean[range]) by 22[18-30]% by advised protein restriction alone; the other 7 patients 
required a combination of reduced protein intake with tyrosine/phenylalanine-free 
supplements to achieve a 33[8-62]% reduction. The initial tyrosine value for patients using 
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amino acid supplements was with dietary restriction alone, with subsequent values using a 
combination of reduced protein intake and amino acid supplementation. Across all 10 




Figure 5.9. Serum tyrosine from 10 AKU patients receiving nitisinone attending the National Alkaptonuria 
Centre.  
All 10 patients had tyrosine >700 µmol/L. Both dietary advice (restriction of dietary protein to a recommended 
minimum level of 0.75 g protein/kg bodyweight) (n=3) and dietary advice in combination with 
tyrosine/phenylalanine free amino acid supplements (n=7) reduced serum tyrosine. Initial tyrosine 
concentrations in the group using amino acid supplements were measured after dietary advice alone, with 
subsequent tyrosine concentrations measured after a combination of dietary advice and amino acid supplement 
use. Data provided by Shirley Judd and Professor Lakshminarayan Ranganath. 
 
5.3 Enzymatic breakdown of tyrosine 
Ammonia-lyases are a non-mammalian enzyme family that can deaminate amino acids. Of 
particular interest here are phenylalanine ammonia lyase (PAL) and tyrosine ammonia lyase 
(TAL). PAL converts L-phenylalanine into trans-cinnamic acid and ammonia. TAL converts L-
tyrosine into p-coumaric acid and ammonia. Reported in the literature are PAL and TAL 
enzymes that can degrade both tyrosine and phenylalanine, usually named after the 
substrate that they exhibit greater specificity towards. Although PAL activity is initially 
demonstrated here in this series of preliminary experiments, TAL was the main focus due to 
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its greater specificity towards tyrosine. In the context of nitisinone-induced tyrosinaemia, a 
specific tyrosine-degrading enzyme would be more useful than a phenylalanine-specific 
enzyme. 
 
5.3.1 Phenylalanine ammonia lyase 
PAL was initially investigated in vitro as it was available to buy commercially as a Grade I, 
buffered aqueous glycerol solution of PAL from Rhodotorula glutinis (part of the pink yeast 
genus), whereas TAL was not available to purchase.  
The first in vitro experiment, shown in Figure 5.10, demonstrates the ability of both 0.01U 
and 0.1U of R. glutinis PAL to degrade phenylalanine and tyrosine in vitro (in 50 mM Tris-HCl 
buffer, pH 8.5, 30°C; conditions used by Xue et al. 294) within 24 hours, at starting substrate 
concentrations of 10, 50 and 100 µmol/L. By 24 hours, PAL was able to degrade tyrosine and 
phenylalanine at all starting substrate concentrations, with 0.1U PAL breaking down the 
substrates faster than 0.01U PAL. It was difficult to tell if PAL was more efficient at breaking 
down phenylalanine over tyrosine. In this particular experiment, the substrates were not 
measured at time 0 making it difficult to judge if the difference in tyrosine and phenylalanine 
concentration at the first time point of 1.8 minutes was due to faster phenylalanine 
degradation or due to variation in starting substrate concentration. With reference to the 
100 µmol/L condition, with 0.1U and 0.01U PAL, both phenylalanine and tyrosine were 
degraded by 4 hours and 24 hours respectively.  
A second in vitro experiment was then carried out using 0.1U of PAL at starting phenylalanine 
and tyrosine concentrations of 100 and 500 µmol/L (Figure 5.11); both substrates were fully 
degraded by PAL by 4 hours from 100 µmol/L and 8 hours from 500 µmol/L. Again, at 100 
µmol/L starting substrate concentration, there was a slight difference in substrate 
concentration making it difficult to tell whether PAL was more efficient at breaking down 
tyrosine or phenylalanine. At 500 µmol/L starting substrate concentration, the starting 
concentrations of tyrosine and phenylalanine incubated with PAL were comparable, and the 
rate of breakdown observed was almost identical, with variations in tyrosine likely due to 
pipetting error. The differences in starting concentration of phenylalanine and tyrosine may 
have been due to differences in solubility (if not fully dissolved, the concentration will be 
affected), or may have been due to error (e.g. weighing, pipetting) when preparing the stock 
solutions. Although the experiments in Figure 5.10 and Figure 5.11 could have been repeated 
with more accurate starting substrate concentrations, it was not deemed necessary as it was 
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clear that PAL is able to break down tyrosine and phenylalanine effectively in vitro, and due 
to subsequent work focussing on TAL.  
 
Figure 5.10. PAL-mediated degradation of phenylalanine and tyrosine in vitro.  
Both 0.01U and 0.1U of PAL enzyme degraded phenylalanine and tyrosine at starting substrate concentrations of 
10 µmol/L (A), 50 µmol/L (B) and 100 µmol/L (C). PAL, phenylalanine ammonia lyase. Phe, phenylalanine. Tyr, 





Figure 5.11. PAL-mediated degradation of phenylalanine and tyrosine at higher concentrations in vitro.  
0.1U of PAL enzyme degraded phenylalanine and tyrosine at starting substrate concentrations of 100 µmol/L (A) 
and 500 µmol/L (B). PAL, phenylalanine ammonia lyase. Phe, phenylalanine. Tyr, tyrosine.  
 
5.3.2 Tyrosine ammonia lyase 
5.3.2.1 Expression, purification and in vitro TAL experiments 
Initially, a TAL enzyme based on the sequence from Rhodobacter capsulatus was custom 
synthesized and purchased from the Protein Expression Facility at the University of 
Manchester (UoM, UK). An in vitro experiment was performed to test the tyrosine degrading 
ability of this enzyme. Following this, it was decided that the expression and purification of 




5.3.2.1.1 pETDuet:Tal vector 
The R. capsulatus TAL sequence was codon optimised for bacterial protein expression and 
integrated into an expression vector called pETDuet-1, and referred to as pETDuet:Tal. The 
modified sequence of R. capsulatus TAL is shown in Figure 5.12. In order to integrate the TAL 
sequence into the pETDuet-1 expression vector, 5’ BamHI and 3’ Xhol restriction enzyme 
binding sites were added. Two stop codons (TAA) were also added before the Xhol restriction 
enzyme sequence to terminate translation of the TAL sequence. In order to allow purification 
of the expressed TAL protein, a histidine·tag (an amino acid motif that has at least 6 histidine 
residues) present in the expression vector was used that fuses to the N-terminus of the 
inserted TAL sequence, therefore the protein was expressed as an N-terminal His-TEV-linker 
fusion protein. The insertion of a tobacco etch virus (TEV) protease cleavage site upstream 
of the TAL sequence, but downstream of the His·tag, can allow cleavage of the fusion protein 
from the tag to obtain purified TAL protein, although this step was not used for the in-house 
purification of TAL. Webcutter 2.0 software shows no predicted cleavage sites for TEV in the 





Figure 5.12. Codon optimised Rhodobacter capsulatus TAL sequence.  
From left to right, N-terminus to C-terminus. Added sequences: 5’ BamHI and 3’ Xhol restriction enzyme binding 
sites, two stop codons (TAA) and a tobacco etch virus (TEV) protease cleavage site with a glycine-serine-glycine 
(GSG) linker sequence. Start codon removed. The protein will be expressed as an N-terminal His-TEV-linker fusion 
protein. Sequence has also been codon optimised with synonymous mutations to bias codons towards those 
preferred by the expression bacteria.   
 
The pETDuet-1 vector is a plasmid designed for the co-expression of two genes as it contains 
two multiple cloning sites, however it was used here for the expression of the single TAL 
gene. The TAL gene was cloned into the pETDuet-1 vector (see Figure 5.13) to be expressed 
under the control of the bacteriophage T7 transcription and regulatory system, to be 
transformed into E. coli JM109(DE3) which contain the T7 RNA polymerase gene, for high 
level protein expression. The multiple cloning site used has a T7 promoter, lac operon and 
ribosome binding site for expression of the target gene. The T7 promoter can be acted upon 
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by T7 RNA polymerase to drive high level expression of the target gene. The lac operon (lacO) 
which is just downstream of the T7 promoter, can be repressed by the lacI protein (gene is 
part of the pETDuet-1 vector) which binds to the lacO to block transcription by T7 RNA 
polymerase, to stop leaky expression. Addition of IPTG causes dissociation of the lacI 
repressor on the lacO, allowing initiation of T7 RNA polymerase transcription and target gene 
expression. IPTG is therefore used to control the expression of the target gene within the 
JM109(DE3) bacteria.  
 
Figure 5.13. pETDuet-1 vector used for bacterial expression of TAL.  
Key features are the presence of the T7 promotor, lac operon (lacO), the lacI gene, ampicillin resistance gene, the 
restriction enzyme binding sites BamHI and Xhol that are to be used to integrate the modified TAL sequence and 
the His·tag (83-100). Another 21 enzyme restriction sites are present but have not been labelled. ORF, open 




5.3.2.1.2 Preliminary in vitro experiment 
The first experiment was conducted using the TAL enzyme supplied by The Protein Expression 
Facility, UoM. This TAL protein was supplied in 25 mM Tris-HCl (pH 7.5), 150 mM NaCl and 
10% glycerol. Tyrosine (100 µmol/L) was incubated with 2, 0.2- and 0.02-mM TAL protein in 
50 mM Tris-HCl, pH 8.5 at 37°C and at 2 mM in PBS over 24 hours, see Figure 5.14. Tyrosine 
(100 µmol/L) was fully degraded by the 2- and 0.2-mM TAL enzyme by 4 hours and 24 hours 
respectively, and was partially degraded by 0.02 mM TAL to approximately 80 µmol/L at 24 
hours. Interestingly, 2 mM of TAL enzyme in PBS was not as efficient at degrading tyrosine as 
the same concentration of TAL in Tris-HCl buffer, reaching approximately 40 µmol/L by 24 
hours in PBS. Having confirmed that this TAL enzyme from R. capsulatus was able to 
breakdown tyrosine, TAL was then expressed and purified in house. 
 
 
Figure 5.14. Preliminary assay of tyrosine degradation by TAL.  
TAL enzyme was incubated with a starting tyrosine concentration of 100 µmol/L at 37°C at various concentrations; 
2, 0.2 and 0.02 mM in 50 mM Tris-HCl and at 2 mM in PBS. The control contained no TAL enzyme. TAL, tyrosine 
ammonia lyase. Assay carried out by Dr Peter Wilson. 
 
5.3.2.1.3 Expression and purification of TAL 
In order to express the TAL enzyme in house, the pETDuet:Tal expression vector was obtained 
from the Protein Expression Facility (UoM, UK). Chemically competent JM109(DE3) bacteria 
were then transformed with the pETDuet:Tal vector. The procedure for transforming the 
bacteria and inducing the expression of TAL protein can be found in section 2.6.2.1.  Once 
grown, the TAL protein was harvested and purified, see section 2.6.2.2 for details.  
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Samples from each step of the purification process were kept for analysis of TAL protein by 
SDS-PAGE gel stained with Coomassie Blue to visualise protein bands. The predicted 
molecular weight for the TAL protein is 55.6 kDa. With reference to Figure 5.15, the cell lysate 
contains all of the proteins expressed by the bacteria (including TAL), and then the soluble 
fraction contains only the proteins released into the supernatant after clarification. The 
soluble fraction contained the TAL protein as expected, which was then retained in the 
purification column with the Ni-NTA beads; the first flow through (FT) and subsequent 2 
washes did not contain the TAL protein. The final elute (E) and desalted elute (DS) both 




Figure 5.15. TAL purification stages.  
6.5 µl samples from each step of the TAL purification procedure was analysed on 4-12% SDS PAGE gel, that was 
stained with Coomassie Blue. Two different molecular weight markers (MWM) were used: a full range Rainbow 
MWM on the left, a Novex Sharp unstained protein standard on the right. Abbreviations: CL, cell lysate; SF, soluble 
fraction; FT, flow through; W1 & W2, wash 1 & 2; E, elute; DS desalted fraction. TAL expression and purification 
and gel carried out by Dr Peter Wilson.  
 
Three purifications of the TAL protein were carried out from the same culture that was split 
into 4 equal aliquots. The 1st TAL protein sample was purified according to the methods, using 
a frozen bacterial pellet re-suspended into lysis buffer as described in section 2.6.2.2. The 2nd 
TAL protein sample was purified in the same way as the 1st, with an increased sonication of 
the cell lysate from an amplitude of 6 microns to 24 microns in an attempt to release more 
TAL protein that was likely to be trapped within inclusion bodies. The 3rd TAL protein sample 
189 
 
was purified using a slightly different method to the 1st and 2nd; a lysozyme extraction was 
used instead of sonication (sonication is a harsh method of purification that could affect the 
enzyme’s activity), to see if the method of purification affected the activity of TAL; see section 
2.6.2.2 (purification of TAL, step 2a). Once lysed and clarified, the 3rd TAL was purified using 
the same methods as the 1st and 2nd.  
In order to quantify the amount of TAL protein purified, a BCA protein assay kit and protocol 
was followed using colorimetric protein detection and quantification of the purple reaction 
product (see section 2.6.2.2.2). Briefly, albumin protein standards were used to generate and 
a standard curve of 562 nm absorbance against known protein concentration and the curve 
used to determine the concentration of the purified TAL protein. The estimated 
concentration of TAL protein obtained from each purification is shown in Table 5.2. The 
increased sonication amplitude during the bacterial cell lysis steps of the 2nd TAL purification 
increased the amount of TAL protein obtained compared to the 1st purification. Using the 
lysozyme extraction method resulted in 3.4- to 5-fold less TAL protein obtained from the 3rd 
TAL purification compared to the 1st and 2nd purifications respectively. 
 
Table 5.2. Estimated concentration of TAL protein, quantified using a BCA protein assay kit. 
Purified TAL Estimated protein 
concentration (mg/ml) 
1st TAL (lysis buffer extraction 
with sonication) 
0.415 
2nd TAL (lysis buffer extraction 
with increased sonication) 
0.61 
3rd TAL (lysozyme extraction, no 
sonication) 
0.122 
BCA assay carried out by Dr Peter Wilson. 
 
The insoluble fraction (cell pellet frozen after bacteria cell lysis) from the 1st TAL purification 
was tested for TAL activity as it was likely that some TAL was trapped within inclusion bodies. 
The cell pellet was re-suspended in 1 ml of elution buffer B which was the final buffer used 
to elute the TAL protein from the desalting column. 200 µl of this sample was used in a 1 ml 
reaction and referred to as insoluble fraction.  
 
5.3.2.1.4 TAL in vitro experiments 
The first in vitro TAL experiment was performed to test the tyrosine-degrading ability of the 
TAL enzyme expressed and purified in house. With reference to Figure 5.16, 2 mM TAL from 
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the 1st (lysis buffer/sonication) and 2nd (lysis buffer/increased sonication) purification, and 1 
mM TAL from the 3rd purification (lysozyme/no sonication) were incubated with 100 µmol/L 
tyrosine in 25 mM Tris-HCl at pH 8.5 over 24 hours at 37°C. Activity of TAL within the insoluble 
fraction (200 µl used; 1 ml reaction volume) from the purification was also tested. All the TAL 
enzymes tested (1st – 3rd) were able to breakdown tyrosine; the 1st and 2nd TAL had broken 
all tyrosine down by 4 hours, with the 3rd breaking tyrosine down at a slower rate, with 
tyrosine broken down by 8 - 24 hours. The 3rd TAL enzyme however was at 1 mM instead of 
2 mM due to the lower protein concentration obtained during the purification limiting the 
amount TAL protein, which was more dilute, that could be added to the 1 ml reaction volume. 
A comparison in activity is therefore difficult. At both 30 minutes and 1 hour, the 1st TAL had 
broken down 1.3-fold more tyrosine than the 3rd TAL and 1.2-fold more at 2 hours, suggesting 
that the 3rd TAL enzyme was more active than the 1st & 2nd (which were almost identical), as 
the fold-change was <2, which was the TAL concentration difference. The increased 
sonication amplitude of the 2nd TAL over the 1st TAL did not appear to affect the activity of 
the enzyme. The ability of the insoluble fraction to breakdown tyrosine confirmed that the 
insoluble fraction still contained active TAL enzyme, trapped within inclusion bodies (highly 
aggregated protein).   
 
 
Figure 5.16. In vitro degradation of tyrosine by TAL.  
2 mM of TAL enzyme from the 1st and 2nd purification, and 1 mM of the 3rd purification was incubated with 100 
µmol/L tyrosine in 25 mM Tris-HCl (pH 8.5) over 24 hours at 37°C. TAL activity was also tested for the insoluble 
fraction from the purification. The control contained no TAL enzyme. TAL, tyrosine ammonia lyase. Assay carried 




In order to test the activity of TAL at breaking down tyrosine at different pH’s, the reaction 
mixture was made up using Tris-HCl at pH 1.5, 4.5 and 8.5 (8.5 was used previously), with 
tyrosine at 100 µmol/L. 2 mM TAL from the 2nd purification was used for this experiment, 
alongside the same insoluble fraction stock and volume used in Figure 5.16. With reference 
to Figure 5.17, neither TAL nor the insoluble fraction was able to breakdown tyrosine at pH 
1.5 or 4.5. TAL at pH 8.5 was able to breakdown tyrosine by 4 hours, as was observed in the 
previous experiment.  
 
 
Figure 5.17. In vitro degradation of tyrosine by TAL at different pH’s.  
2 mM of TAL enzyme from the 2nd purification was incubated with 100 µmol/L tyrosine in 25 mM Tris-HCl over 
24 hours at 37°C at pH 1.5, 4.5 and 8.5. The insoluble fraction (same stock and amount used in Figure 5.16), was 
tested in 25 mM Tris-HCl at pH 1.5 and 4.5. The control contained no TAL enzyme. TAL, tyrosine ammonia lyase. 
Assay carried out and samples collected by Dr Peter Wilson. 
 
5.4 Discussion 
The treatment of AKU with the HGA-lowering drug nitisinone has proven to be an effective 
treatment in AKU patients by lowering HGA 117. However, data from clinical trial 52 and off-
label prescription use at the NAC 53 clearly demonstrate the associated elevated tyrosine in 
patient’s plasma. Although tolerated by many individuals, tyrosinaemia can cause eye and 
skin keratopathy in a minority of patients requiring a lower dose or cessation of nitisinone, 
or a strict low protein diet, to resolve symptoms. Low-dose nitisinone, ranging from 0.5-2 mg 
daily, has caused eye complications in 5 reported AKU patients to date 40,127,129,130. 
Attempting to restrict tyrosine and phenylalanine intake from the diet, whilst still taking 
nitisinone to keep HGA low, is the most logical approach to combat elevated tyrosine. A 
protein restricted diet however proves very difficult to maintain and often causes 
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keratopathy to return when not adhered to 130. Therefore, finding an alternative strategy to 
reduce dietary uptake of tyrosine and/or phenylalanine would allow nitisinone-treated 
patients to consume a normal protein diet. Before such strategies are implemented, the 
findings reported here showed that reducing dietary tyrosine/phenylalanine is effective at 
reducing tyrosine in AKU mice, with evidence that lowering protein intake in patients is also 
achievable, therefore establishing a proof-of-principle in targeting dietary 
tyrosine/phenylalanine in AKU patients who are on nitisinone. 
Tyrosine threshold recommendations with nitisinone treatment, which are often arbitrary, 
vary in the literature. In HT-1 children <12 years, the recommended tyrosine level is 200-400 
µmol/L, with concentrations after this age allowed to rise, with eye complications 
experienced >800 µmol/L 132. Another HT-1 review of 22 centres treating patients aged 0-24 
years found maximum acceptable tyrosine levels to be 200-800 µmol/L, with 400 µmol/L 
determined to be a safe and feasible target 145. A report of an adult AKU patient who 
experienced eye keratopathy whilst receiving low-dose nitisinone (0.5-1.5 mg daily) suggests 
a target tyrosine of <600 µmol/L 129, whilst a more recent NAC publication suggests <500 
µmol/L is acceptable 117. NAC tyrosine thresholds are designed to fit a dietetic care plan that 
aims to reduce serum tyrosine in order to prevent symptomatic keratopathy, with systematic 
removal of dietary protein, whilst taking into account compliance difficulties experienced in 
patients.  
 
5.4.1 Effect of nitisinone 
It is clear from reported data in human patients, and the data presented here in mice, that 
nitisinone is very effective at inhibiting 4-HPPD and reducing circulating HGA. This metabolic 
block however causes upstream effects in the tyrosine metabolism pathway. In AKU mice 
treated with nitisinone here, plasma HGA was lowered, with significant elevations in plasma 
tyrosine, phenylalanine (although not to the extent of tyrosine), HPPA and HPLA. The most 
concerning change is the substantial increase in circulating tyrosine, due to ocular and skin 
keratopathy risks, in addition to concerns about neural cognition due to tyrosine being a 
precursor to some neurotransmitters. Although mice do not experience keratopathy of the 
eye for unknown reasons when rats and other laboratory animals experience corneal lesions 
with nitisinone-induced tyrosinaemia, the tyrosine measured in the eyes of mice on 
nitisinone (Figure 5.2) was clearly elevated compared to controls, agreeing with previous 
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published work on nitisinone-induced tyrosinaemia 120–122 in experimental animals, that 
shows the tyrosine elevation occurs not just in the plasma, but also the eye.  
Lock et al. reported that tyrosine within the aqueous humour of mice treated with nitisinone 
was approximately 2,200 µmol/L, with a plasma level of approximately 1200 µmol/L 121. Here, 
tyrosine within the whole eye homogenate of nitisinone-treated AKU mice was about 1,100 
µmol/L with a plasma tyrosine of about 600 µmol/L. The relationship/fold-change between 
plasma and ocular tyrosine reported by Lock et al. is the same as reported here, with ocular 
tyrosine being 2-fold greater than that of the plasma. The concentrations here however may 
not truly represent the concentration of tyrosine in the eye, as matrix-matched calibrators 
were not used to quantitate the tyrosine in the eye (calibrators with a serum matrix were 
used, the samples were in a methanol/water matrix) which could affect the concentration 
obtained, in addition to homogenate being of the whole eye, rather than sampling the 
aqueous humour directly which is situated in the small anterior cavity within the anterior and 
posterior chambers of the eye between the iris and cornea. Ocular lesions are thought to 
occur due to a build-up of tyrosine within the eye, which reaches saturation in aqueous 
solutions at about 4,000 µmol/L at body temperature 295, where it then precipitates as 
needle-shaped tyrosine crystals that damage cell membranes 296. In rats where corneal 
lesions are observed, ocular tyrosine increases to 3500-4000 µmol/L with nitisinone 
treatment 120, which is close to the reported solubility, and is much higher than the ocular 
tyrosine in mice with nitisinone treatment.  
Although the main focus of elevated tyrosine is towards eye keratopathy and potential 
neurocognitive affects, it’s not known how increased tyrosine in the plasma affects other 
tissues. Recent data from Khedr et al. investigated the distribution of tyrosine within 
nitisinone-treated AKU mice compared to untreated AKU and WT control mice, showing that 
tyrosine was increased in all the tissues investigated; 6.5-fold in bone from the femur, 7.8-
fold in the brain, 8.8-fold in the heart, 7.4-fold in the kidney, 4.7-fold in the liver and 6.0-fold 
in the quadriceps muscle 297. This has been described by the authors as “tyrosinosis” as 
elevated tyrosine is not limited to the circulation, but extended to tissues, and is likely to be 
elevated in all tissues. Additional experimental data was collected by Khedr et al. in human 
AKU patients and healthy volunteers, who were injected with isotopically-labelled tyrosine 
and phenylalanine; the tracer and tracee ratios demonstrated that tyrosine decay was almost 
halted with nitisinone treatment, with phenylalanine being unaffected, with the extracellular 
tyrosine pool estimated to be 5-fold higher in nitisinone-treated AKU patients, and the 
intracellular pool estimated to be 3-fold greater, than controls.  
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In addition to tyrosine elevation, substantial increases in both HPPA and HPLA have been 
observed in mice and humans. In the tyrosine tracer study in humans, HPLA was not detected 
in both AKU individuals and healthy controls in the absence of nitisinone; this suggests that 
the conversion of HPPA to HPLA does not usually occur in untreated AKU patients, but does 
occur with nitisinone treatment and the blocking of the tyrosine pathway 297. Another recent 
paper has quantified the flux of tyrosine metabolites during nitisinone treatment in human 
AKU patients using SONIA-1 trial data, and also documents the significant increases in 
tyrosine, HPPA and HPLA, suggesting that these large increases reflect the tyrosine 
metabolite pool that would have been directed towards pigment formation in the absence 
of nitisinone 298. These metabolite increases were also observed here in mice, however the 
effect of elevated HPPA or HPLA is unknown.  
Further metabolomic analysis of urine and serum in both human AKU patients and AKU mice 
has also revealed other changes in the metabolome that occur with nitisinone treatment;   
these significantly altered metabolites indicate alterations to tyrosine, tryptophan, purine 
and TCA cycle metabolism 218,299. Metabolomic data investigating both urine and serum in 
humans and mice also demonstrates many other metabolite differences in the untreated-
AKU metabolic state and also with nitisinone treatment; these include the presence of HGA 
biotransformation products that exist in AKU, which are then reduced with nitisinone-
treatment, in addition to changes in tyrosine, purine and TCA cycle metabolites in the AKU 
disease state 231. It is clear from these evaluations that many changes in tyrosine metabolism 
occur not only with nitisinone, but also in the AKU metabolic state, however the effects of 
these changes remain unknown.  
 
5.4.2 Tyrosine/phenylalanine dietary restriction 
The tyrosine/phenylalanine free diet study here in mice (Figure 5.3) clearly showed a dose-
responsive reduction in plasma tyrosine, with all groups reaching <400 µmol/L, which is 
below the threshold used by the NAC in human patients. The least restricted group (5 mg/ml 
phenylalanine) reduced tyrosine to 389 µmol/L at 3 days, achieved with approximately 68% 
phenylalanine/no tyrosine. Furthermore, in human AKU patients observed at the NAC, it was 
shown that human patients can reduce serum tyrosine with dietary intervention after advice 
from a specialist dietician (Figure 5.9). Tyrosine was significantly lowered either by a low 
protein diet alone or in combination with prescribed tyrosine/phenylalanine free amino acid 
supplementation. Although only 4 of these 10 patients achieved tyrosine <700 µmol/L, 
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tyrosine was greatly reduced in some patients, notably from 1,084 µmol/L to 762 µmol/L, 
and from 1,217 µmol/L to 859 µmol/L. Of the 4 patients that reduced tyrosine below 700 
µmol/L, only 1 patient achieved this with dietary advice alone; the other 3 patients used 
tyrosine/phenylalanine-free amino acid supplementation. Prior to nitisinone, most adult AKU 
patients will have consumed a normal protein diet throughout their life, therefore adaption 
to dietary changes can be difficult, especially in the absence of tyrosine-related keratopathy 
where no benefit is perceived. 
The NAC patient data was not collected as a controlled trial, but as an observational study 
where patients are only advised to restrict their protein intake, therefore strict monitoring 
of compliance and protein intake was not carried out. After specialist advice, patients were 
responsible for restricting dietary protein in their daily lives, with guidance from the dietician 
if needed. Progress with dietary compliance is a long-term iterative process, since achieving 
long-term, sustained behaviour change in adults is a recognised national dilemma. Dietetic 
intervention is therefore on going in NAC patients. Compliance is the most likely reason that 
only 1/10 NAC patients achieved <500 µmol/L tyrosine and is why mice were used for the 
restriction experiments reported here. The diets of mice are easy to control, in addition to 
eliminating other confounding factors such as lifestyle, exercise, mobility and disease severity 
differences. The mouse data provides evidence that dietary restriction of 
tyrosine/phenylalanine can effectively reduce nitisinone-induced tyrosinaemia, providing 
the rationale to carry out a controlled trial in human AKU patients, where lower tyrosine 
levels than those observed here would be expected. 
In mice, the dose response observed due to phenylalanine supplementation, in the absence 
of tyrosine (Figure 5.5), suggests that tyrosine derived from phenylalanine is important to 
target. However, phenylalanine-only restriction did not effectively lower tyrosine, even in the 
completely phenylalanine free group, suggesting that targeting removal of dietary 
phenylalanine alone is ineffective at reducing nitisinone-induced tyrosinaemia. This is an 
important consideration as emerging phenylalanine-lowering strategies for the metabolic 
disease PKU may have been beneficial for nitisinone-induced tyrosinaemia if phenylalanine 
restriction alone had proven effective. Such strategies include enzymatic phenylalanine 
degradation by exogenous phenylalanine ammonia lyase enzyme (detailed in section 
1.2.6.4.3), diets supplemented with naturally occurring glycomacropeptide (GMP) protein 
that is naturally low in phenylalanine instead of synthetic amino acid foods, and genetically 
modified probiotics that target phenylalanine-degradation in the intestine 300,301.  
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Moreover, due to phenylalanine being an essential amino acid, its restriction alone could lead 
to inadequate protein turnover, with the balance of catabolism/anabolism disrupted, causing 
a loss of lean mass 302. Although not significantly different to the control group in the 
phenylalanine-only restriction study, there was a significant body weight reduction in the 
phenylalanine free and 0.625 mg/ml groups compared to the 2.5 mg/ml group (Figure 5.5) 
at 7 days. This weight loss was seen in the presence of tyrosine, suggesting that phenylalanine 
restriction could lead to catabolism, therefore targeting tyrosine would be more desirable. 
At 14 days of restriction, no significant weight changes were seen in Figure 5.3 in which 
tyrosine was absent and phenylalanine was partially present. The presence of nitisinone 
however did appear to affect weight of the mice; the comparison of weight change (Figure 
5.7) between the tyrosine and phenylalanine free groups from Figure 5.4 and Figure 5.5 at 7 
days showed that the untreated mice lost significantly more weight than the nitisinone-
treated group. This is most likely due to the increase in the tyrosine pool in the circulation 
and tissues, as described above by Khedr et al. 297, perhaps protecting mice from muscle 
catabolism as it would take longer to deplete the highly elevated tyrosine pool than it would 
in mice that do not have tyrosinaemia.  
It is essential to balance lowering protein intake in order to lower circulating tyrosine, with 
maintaining a healthy weight and muscle mass, since catabolism itself provides residual 
tyrosine. A recent publication documenting the nutritional status of AKU patients attending 
the NAC at their baseline visit suggested that AKU patients, who have a lower muscle mass 
and higher body fat composition, are experiencing a protein/energy dilemma, with a reduced 
protein intake that is consistently at the minimum end of the reference range, that is not 
compensated for by fat, carbohydrates or other food groups, leading to an energy deficit that 
can cause catabolism to occur 293. The report also highlighted the complex nature of dietary 
intervention in AKU patients, who have decreased mobility as the disease progresses, where 
reduced muscle functionality leads to muscle atrophy, and therefore a further reduced basal 
metabolic rate, combined with periods of high metabolic demand such as joint replacement 
surgery that alters physical activity and impacts on muscle and fat reserves. During yearly 
routine NAC visits, anthropometric data such as such as grip, mid-upper arm circumference 
and bioimpedance data such as lean mass and fat mass is collected to provide sequential 
evidence of body composition trends to minimise risk of catabolism, and are considered 
during patient monitoring. These parameters were not investigated in the AKU patients 
presented in the observational study presented here, as less than half of the tyrosine 
concentrations were measured at a routine NAC visit where such anthropometric data is 
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collected. These parameters are however worthy of investigation in both mice and humans 
(this data is already being collected at the NAC) in future studies. Attempts were made to 
record food and water intake in a subset of mice subjected to dietary restriction, using the 
experimental conditions of the first tyrosine/phenylalanine restriction study. If dietary 
restriction had caused the mice to become deficient in tyrosine and/or phenylalanine, it is 
possible that they could reach a catabolic state where muscle breakdown releases 
tyrosine/phenylalanine. At the same time, food intake may also have increased in an attempt 
to consume more dietary protein and amino acids. In the studies here, increased food intake 
of the restricted diets would not increase the pool of the potentially deficient tyrosine and/or 
phenylalanine amino acids, but instead would increase calorie intake. Increased calorie 
intake above the calorific needs of the mouse would increase fat mass, potentially 
contributing to an overall increase in bodyweight, possibly concealing muscle catabolism. The 
cage system that was available to use for studying food/water intake however was not 
suitable, despite having an accuracy of 0.02 g for food intake and 0.01 g for water intake. The 
diet was crumbly, the water bottles dripped water to such an extent that the drip tray 
overflowed and the behaviour of the mice regarding the movement of food into the cage 
prevented adequate recordings of intake, and the results were therefore dismissed. In the 
future, factors such as lean mass and grip strength to assess muscle function could be 
investigated to indicate more clearly the anabolic/catabolic state of the mice.  
In addition to decreased tyrosine, other metabolic improvements were seen with dietary 
restriction in mice. HGA, which is lowered with nitisinone treatment, was then significantly 
lowered in the restricted groups compared to the control in the tyrosine/phenylalanine free 
studies. Both HPPA and HPLA, which were increased with nitisinone, were also significantly 
reduced compared to the control with restriction. Although it is not known what effect 
elevated HPPA and HPLA has, reducing them back towards normal physiological levels would 
be desirable. Although only elevating 1.5-fold in mice with nitisinone, phenylalanine in mice 
was significantly reduced after 3 days in the first tyrosine/phenylalanine restriction study 
compared to the controls, but this was not maintained to 14 days suggesting normal 
phenylalanine levels with no weight loss observed. In human NAC patients, phenylalanine 
levels were within the normal reference range at all-time points during the observation 
period. Overall, it would appear that reducing tyrosine in nitisinone-induced tyrosinaemia 
also reduces other upstream, off-target metabolic effects of nitisinone such as reducing HPPA 
and HPLA, therefore it’s very likely that reducing tyrosine may also normalise other metabolic 
affects that have been identified by metabolomics analysis as described above 218,231,299. 
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Metabolomic evaluation of the plasma samples collected in the dietary restriction studies 
here was not performed, but would have been beneficial and should be considered in future 
studies. 
 
5.4.3 Tyrosine ammonia lyase 
Tyrosine degradation via the non-mammalian TAL enzyme was investigated here in vitro. This 
enzyme has the potential to be applied to AKU patients, in addition to HT-1 patients, with 
elevated tyrosine as a consequence of nitisinone treatment. The dietary studies in nitisinone-
treated AKU mice have shown the proof-of-concept that reducing the uptake of dietary 
tyrosine/phenylalanine can reduce plasma tyrosine levels. TAL could be taken orally after or 
with a normal protein meal, in order to deplete tyrosine in the gastrointestinal tract, by 
converting it to coumaric acid, leaving less tyrosine available for absorption into the 
circulation.  
This scenario of tyrosine degradation by an exogenous enzyme however is not a new concept. 
Phenylalanine breakdown by the administration of PAL, another ammonia lyase enzyme, has 
been greatly studied as an enzyme substitution therapy for PKU. A modified form of PAL has 
recently been approved for the treatment of PKU by the Food and Drug Administration and 
the European Medicine’s Agency. The research conducted with phenylalanine/PAL, 
described in section 1.2.6.4.3, highlights many challenges and issues which should be 
considered before developing a TAL therapeutic, due to the synonymous nature of 
tyrosine/TAL, and its application to metabolic disease. Although the licensed form of PAL is 
an injectable form (subcutaneous administration), which may not be considered the most 
suitable form or the desirable form that a TAL enzyme would take for nitisinone-treated AKU 
patients, aspects of the journey from the discovery of PAL to its use in human clinical trials 
will be applicable to the potential development of the TAL enzyme, which will undoubtedly 
experience similar challenges. 
Presented here was a series of in vitro experiments that show the ability of the Rhodobacter 
capsulatus TAL (RcTAL) enzyme to breakdown tyrosine. Due to TAL not being available to buy 
commercially, it was necessary to either request a custom synthesis or express a TAL enzyme 
in the laboratory. In order to do this, a gene sequence for TAL was required. After a literature 
search, it was decided that a TAL sequence from Rhodobacter capsulatus, a purple 
photosynthetic bacterium, would be used. Kyndt et al. expressed the RcTAL enzyme using an 
E. coli expression system 154, and calculated the catalytic efficiency with tyrosine and 
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phenylalanine, and compared these values with already reported catalytic efficiencies of two 
other PAL/TAL enzymes expressed in E. coli from Zea mays (maize) 303 and Petroselinum 
crispum (parsley) 304. The RcTAL enzyme had a 150-fold greater catalytic efficiency with 
tyrosine as a substrate than phenylalanine. The enzyme from Z. mays had similar reported 
catalytic efficiency with tyrosine and phenylalanine as substrates, however this was 375-fold 
lower than RcTAL with tyrosine. The enzyme from P. crispum exhibited very low catalytic 
efficiency with tyrosine as a substrate and was much more efficient as a PAL enzyme 
degrading phenylalanine. An enzyme with more TAL activity over PAL activity was desirable. 
A later publication by Xue et al. in 2007 compared the kinetic properties of two TAL enzymes 
expressed in their laboratory from Rhodobacter sphaeroides (a purple photosynthetic 
bacterium) and R. capsulatus 294, which were the only reported PAL/TAL enzymes that prefer 
tyrosine as a substrate than phenylalanine. With tyrosine as a substrate, RcTAL had a greater 
catalytic efficiency compared with R. sphaeroides and was therefore chosen for the work 
here.  
The expression and purification of the RcTAL enzyme in house however was only the first, 
and relatively minor, challenge to address in the application of TAL to nitisinone-induced 
tyrosinaemia as an enzyme therapy. Our capabilities and resources in the further 
development of TAL was limited, with more sophisticated techniques needed to develop it 
further. 
A TAL enzyme therapy would ideally be oral, as nitisinone is currently the best treatment 
option for AKU and would be a lifelong therapy until curative therapies such as enzyme/gene 
therapy are successful in restoring long-term enzyme activity. Injectable therapeutics are not 
very patient friendly, especially if daily administration is required; the PAL/pegvaliase 
administration in the final phase III PKU clinical trial was administered daily via subcutaneous 
injection. In addition to the practicality of injecting a therapeutic daily, repeat injection of a 
non-mammalian protein will almost certainly cause an immune response 305, as was 
described with the injection of PAL into PKU animals and patients, leading to neutralisation 
of the therapeutic effect 166,181. Even with PEGylation, which is designed to decrease 
immunogenicity and increase the half-life by preventing rapid degradation of a therapeutic 
protein 306, antibodies to the PEGylated PAL protein were still produced in the PKU clinical 
trials 190,191, with adverse events such as injection site reactions, hypersensitivity and even 
anaphylaxis reported. The FDA/EMA approved form of PAL/pegvaliase (PALYNZIQ®) that is 
administered subcutaneously has allergy warnings including severe anaphylaxis 
(https://www.biomarin.com/products/palynziq/ [accessed 05.02.2020]).  
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The National PKU Alliance conducted a survey in 2016 to assess current health status and 
interest in new treatments, with PKU individuals reporting a desire for new treatments that 
reduce their blood phenylalanine levels whilst allowing intake of natural protein to increase, 
with reduced or discontinued intake of medical foods, with a preference for oral 
administration, and reported a general dislike for injectable therapeutics 307. In addition to 
PKU, other patient groups also report a preference for oral therapeutics over 
injectable/intravenous methods, such as in type II diabetes 308, rheumatoid arthritis 309 and 
cancer 310,311. Injecting a TAL enzyme daily would not have been an attractive therapy for 
reducing/preventing nitisinone-induced tyrosinaemia in the absence of a protein restricted 
diet in AKU patients and was therefore not considered further here. Although not a preferred 
route of administration, PKU patients in the pegvaliase trials reportedly consumed more 
natural protein in their diets and also consumed less medical food 191, which would be a 
desirable outcome with the application of a TAL enzyme to nitisinone-treated AKU patients. 
The efficacy of PAL/pegvaliase on phenylalanine levels however was not assessed in the 
absence of dietary management.  
Development of TAL for oral administration in nitisinone-treated AKU patients would 
therefore be the target of future research; oral PAL administration for the phenylalanine 
degradation in PKU was only partially explored. As highlighted early on in PAL research, the 
main challenge of orally dosing TAL would be in preventing proteolytic degradation of the 
protein by digestive enzymes 161,162. The first proteolytic attack for an orally administered 
protein would be from pepsin released by the stomach, an endopeptidase which 
preferentially prefers hydrolysing links with aromatic amino acids, responsible for 15% 
protein digestion 312. Once the contents of the stomach is released into the duodenum, it 
mixes with bile and pancreatic secretions, with the latter being rich in digestive enzymes 313. 
The main proteolytic pancreatic enzymes are trypsin, chymotrypsin, lipase, carboxypeptidase 
A and B and elastase. Approximately 50% ingested protein is digested in the duodenum, 
hydrolysed into amino acids and peptides 2-4 amino acids in length 314,315. Most amino acids 
are then absorbed by the duodenum, jejunum and proximal ileum therefore TAL would need 
to not only survive proteolytic digestion, but also be active immediately in the intestine to 
prevent tyrosine absorption into the bloodstream via the enterocytes of the intestinal 
epithelium. The enterocytes also have peptidases situated in the brush border that are 
present to break down di- and tri-peptides, although this can also occur intracellularly, as di- 
and tri-peptides are taken up faster than free amino acids.  
201 
 
Following successful protease protection, TAL enzyme activity in the gastrointestinal 
environment would then be crucial for efficient tyrosine breakdown. Due to the secretion of 
acidic gastric fluid, the pH of the stomach in healthy individuals in a fasting state is 
approximately 1.0-2.5, increasing to 6.6 in the jejunum and 7.4 in the ileum 316. The acidic pH 
of the stomach may be an issue for the TAL enzyme, which was shown here to be inactive at 
pH 1.5 and pH 4.5 in vitro. The insoluble fraction containing TAL within un-lysed E. coli 
bacteria also showed no activity at pH 1.5 and 4.5. A PAL enzyme was previously shown to 
retain activity at pH 8.5 after a 10 minute exposure to a broad pH range of 4-12 in vitro, with 
the authors suggesting that the enzyme may have enough pH tolerance to remain active after 
transit through the stomach 185. The TAL enzyme here was tested separately, and not 
sequentially at low pH followed by pH 8.5, therefore it’s not known if the enzyme was just 
inactive at lower pH’s with further activity possible at pH 8.5, or denatured and permanently 
inactivated 317. A TAL enzyme however would potentially be given orally with/after a meal, 
during which the pH of the stomach contents has been shown to increase from fasting levels 
of pH 1.0-1.5 to pH 5-7, taking up to 3 hours to return to pre-meal levels in humans 318. It was 
shown that gastric pH remains high, decreasing at a slow rate until 50-60% of the contents 
has emptied. This study also found that a liquid meal resulted in a pH of 5.5 at 50% gastric 
emptying, and pH 4.6 for a solid meal. Consuming TAL with food may therefore offer some 
protection due to the rise in gastric pH. Once in the duodenum, the acidic gastric contents is 
mixed with pancreatic juice that is highly alkaline at pH 8.0-9.5 with a high bicarbonate 
content 313. The pancreatic and intestinal digestive enzymes require a neutral or slightly 
alkaline pH to function therefore the acidity of the stomach contents must be neutralised. 
The pH within the duodenum and intestine (6.6 in the jejunum as mentioned above in the 
fasting state) is therefore likely to be favourable towards the alkaline optimum of TAL, with 
RcTAL shown to be active at pH 8.5 here in vitro, with further testing at more pH levels with 
decimal increments needed to assess the pH optimum further. The optimum pH has been 
reported for a few PAL/TAL enzymes, with optimum pH’s of 8.0-8.5 in Zea mays TAL 303, 8.5-
9.0 in Rhodobacter spaeroides TAL 150 and 8.0-9.0 in Rhodotorula glutinis PAL 174.  
In vivo TAL experiments with nitisinone-treated AKU mice were not carried out in this thesis, 
with more in vitro work required before pursuing mouse studies, investigating factors such 
as catalytic efficiency and survival in acidic and protease-rich environments, with 
modifications/protection techniques likely needed to improve these characteristics. A few 
protection strategies were investigated in PAL in the literature. The retention of PAL within 
E. coli was shown to offer protease protection in vitro and in vivo in PKU mice 180. The 
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insoluble fraction of the TAL protein expression and purification was tested here in vitro, and 
was shown to breakdown tyrosine with the standard assay conditions at pH 8.5, but did not 
breakdown tyrosine at pH 4.5. Whether or not TAL within the insoluble fraction or the 
expression E. coli would preserve activity after transit through the stomach is unknown. The 
effect of proteases on the TAL expressed here was not investigated. An online tool however 
can be used to predict potential cleavage sites by proteases or chemicals (ExPASy 
PeptideCutter: https://web.expasy.org/peptide_cutter/). For the RcTAL amino acid 
sequence, the main digestive proteases are predicted to cleave RcTAL in numerous positions, 
with pepsin at pH 1.3 predicted to cleave at 111 positions, pepsin at pH >2 at 123 positions, 
chymotrypsin at 118 positions and trypsin at 42 positions, see Appendix section 8.2, Table 
8.1 for all results. The likelihood of TAL being cleaved by proteases is therefore very high. 
Protease inhibitors, as used by Sarkissian et al. with PAL 180, could be used in conjunction with 
TAL, however it would be more ideal to find strategies that improve protease resistance 
without affecting normal digestion of food which could affect nutrition, in addition to the 
role that proteases play in freeing tyrosine from protein peptides, which is needed in order 
for TAL to metabolise tyrosine. More sophisticated methods could be used to introduce 
protease resistance, such as mutagenesis of protease cleavage sites in the TAL sequence, as 
was investigated in RtPAL, where mutating primary trypsin and chymotrypsin cleavage sites 
lead to intact PAL protein after incubation with proteases 181. Encapsulating the enzyme to 
protect it from proteases/pH environment is another strategy that could be used. The early 
PAL work encapsulated the PAL enzyme in a semi-permeable gel capsule 160 and then later 
PAL was immobilised into semi-permeable “artificial cells” designed to allow the passage of 
small molecules such as amino acids, but protect the contents from enzymes 172. Despite 
immobilised PAL not being as active as the free form, it was still able to reduce phenylalanine 
significantly when dosed orally in experimental HPA animals, but the effect was not 
reproduced in PKU mice 177.  
The encapsulation of TAL would need to provide protection in the stomach, but then allow 
either tyrosine entry and subsequent degradation within the capsule or the release of the 
enzyme into the intestinal environment for tyrosine degradation. Many sophisticated 
techniques now exist and are researched intensively for the gastric protection of proteins for 
oral administration. Enzyme replacement therapies are used for diseases with lack of 
intestinal enzymes, such as the lack of lactase in lactose intolerance and lack of pancreatic 
enzymes such as proteases, lipase and amylase in exocrine pancreatic deficiency. Delivery of 
these absent enzymes requires gastric protection followed by enzyme activity in the 
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intestine. For example, the incorporation of lactase enzyme into a hydrogel, made from food-
grade materials, co-loaded with a buffer was shown to protect the acid-sensitive lactase 
enzyme from acid deactivation after exposure to gastric conditions in vitro, with only a small 
shift in pH from 7.2 to 6.6 within the hydrogel 319. Other recent encapsulation techniques for 
lactase have included microcapsules formed with gelatin/gum arabic 320, spray congealed 
lipid micro-particles 321, polysaccharide gel beads 322 and aqueous gelatin/maltodextrin 
microgels 323. A review in 2010 reported that pancreatic enzyme replacement preparations 
available from pharmaceutical companies are usually enteric-coated capsules containing 
mini-microspheres, pellets or micro-tables <2mm in size, designed to mix with gastric 
contents, coated with pH-sensitive and acid-resistant polymers that release the contents at 
pH 5.0-5.5 to prevent acid denaturation of the enzyme in the stomach 324.  
These approaches for the gastric protection of other intestinal enzymes would likely be 
applicable to TAL. A collaborative effort would undoubtedly be needed in order to identify 
the most suitable method of encapsulation followed by testing in an animal model and then 
human patients. A review by McClements in 2018 highlighted the range of food grade 
colloidal-systems (the even distribution of particles within a solution) that can be designed 
to encapsulate, retain, protect and deliver bioactive proteins to the intestine, that includes 
microemulsions, emulsions, nanoemulsions, solid lipid nanoparticle, liposomes and 
microgels 325. The review also highlights the complex nature of protein encapsulation, with 
the need to consider factors regarding protein characteristics such as molecular weight, 
conformation, electrical properties, polarity, solubility and stability; particle characteristics 
such as composition, size, shape, loading of protein, retention/release properties; and end 
product requirements such as appearance, product form such as small beverage, gummy-
type product or solid tablet, dose, storage and ingredient selection. 
In addition to the protection of TAL from proteases and low pH, maximising catalytic 
efficiency would also be desirable. TAL was shown to degrade tyrosine in vitro here, however 
its catalytic efficiency was not investigated, and it is not known how much of the enzyme 
would need to be ingested to metabolise a sufficient amount of tyrosine to prevent 
tyrosinaemia. A more efficient enzyme would require less protein to be incorporated into a 
therapeutic formulation, which ideally needs to be small. Once the most suitable TAL enzyme 
has been selected, genetic/protein-engineering technology could then be used to alter the 
amino acid sequence to improve catalytic efficiency, in addition to other features such as 
protease resistance, pH stability and solubility. Due to the enormous amount of different 
sequences that could be created by mutagenesis, it can be necessary to identify ‘hotspots’ 
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within an enzyme where mutations are likely to be beneficial using high-throughput 
screening, followed by individual amino acid optimization 326. Directed evolution of enzymes 
is one of the most powerful techniques in protein engineering, and involves repeated rounds 
of random mutagenesis of the gene of interest, expression of the mutated protein and 
screening or selection of desirable properties 327. Further to this, researchers have now begun 
to use models of protein sequence-function relationships combined with multivariate 
statistical analysis to guide the evolutionary process. For example, a company called Codexis 
with expertise in protein engineering have developed an algorithm to assign mutations to be 
either beneficial, neutral or deleterious on enzyme function before being incorporated into 
the sequence 328,329.  
Watt et al. in 2006 identified a single active site residue responsible for substrate selection 
in PALs/TALs; replacing His89 with Phe in TAL completely switches the substrate specificity 
from tyrosine to phenylalanine, converting it to an active PAL 150. A corresponding mutation 
in PAL causes the enzyme to lose phenylalanine specificity and gain tyrosine specificity. Not 
only could TAL be engineered to have a greater substrate specificity towards tyrosine, it could 
also be engineered to have phenylalanine activity, or a combination of both. The dietary 
restriction studies here in mice demonstrated that phenylalanine restriction alone would not 
be effective at reducing nitisinone-induced tyrosinaemia, therefore an enzyme with just PAL 
activity would not be useful. A TAL enzyme with phenylalanine activity could be beneficial, 
as the dietary studies showed that phenylalanine reduction with no tyrosine elicited a dose-
responsive reduction in plasma tyrosine. The TAL enzyme expressed here was not tested 
against phenylalanine in vitro, and should be included in future assays. Whether a specific 
TAL or a combined TAL/PAL approach would be better for reducing tyrosinaemia would need 
further investigation.  
The development of TAL clearly has a long way to go in order to be a therapeutic for 
nitisinone-induced tyrosinaemia in AKU patients. The safety of a new therapy is also crucial 
to assess. Coumaric acid, produced by TAL deaminating tyrosine, would not be expected to 
cause adverse effects as it is already consumed naturally in the diet in many fruits, 
vegetables, cereals and red wines, and has been shown to be antioxidant 330,331, antimicrobial 
332 anti-inflammatory and immunosuppressive 333. The antioxidant and anti-inflammatory 
properties could be beneficial for the osteoarthropathy manifestations of AKU, with 
oxidative stress recently shown to occur in an AKU cell model 334. Ammonia production is also 
a potential negative affect of TAL. No side effects however were noted with the application 
of PAL in PKU which also forms ammonia as a by-product. Ammonia is naturally generated in 
205 
 
the body from amino acids obtained from dietary protein and catabolism of glutamine, in 
addition to other reactions, with around 1000 mmol produced a day in adult humans 335,336. 
Due to the high toxicity of ammonia, mechanisms have evolved such as the urea cycle that 
are designed to metabolise and clear excess ammonia, therefore it’s likely that any ammonia 
produced by TAL would be cleared efficiently.  
 
5.4.4 Future of nitisinone-induced tyrosinaemia in AKU 
Nitisinone is a lifelong treatment for AKU and is associated with hyper-tyrosinaemia. Removal 
of tyrosine/phenylalanine, but not phenylalanine alone, from the diet of mice is effective at 
reducing circulating tyrosine. Protein restriction coupled with tyrosine/phenylalanine-free 
amino acid supplementation was able to reduce tyrosine levels in patients observed at the 
NAC, although these reductions were greater in mice, most likely owing to patient 
compliance. A controlled dietary restriction trial in AKU patients would likely see results 
similar to the mouse data shown here. The mouse dietary restriction data suggests that 
strategies reducing tyrosine uptake from the intestine, such as degradation of tyrosine by an 
exogenous enzyme or a tyrosine-specific binder that prevents uptake into the circulation, 
that allow a normal protein diet to be consumed, could be investigated not only for 
nitisinone-treated AKU patients, but also for nitisinone-treated HT-1 patients. Ideally, a 
strategy to reduce nitisinone-induced tyrosinaemia would be an oral therapy since other 
routes such as injectable or intravenous administration would not be desirable or patient 
friendly. The potential application of tyrosine ammonia lyase could be a promising oral 
























Over 100 years on from the identification of AKU as the world’s first described genetic 
disease, no cure for this ultra-rare condition exists. The low incidence and relatively normal 
lifespan of AKU sufferers perhaps drew away the attention of the scientific and research 
community. It was not until the 1990’s that the HGD gene was identified and cloned, the first 
human mutations were described and an AKU mouse model discovered as a result of an ENU 
mutagenesis programme. In recent years, our knowledge of AKU pathophysiology has greatly 
increased with advancements in our understanding of disease pathology and progression, 
genetic characterisation of mutations and the introduction of nitisinone as a disease-
modifying therapy. The success of nitisinone-treatment in AKU was built upon pre-clinical 
studies using the ENU BALB/c Hgd-/- AKU mouse model, which was able to show not only the 
progression of initial pigmentation within individual chondrocytes of articular cartilage, but 
also demonstrated the ability of nitisinone to lower HGA and prevent/halt ochronosis. Here 
in this thesis, a new mouse model of AKU was generated and phenotyped, providing some 
new information and experimental findings that would not have been possible in the existing 
ENU AKU model.  
Although both the newer targeted Hgd tm1a -/- and the ENU mutagenesis BALB/c Hgd-/- AKU 
models can continue to be used for future research as the metabolic and ochronotic 
phenotypes were comparable, the knockout-first model is considered superior as it is 
specifically targeted to the Hgd gene, it has an endogenous LacZ reporter gene that can be 
used to localise Hgd gene expression and can be manipulated to obtain the conditional Hgd 
tm1d allele to conduct both tissue specific and inducible Hgd deletion.   
Despite the advancement in our knowledge of AKU and the introduction of a pharmacological 
therapy, the process of ochronotic pigmentation still remains somewhat of a mystery. The 
composition of ochronotic pigment and the mechanism of deposition is still unknown. The 
AKU research community need to continue to explore ochronotic pathophysiology, even with 
the introduction of nitisinone, in order to understand more about the damage and processes 
involved, as many patients will already have a level of ochronosis that could one day be 
reversed, cleared or prevented by other means. The phenotyping of the new targeted Hgd 
tm1a -/- AKU mouse has provided the most thorough evaluation of tissue ochronosis in mice 
to date, showing that across a variety of musculoskeletal and other tissues that pigmentation 
is present only within calcified cartilage in mice, and may be accelerated in areas of greater 
physiological stress/load. AKU mouse models are likely to play a role in future ochronosis 
research, however they are limited to the early stages of human ochronotic pigment 
deposition. This Hgd tm1a -/- AKU mouse model, along with heterozygous Hgd tm1a mice, 
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has also provided in-depth metabolic phenotyping that includes both urine and plasma HGA 
and other tyrosine pathway metabolites that had not all previously been reported in AKU 
mice, with the tm1a model also being used by others for untargeted metabolomic profiling 
experiments extending beyond the tyrosine pathway, investigating nitisinone and the AKU 
disease state on the wider metabolome for example.  
Nitisinone has proven to be an effective drug therapy for human AKU patients throughout 
the DevelopAKUre trials and its use at the NAC, however like many other drugs, it is not a 
perfect therapy. As a consequence of the metabolic block that nitisinone introduces to the 
tyrosine metabolic pathway, AKU patients treated with nitisinone are required to restrict 
dietary protein intake in order to lower circulating tyrosine levels. Although most, if not all, 
patients would trade the debilitating manifestations of AKU osteoarthropathy for nitisinone 
with a restricted protein diet, most of these adult AKU patients find it difficult to adhere to a 
restricted diet. The impact of finding a strategy to combat nitisinone-induced tyrosinaemia 
will not only allow adult patients to consume a normal diet without potentially damaging 
keratopathy, but could allow nitisinone administration to children by removing the risk of 
neurocognitive deficits that could be associated with increased tyrosine. The dietary 
restriction work presented here demonstrates the feasibility of targeting removal of dietary 
tyrosine/phenylalanine via an oral therapeutic that would prevent intestinal tyrosine 
absorption, whilst demonstrating the ineffectiveness of phenylalanine-only dietary 
restriction. Using an exogenous enzyme such as TAL was explored in vitro and is deemed 
plausible, with further investigation and collaborative effort required for successful 
application to AKU, and potentially HT-1 patients, treated with nitisinone.  
Currently, nitisinone is the only disease-modifying treatment option available for AKU. Single 
gene diseases however have the possibility of being cured in the future by gene therapy.  
With the continuous development and advancement in molecular biology technology and 
knowledge, gene therapy may soon no longer be a concept, but a reality. The new targeted 
and conditional AKU mouse model was used here to determine the location and level of Hgd 
mRNA required to rescue AKU. In adult mice, Hgd expression has been precisely localised to 
the cytoplasm of hepatocytes and the cytoplasm of proximal convoluted tubule cells in the 
kidney cortex, in addition to low level expression in developing male germ cells located within 
the testis and epididymis, all confirmed with mRNA expression data. Initiation of Hgd 
expression in the developing liver and kidney was also determined using the LacZ reporter 
gene. MxCre recombinase was then used to specifically delete Hgd in the liver of the 
conditional Hgd tm1d (fl/fl) MxCre mouse model, leaving kidney Hgd expression intact. These 
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experiments revealed firstly that kidney Hgd expression is unable to metabolise a sufficient 
amount of HGA to reduce the circulating HGA load that ultimately leads to ochronotic 
pigmentation and joint disease. The liver has therefore been established as the target organ 
for future gene/enzyme replacement therapy in AKU. The Hgd tm1d (fl/fl) MxCre model was 
then used in a dose response experiment to determine the minimum range of liver Hgd 
mRNA required to reduce circulating HGA, which is critical prerequisite information required 
for the development of a gene therapy. It was also demonstrated using isotopically-labelled 
HGA and the presence of a downstream-labelled metabolite that HGA could be taken up from 
the circulation by hepatocytes to be metabolised, establishing that HGA formed by 
uncorrected cells in a post-gene therapy scenario will likely be metabolised by corrected cells; 
an important concept for the success of gene therapy. This work using the conditional mouse 
model of AKU has provided insights and perspectives, that could not have been achieved in 
human patients, that will hopefully pave the way for future work that ultimately leads to the 






















1. Ferreira, C. R. & van Karnebeek, C. D. M. Inborn errors of metabolism. in Handbook of 
Clinical Neurology vol. 162 449–481 (Elsevier B.V., 2019). 
2. Vernon, H. J. Inborn errors of metabolism: advances in diagnosis and therapy. JAMA 
Pediatr. 169, 778–782 (2015). 
3. Das, S. K. Inborn errors of metabolism: challenges and management. Indian J. Clin. 
Biochem. 28, 311–313 (2013). 
4. La Du, B. N., Zannoni, V. G., Laster, L. & Seegmiller, J. E. The nature of the defect in 
tyrosine metabolism in alcaptonuria. J. Biol. Chem. 230, 250–261 (1958). 
5. Stenn, F., Milgram, J., Lee, S., Weigand, R. & Veis, A. Biochemical identification of 
homogentisic acid pigment in an ochronotic egyptian mummy. Science (80-. ). 197, 
566–568 (1977). 
6. Lee, S. L. & Stenn, F. F. Characterization of mummy bone ochronotic pigment. JAMA 
J. Am. Med. Assoc. 240, 136 (1978). 
7. Scribonius, G. De inspectione urinarum. (1584). 
8. O’Brien, W. M., La Du, B. N. & Bunim, J. J. Biochemical, pathologic and clinical aspects 
of alcaptonuria, ochronosis and ochronotic arthropathy. Am. J. Med. 34, 813–838 
(1963). 
9. Boedeker, C. Ueber das alcapton; ein neuer beitrag zur frage: welche stoffe des hams 
kannen kupferreduction bewirken? Ztschr. rat. med. 130 (1859). 
10. Virchow, R. L. Rudolph Virchow on ochronosis.1866. Arthritis Rheum. 9, 66–71 (1866). 
11. Kirk, R. New acid found in human urine which darkens with alkalies (alcaptonuria). J. 
Anat. Physiol. 23, 69–80 (1888). 
12. Wolkow, M. & Baumann, E. Ueber das wesen der alkaptonurie. Physiol. Chemie 15, 
22–285 (1891). 
13. Albrecht, A. Ueber ochronose. Ztschr. Heilk 23, 366 (1954). 
14. Osler, W. Ochronosis: the pigmentaion of cartilages, sclerotics, and skin in 
alkaptonuria. Lancet 163, 10–11 (1904). 
15. Watson, J. D. & Crick, F. H. C. Molecular structure of nucleic acids: a structure for 
deoxyribose nucleic acid. Nature 171, 737–738 (1953). 
212 
 
16. Garrod, A. E. The incidence of alkaptonuria: a study in chemical individuality. Lancet 
160, 1616–1620 (1902). 
17. Garrod, A. E. & Hele, T. S. The uniformity of the homogentisic acid excretion in 
alkaptonuria. J. Physiol. 33, 198–205 (1905). 
18. Garrod, A. The Croonian lectures on inborn errors of metabolism. Lancet 172, 1–7 
(1908). 
19. Neubauer, O. Über den abbau der aminosäuren im gesunden und kranken 
organismus. Dtsch. Arch. Klin. Med. 95, 211–256 (1909). 
20. Phornphutkul, C. et al. Natural history of alkaptonuria. N. Engl. J. Med. 347, 2111–
2121 (2002). 
21. Milch, R. A. Studies of alcaptonuria: inheritance of 47 cases in eight highly inter-
related dominican kindreds. Am. J. Hum. Genet. 12, 76–85 (1960). 
22. Zatková, A. et al. High frequency of alkaptonuria in Slovakia: evidence for the 
appearance of multiple mutations in HGO involving different mutational hot spots. 
Am. J. Hum. Genet. 67, 1333–1339 (2000). 
23. Goicoechea De Jorge, E. et al. Alkaptonuria in the Dominican Republic: identification 
of the founder AKU mutation and further evidence of mutation hot spots in the HGO 
gene. J. Med. Genet. 39, e40 (2002). 
24. Al-sbou, M., Mwafi, N. & Lubad, M. A. Identification of forty cases with alkaptonuria 
in one village in Jordan. Rheumatol. Int. 32, 3737–3740 (2012). 
25. Al-sbou, M. & Mwafi, N. Nine cases of alkaptonuria in one family in southern Jordan. 
Rheumatol. Int. 32, 621–625 (2012). 
26. Islam, M. M., Ababneh, F. M. & Khan, M. H. R. Consanguineous marriage in Jordan: an 
update. J. Biosoc. Sci. 50, 573–578 (2018). 
27. Moss, A. & Schoenheimer, R. The conversion of phenylalanine to tyrosine in normal 
rats. J. Biol. Chem. 135, 415–429 (1940). 
28. Ranganath, L. R., Jarvis, J. C., Gallagher, J. A. & Ranganath, L. R. Recent advances in 




29. Verma, S. Early detection of alkaptonuria. Indian J. Dermatol. Venereol. Leprol. 71, 
189–191 (2005). 
30. Thalagahage, K. N. H., Jayaweera, J. A. A. S., Kumbukgolla, W. W. & Senavirathne, I. 
Detection of alkaptonuria in a 1-week-old infant. BMJ Case Rep. 2015, bcr2014208505 
(2015). 
31. Peker, E., Yonden, Z. & Sogut, S. From darkening urine to early diagnosis of 
alkaptonuria. Indian J. Dermatol. Venereol. Leprol. 74, 700 (2008). 
32. Tokuhara, Y. et al. Absorbance measurements of oxidation of homogentisic acid 
accelerated by the addition of alkaline solution with sodium hypochlorite 
pentahydrate. Sci. Rep. 8, 11364 (2018). 
33. Milch, R. A., Titus, E. D. & Loo, T. L. Atmospheric oxidation of homogentisic acid: 
spectrophotometric studies. Science 126, 209–210 (1957). 
34. Consden, R., Forbes, H. A. W., Glynn, L. E. & Stanier, W. M. Observations on the 
oxidation of homogentisic acid in urine. Biochem. J. 50, 274–278 (1951). 
35. Tokuhara, Y. et al. Detection of novel visible-light region absorbance peaks in the urine 
after alkalization in patients with alkaptonuria. PLoS One 9, e86606 (2014). 
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8.1 Alignment of HGD across different species 
Figure 8.1 shows the gene/protein tree alignment of HGD across different species, generated 
from the Ensembl gene tree tool. The HGD gene is highly conserved gene.  
 
 
Figure 8.1. Gene/protein alignment of HGD between different species.  
Across most species, the HGD gene is very well conserved. Number in brackets after species group represents the 
number of HGD homologs within the group. Image adapted the Ensemble gene tree tool 
(https://www.ensembl.org/index.html).  
 
8.1.1 Alignment of human and mouse HGD nucleotide sequences 
To show how conserved the HGD gene is between humans and mice, the NCBI BLAST tool 
was used to align the nucleotide sequences (CCDS; consensus CDS sequence) and calculate 
how identical they are. The CCDS sequences for human HGD was NCBI gene ID 3081 and 
mouse Hgd was NCBI gene ID 15233. Both the mouse and human sequences contain 1338 
nt, with 88.42% of nucleotides being identical (1183/1338 nt identical). The sequence below 
shows a dot (·) where the nucleotide is identical, and then red letter where the mouse 





Human  1     ATGGCTGAGTTAAAGTACATTTCTGGATTTGGGAATGAGTGTTCTTCAGAGGATCCTCGC  60 
Mouse  1     .....A....................................G.................  60 
 
Human  61    TGCCCAGGTTCCCTGCCAGAAGGACAGAATAATCCTCAGGTCTGCCCCTACAATCTCTAT  120 
Mouse  61    ..T..............CA..................................C.....C  120 
 
Human  121   GCTGAGCAGCTCTCAGGATCGGCTTTCACTTGTCCACGGAGCACCAATAAGAGAAGCTGG  180 
Mouse  121   ..............G.....A..C................A...................  180 
 
Human  181   CTGTATAGGATTCTACCTTCAGTTTCTCACAAGCCCTTTGAATCCATTGACGAAGGCCAA  240 
Mouse  181   ..............T.................A........G.....C...C.......T  240 
 
Human  241   GTCACTCACAACTGGGATGAAGTTGATCCTGATCCTAACCAGCTTAGATGGAAACCATTT  300 
Mouse  241   .........................GC.................A...............  300 
 
Human  301   GAGATTCCAAAAGCATCTCAGAAGAAAGTAGACTTTGTGAGTGGCCTGCATACCTTGTGT  360 
Mouse  301   ..............G...G..........G..............TT..T.C.....A...  360 
 
Human  361   GGAGCTGGAGACATAAAGTCTAACAATGGGCTTGCTATCCACATTTTCCTCTGCAATACC  420 
Mouse  361   .....A........C...........C..C......G.G........T..G..T..CT..  420 
 
Human  421   TCCATGGAGAACAGATGCTTTTACAATTCAGATGGGGACTTCTTGATTGTTCCGCAGAAA  480 
Mouse  421   ..............G...........C...........T...C..........C......  480 
 
Human  481   GGGAACCTTCTCATTTACACCGAGTTTGGCAAGATGCTTGTACAGCCCAATGAGATCTGC  540 
Mouse  481   .....A..............................TCCC.G...........A......  540 
 
Human  541   GTCATTCAGAGAGGAATGCGGTTCAGCATAGATGTCTTTGAGGAGACCAGGGGCTACATC  600 
Mouse  541   ....................A......G.C..............................  600 
 
Human  601   TTGGAGGTCTATGGTGTCCACTTTGAGTTACCTGACCTTGGACCAATTGGGGCCAATGGC  660 
Mouse  601   C.....................................G.....C..C..A..A......  660 
 
Human  661   TTGGCCAATCCTCGTGATTTCTTGATACCCATTGCCTGGTATGAGGATCGCCAAGTACCA  720 
Mouse  661   ..............A...........T...G.............A.....T.G...G...  720 
 
Human  721   GGTGGTTACACGGTCATTAATAAATACCAGGGCAAGCTGTTTGCTGCCAAACAGGATGTC  780 
Mouse  721   ...........T..G..........T...................TG.............  780 
 
Human  781   TCCCCGTTCAATGTTGTGGCCTGGCACGGGAATTATACACCCTACAAGTACAACCTGAAG  840 
Mouse  781   ..T..A........C...........T..A..C..C....................AG..  840 
 
Human  841   AATTTCATGGTTATCAACTCAGTGGCCTTTGACCATGCAGACCCATCCATTTTCACAGTA  900 
Mouse  841   ..C........C.....TG.G..A..............G..T..T...........C..G  900 
 
Human  901   TTGACTGCTAAGTCTGTCCGCCCTGGAGTGGCCATTGCTGATTTTGTCATCTTCCCACCT  960 
Mouse  901   C.......C..A..CC....A.....G.....T........C..................  960 
 
Human  961   CGATGGGGGGTTGCTGATAAGACCTTCAGGCCTCCTTATTACCATAGGAACTGCATGAGT  1020 
Mouse  961   ..G.....A.....A.....A........A..............C...............  1020 
 
Human  1021  GAGTTCATGGGACTCATCCGAGGTCACTATGAGGCAAAGCAAGGTGGGTTCCTGCCAGGG  1080 
Mouse  1021  ...........C......AA...........................A............  1080 
 
Human  1081  GGAGGGAGTCTACACAGCACAATGACCCCCCATGGACCTGATGCTGACTGCTTTGAGAAG  1140 
Mouse  1081  ..C..C..C..G.....TG.C........T..C..C..C.....A...........A...  1140 
 
Human  1141  GCCAGCAAGGTCAAGCTGGCACCTGAGAGGATTGCCGATGGCACCATGGCATTTATGTTT  1200 
Mouse  1141  ..........C...A..C.AG..A........A..T..C...........G.........  1200 
 
Human  1201  GAATCATCTTTAAGTCTGGCGGTCACAAAGTGGGGACTCAAGGCCTCCAGGTGTTTGGAT  1260 
Mouse  1201  .....T..C......T..........C...............A...GT..C.........  1260 
 
Human  1261  GAGAACTACCACAAGTGCTGGGAGCCACTCAAGAGCCACTTCACTCCCAACTCCAGGAAC  1320 
Mouse  1261  .........T....A..T........T...CG............C.....T.......G.  1320 
 
Human  1321  CCAGCAGAACCTAATTGA  1338 




8.2 Predicted cleavage sites in Rhodobacter capsulatus TAL amino acid sequence 
The potential cleavage of the RcTAL amino acid sequence by proteases/chemicals was 
predicted using an online tool called ExPASy PeptideCutter, with the results shown in Table 
8.1 (https://web.expasy.org/peptide_cutter/ [accessed 06.02.2020). 
 
Table 8.1. Potential protease and chemical cleavage sites in RcTAL. 
Name of enzyme 
No. of 
cleavages 
Positions of cleavage sites 
Arg-C proteinase 41 
30 32 40 42 45 49 58 73 105 111 129 167 169 176 186 197 222 229 
253 260 264 274 277 283 284 291 304 322 376 380 420 449 450 452 
490 493 495 497 504 507 521 
Asp-N endopeptidase 27 
9 14 77 127 152 171 184 197 224 269 288 293 298 314 317 320 332 
360 382 438 473 476 477 490 493 505 527 
Asp-N endopeptidase + 
N-terminal Glu  
49 
9 14 23 40 50 55 77 81 102 124 127 140 152 171 178 184 197 218 
224 235 242 250 262 269 288 292 293 298 314 317 320 326 332 338 
360 374 382 383 417 438 473 476 477 479 490 493 505 513 527 
BNPS-Skatole  5 101 245 314 319 485 
CNBr  12 1 108 160 170 184 209 235 352 406 419 443 473 
Chymotrypsin-high 
specificity (C-term to 
[FYW], not before P)  
14 61 67 89 101 138 245 249 301 314 319 351 393 405 485 
Chymotrypsin-low 
specificity (C-term to 
[FYWML], not before P)  
104 
1 3 12 14 18 20 29 39 47 50 52 59 61 67 70 74 83 87 89 90 91 99 101 
107 108 109 112 116 134 138 154 157 160 162 164 170 184 187 192 
194 200 202 209 215 228 230 234 235 238 241 245 249 252 259 265 
269 279 285 290 301 303 309 314 317 319 328 346 347 351 352 355 
358 363 367 370 373 381 386 393 394 395 401 405 406 415 416 419 
431 443 455 458 465 467 469 473 475 476 485 487 492 503 509 512 
520 
Clostripain  41 
30 32 40 42 45 49 58 73 105 111 129 167 169 176 186 197 222 229 
253 260 264 274 277 283 284 291 304 322 376 380 420 449 450 452 
490 493 495 497 504 507 521 
Formic acid  27 
10 15 78 128 153 172 185 198 225 270 289 294 299 315 318 321 333 




24 41 51 56 82 103 125 141 179 219 236 243 251 263 293 327 339 
375 384 418 480 514 
Hydroxylamine 2 204 434 
Iodosobenzoic acid  5 101 245 314 319 485 
LysC 4 9 98 385 388 
LysN 4 8 97 384 387 
NTCB (2-nitro-5-
thiocyanobenzoic acid)  
7 10 22 42 187 275 325 340 
Pepsin (pH1.3)  111 
2 3 12 13 14 17 18 19 20 39 50 66 69 74 82 83 86 87 90 91 99 106 
108 109 112 115 116 133 134 137 153 156 162 163 164 187 191 193 
194 200 201 202 214 215 227 228 233 234 237 238 249 251 258 259 
265 268 269 278 289 302 303 309 316 317 327 328 337 346 350 351 
358 362 363 366 367 369 370 372 373 381 385 386 393 394 400 401 
243 
 
404 405 414 415 416 430 431 456 457 464 465 466 467 468 469 474 
475 476 486 487 491 503 508 519 520 
Pepsin (pH>2)  123 
2 3 12 13 14 17 18 19 20 39 50 66 69 74 82 83 86 87 88 89 90 91 99 
101 106 108 109 112 115 116 133 134 137 153 156 162 163 164 187 
191 193 194 200 201 202 214 215 227 228 233 234 237 238 244 249 
251 258 259 265 268 269 278 289 300 301 302 303 309 313 314 316 
317 318 319 327 328 337 346 350 351 358 362 363 366 367 369 370 
372 373 381 385 386 393 394 400 401 404 405 414 415 416 430 431 
456 457 464 465 466 467 468 469 474 475 476 484 485 486 487 491 
503 508 519 520 
Proline-
endopeptidase [*] 
7 247 254 256 292 296 508 523 
Proteinase K  286 
2 3 7 8 12 13 14 17 18 19 20 21 24 25 26 27 28 33 35 36 38 39 41 44 
46 48 50 51 53 54 55 56 60 61 63 64 65 67 70 71 74 75 77 81 82 83 
87 88 89 91 92 93 95 99 101 102 103 104 106 107 109 110 112 115 
116 119 122 125 126 127 130 131 132 133 134 136 138 139 141 142 
144 147 148 150 154 155 157 158 161 162 163 164 171 177 179 180 
182 183 187 192 193 194 195 196 200 201 202 203 206 208 210 211 
212 213 214 215 216 218 219 220 221 223 224 226 227 228 232 233 
234 236 237 238 242 243 244 245 248 249 250 251 252 259 261 262 
263 265 266 268 269 272 275 278 279 280 281 282 285 286 287 288 
290 293 297 300 301 303 305 306 309 310 312 313 314 316 317 319 
323 324 325 327 328 331 332 336 337 339 342 343 345 346 351 354 
356 357 358 359 362 363 365 366 367 368 369 370 371 373 374 375 
378 379 381 382 384 386 390 392 393 394 399 401 405 408 410 411 
412 413 414 415 416 417 418 421 423 424 426 428 431 433 436 440 
441 445 446 447 448 451 453 455 456 458 461 463 464 465 466 467 
468 469 470 472 475 476 480 483 485 487 488 489 492 496 498 499 
503 505 509 510 513 514 515 516 517 520 525 526 527 531 
Staphylococcal 
peptidase I  
22 
24 41 51 56 82 103 125 141 179 219 236 243 251 263 293 327 339 
375 384 418 480 514 
Thermolysin 211 
2 7 11 12 13 16 17 19 20 25 26 32 34 37 38 43 45 47 49 52 53 54 59 
62 66 69 70 73 74 76 80 86 87 90 91 94 98 101 105 106 107 108 109 
111 114 115 118 121 126 129 130 131 132 133 135 137 143 147 149 
156 157 159 160 161 162 163 169 170 176 181 182 183 186 191 193 
194 195 199 200 201 202 207 208 210 211 212 213 214 217 220 222 
223 226 227 231 232 233 234 237 241 247 248 249 258 260 264 265 
267 268 271 274 278 280 281 284 286 287 296 302 304 308 309 311 
312 316 322 323 330 335 341 344 345 350 351 353 355 356 357 358 
362 364 365 366 367 369 370 372 373 377 378 380 385 391 392 393 
398 400 404 405 407 409 411 413 414 415 416 420 422 425 427 430 
435 440 442 445 446 447 450 452 454 457 460 462 463 464 465 466 
467 468 469 471 472 475 482 486 488 495 497 498 502 504 508 509 
512 515 516 519 524 525 526 530 
Thrombin 1 167 
Trypsin 42 
9 30 32 40 42 45 49 58 73 98 105 111 129 167 169 176 186 197 222 
229 260 264 274 277 283 284 304 322 376 380 385 388 420 449 450 
452 490 493 495 497 504 521 
These enzymes do not cut: Caspase 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, Enterokinase, Factor Xa, Granzyme B, Tobacco 
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